



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C12N 15/12, 15/63, C07K 14/705, 16/18, A61K 38/17, G01N 33/50	A3	(11) International Publication Number: WO 99/61471 (43) International Publication Date: 2 December 1999 (02.12.99)																												
(21) International Application Number: PCT/US99/11904 (22) International Filing Date: 28 May 1999 (28.05.99) (30) Priority Data: <table border="0"> <tr> <td>60/087,260</td> <td>29 May 1998 (29.05.98)</td> <td>US</td> </tr> <tr> <td>60/091,674</td> <td>2 July 1998 (02.07.98)</td> <td>US</td> </tr> <tr> <td>60/102,954</td> <td>2 October 1998 (02.10.98)</td> <td>US</td> </tr> <tr> <td>60/109,869</td> <td>24 November 1998 (24.11.98)</td> <td>US</td> </tr> </table> (63) Related by Continuation (CON) or Continuation-in-Part (CIP) to Earlier Applications <table border="0"> <tr> <td>US</td> <td>60/087,260 (CIP)</td> </tr> <tr> <td>Filed on</td> <td>29 May 1998 (29.05.98)</td> </tr> <tr> <td>US</td> <td>60/091,674 (CIP)</td> </tr> <tr> <td>Filed on</td> <td>2 July 1998 (02.07.98)</td> </tr> <tr> <td>US</td> <td>60/102,954 (CIP)</td> </tr> <tr> <td>Filed on</td> <td>2 October 1998 (02.10.98)</td> </tr> <tr> <td>US</td> <td>60/109,869 (CIP)</td> </tr> <tr> <td>Filed on</td> <td>24 November 1998 (24.11.98)</td> </tr> </table> (71) Applicant (for all designated States except US): INCYTE PHARMACEUTICALS, INC. [US/US]; 3174 Porter Drive, Palo Alto, CA 94304 (US).		60/087,260	29 May 1998 (29.05.98)	US	60/091,674	2 July 1998 (02.07.98)	US	60/102,954	2 October 1998 (02.10.98)	US	60/109,869	24 November 1998 (24.11.98)	US	US	60/087,260 (CIP)	Filed on	29 May 1998 (29.05.98)	US	60/091,674 (CIP)	Filed on	2 July 1998 (02.07.98)	US	60/102,954 (CIP)	Filed on	2 October 1998 (02.10.98)	US	60/109,869 (CIP)	Filed on	24 November 1998 (24.11.98)	(72) Inventors; and (75) Inventors/Applicants (for US only): TANG, Y., Tom [CN/US]; 4230 Ranwick Court, San Jose, CA 95118 (US). LAL, Preeti [IN/US]; 2382 Lass Drive, Santa Clara, CA 95054 (US). HILLMAN, Jennifer, L. [US/US]; 230 Monroe Drive #12, Mountain View, CA 94040 (US). YUE, Henry [US/US]; 826 Lois Avenue, Sunnyvale, CA 94087 (US). GUEGLER, Karl, J. [CH/US]; 1048 Oakland Avenue, Menlo Park, CA 94025 (US). CORLEY, Neil, C. [US/US]; 1240 Dale Avenue #30, Mountain View, CA 94040 (US). BANDMAN, Olga [US/US]; 366 Anna Avenue, Mountain View, CA 94043 (US). PATTERSON, Chandra [US/US]; 490 Sherwood Way #1, Menlo Park, CA 94025 (US). GORGONE, Gina, A. [US/US]; 1253 Pinecrest Drive, Boulder Creek, CA 95006 (US). KASER, Matthew, R. [GB/US]; 4793 Ewing Road, Castro Valley, CA 94546-1017 (US). BAUGHN, Mariah, R. [US/US]; 14244 Santiago Road, San Leandro, CA 94577 (US). AU-YOUNG, Janice [US/US]; 1419 Kains Avenue, Berkeley, CA 94702 (US). (74) Agents: BILLINGS, Lucy, J. et al.; Incyte Pharmaceuticals, Inc., 3174 Porter Drive, Palo Alto, CA 94304 (US). (81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i> (88) Date of publication of the international search report: 16 March 2000 (16.03.00)
60/087,260	29 May 1998 (29.05.98)	US																												
60/091,674	2 July 1998 (02.07.98)	US																												
60/102,954	2 October 1998 (02.10.98)	US																												
60/109,869	24 November 1998 (24.11.98)	US																												
US	60/087,260 (CIP)																													
Filed on	29 May 1998 (29.05.98)																													
US	60/091,674 (CIP)																													
Filed on	2 July 1998 (02.07.98)																													
US	60/102,954 (CIP)																													
Filed on	2 October 1998 (02.10.98)																													
US	60/109,869 (CIP)																													
Filed on	24 November 1998 (24.11.98)																													
(54) Title: HUMAN TRANSMEMBRANE PROTEINS (57) Abstract <p>The invention provides human transmembrane proteins (HTMPN) and polynucleotides which identify and encode HTMPN. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating, or preventing disorders associated with expression of HTMPN.</p>																														

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 99/11904

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C12N15/12 C12N15/63 C07K14/705 C07K16/18 A61K38/17
G01N33/50

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C12N C07K A61K G01N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No
A	EP 0 834 563 A (SMITHKLINE BEECHAM CORP) 8 April 1998 (1998-04-08) the whole document	
A	--- LOO T.W. ET AL.: "Drug-stimulated ATPase Activity of Human P-glycoprotein Requires Movement between Transmembrane Segments 6 and 12" JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 272, no. 34, 22 August 1997 (1997-08-22), pages 20986-20989, XP002116312 the whole document --- -/-	

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- *Z* document member of the same patent family

Date of the actual completion of the international search

27 September 1999

Date of mailing of the international search report

18. 1. 00

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx 31 651 epo.nl,
Fax: (+31-70) 340-3016

Authorized officer

Schonwasser, D

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 99/11904

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No
X	<p>HILLIER L. ET AL.: "WashU-NCI human EST Project; af42e03.s1 Soares total fetus Nb2HF8 9w Homo sapiens cDNA clone 1034332 3'"</p> <p>EMBL DATABASE ENTRY AA779652; ACCESSION NO. AA779652,6 February 1998 (1998-02-06), XP002116313</p> <p>Amino acids 90-240 of SEQ ID NO:1 are identical to amino acids 1-151 of AA779652.</p> <p>---</p>	5,6,9-11
X	<p>HILLIER L. ET AL.: "WashU-Merck EST Project 1997; aal8a10.r1 Soares NhHMPu S1 Homo sapiens cDNA clone 813594 5'"</p> <p>EMBL DATABASE ENTRY HS1247817; ACCESSION NO. AA447814,10 June 1997 (1997-06-10), XP002116314</p> <p>Amino acids 62 -209 of SEQ ID NO:1 are identical to amino acids 1-148 of AA447814.</p> <p>-----</p>	5,6,9-11

INTERNATIONAL SEARCH REPORT

International application No
PCT/US 99/11904

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons

- 1 ☒ Claims Nos. because they relate to subject matter not required to be searched by this Authority, namely
Although claim 19 is directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
- 2 ☒ Claims Nos. 17,18,20 because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful international Search can be carried out, specifically:
It is not possible to carry out a meaningful search for claims 17,18 and 20, since the claimed agonists and antagonists are not sufficiently described.
- 3 ☐ Claims Nos. because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

- 1 ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims
- 2 ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee
- 3 ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
- 4 ☒ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims, it is covered by claims Nos.
1-20 (all partially)

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest
- ☐ No protest accompanied the payment of additional search fees

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Claims Nos.: 17,18,20

It is not possible to carry out a meaningful search for claims 17,18 and 20, since the claimed agonists and antagonists are not sufficiently described.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

1. Claim : .

Invention 1: Claims 1-20 (all partially)

A substantially purified polypeptide comprising the amino acid sequence SEQ ID NO:1 or a fragment thereof, an isolated and substantially purified polynucleotide encoding said polypeptide, a method for detecting said polynucleotide, an expression vector and a host cell comprising the polynucleotide, a method of producing the above mentioned polypeptide, a pharmaceutical composition comprising said polypeptide as well as an antibody against said polypeptide and a method for treating or preventing a disorder associated with decreased expression or activity of human transmembrane proteins.

Inventions 2-79: Claims 1-20 (all partially)

The inventions No. 2 - 79 relate to subject-matter as defined above for "subject 1", whereby each invention refers to one of the polypeptide sequences of SEQ ID NO:2 to SEQ ID NO:79 (and the respective nucleotide sequences of SEQ ID NO:80 to SEQ ID NO:158).

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 99/11904

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 0834563 A	08-04-1998	JP 10179178 A	07-07-1998
		US 5824504 A	20-10-1998



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C07K 14/00		A2	(11) International Publication Number: WO 99/61471
			(43) International Publication Date: 2 December 1999 (02.12.99)
(21) International Application Number: PCT/US99/11904 (22) International Filing Date: 28 May 1999 (28.05.99) (30) Priority Data: 60/087,260 29 May 1998 (29.05.98) US 60/091,674 2 July 1998 (02.07.98) US 60/102,954 2 October 1998 (02.10.98) US 60/109,869 24 November 1998 (24.11.98) US (63) Related by Continuation (CON) or Continuation-in-Part (CIP) to Earlier Applications US 60/087,260 (CIP) Filed on 29 May 1998 (29.05.98) US 60/091,674 (CIP) Filed on 2 July 1998 (02.07.98) US 60/102,954 (CIP) Filed on 2 October 1998 (02.10.98) US 60/109,869 (CIP) Filed on 24 November 1998 (24.11.98) (71) Applicant (for all designated States except US): INCYTE PHARMACEUTICALS, INC. [US/US]; 3174 Porter Drive, Palo Alto, CA 94304 (US).		(72) Inventors; and (75) Inventors/Applicants (for US only): TANG, Y., Tom [CN/US]; 4230 Ranwick Court, San Jose, CA 95118 (US). LAL, Preeti [IN/US]; 2382 Lass Drive, Santa Clara, CA 95054 (US). HILLMAN, Jennifer, L. [US/US]; 230 Monroe Drive #12, Mountain View, CA 94040 (US). YUE, Henry [US/US]; 826 Lois Avenue, Sunnyvale, CA 94087 (US). GUEGLER, Karl, J. [CH/US]; 1048 Oakland Avenue, Menlo Park, CA 94025 (US). CORLEY, Neil, C. [US/US]; 1240 Dale Avenue #30, Mountain View, CA 94040 (US). BANDMAN, Olga [US/US]; 366 Anna Avenue, Mountain View, CA 94043 (US). PATTERSON, Chandra [US/US]; 490 Sherwood Way #1, Menlo Park, CA 94025 (US). GORGONE, Gina, A. [US/US]; 1253 Pinecrest Drive, Boulder Creek, CA 95006 (US). KASER, Matthew, R. [GB/US]; 4793 Ewing Road, Castro Valley, CA 94546-1017 (US). BAUGHN, Mariah, R. [US/US]; 14244 Santiago Road, San Leandro, CA 94577 (US). AU-YOUNG, Janice [US/US]; 1419 Kains Avenue, Berkeley, CA 94702 (US). (74) Agents: BILLINGS, Lucy, J. et al.; Incyte Pharmaceuticals, Inc., 3174 Porter Drive, Palo Alto, CA 94304 (US). (81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published Without international search report and to be republished upon receipt of that report.	
(54) Title: HUMAN TRANSMEMBRANE PROTEINS			
(57) Abstract			
<p>The invention provides human transmembrane proteins (HTMPN) and polynucleotides which identify and encode HTMPN. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating, or preventing disorders associated with expression of HTMPN.</p>			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon	KR	Republic of Korea	PL	Poland		
CN	China	KZ	Kazakstan	PT	Portugal		
CU	Cuba	LC	Saint Lucia	RO	Romania		
CZ	Czech Republic	LI	Liechtenstein	RU	Russian Federation		
DE	Germany	LK	Sri Lanka	SD	Sudan		
DK	Denmark	LR	Liberia	SE	Sweden		
EE	Estonia			SG	Singapore		

HUMAN TRANSMEMBRANE PROTEINS

TECHNICAL FIELD

5 This invention relates to nucleic acid and amino acid sequences of human transmembrane proteins and to the use of these sequences in the diagnosis, treatment, and prevention of immune, reproductive, smooth muscle, neurological, gastrointestinal, developmental, and cell proliferative disorders.

10 BACKGROUND OF THE INVENTION

Eukaryotic organisms are distinct from prokaryotes in possessing many intracellular organelle and vesicle structures. Many of the metabolic reactions which distinguish eukaryotic biochemistry from prokaryotic biochemistry take place within these structures. In particular, many cellular functions require very stringent reaction
15 conditions, and the organelles and vesicles enable compartmentalization and isolation of reactions which might otherwise disrupt cytosolic metabolic processes. The organelles include mitochondria, smooth and rough endoplasmic reticula, sarcoplasmic reticulum, and the Golgi body. The vesicles include phagosomes, lysosomes, endosomes, peroxisomes, and secretory vesicles. Organelles and vesicles are bounded by single or
20 double membranes.

Biological membranes are highly selective permeable barriers made up of lipid bilayer sheets composed of phosphoglycerides, fatty acids, cholesterol, phospholipids, glycolipids, proteoglycans, and proteins. Membranes contain ion pumps, ion channels, and specific receptors for external stimuli which transmit biochemical signals across the
25 membranes. These membranes also contain second messenger proteins which interact with these pumps, channels, and receptors to amplify and regulate transmission of these signals.

Plasma Membrane Proteins

Plasma membrane proteins (MPs) are divided into two groups based upon methods
30 of protein extraction from the membrane. Extrinsic or peripheral membrane proteins can be released using extremes of ionic strength or pH, urea, or other disruptors of protein interactions. Intrinsic or integral membrane proteins are released only when the lipid

bilayer of the membrane is dissolved by detergent.

Transmembrane proteins (TM) are characterized by an extracellular, a transmembrane, and an intracellular domain. TM domains are typically comprised of 15 to 25 hydrophobic amino acids which are predicted to adopt an α -helical conformation.

5 TM proteins are classified as bitopic (Types I and II) proteins, which span the membrane once, and polytopic (Types III and IV) (Singer, S.J. (1990) *Annu. Rev. Cell Biol.* 6:247-96) proteins which contain multiple membrane-spanning segments. TM proteins that act as cell-surface receptor proteins involved in signal transduction include growth and differentiation factor receptors, and receptor-interacting proteins such as *Drosophila*

10 pecanex and frizzled proteins, LIV-1 protein, NF2 protein, and GNS1/SUR4 eukaryotic integral membrane proteins. TM proteins also act as transporters of ions or metabolites, such as gap junction channels (connexins), and ion channels, and as cell anchoring proteins, such as lectins, integrins, and fibronectins. TM proteins are found in vesicle organelle-forming molecules, such as calveolins; or cell recognition molecules, such as

15 cluster of differentiation (CD) antigens, glycoproteins, and mucins.

Many membrane proteins (MPs) contain amino acid sequence motifs that serve to localize proteins to specific subcellular sites. Examples of these motifs include PDZ domains, KDEL, RGD, NGR, and GSL sequence motifs, von Willebrand factor A (vWFA) domains, and EGF-like domains. RGD, NGR, and GSL motif-containing

20 peptides have been used as drug delivery agents in targeted cancer treatment of tumor vasculature (Arap, W. et al. (1998) *Science*, 279:377-380). Membrane proteins may also contain amino acid sequence motifs that serve to interact with extracellular or intracellular molecules, such as carbohydrate recognition domains.

Chemical modification of amino acid residue side chains alters the manner in

25 which MPs interact with other molecules, for example, phospholipid membranes. Examples of such chemical modifications to amino acid residue side chains are covalent bond formation with glycosaminoglycans, oligosaccharides, phospholipids, acetyl and palmitoyl moieties, ADP-ribose, phosphate, and sulphate groups.

RNA-encoding membrane proteins may have alternative splice sites which give

30 rise to proteins encoded by the same gene but with different messenger RNA and amino acid sequences. Splice variant membrane proteins may interact with other ligand and protein isoforms.

G-Protein Coupled Receptors

G-protein coupled receptors (GPCR) are a superfamily of integral membrane proteins which transduce extracellular signals. GPCRs include receptors for biogenic amines, lipid mediators of inflammation, peptide hormones, and sensory signal mediators.

5 The structure of these highly-conserved receptors consists of seven hydrophobic transmembrane (serpentine) regions, cysteine disulfide bridges between the second and third extracellular loops, an extracellular N-terminus, and a cytoplasmic C-terminus. Three extracellular loops alternate with three intracellular loops to link the seven transmembrane regions. The most conserved parts of these proteins are the
10 transmembrane regions and the first two cytoplasmic loops. A conserved, acidic-Arg-aromatic residue triplet present in the second cytoplasmic loop may interact with G proteins. A GPCR consensus pattern is characteristic of most proteins belonging to this superfamily (ExpASy PROSITE document PS00237; and Watson, S. and S. Arkinstall (1994) The G-protein Linked Receptor Facts Book, Academic Press, San Diego,
15 CA, pp 2-6). Mutations and changes in transcriptional activation of GPCR-encoding genes have been associated with neurological disorders such as schizophrenia, Parkinson's disease, Alzheimer's disease, drug addiction, and feeding disorders.

Scavenger Receptors

Macrophage scavenger receptors with broad ligand specificity may participate in
20 the binding of low density lipoproteins (LDL) and foreign antigens. Scavenger receptors types I and II are trimeric membrane proteins with each subunit containing a small N-terminal intracellular domain, a transmembrane domain, a large extracellular domain, and a C-terminal cysteine-rich domain. The extracellular domain contains a short spacer domain, an α -helical coiled-coil domain, and a triple helical collagenous domain. These
25 receptors have been shown to bind a spectrum of ligands, including chemically modified lipoproteins and albumin, polyribonucleotides, polysaccharides, phospholipids, and asbestos (Matsumoto, A. et al. (1990) Proc. Natl. Acad. Sci. 87:9133-9137; and Elomaa, O. et al. (1995) Cell 80:603-609). The scavenger receptors are thought to play a key role in atherogenesis by mediating uptake of modified LDL in arterial walls, and in host
30 defense by binding bacterial endotoxins, bacteria, and protozoa.

Tetraspan family proteins

The transmembrane 4 superfamily (TM4SF) or tetraspan family is a multigene

family encoding type III integral membrane proteins (Wright, M.D. and Tomlinson, M.G. (1994) Immunol. Today 15:588). TM4SF is comprised of membrane proteins which traverse the cell membrane four times. Members of the TM4SF include platelet and endothelial cell membrane proteins, melanoma-associated antigens, leukocyte surface glycoproteins, colonal carcinoma antigens, tumor-associated antigens, and surface proteins of the schistosome parasites (Jankowski, S.A. (1994) Oncogene 9:1205-1211). Members of the TM4SF share about 25-30% amino acid sequence identity with one another.

A number of TM4SF members have been implicated in signal transduction, control of cell adhesion, regulation of cell growth and proliferation, including development and oncogenesis, and cell motility, including tumor cell metastasis. Expression of TM4SF proteins is associated with a variety of tumors and the level of expression may be altered when cells are growing or activated.

Tumor Antigens

Tumor antigens are surface molecules that are differentially expressed in tumor cells relative to normal cells. Tumor antigens distinguish tumor cells immunologically from normal cells and provide diagnostic and therapeutic targets for human cancers (Takagi, S. et al. (1995) Int. J. Cancer 61: 706-715; Liu, E. et al. (1992) Oncogene 7: 1027-1032).

Ion channels

Ion channels are found in the plasma membranes of virtually every cell in the body. For example, chloride channels mediate a variety of cellular functions including regulation of membrane potentials and absorption and secretion of ions across epithelial membranes. When present in intracellular membranes of the Golgi apparatus and endocytic vesicles, chloride channels also regulate organelle pH (see, e.g., Greger, R. (1988) Annu. Rev. Physiol. 50:111-122). Electrophysiological and pharmacological properties of chloride channels, including ion conductance, current-voltage relationships, and sensitivity to modulators, suggest that different chloride channels exist in muscles, neurons, fibroblasts, epithelial cells, and lymphocytes.

Many channels have sites for phosphorylation by one or more protein kinases including protein kinase A, protein kinase C, tyrosine kinase, and casein kinase II, all of which regulate ion channel activity in cells. Inappropriate phosphorylation of proteins in cells has been linked to changes in cell cycle progression and cell differentiation. Changes

in the cell cycle have been linked to induction of apoptosis or cancer. Changes in cell differentiation have been linked to diseases and disorders of the reproductive system, immune system, and skeletal muscle.

Proton pumps

- 5 Proton ATPases are a large class of membrane proteins that use the energy of ATP hydrolysis to generate an electrochemical proton gradient across a membrane. The resultant gradient may be used to transport other ions across the membrane (Na^+ , K^+ , or Cl^-) or to maintain organelle pH. Proton ATPases are further subdivided into the mitochondrial F-ATPases, the plasma membrane ATPases, and the vacuolar ATPases.
- 10 The vacuolar ATPases establish and maintain an acidic pH within various vesicles involved in the processes of endocytosis and exocytosis (Mellman, I. et al. (1986) *Ann. Rev. Biochem.* 55:663-700).

- Proton-coupled, 12 membrane-spanning domain transporters such as PEPT 1 and PEPT 2 are responsible for gastrointestinal absorption and for renal reabsorption of
- 15 peptides using an electrochemical H^+ gradient as the driving force. Another type of peptide transporter, the TAP transporter, is a heterodimer consisting of TAP 1 and TAP 2 and is associated with antigen processing. Peptide antigens are transported across the membrane of the endoplasmic reticulum by TAP so they can be expressed on the cell surface in association with MHC molecules. Each TAP protein consists of multiple
- 20 hydrophobic membrane spanning segments and a highly conserved ATP-binding cassette (Boll, M. et al. (1996) *Proc. Natl. Acad. Sci.* 93:284-289). Pathogenic microorganisms, such as herpes simplex virus, may encode inhibitors of TAP-mediated peptide transport in order to evade immune surveillance (Marusina, K. and Manaco, J.J. (1996) *Curr. Opin. Hematol.* 3:19-26).

25 ABC Transporters

- The ATP-binding cassette (ABC) transporters, also called the "traffic ATPases", comprise a superfamily of membrane proteins that mediate transport and channel functions in prokaryotes and eukaryotes (Higgins, C.F. (1992) *Annu. Rev. Cell Biol.* 8:67-113). ABC proteins share a similar overall structure and significant sequence homology. All
- 30 ABC proteins contain a conserved domain of approximately two hundred amino acid residues which includes one or more nucleotide binding domains. Mutations in ABC transporter genes are associated with various disorders, such as hyperbilirubinemia

II/Dubin-Johnson syndrome, recessive Stargardt's disease, X-linked adrenoleukodystrophy, multidrug resistance, celiac disease, and cystic fibrosis.

Membrane Proteins Associated with Intercellular Communication

Intercellular communication is essential for the development and survival of multicellular organisms. Cells communicate with one another through the secretion and uptake of protein signaling molecules. The uptake of proteins into the cell is achieved by endocytosis, in which the interaction of signaling molecules with the plasma membrane surface, often via binding to specific receptors, results in the formation of plasma membrane-derived vesicles that enclose and transport the molecules into the cytosol. The secretion of proteins from the cell is achieved by exocytosis, in which molecules inside of the cell are packaged into membrane-bound transport vesicles derived from the *trans*-Golgi network. These vesicles fuse with the plasma membrane and release their contents into the surrounding extracellular space. Endocytosis and exocytosis result in the removal and addition of plasma membrane components and the recycling of these components is essential to maintain the integrity, identity, and functionality of both the plasma membrane and internal membrane-bound compartments.

Lysosomes are the site of degradation of intracellular material during autophagy and of extracellular molecules following endocytosis. Lysosomal enzymes are packaged into vesicles which bud from the *trans*-Golgi network. These vesicles fuse with endosomes to form the mature lysosome in which hydrolytic digestion of endocytosed material occurs. Lysosomes can fuse with autophagosomes to form a unique compartment in which the degradation of organelles and other intracellular components occurs. Protein sorting by transport vesicles, such as the endosome, has important consequences for a variety of physiological processes including cell surface growth, the biogenesis of distinct intracellular organelles, endocytosis, and the controlled secretion of hormones and neurotransmitters (Rothman, J.E. and Wieland, F.T. (1996) *Science* 272:227-234). In particular, neurodegenerative disorders and other neuronal pathologies are associated with biochemical flaws during endosomal protein sorting or endosomal biogenesis (Mayer R.J. et al. (1996) *Adv. Exp. Med. Biol.* 389:261-269).

Peroxisomes are organelles independent from the secretory pathway. They are the site of many peroxide-generating oxidative reactions in the cell. Peroxisomes are unique among eukaryotic organelles in that their size, number, and enzyme content vary

depending upon organism, cell type, and metabolic needs. The majority of peroxisome-associated proteins are membrane-bound or are found proximal to the cytosolic or the luminal side of the peroxisome membrane (Waterham, H.R. and Cregg, J.M. (1997) *BioEssays* 19:57-66).

5 Genetic defects in peroxisome proteins which result in peroxisomal deficiencies have been linked to a number of human pathologies, including Zellweger syndrome, rhizomelic chondrodysplasia punctata, X-linked adrenoleukodystrophy, acyl-CoA oxidase deficiency, bifunctional enzyme deficiency, classical Refsum's disease, DHAP alkyl transferase deficiency, and acatalasemia (Moser, H.W. and Moser, A.B. (1996) *Ann. NY*
10 *Acad. Sci.* 804:427-441). In addition, Gartner, J. et al. (1991; *Pediatr. Res.* 29:141-146) found a 22 kDa integral membrane protein associated with lower density peroxisome-like subcellular fractions in patients with Zellweger syndrome.

Normal embryonic development and control of germ cell maturation is modulated by a number of secretory proteins which interact with their respective membrane-bound
15 receptors. Cell fate during embryonic development is determined by members of the activin/TGF- β superfamily, cadherins, IGF-2, and other morphogens. In addition, proliferation, maturation, and redifferentiation of germ cell and reproductive tissues are regulated, for example, by IGF-2, inhibins, activins, and follistatins (Petraglia, F. (1997) *Placenta* 18:3-8; Mather, J.P. et al. (1997) *Proc. Soc. Exp. Biol. Med.* 215:209-222).

20 **Endoplasmic Reticulum Membrane Proteins**

The normal functioning of the eukaryotic cell requires that all newly synthesized proteins be correctly folded, modified, and delivered to specific intra- and extracellular sites. Newly synthesized membrane and secretory proteins enter a cellular sorting and distribution network during or immediately after synthesis and are routed to specific
25 locations inside and outside of the cell. The initial compartment in this process is the endoplasmic reticulum (ER) where proteins undergo modifications such as glycosylation, disulfide bond formation, and assembly into oligomers. The modified proteins are then transported through a series of membrane-bound compartments which include the various cisternae of the Golgi complex, where further carbohydrate modifications occur.

30 Transport between compartments occurs by means of vesicles that bud and fuse in a manner specific to the type of protein being transported. Once within the secretory pathway, proteins do not have to cross a membrane to reach the cell surface.

Although the majority of proteins processed through the ER are transported out of the organelle, some are retained. The signal for retention in the ER in mammalian cells consists of the tetrapeptide sequence, KDEL, located at the carboxyl terminus of proteins (Munro, S. (1986) Cell 46:291-300). Proteins containing this sequence leave the ER but
5 are quickly retrieved from the early Golgi cisternae and returned to the ER, while proteins lacking this signal continue through the secretory pathway.

Disruptions in the cellular secretory pathway have been implicated in several human diseases. In familial hypercholesterolemia the low density lipoprotein receptors remain in the ER, rather than moving to the cell surface (Pathak, R.K. (1988) J. Cell Biol.
10 106:1831-1841). Altered transport and processing of the β -amyloid precursor protein (β APP) involves the putative vesicle transport protein presenilin, and may play a role in early-onset Alzheimer's disease (Levy-Lahad, E. et al. (1995) Science 269:973-977). Changes in ER-derived calcium homeostasis have been associated with diseases such as cardiomyopathy, cardiac hypertrophy, myotonic dystrophy, Brody disease, Smith-McCort
15 dysplasia, and diabetes mellitus.

Mitochondrial Membrane Proteins

The mitochondrial electron transport (or respiratory) chain is a series of three enzyme complexes in the mitochondrial membrane that is responsible for the transport of electrons from NADH to oxygen and the coupling of this oxidation to the synthesis of
20 ATP (oxidative phosphorylation). ATP then provides the primary source of energy for driving the many energy-requiring reactions of a cell.

Most of the protein components of the mitochondrial respiratory chain are the products of nuclear encoded genes that are imported into the mitochondria and the remainder are products of mitochondrial genes. Defects and altered expression of
25 enzymes in the respiratory chain are associated with a variety of disease conditions in man, including, for example, neurodegenerative diseases, myopathies, and cancer.

Lymphocyte and Leukocyte Membrane Proteins

The B-cell response to antigens, which is modulated through receptors, is an essential component of the normal immune system. Mature B cells recognize foreign
30 antigens through B cell receptors (BCR) which are membrane-bound, specific antibodies that bind foreign antigens. The antigen/receptor complex is internalized and the antigen is proteolytically processed. To generate an efficient response to complex antigens, the

BCR, BCR-associated proteins, and T cell response are all required. Proteolytic fragments of the antigen are complexed with major histocompatibility complex-II (MHCII) molecules on the surface of the B cells where the complex can be recognized by T cells. In contrast, macrophages and other lymphoid cells present antigens in association with MHC I molecules to T cells. T cells recognize and are activated by the MHC I-antigen complex through interactions with the T cell receptor/CD3 complex, a T cell-surface multimeric protein located in the plasma membrane. T cells activated by antigen presentation secrete a variety of lymphokines that induce B cell maturation and T cell proliferation and activate macrophages, which kill target cells.

- 10 Leukocytes have a fundamental role in the inflammatory and immune response and include monocytes/macrophages, mast cells, polymorphonucleoleukocytes, natural killer cells, neutrophils, eosinophils, basophils, and myeloid precursors. Leukocyte membrane proteins include members of the CD antigens, N-CAM, I-CAM, human leukocyte antigen (HLA) class I and HLA class II gene products, immunoglobulins, immunoglobulin
15 receptors, complement, complement receptors, interferons, interferon receptors, interleukin receptors, and chemokine receptors.

Abnormal lymphocyte and leukocyte activity has been associated with acute disorders, such as AIDS, immune hypersensitivity, leukemias, leukopenia, systemic lupus, granulomatous disease, and eosinophilia.

20 **Apoptosis-Associated Membrane Proteins**

- A variety of ligands, receptors, enzymes, tumor suppressors, viral gene products, pharmacological agents, and inorganic ions have important positive or negative roles in regulating and implementing the apoptotic destruction of a cell. Although some specific components of the apoptotic pathway have been identified and characterized, many
25 interactions between the proteins involved are undefined, leaving major aspects of the pathway unknown.

- A requirement for calcium in apoptosis was previously suggested by studies showing the involvement of calcium levels in DNA cleavage and Fas-mediated cell death (Hewish, D.R. and L.A. Burgoyne (1973) *Biochem. Biophys. Res. Comm.* 52:504-510; Vignaux, F. et al. (1995) *J. Exp. Med.* 181:781-786; Oshimi, Y. and S. Miyazaki (1995) *J. Immunol.* 154:599-609). Other studies show that intracellular calcium concentrations
30 increase when apoptosis is triggered in thymocytes by either T cell receptor cross-linking

or by glucocorticoids and cell death can be prevented by blocking this increase (McConkey, D.J. et al. (1989) J. Immunol. 143:1801-1806; McConkey, D.J. et al. (1989) Arch. Biochem. Biophys. 269:365-370). Therefore, membrane proteins such as calcium channels are important for the apoptotic response.

5 Tumorigenesis

Tumorigenesis is associated with the activation of oncogenes which are derived from normal cellular genes. These oncogenes encode oncoproteins which are capable of converting normal cells into malignant cells. Some oncoproteins are mutant isoforms of the normal protein and other oncoproteins are abnormally expressed with respect to
10 location or level of expression. The latter category of oncoprotein causes cancer by altering transcriptional control of cell proliferation. Five classes of oncoproteins are known to affect the cell cycle controls. These classes include growth factors, growth factor receptors, intracellular signal transducers, nuclear transcription factors, and cell-cycle control proteins. These proteins include those which are modified by glycosylation,
15 phosphorylation, glycosaminoglycan attachment, sulphation, and lipidation.

Modulation of factors which act in the coordination of the human cell division cycle may provide an important means to reduce tumorigenesis. An example of the metastasis-associated proteins is the lysosomal membrane glycoprotein P2B/LAMP-1 which is also expressed in normal tissues. (Heffernan, M. et al. (1989) Cancer Res.
20 49:6077-6084.) In addition, mammalian proteins homologous to the plant pathogenesis-related proteins have been identified in hyperplastic glioma. (Murphy, E.V. et al. (1995) Gene 159:131-135.)

The discovery of new human transmembrane proteins and the polynucleotides encoding them satisfies a need in the art by providing new compositions which are useful
25 in the diagnosis, prevention, and treatment of immune, reproductive, smooth muscle, neurological, gastrointestinal, developmental, and cell proliferative disorders.

SUMMARY OF THE INVENTION

30 The invention features substantially purified polypeptides, human transmembrane proteins, referred to collectively as "HTMPN" and individually as "HTMPN-1", "HTMPN-2", "HTMPN-3", "HTMPN-4", "HTMPN-5", "HTMPN-6", "HTMPN-7", "HTMPN-8", "HTMPN-9", "HTMPN-10", "HTMPN-11", "HTMPN-12", "HTMPN-13",

"HTMPN-14", "HTMPN-15", "HTMPN-16", "HTMPN-17", "HTMPN-18", "HTMPN-19", "HTMPN-20", "HTMPN-21", "HTMPN-22", "HTMPN-23", "HTMPN-24", "HTMPN-25", "HTMPN-26", "HTMPN-27", "HTMPN-28", "HTMPN-29", "HTMPN-30", "HTMPN-31", "HTMPN-32", "HTMPN-33", "HTMPN-34", "HTMPN-35",
5 "HTMPN-36", "HTMPN-37", "HTMPN-38", "HTMPN-39", "HTMPN-40", "HTMPN-41", "HTMPN-42", "HTMPN-43", "HTMPN-44", "HTMPN-45", "HTMPN-46", "HTMPN-47", "HTMPN-48", "HTMPN-49", "HTMPN-50", "HTMPN-51", "HTMPN-52", "HTMPN-53", "HTMPN-54", "HTMPN-55", "HTMPN-56", "HTMPN-57", "HTMPN-58", "HTMPN-59", "HTMPN-60", "HTMPN-61", "HTMPN-62", "HTMPN-63", "HTMPN-64", "HTMPN-65", "HTMPN-66", "HTMPN-67", "HTMPN-68", "HTMPN-69", "HTMPN-70", "HTMPN-71", "HTMPN-72", "HTMPN-73", "HTMPN-74", "HTMPN-75", "HTMPN-76", "HTMPN-77", "HTMPN-78", and "HTMPN-79". In one aspect, the invention provides a substantially purified polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2,
15 SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:31, SEQ ID NO:32, SEQ ID NO:33, SEQ ID NO:34, SEQ ID NO:35, SEQ ID NO:36, SEQ ID NO:37, SEQ ID NO:38, SEQ ID NO:39, SEQ ID NO:40, SEQ ID NO:41, SEQ ID NO:42, SEQ ID NO:43, SEQ ID NO:44, SEQ ID NO:45, SEQ ID NO:46, SEQ ID NO:47, SEQ ID NO:48, SEQ ID NO:49, SEQ ID NO:50, SEQ ID NO:51, SEQ ID NO:52, SEQ ID NO:53, SEQ ID NO:54, SEQ ID NO:55, SEQ ID NO:56, SEQ ID NO:57, SEQ ID NO:58, SEQ ID NO:59, SEQ ID NO:60, SEQ ID NO:61, SEQ ID NO:62, SEQ ID NO:63, SEQ ID NO:64, SEQ ID NO:65, SEQ ID NO:66, SEQ ID NO:67, SEQ ID NO:68, SEQ ID NO:69, SEQ ID NO:70, SEQ ID NO:71, SEQ ID NO:72, SEQ ID NO:73, SEQ ID NO:74, SEQ ID NO:75, SEQ ID NO:76, SEQ ID NO:77, SEQ ID NO:78, and SEQ ID NO:79 (SEQ ID NO:1-79), and fragments thereof.

30 The invention further provides a substantially purified variant having at least 90% amino acid identity to at least one of the amino acid sequences selected from the group consisting of SEQ ID NO:1-79, and fragments thereof. The invention also provides an

isolated and purified polynucleotide encoding the polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-79, and fragments thereof. The invention also includes an isolated and purified polynucleotide variant having at least 90% polynucleotide sequence identity to the polynucleotide encoding the polypeptide

5 comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-79, and fragments thereof.

Additionally, the invention provides an isolated and purified polynucleotide which hybridizes under stringent conditions to the polynucleotide encoding the polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-

10 79, and fragments thereof. The invention also provides an isolated and purified polynucleotide having a sequence which is complementary to the polynucleotide encoding the polypeptide comprising the amino acid sequence selected from the group consisting of SEQ ID NO:1-79, and fragments thereof.

The invention also provides an isolated and purified polynucleotide comprising a

15 polynucleotide sequence selected from the group consisting of SEQ ID NO:80, SEQ ID NO:81, SEQ ID NO:82, SEQ ID NO:83, SEQ ID NO:84, SEQ ID NO:85, SEQ ID NO:86, SEQ ID NO:87, SEQ ID NO:88, SEQ ID NO:89, SEQ ID NO:90, SEQ ID NO:91, SEQ ID NO:92, SEQ ID NO:93, SEQ ID NO:94, SEQ ID NO:95, SEQ ID NO:96, SEQ ID NO:97, SEQ ID NO:98, SEQ ID NO:99, SEQ ID NO:100, SEQ ID NO:101, SEQ ID

20 NO:102, SEQ ID NO:103, SEQ ID NO:104, SEQ ID NO:105, SEQ ID NO:106, SEQ ID NO:107, SEQ ID NO:108, SEQ ID NO:109, SEQ ID NO:110, SEQ ID NO:111, SEQ ID NO:112, SEQ ID NO:113, SEQ ID NO:114, SEQ ID NO:115, SEQ ID NO:116, SEQ ID NO:117, SEQ ID NO:118, SEQ ID NO:119, SEQ ID NO:120, SEQ ID NO:121, SEQ ID NO:122, SEQ ID NO:123, SEQ ID NO:124, SEQ ID NO:125, SEQ ID NO:126, SEQ ID

25 NO:127, SEQ ID NO:128, SEQ ID NO:129, SEQ ID NO:130, SEQ ID NO:131, SEQ ID NO:132, SEQ ID NO:133, SEQ ID NO:134, SEQ ID NO:135, SEQ ID NO:136, SEQ ID NO:137, SEQ ID NO:138, SEQ ID NO:139, SEQ ID NO:140, SEQ ID NO:141, SEQ ID NO:142, SEQ ID NO:143, SEQ ID NO:144, SEQ ID NO:145, SEQ ID NO:146, SEQ ID NO:147, SEQ ID NO:148, SEQ ID NO:149, SEQ ID NO:150, SEQ ID NO:151, SEQ ID

30 NO:152, SEQ ID NO:153, SEQ ID NO:154, SEQ ID NO:155, SEQ ID NO:156, SEQ ID NO:157, and SEQ ID NO:158 (SEQ ID NO:80-158), and fragments thereof. The invention further provides an isolated and purified polynucleotide variant having at least

90% polynucleotide sequence identity to the polynucleotide sequence selected from the group consisting of SEQ ID NO:80-158, and fragments thereof. The invention also provides an isolated and purified polynucleotide having a sequence which is complementary to the polynucleotide comprising a polynucleotide sequence selected from
5 the group consisting of SEQ ID NO:80-158, and fragments thereof.

The invention also provides a method for detecting a polynucleotide in a sample containing nucleic acids, the method comprising the steps of (a) hybridizing the complement of the polynucleotide sequence to at least one of the polynucleotides of the sample, thereby forming a hybridization complex; and (b) detecting the hybridization
10 complex, wherein the presence of the hybridization complex correlates with the presence of a polynucleotide in the sample. In one aspect, the method further comprises amplifying the polynucleotide prior to hybridization.

The invention further provides an expression vector containing at least a fragment of the polynucleotide encoding the polypeptide comprising an amino acid sequence
15 selected from the group consisting of SEQ ID NO:1-79, and fragments thereof. In another aspect, the expression vector is contained within a host cell.

The invention also provides a method for producing a polypeptide, the method comprising the steps of: (a) culturing the host cell containing an expression vector containing at least a fragment of a polynucleotide under conditions suitable for the
20 expression of the polypeptide; and (b) recovering the polypeptide from the host cell culture.

The invention also provides a pharmaceutical composition comprising a substantially purified polypeptide having the amino acid sequence selected from the group consisting of SEQ ID NO:1-79, and fragments thereof, in conjunction with a suitable
25 pharmaceutical carrier.

The invention further includes a purified antibody which binds to a polypeptide selected from the group consisting of SEQ ID NO:1-79, and fragments thereof. The invention also provides a purified agonist and a purified antagonist to the polypeptide.

The invention also provides a method for treating or preventing a disorder
30 associated with decreased expression or activity of HTMPN, the method comprising administering to a subject in need of such treatment an effective amount of a pharmaceutical composition comprising a substantially purified polypeptide having the

amino acid sequence selected from the group consisting of SEQ ID NO:1-79, and fragments thereof, in conjunction with a suitable pharmaceutical carrier.

The invention also provides a method for treating or preventing a disorder associated with increased expression or activity of HTMPN, the method comprising
5 administering to a subject in need of such treatment an effective amount of an antagonist of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-79, and fragments thereof.

BRIEF DESCRIPTION OF THE TABLES

10 Table 1 shows nucleotide and polypeptide sequence identification numbers (SEQ ID NOs), clone identification numbers (clone ID), cDNA libraries, and cDNA fragments used to assemble full-length sequences encoding HTMPN.

Table 2 shows features of each polypeptide sequence including predicted transmembrane sequences, potential motifs, homologous sequences, and methods and
15 algorithms used for identification of HTMPN.

Table 3 shows the tissue-specific expression patterns of each nucleic acid sequence as determined by northern analysis, diseases, disorders, or conditions associated with these tissues, and the vector into which each cDNA was cloned.

Table 4 describes the tissues used to construct the cDNA libraries from which
20 Incyte cDNA clones encoding HTMPN were isolated.

Table 5 shows the programs, their descriptions, references, and threshold parameters used to analyze HTMPN.

DESCRIPTION OF THE INVENTION

25 Before the present proteins, nucleotide sequences, and methods are described, it is understood that this invention is not limited to the particular machines, materials and methods described, as these may vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to limit the scope of the present invention which will be limited only by the
30 appended claims.

It must be noted that as used herein and in the appended claims, the singular forms "a," "an," and "the" include plural reference unless the context clearly dictates otherwise.

Thus, for example, a reference to "a host cell" includes a plurality of such host cells, and a reference to "an antibody" is a reference to one or more antibodies and equivalents thereof known to those skilled in the art, and so forth.

Unless defined otherwise, all technical and scientific terms used herein have the same meanings as commonly understood by one of ordinary skill in the art to which this invention belongs. Although any machines, materials, and methods similar or equivalent to those described herein can be used to practice or test the present invention, the preferred machines, materials and methods are now described. All publications mentioned herein are cited for the purpose of describing and disclosing the cell lines, protocols, reagents and vectors which are reported in the publications and which might be used in connection with the invention. Nothing herein is to be construed as an admission that the invention is not entitled to antedate such disclosure by virtue of prior invention.

DEFINITIONS

"HTMPN" refers to the amino acid sequences of substantially purified HTMPN obtained from any species, particularly a mammalian species, including bovine, ovine, porcine, murine, equine, and preferably the human species, from any source, whether natural, synthetic, semi-synthetic, or recombinant.

The term "agonist" refers to a molecule which, when bound to HTMPN, increases or prolongs the duration of the effect of HTMPN. Agonists may include proteins, nucleic acids, carbohydrates, or any other molecules which bind to and modulate the effect of HTMPN.

An "allelic variant" is an alternative form of the gene encoding HTMPN. Allelic variants may result from at least one mutation in the nucleic acid sequence and may result in altered mRNAs or in polypeptides whose structure or function may or may not be altered. Any given natural or recombinant gene may have none, one, or many allelic forms. Common mutational changes which give rise to allelic variants are generally ascribed to natural deletions, additions, or substitutions of nucleotides. Each of these types of changes may occur alone, or in combination with the others, one or more times in a given sequence.

"Altered" nucleic acid sequences encoding HTMPN include those sequences with deletions, insertions, or substitutions of different nucleotides, resulting in a polynucleotide the same as HTMPN or a polypeptide with at least one functional characteristic of

HTMPN. Included within this definition are polymorphisms which may or may not be readily detectable using a particular oligonucleotide probe of the polynucleotide encoding HTMPN, and improper or unexpected hybridization to allelic variants, with a locus other than the normal chromosomal locus for the polynucleotide sequence encoding HTMPN.

- 5 The encoded protein may also be "altered," and may contain deletions, insertions, or substitutions of amino acid residues which produce a silent change and result in a functionally equivalent HTMPN. Deliberate amino acid substitutions may be made on the basis of similarity in polarity, charge, solubility, hydrophobicity, hydrophilicity, and/or the amphipathic nature of the residues, as long as the biological or immunological activity of
- 10 HTMPN is retained. For example, negatively charged amino acids may include aspartic acid and glutamic acid, positively charged amino acids may include lysine and arginine, and amino acids with uncharged polar head groups having similar hydrophilicity values may include leucine, isoleucine, and valine; glycine and alanine; asparagine and glutamine; serine and threonine; and phenylalanine and tyrosine.

- 15 The terms "amino acid" or "amino acid sequence" refer to an oligopeptide, peptide, polypeptide, or protein sequence, or a fragment of any of these, and to naturally occurring or synthetic molecules. In this context, "fragments," "immunogenic fragments," or "antigenic fragments" refer to fragments of HTMPN which are preferably at least 5 to about 15 amino acids in length, most preferably at least 14 amino acids, and which retain
- 20 some biological activity or immunological activity of HTMPN. Where "amino acid sequence" is recited to refer to an amino acid sequence of a naturally occurring protein molecule, "amino acid sequence" and like terms are not meant to limit the amino acid sequence to the complete native amino acid sequence associated with the recited protein molecule.

- 25 "Amplification" relates to the production of additional copies of a nucleic acid sequence. Amplification is generally carried out using polymerase chain reaction (PCR) technologies well known in the art.

- The term "antagonist" refers to a molecule which, when bound to HTMPN, decreases the amount or the duration of the effect of the biological or immunological
- 30 activity of HTMPN. Antagonists may include proteins, nucleic acids, carbohydrates, antibodies, or any other molecules which decrease the effect of HTMPN.

The term "antibody" refers to intact molecules as well as to fragments thereof, such

as Fab, F(ab')₂, and Fv fragments, which are capable of binding the epitopic determinant. Antibodies that bind HTMPN polypeptides can be prepared using intact polypeptides or using fragments containing small peptides of interest as the immunizing antigen. The polypeptide or oligopeptide used to immunize an animal (e.g., a mouse, a rat, or a rabbit)
5 can be derived from the translation of RNA, or synthesized chemically, and can be conjugated to a carrier protein if desired. Commonly used carriers that are chemically coupled to peptides include bovine serum albumin, thyroglobulin, and keyhole limpet hemocyanin (KLH). The coupled peptide is then used to immunize the animal.

The term "antigenic determinant" refers to that fragment of a molecule (i.e., an epitope) that makes contact with a particular antibody. When a protein or a fragment of a
10 protein is used to immunize a host animal, numerous regions of the protein may induce the production of antibodies which bind specifically to antigenic determinants (given regions or three-dimensional structures on the protein). An antigenic determinant may compete with the intact antigen (i.e., the immunogen used to elicit the immune response) for
15 binding to an antibody.

The term "antisense" refers to any composition containing a nucleic acid sequence which is complementary to the "sense" strand of a specific nucleic acid sequence. Antisense molecules may be produced by any method including synthesis or transcription. Once introduced into a cell, the complementary nucleotides combine with natural
20 sequences produced by the cell to form duplexes and to block either transcription or translation. The designation "negative" can refer to the antisense strand, and the designation "positive" can refer to the sense strand.

The term "biologically active," refers to a protein having structural, regulatory, or biochemical functions of a naturally occurring molecule. Likewise, "immunologically
25 active" refers to the capability of the natural, recombinant, or synthetic HTMPN, or of any oligopeptide thereof, to induce a specific immune response in appropriate animals or cells and to bind with specific antibodies.

The terms "complementary" or "complementarity" refer to the natural binding of polynucleotides by base pairing. For example, the sequence "5' A-G-T 3'" bonds to the
30 complementary sequence "3' T-C-A 5'." Complementarity between two single-stranded molecules may be "partial," such that only some of the nucleic acids bind, or it may be "complete," such that total complementarity exists between the single stranded molecules.

The degree of complementarity between nucleic acid strands has significant effects on the efficiency and strength of the hybridization between the nucleic acid strands. This is of particular importance in amplification reactions, which depend upon binding between nucleic acids strands, and in the design and use of peptide nucleic acid (PNA) molecules.

5 A "composition comprising a given polynucleotide sequence" or a "composition comprising a given amino acid sequence" refer broadly to any composition containing the given polynucleotide or amino acid sequence. The composition may comprise a dry formulation or an aqueous solution. Compositions comprising polynucleotide sequences encoding HTMPN or fragments of HTMPN may be employed as hybridization probes.

10 The probes may be stored in freeze-dried form and may be associated with a stabilizing agent such as a carbohydrate. In hybridizations, the probe may be deployed in an aqueous solution containing salts (e.g., NaCl), detergents (e.g., sodium dodecyl sulfate: SDS), and other components (e.g., Denhardt's solution, dry milk, salmon sperm DNA, etc.).

"Consensus sequence" refers to a nucleic acid sequence which has been
15 resequenced to resolve uncalled bases, extended using XL-PCR kit (Perkin-Elmer, Norwalk CT) in the 5' and/or the 3' direction, and resequenced, or which has been assembled from the overlapping sequences of more than one Incyte Clone using a computer program for fragment assembly, such as the GELVIEW Fragment Assembly system (GCG, Madison WI). Some sequences have been both extended and assembled to
20 produce the consensus sequence.

The term "correlates with expression of a polynucleotide" indicates that the detection of the presence of nucleic acids, the same or related to a nucleic acid sequence encoding HTMPN, by northern analysis is indicative of the presence of nucleic acids encoding HTMPN in a sample, and thereby correlates with expression of the transcript
25 from the polynucleotide encoding HTMPN.

A "deletion" refers to a change in the amino acid or nucleotide sequence that results in the absence of one or more amino acid residues or nucleotides.

The term "derivative" refers to the chemical modification of a polypeptide sequence, or a polynucleotide sequence. Chemical modifications of a polynucleotide
30 sequence can include, for example, replacement of hydrogen by an alkyl, acyl, or amino group. A derivative polynucleotide encodes a polypeptide which retains at least one biological or immunological function of the natural molecule. A derivative polypeptide is

one modified by glycosylation, pegylation, or any similar process that retains at least one biological or immunological function of the polypeptide from which it was derived.

The term "similarity" refers to a degree of complementarity. There may be partial similarity or complete similarity. The word "identity" may substitute for the word
5 "similarity." A partially complementary sequence that at least partially inhibits an identical sequence from hybridizing to a target nucleic acid is referred to as "substantially similar." The inhibition of hybridization of the completely complementary sequence to the target sequence may be examined using a hybridization assay (Southern or northern blot, solution hybridization, and the like) under conditions of reduced stringency. A
10 substantially similar sequence or hybridization probe will compete for and inhibit the binding of a completely similar (identical) sequence to the target sequence under conditions of reduced stringency. This is not to say that conditions of reduced stringency are such that non-specific binding is permitted, as reduced stringency conditions require that the binding of two sequences to one another be a specific (i.e., a selective) interaction.
15 The absence of non-specific binding may be tested by the use of a second target sequence which lacks even a partial degree of complementarity (e.g., less than about 30% similarity or identity). In the absence of non-specific binding, the substantially similar sequence or probe will not hybridize to the second non-complementary target sequence.

The phrases "percent identity" or "% identity" refer to the percentage of sequence
20 similarity found in a comparison of two or more amino acid or nucleic acid sequences. Percent identity can be determined electronically, e.g., by using the MEGALIGN program (DNASTAR, Madison WI) which creates alignments between two or more sequences according to methods selected by the user, e.g., the clustal method. (See, e.g., Higgins, D.G. and P.M. Sharp (1988) Gene 73:237-244.) The clustal algorithm groups sequences
25 into clusters by examining the distances between all pairs. The clusters are aligned pairwise and then in groups. The percentage similarity between two amino acid sequences, e.g., sequence A and sequence B, is calculated by dividing the length of sequence A, minus the number of gap residues in sequence A, minus the number of gap residues in sequence B, into the sum of the residue matches between sequence A and
30 sequence B, times one hundred. Gaps of low or of no similarity between the two amino acid sequences are not included in determining percentage similarity. Percent identity between nucleic acid sequences can also be counted or calculated by other methods known

in the art, e.g., the Jotun Hein method. (See, e.g., Hein, J. (1990) *Methods Enzymol.* 183:626-645.) Identity between sequences can also be determined by other methods known in the art, e.g., by varying hybridization conditions.

“Human artificial chromosomes” (HACs) are linear microchromosomes which
5 may contain DNA sequences of about 6 kb to 10 Mb in size, and which contain all of the elements required for stable mitotic chromosome segregation and maintenance.

The term “humanized antibody” refers to antibody molecules in which the amino acid sequence in the non-antigen binding regions has been altered so that the antibody more closely resembles a human antibody, and still retains its original binding ability.

10 “Hybridization” refers to any process by which a strand of nucleic acid binds with a complementary strand through base pairing.

The term “hybridization complex” refers to a complex formed between two nucleic acid sequences by virtue of the formation of hydrogen bonds between complementary bases. A hybridization complex may be formed in solution (e.g., C_{0t} or R_{0t} analysis) or
15 formed between one nucleic acid sequence present in solution and another nucleic acid sequence immobilized on a solid support (e.g., paper, membranes, filters, chips, pins or glass slides, or any other appropriate substrate to which cells or their nucleic acids have been fixed).

The words “insertion” or “addition” refer to changes in an amino acid or nucleotide
20 sequence resulting in the addition of one or more amino acid residues or nucleotides, respectively, to the sequence found in the naturally occurring molecule.

“Immune response” can refer to conditions associated with inflammation, trauma, immune disorders, or infectious or genetic disease, etc. These conditions can be characterized by expression of various factors, e.g., cytokines, chemokines, and other
25 signaling molecules, which may affect cellular and systemic defense systems.

The term “microarray” refers to an arrangement of distinct polynucleotides on a substrate.

The terms “element” or “array element” in a microarray context, refer to hybridizable polynucleotides arranged on the surface of a substrate.

30 The term “modulate” refers to a change in the activity of HTMPN. For example, modulation may cause an increase or a decrease in protein activity, binding characteristics, or any other biological, functional, or immunological properties of HTMPN.

The phrases "nucleic acid" or "nucleic acid sequence" refer to a nucleotide, oligonucleotide, polynucleotide, or any fragment thereof. These phrases also refer to DNA or RNA of genomic or synthetic origin which may be single-stranded or double-stranded and may represent the sense or the antisense strand, to peptide nucleic acid (PNA), or to
5 any DNA-like or RNA-like material. In this context, "fragments" refers to those nucleic acid sequences which, when translated, would produce polypeptides retaining some functional characteristic, e.g., antigenicity, or structural domain characteristic, e.g., ATP-binding site, of the full-length polypeptide.

The terms "operably associated" or "operably linked" refer to functionally related
10 nucleic acid sequences. A promoter is operably associated or operably linked with a coding sequence if the promoter controls the translation of the encoded polypeptide. While operably associated or operably linked nucleic acid sequences can be contiguous and in the same reading frame, certain genetic elements, e.g., repressor genes, are not contiguously linked to the sequence encoding the polypeptide but still bind to operator
15 sequences that control expression of the polypeptide.

The term "oligonucleotide" refers to a nucleic acid sequence of at least about 6 nucleotides to 60 nucleotides, preferably about 15 to 30 nucleotides, and most preferably about 20 to 25 nucleotides, which can be used in PCR amplification or in a hybridization assay or microarray. "Oligonucleotide" is substantially equivalent to the terms
20 "amplimer," "primer," "oligomer," and "probe," as these terms are commonly defined in the art.

"Peptide nucleic acid" (PNA) refers to an antisense molecule or anti-gene agent which comprises an oligonucleotide of at least about 5 nucleotides in length linked to a peptide backbone of amino acid residues ending in lysine. The terminal lysine confers
25 solubility to the composition. PNAs preferentially bind complementary single stranded DNA or RNA and stop transcript elongation, and may be pegylated to extend their lifespan in the cell.

The term "sample" is used in its broadest sense. A sample suspected of containing nucleic acids encoding HTMPN, or fragments thereof, or HTMPN itself, may comprise a
30 bodily fluid; an extract from a cell, chromosome, organelle, or membrane isolated from a cell; a cell; genomic DNA, RNA, or cDNA, in solution or bound to a substrate; a tissue; a tissue print; etc.

The terms "specific binding" or "specifically binding" refer to that interaction between a protein or peptide and an agonist, an antibody, or an antagonist. The interaction is dependent upon the presence of a particular structure of the protein, e.g., the antigenic determinant or epitope, recognized by the binding molecule. For example, if an antibody
5 is specific for epitope "A," the presence of a polypeptide containing the epitope A, or the presence of free unlabeled A, in a reaction containing free labeled A and the antibody will reduce the amount of labeled A that binds to the antibody.

The term "stringent conditions" refers to conditions which permit hybridization between polynucleotides and the claimed polynucleotides. Stringent conditions can be
10 defined by salt concentration, the concentration of organic solvent, e.g., formamide, temperature, and other conditions well known in the art. In particular, stringency can be increased by reducing the concentration of salt, increasing the concentration of formamide, or raising the hybridization temperature.

The term "substantially purified" refers to nucleic acid or amino acid sequences
15 that are removed from their natural environment and are isolated or separated, and are at least about 60% free, preferably about 75% free, and most preferably about 90% free from other components with which they are naturally associated.

A "substitution" refers to the replacement of one or more amino acids or nucleotides by different amino acids or nucleotides, respectively.

20 "Substrate" refers to any suitable rigid or semi-rigid support including membranes, filters, chips, slides, wafers, fibers, magnetic or nonmagnetic beads, gels, tubing, plates, polymers, microparticles and capillaries. The substrate can have a variety of surface forms, such as wells, trenches, pins, channels and pores, to which polynucleotides or polypeptides are bound.

25 "Transformation" describes a process by which exogenous DNA enters and changes a recipient cell. Transformation may occur under natural or artificial conditions according to various methods well known in the art, and may rely on any known method for the insertion of foreign nucleic acid sequences into a prokaryotic or eukaryotic host cell. The method for transformation is selected based on the type of host cell being
30 transformed and may include, but is not limited to, viral infection, electroporation, heat shock, lipofection, and particle bombardment. The term "transformed" cells includes stably transformed cells in which the inserted DNA is capable of replication either as an

autonomously replicating plasmid or as part of the host chromosome, as well as transiently transformed cells which express the inserted DNA or RNA for limited periods of time.

A "variant" of HTMPN polypeptides refers to an amino acid sequence that is altered by one or more amino acid residues. The variant may have "conservative" changes, wherein a substituted amino acid has similar structural or chemical properties (e.g., replacement of leucine with isoleucine). More rarely, a variant may have "nonconservative" changes (e.g., replacement of glycine with tryptophan). Analogous minor variations may also include amino acid deletions or insertions, or both. Guidance in determining which amino acid residues may be substituted, inserted, or deleted without abolishing biological or immunological activity may be found using computer programs well known in the art, for example, LASERGENE software (DNASTAR).

The term "variant," when used in the context of a polynucleotide sequence, may encompass a polynucleotide sequence related to HTMPN. This definition may also include, for example, "allelic" (as defined above), "splice," "species," or "polymorphic" variants. A splice variant may have significant identity to a reference molecule, but will generally have a greater or lesser number of polynucleotides due to alternate splicing of exons during mRNA processing. The corresponding polypeptide may possess additional functional domains or an absence of domains. Species variants are polynucleotide sequences that vary from one species to another. The resulting polypeptides generally will have significant amino acid identity relative to each other. A polymorphic variant is a variation in the polynucleotide sequence of a particular gene between individuals of a given species. Polymorphic variants also may encompass "single nucleotide polymorphisms" (SNPs) in which the polynucleotide sequence varies by one base. The presence of SNPs may be indicative of, for example, a certain population, a disease state, or a propensity for a disease state.

THE INVENTION

The invention is based on the discovery of new human transmembrane proteins (HTMPN), the polynucleotides encoding HTMPN, and the use of these compositions for the diagnosis, treatment, or prevention of immune, reproductive, smooth muscle, neurological, gastrointestinal, developmental, and cell proliferative disorders.

Table 1 lists the Incyte Clones used to derive full length nucleotide sequences encoding HTMPN. Columns 1 and 2 show the sequence identification numbers (SEQ ID

NOs) of the amino acid and nucleic acid sequences, respectively. Column 3 shows the Clone ID of the Incyte Clone in which nucleic acids encoding each HTMPN were identified, and column 4, the cDNA libraries from which these clones were isolated. Column 5 shows Incyte clones, their corresponding cDNA libraries, and shotgun
 5 sequences. The clones and shotgun sequences are part of the consensus nucleotide sequence of each HTMPN and are useful as fragments in hybridization technologies.

The columns of Table 2 show various properties of the polypeptides of the invention: column 1 references the SEQ ID NO; column 2 shows the number of amino acid residues in each polypeptide; column 3, potential phosphorylation sites; column 4,
 10 potential glycosylation sites; column 5, the amino acid residues comprising signature sequences and motifs; column 6, the identity of each protein; and column 7, analytical methods used to identify each protein through sequence homology and protein motifs. Hidden Markov Model analysis indicates the presence of one or more potential transmembrane motifs in each of SEQ ID NO:63, SEQ ID NO:64, SEQ ID NO: 66, SEQ
 15 ID NO:67, SEQ ID NO:68, SEQ ID NO:69, SEQ ID NO:70, SEQ ID NO:71, SEQ ID NO:72, SEQ ID NO:73, SEQ ID NO:74, SEQ ID NO: 75, SEQ ID NO:76, SEQ ID NO:77, and SEQ ID NO: 79; as well as the presence of one or more potential signal peptide motifs in each of SEQ ID NO:63, SEQ ID NO:64, SEQ ID NO:66, SEQ ID NO:67, SEQ ID NO:71, SEQ ID NO:72, SEQ ID NO:75, SEQ ID NO:77, and SEQ ID
 20 NO:79.

Motifs analysis indicates the presence of a potential ATP/GTP binding site in SEQ ID NO:68, a potential calcium-binding site also in SEQ ID NO:68, a potential leucine zipper gene regulatory motif in each of SEQ ID NO:68 and SEQ ID NO:73; and a potential microbody (single-membraned organelle) targeting signal site in SEQ ID NO:78.
 25 BLOCKS analysis indicates the presence of two potential PMP-22 integral membrane glycoprotein motifs and a trehalase motif, all in SEQ ID NO:77, as well as a potential protein-splicing motif in SEQ ID NO:66. PRINTS analysis indicates the presence of a potential G-protein coupled receptor motif in SEQ ID NO:79.

The columns of Table 3 show the tissue-specificity and diseases, disorders, or
 30 conditions associated with nucleotide sequences encoding HTMPN. The first column of Table 3 lists the nucleotide sequence identifiers. The second column lists tissue categories which express HTMPN as a fraction of total tissue categories expressing HTMPN. The

third column lists the diseases, disorders, or conditions associated with those tissues expressing HTMPN. The fourth column lists the vectors used to subclone the cDNA library. Of particular note is the expression of HTMPN in tissue involved in inflammation and the immune response and with cell proliferative conditions including cancer, and in
5 reproductive, gastrointestinal, fetal, smooth muscle, cardiovascular, urologic, endocrine, developmental, and nervous tissue.

The following fragments of the nucleotide sequences encoding HTMPN are useful in hybridization or amplification technologies to identify SEQ ID NO:121-158 and to distinguish between SEQ ID NO:121-158 and related polynucleotide sequences. The
10 useful fragments are the fragment of SEQ ID NO:121 from about nucleotide 151 to about nucleotide 189; the fragment of SEQ ID NO:122 from about nucleotide 280 to about nucleotide 318; the fragment of SEQ ID NO:123 from about nucleotide 505 to about nucleotide 558; the fragments of SEQ ID NO:124 from about nucleotide 1 to about nucleotide 21 and from about nucleotide 694 to about nucleotide 720; the fragment of SEQ
15 ID NO:125 from about nucleotide 331 to about nucleotide 378; the fragment of SEQ ID NO:126 from about nucleotide 1012 to about nucleotide 1047; the fragment of SEQ ID NO:127 from about nucleotide 1070 to about nucleotide 1106; the fragment of SEQ ID NO:128 from about nucleotide 133 to about nucleotide 186; the fragment of SEQ ID NO:129 from about nucleotide 432 to about nucleotide 482; the fragments of SEQ ID
20 NO:130 from about nucleotide 1745 to about nucleotide 1795 and from about nucleotide 1910 to about nucleotide 1979; the fragment of SEQ ID NO:131 from about nucleotide 322 to about nucleotide 375; the fragment of SEQ ID NO:132 from about nucleotide 147 to about nucleotide 203; the fragment of SEQ ID NO:133 from about nucleotide 557 to about nucleotide 613; the fragment of SEQ ID NO:134 from about nucleotide 509 to about
25 nucleotide 595; the fragment of SEQ ID NO:135 from about nucleotide 808 to about nucleotide 848; the fragment of SEQ ID NO:136 from about nucleotide 216 to about nucleotide 260; the fragment of SEQ ID NO:137 from about nucleotide 132 to about nucleotide 188; the fragment of SEQ ID NO:138 from about nucleotide 231 to about nucleotide 278; the fragment of SEQ ID NO:139 from about nucleotide 303 to about
30 nucleotide 350; the fragment of SEQ ID NO:140 from about nucleotide 507 to about nucleotide 550; the fragment of SEQ ID NO:141 from about nucleotide 433 to about nucleotide 477; the fragment of SEQ ID NO:142 from about nucleotide 266 to about

nucleotide 314; the fragment of SEQ ID NO:143 from about nucleotide 3 to about nucleotide 48; the fragment of SEQ ID NO:144 from about nucleotide 76 to about nucleotide 122; the fragment of SEQ ID NO:145 from about nucleotide 93 to about nucleotide 139; the fragment of SEQ ID NO:146 from about nucleotide 241 to about nucleotide 286; the
5 fragment of SEQ ID NO:147 from about nucleotide 43 to about nucleotide 89; the fragment of SEQ ID NO:148 from about nucleotide 219 to about nucleotide 265; the fragment of SEQ ID NO:149 from about nucleotide 619 to about nucleotide 663; the fragment of SEQ ID NO:150 from about nucleotide 25 to about nucleotide 69; the fragment of SEQ ID NO:151 from about nucleotide 175 to about nucleotide 221; the
10 fragment of SEQ ID NO:152 from about nucleotide 94 to about nucleotide 138; the fragment of SEQ ID NO:153 from about nucleotide 46 to about nucleotide 90; the fragment of SEQ ID NO:154 from about nucleotide 1081 to about nucleotide 1127; the fragment of SEQ ID NO:155 from about nucleotide 31 to about nucleotide 77; the fragment of SEQ ID NO:156 from about nucleotide 157 to about nucleotide 201; the
15 fragment of SEQ ID NO:157 from about nucleotide 216 to about nucleotide 259; and the fragment of SEQ ID NO:158 from about nucleotide 517 to about nucleotide 561. The polypeptides encoded by these fragments may be useful, for example, as antigenic polypeptides.

The invention also encompasses HTMPN variants. A preferred HTMPN variant is
20 one which has at least about 80%, more preferably at least about 90%, and most preferably at least about 95% amino acid sequence identity to the HTMPN amino acid sequence, and which contains at least one functional or structural characteristic of HTMPN.

The invention also encompasses polynucleotides which encode HTMPN. In a particular embodiment, the invention encompasses a polynucleotide sequence comprising
25 a sequence selected from the group consisting of SEQ ID NO:80-158, which encodes HTMPN.

The invention also encompasses a variant of a polynucleotide sequence encoding HTMPN. In particular, such a variant polynucleotide sequence will have at least about 80%, more preferably at least about 90%, and most preferably at least about 95%
30 polynucleotide sequence identity to the polynucleotide sequence encoding HTMPN. A particular aspect of the invention encompasses a variant of a polynucleotide sequence comprising a sequence selected from the group consisting of SEQ ID NO:80-158 which

has at least about 80%, more preferably at least about 90%, and most preferably at least about 95% polynucleotide sequence identity to a nucleic acid sequence selected from the group consisting of SEQ ID NO:80-158. Any one of the polynucleotide variants described above can encode an amino acid sequence which contains at least one functional or
5 structural characteristic of HTMPN.

It will be appreciated by those skilled in the art that as a result of the degeneracy of the genetic code, a multitude of polynucleotide sequences encoding HTMPN, some bearing minimal similarity to the polynucleotide sequences of any known and naturally occurring gene, may be produced. Thus, the invention contemplates each and every
10 possible variation of polynucleotide sequence that could be made by selecting combinations based on possible codon choices. These combinations are made in accordance with the standard triplet genetic code as applied to the polynucleotide sequence of naturally occurring HTMPN, and all such variations are to be considered as being specifically disclosed.

15 Although nucleotide sequences which encode HTMPN and its variants are preferably capable of hybridizing to the nucleotide sequence of the naturally occurring HTMPN under appropriately selected conditions of stringency, it may be advantageous to produce nucleotide sequences encoding HTMPN or its derivatives possessing a substantially different codon usage, e.g., inclusion of non-naturally occurring codons.
20 Codons may be selected to increase the rate at which expression of the peptide occurs in a particular prokaryotic or eukaryotic host in accordance with the frequency with which particular codons are utilized by the host. Other reasons for substantially altering the nucleotide sequence encoding HTMPN and its derivatives without altering the encoded amino acid sequences include the production of RNA transcripts having more desirable
25 properties, such as a greater half-life, than transcripts produced from the naturally occurring sequence.

The invention also encompasses production of DNA sequences which encode HTMPN and HTMPN derivatives, or fragments thereof, entirely by synthetic chemistry. After production, the synthetic sequence may be inserted into any of the many available
30 expression vectors and cell systems using reagents well known in the art. Moreover, synthetic chemistry may be used to introduce mutations into a sequence encoding HTMPN or any fragment thereof.

Also encompassed by the invention are polynucleotide sequences that are capable of hybridizing to the claimed polynucleotide sequences, and, in particular, to those shown in SEQ ID NO:80-158 and fragments thereof under various conditions of stringency. (See, e.g., Wahl, G.M. and S.L. Berger (1987) *Methods Enzymol.* 152:399-407; Kimmel, A.R. 5 (1987) *Methods Enzymol.* 152:507-511.) For example, stringent salt concentration will ordinarily be less than about 750 mM NaCl and 75 mM trisodium citrate, preferably less than about 500 mM NaCl and 50 mM trisodium citrate, and most preferably less than about 250 mM NaCl and 25 mM trisodium citrate. Low stringency hybridization can be obtained in the absence of organic solvent, e.g., formamide, while high stringency 10 hybridization can be obtained in the presence of at least about 35% formamide, and most preferably at least about 50% formamide. Stringent temperature conditions will ordinarily include temperatures of at least about 30°C, more preferably of at least about 37°C, and most preferably of at least about 42°C. Varying additional parameters, such as hybridization time, the concentration of detergent, e.g., sodium dodecyl sulfate (SDS), and 15 the inclusion or exclusion of carrier DNA, are well known to those skilled in the art. Various levels of stringency are accomplished by combining these various conditions as needed. In a preferred embodiment, hybridization will occur at 30°C in 750 mM NaCl, 75 mM trisodium citrate, and 1% SDS. In a more preferred embodiment, hybridization will occur at 37°C in 500 mM NaCl, 50 mM trisodium citrate, 1% SDS, 35% formamide, and 20 100 µg/ml denatured salmon sperm DNA (ssDNA). In a most preferred embodiment, hybridization will occur at 42°C in 250 mM NaCl, 25 mM trisodium citrate, 1% SDS, 50 % formamide, and 200 µg/ml ssDNA. Useful variations on these conditions will be readily apparent to those skilled in the art.

The washing steps which follow hybridization can also vary in stringency. Wash 25 stringency conditions can be defined by salt concentration and by temperature. As above, wash stringency can be increased by decreasing salt concentration or by increasing temperature. For example, stringent salt concentration for the wash steps will preferably be less than about 30 mM NaCl and 3 mM trisodium citrate, and most preferably less than about 15 mM NaCl and 1.5 mM trisodium citrate. Stringent temperature conditions for the 30 wash steps will ordinarily include temperature of at least about 25°C, more preferably of at least about 42°C, and most preferably of at least about 68°C. In a preferred embodiment, wash steps will occur at 25°C in 30 mM NaCl, 3 mM trisodium citrate, and 0.1% SDS. In

a more preferred embodiment, wash steps will occur at 42°C in 15 mM NaCl, 1.5 mM trisodium citrate, and 0.1% SDS. In a most preferred embodiment, wash steps will occur at 68°C in 15 mM NaCl, 1.5 mM trisodium citrate, and 0.1% SDS. Additional variations on these conditions will be readily apparent to those skilled in the art.

5 Methods for DNA sequencing are well known in the art and may be used to practice any of the embodiments of the invention. The methods may employ such enzymes as the Klenow fragment of DNA polymerase I, SEQUENASE (US Biochemical, Cleveland OH), Taq polymerase (Perkin-Elmer), thermostable T7 polymerase (Amersham Pharmacia Biotech, Piscataway NJ), or combinations of polymerases and proofreading
10 exonucleases such as those found in the ELONGASE amplification system (Life Technologies, Gaithersburg MD). Preferably, sequence preparation is automated with machines such as the Hamilton MICROLAB 2200 (Hamilton, Reno NV), Peltier Thermal Cycler 200 (PTC200; MJ Research, Watertown MA) and the ABI CATALYST 800 (Perkin-Elmer). Sequencing is then carried out using either ABI 373 or 377 DNA
15 sequencing systems (Perkin-Elmer) or the MEGABACE 1000 DNA sequencing system (Molecular Dynamics, Sunnyvale CA). The resulting sequences are analyzed using a variety of algorithms which are well known in the art. (See, e.g., Ausubel, F.M. (1997) Short Protocols in Molecular Biology, John Wiley & Sons, New York NY, unit 7.7; Meyers, R.A. (1995) Molecular Biology and Biotechnology, Wiley VCH, New York NY,
20 pp. 856-853.)

The nucleic acid sequences encoding HTMPN may be extended utilizing a partial nucleotide sequence and employing various PCR-based methods known in the art to detect upstream sequences, such as promoters and regulatory elements. For example, one method which may be employed, restriction-site PCR, uses universal and nested primers to
25 amplify unknown sequence from genomic DNA within a cloning vector. (See, e.g., Sarkar, G. (1993) PCR Methods Applic. 2:318-322.) Another method, inverse PCR, uses primers that extend in divergent directions to amplify unknown sequence from a circularized template. The template is derived from restriction fragments comprising a known genomic locus and surrounding sequences. (See, e.g., Triglia, T. et al. (1988)
30 Nucleic Acids Res. 16:8186.) A third method, capture PCR, involves PCR amplification of DNA fragments adjacent to known sequences in human and yeast artificial chromosome DNA. (See, e.g., Lagerstrom, M. et al. (1991) PCR Methods Applic. 1:111-119.) In this

method, multiple restriction enzyme digestions and ligations may be used to insert an engineered double-stranded sequence into a region of unknown sequence before performing PCR. Other methods which may be used to retrieve unknown sequences are known in the art. (See, e.g., Parker, J.D. et al. (1991) *Nucleic Acids Res.* 19:3055-306).

5 Additionally, one may use PCR, nested primers, and PROMOTERFINDER libraries (Clontech, Palo Alto CA) to walk genomic DNA. This procedure avoids the need to screen libraries and is useful in finding intron/exon junctions. For all PCR-based methods, primers may be designed using commercially available software, such as OLIGO 4.06 Primer Analysis software (National Biosciences, Plymouth MN) or another appropriate

10 program, to be about 22 to 30 nucleotides in length, to have a GC content of about 50% or more, and to anneal to the template at temperatures of about 68°C to 72°C.

When screening for full-length cDNAs, it is preferable to use libraries that have been size-selected to include larger cDNAs. In addition, random-primed libraries, which often include sequences containing the 5' regions of genes, are preferable for situations in

15 which an oligo d(T) library does not yield a full-length cDNA. Genomic libraries may be useful for extension of sequence into 5' non-transcribed regulatory regions.

Capillary electrophoresis systems which are commercially available may be used to analyze the size or confirm the nucleotide sequence of sequencing or PCR products. In particular, capillary sequencing may employ flowable polymers for electrophoretic

20 separation, four different nucleotide-specific, laser-stimulated fluorescent dyes, and a charge coupled device camera for detection of the emitted wavelengths. Output/light intensity may be converted to electrical signal using appropriate software (e.g., GENOTYPER and SEQUENCE NAVIGATOR, Perkin-Elmer), and the entire process from loading of samples to computer analysis and electronic data display may be computer

25 controlled. Capillary electrophoresis is especially preferable for sequencing small DNA fragments which may be present in limited amounts in a particular sample.

In another embodiment of the invention, polynucleotide sequences or fragments thereof which encode HTMPN may be cloned in recombinant DNA molecules that direct expression of HTMPN, or fragments or functional equivalents thereof, in appropriate host

30 cells. Due to the inherent degeneracy of the genetic code, other DNA sequences which encode substantially the same or a functionally equivalent amino acid sequence may be produced and used to express HTMPN.

The nucleotide sequences of the present invention can be engineered using methods generally known in the art in order to alter HTMPN-encoding sequences for a variety of purposes including, but not limited to, modification of the cloning, processing, and/or expression of the gene product. DNA shuffling by random fragmentation and PCR
5 reassembly of gene fragments and synthetic oligonucleotides may be used to engineer the nucleotide sequences. For example, oligonucleotide-mediated site-directed mutagenesis may be used to introduce mutations that create new restriction sites, alter glycosylation patterns, change codon preference, produce splice variants, and so forth.

In another embodiment, sequences encoding HTMPN may be synthesized, in
10 whole or in part, using chemical methods well known in the art. (See, e.g., Caruthers, M.H. et al. (1980) Nucl. Acids Res. Symp. Ser. 215-223, and Horn, T. et al. (1980) Nucl. Acids Res. Symp. Ser. 225-232.) Alternatively, HTMPN itself or a fragment thereof may be synthesized using chemical methods. For example, peptide synthesis can be performed using various solid-phase techniques. (See, e.g., Roberge, J.Y. et al. (1995) Science
15 269:202-204.) Automated synthesis may be achieved using the ABI 431A Peptide Synthesizer (Perkin-Elmer). Additionally, the amino acid sequence of HTMPN, or any part thereof, may be altered during direct synthesis and/or combined with sequences from other proteins, or any part thereof, to produce a variant polypeptide.

The peptide may be substantially purified by preparative high performance liquid
20 chromatography. (See, e.g., Chiez, R.M. and F.Z. Regnier (1990) Methods Enzymol. 182:392-421.) The composition of the synthetic peptides may be confirmed by amino acid analysis or by sequencing. (See, e.g., Creighton, T. (1984) Proteins, Structures and Molecular Properties, WH Freeman, New York NY.)

In order to express a biologically active HTMPN, the nucleotide sequences
25 encoding HTMPN or derivatives thereof may be inserted into an appropriate expression vector, i.e., a vector which contains the necessary elements for transcriptional and translational control of the inserted coding sequence in a suitable host. These elements include regulatory sequences, such as enhancers, constitutive and inducible promoters, and 5' and 3' untranslated regions in the vector and in polynucleotide sequences encoding
30 HTMPN. Such elements may vary in their strength and specificity. Specific initiation signals may also be used to achieve more efficient translation of sequences encoding HTMPN. Such signals include the ATG initiation codon and adjacent sequences, e.g. the

Kozak sequence. In cases where sequences encoding HTMPN and its initiation codon and upstream regulatory sequences are inserted into the appropriate expression vector, no additional transcriptional or translational control signals may be needed. However, in cases where only coding sequence, or a fragment thereof, is inserted, exogenous
5 translational control signals including an in-frame ATG initiation codon should be provided by the vector. Exogenous translational elements and initiation codons may be of various origins, both natural and synthetic. The efficiency of expression may be enhanced by the inclusion of enhancers appropriate for the particular host cell system used. (See, e.g., Scharf, D. et al. (1994) *Results Probl. Cell Differ.* 20:125-162.)

10 Methods which are well known to those skilled in the art may be used to construct expression vectors containing sequences encoding HTMPN and appropriate transcriptional and translational control elements. These methods include in vitro recombinant DNA techniques, synthetic techniques, and in vivo genetic recombination. (See, e.g., Sambrook, J. et al. (1989) Molecular Cloning, A Laboratory Manual, Cold Spring Harbor Press, Plainview NY, ch. 4, 8, and 16-17; Ausubel, F.M. et al. (1995) Current Protocols in
15 Molecular Biology, John Wiley & Sons, New York NY, ch. 9, 13, and 16.)

A variety of expression vector/host systems may be utilized to contain and express sequences encoding HTMPN. These include, but are not limited to, microorganisms such as bacteria transformed with recombinant bacteriophage, plasmid, or cosmid DNA
20 expression vectors; yeast transformed with yeast expression vectors; insect cell systems infected with viral expression vectors (e.g., baculovirus); plant cell systems transformed with viral expression vectors (e.g., cauliflower mosaic virus, CaMV, or tobacco mosaic virus, TMV) or with bacterial expression vectors (e.g., Ti or pBR322 plasmids); or animal cell systems. The invention is not limited by the host cell employed.

25 In bacterial systems, a number of cloning and expression vectors may be selected depending upon the use intended for polynucleotide sequences encoding HTMPN. For example, routine cloning, subcloning, and propagation of polynucleotide sequences encoding HTMPN can be achieved using a multifunctional E. coli vector such as PBLUESCRIPT (Stratagene, La Jolla CA) or pSPORT1 plasmid (Life Technologies).
30 Ligation of sequences encoding HTMPN into the vector's multiple cloning site disrupts the *lacZ* gene, allowing a colorimetric screening procedure for identification of transformed bacteria containing recombinant molecules. In addition, these vectors may be

useful for in vitro transcription, dideoxy sequencing, single strand rescue with helper phage, and creation of nested deletions in the cloned sequence. (See, e.g., Van Heeke, G. and S.M. Schuster (1989) J. Biol. Chem. 264:5503-5509.) When large quantities of HTMPN are needed, e.g. for the production of antibodies, vectors which direct high level expression of HTMPN may be used. For example, vectors containing the strong, inducible T5 or T7 bacteriophage promoter may be used.

Yeast expression systems may be used for production of HTMPN. A number of vectors containing constitutive or inducible promoters, such as alpha factor, alcohol oxidase, and PGH, may be used in the yeast Saccharomyces cerevisiae or Pichia pastoris. In addition, such vectors direct either the secretion or intracellular retention of expressed proteins and enable integration of foreign sequences into the host genome for stable propagation. (See, e.g., Ausubel, 1995, supra; Grant et al. (1987) Methods Enzymol. 153:516-54; and Scorer, C. A. et al. (1994) Bio/Technology 12:181-184.)

Plant systems may also be used for expression of HTMPN. Transcription of sequences encoding HTMPN may be driven viral promoters, e.g., the 35S and 19S promoters of CaMV used alone or in combination with the omega leader sequence from TMV (Takamatsu, N. (1987) EMBO J. 6:307-311). Alternatively, plant promoters such as the small subunit of RUBISCO or heat shock promoters may be used. (See, e.g., Coruzzi, G. et al. (1984) EMBO J. 3:1671-1680; Broglie, R. et al. (1984) Science 224:838-843; and Winter, J. et al. (1991) Results Probl. Cell Differ. 17:85-105.) These constructs can be introduced into plant cells by direct DNA transformation or pathogen-mediated transfection. (See, e.g., The McGraw Hill Yearbook of Science and Technology (1992) McGraw Hill, New York NY, pp. 191-196.)

In mammalian cells, a number of viral-based expression systems may be utilized. In cases where an adenovirus is used as an expression vector, sequences encoding HTMPN may be ligated into an adenovirus transcription/translation complex consisting of the late promoter and tripartite leader sequence. Insertion in a non-essential E1 or E3 region of the viral genome may be used to obtain infective virus which expresses HTMPN in host cells. (See, e.g., Logan, J. and T. Shenk (1984) Proc. Natl. Acad. Sci. 81:3655-3659.) In addition, transcription enhancers, such as the Rous sarcoma virus (RSV) enhancer, may be used to increase expression in mammalian host cells. SV40 or EBV-based vectors may also be used for high-level protein expression.

Human artificial chromosomes (HACs) may also be employed to deliver larger fragments of DNA than can be contained in and expressed from a plasmid. HACs of about 6 kb to 10 Mb are constructed and delivered via conventional delivery methods (liposomes, polycationic amino polymers, or vesicles) for therapeutic purposes. (See, e.g.,
5 Harrington, J.J. et al. (1997) Nat Genet. 15:345-355.)

For long term production of recombinant proteins in mammalian systems, stable expression of HTMPN in cell lines is preferred. For example, sequences encoding HTMPN can be transformed into cell lines using expression vectors which may contain viral origins of replication and/or endogenous expression elements and a selectable marker
10 gene on the same or on a separate vector. Following the introduction of the vector, cells may be allowed to grow for about 1 to 2 days in enriched media before being switched to selective media. The purpose of the selectable marker is to confer resistance to a selective agent, and its presence allows growth and recovery of cells which successfully express the introduced sequences. Resistant clones of stably transformed cells may be propagated
15 using tissue culture techniques appropriate to the cell type.

Any number of selection systems may be used to recover transformed cell lines. These include, but are not limited to, the herpes simplex virus thymidine kinase and adenine phosphoribosyltransferase genes, for use in *tk* or *apr* cells, respectively. (See, e.g., Wigler, M. et al. (1977) Cell 11:223-232; Lowy, I. et al. (1980) Cell 22:817-823.)
20 Also, antimetabolite, antibiotic, or herbicide resistance can be used as the basis for selection. For example, *dhfr* confers resistance to methotrexate; *neo* confers resistance to the aminoglycosides, neomycin and G-418; and *als* or *pat* confer resistance to chlorsulfuron and phosphinotricin acetyltransferase, respectively. (See, e.g., Wigler, M. et al. (1980) Proc. Natl. Acad. Sci. 77:3567-3570; Colbere-Garapin, F. et al. (1981) J. Mol.
25 Biol. 150:1-14.) Additional selectable genes have been described, e.g., *trpB* and *hisD*, which alter cellular requirements for metabolites. (See, e.g., Hartman, S.C. and R.C. Mulligan (1988) Proc. Natl. Acad. Sci. 85:8047-8051.) Visible markers, e.g., anthocyanins, green fluorescent proteins (GFP; Clontech), β glucuronidase and its substrate β -glucuronide, or luciferase and its substrate luciferin may be used. These
30 markers can be used not only to identify transformants, but also to quantify the amount of transient or stable protein expression attributable to a specific vector system. (See, e.g., Rhodes, C.A. (1995) Methods Mol. Biol. 55:121-131.)

Although the presence/absence of marker gene expression suggests that the gene of interest is also present, the presence and expression of the gene may need to be confirmed. For example, if the sequence encoding HTMPN is inserted within a marker gene sequence, transformed cells containing sequences encoding HTMPN can be identified by the absence
5 of marker gene function. Alternatively, a marker gene can be placed in tandem with a sequence encoding HTMPN under the control of a single promoter. Expression of the marker gene in response to induction or selection usually indicates expression of the tandem gene as well.

In general, host cells that contain the nucleic acid sequence encoding HTMPN and
10 that express HTMPN may be identified by a variety of procedures known to those of skill in the art. These procedures include, but are not limited to, DNA-DNA or DNA-RNA hybridizations, PCR amplification, and protein bioassay or immunoassay techniques which include membrane, solution, or chip based technologies for the detection and/or quantification of nucleic acid or protein sequences.

15 Immunological methods for detecting and measuring the expression of HTMPN using either specific polyclonal or monoclonal antibodies are known in the art. Examples of such techniques include enzyme-linked immunosorbent assays (ELISAs), radioimmunoassays (RIAs), and fluorescence activated cell sorting (FACS). A two-site, monoclonal-based immunoassay utilizing monoclonal antibodies reactive to two
20 non-interfering epitopes on HTMPN is preferred, but a competitive binding assay may be employed. These and other assays are well known in the art. (See, e.g., Hampton, R. et al. (1990) Serological Methods, a Laboratory Manual, APS Press, St Paul MN, Sect. IV; Coligan, J. E. et al. (1997) Current Protocols in Immunology, Greene Pub. Associates and Wiley-Interscience, New York NY; and Pound, J.D. (1998) Immunochemical Protocols,
25 Humana Press, Totowa NJ).

A wide variety of labels and conjugation techniques are known by those skilled in the art and may be used in various nucleic acid and amino acid assays. Means for producing labeled hybridization or PCR probes for detecting sequences related to polynucleotides encoding HTMPN include oligolabeling, nick translation, end-labeling, or
30 PCR amplification using a labeled nucleotide. Alternatively, the sequences encoding HTMPN, or any fragments thereof, may be cloned into a vector for the production of an mRNA probe. Such vectors are known in the art, are commercially available, and may be

used to synthesize RNA probes in vitro by addition of an appropriate RNA polymerase such as T7, T3, or SP6 and labeled nucleotides. These procedures may be conducted using a variety of commercially available kits, such as those provided by Amersham Pharmacia Biotech, Promega (Madison WI), and US Biochemical. Suitable reporter molecules or
5 labels which may be used for ease of detection include radionuclides, enzymes, fluorescent, chemiluminescent, or chromogenic agents, as well as substrates, cofactors, inhibitors, magnetic particles, and the like.

Host cells transformed with nucleotide sequences encoding HTMPN may be cultured under conditions suitable for the expression and recovery of the protein from cell
10 culture. The protein produced by a transformed cell may be secreted or retained intracellularly depending on the sequence and/or the vector used. As will be understood by those of skill in the art, expression vectors containing polynucleotides which encode HTMPN may be designed to contain signal sequences which direct secretion of HTMPN through a prokaryotic or eukaryotic cell membrane.

15 In addition, a host cell strain may be chosen for its ability to modulate expression of the inserted sequences or to process the expressed protein in the desired fashion. Such modifications of the polypeptide include, but are not limited to, acetylation, carboxylation, glycosylation, phosphorylation, lipidation, and acylation. Post-translational processing which cleaves a "prepro" form of the protein may also be used to specify protein targeting,
20 folding, and/or activity. Different host cells which have specific cellular machinery and characteristic mechanisms for post-translational activities (e.g., CHO, HeLa, MDCK, HEK293, and WI38), are available from the American Type Culture Collection (ATCC, Bethesda MD) and may be chosen to ensure the correct modification and processing of the foreign protein.

25 In another embodiment of the invention, natural, modified, or recombinant nucleic acid sequences encoding HTMPN may be ligated to a heterologous sequence resulting in translation of a fusion protein in any of the aforementioned host systems. For example, a chimeric HTMPN protein containing a heterologous moiety that can be recognized by a commercially available antibody may facilitate the screening of peptide libraries for
30 inhibitors of HTMPN activity. Heterologous protein and peptide moieties may also facilitate purification of fusion proteins using commercially available affinity matrices. Such moieties include, but are not limited to, glutathione S-transferase (GST), maltose

binding protein (MBP), thioredoxin (Trx), calmodulin binding peptide (CBP), 6-His, FLAG, *c-myc*, and hemagglutinin (HA). GST, MBP, Trx, CBP, and 6-His enable purification of their cognate fusion proteins on immobilized glutathione, maltose, phenylarsine oxide, calmodulin, and metal-chelate resins, respectively. FLAG, *c-myc*, and
5 hemagglutinin (HA) enable immunoaffinity purification of fusion proteins using commercially available monoclonal and polyclonal antibodies that specifically recognize these epitope tags. A fusion protein may also be engineered to contain a proteolytic cleavage site located between the HTMPN encoding sequence and the heterologous protein sequence, so that HTMPN may be cleaved away from the heterologous moiety
10 following purification. Methods for fusion protein expression and purification are discussed in Ausubel (1995, supra, ch 10). A variety of commercially available kits may also be used to facilitate expression and purification of fusion proteins.

In a further embodiment of the invention, synthesis of radiolabeled HTMPN may be achieved in vitro using the TNT rabbit reticulocyte lysate or wheat germ extract
15 systems (Promega). These systems couple transcription and translation of protein-coding sequences operably associated with the T7, T3, or SP6 promoters. Translation takes place in the presence of a radiolabeled amino acid precursor, preferably ³⁵S-methionine.

Fragments of HTMPN may be produced not only by recombinant production, but also by direct peptide synthesis using solid-phase techniques. (See, e.g., Creighton, supra,
20 pp. 55-60.) Protein synthesis may be performed by manual techniques or by automation. Automated synthesis may be achieved, for example, using the ABI 431A Peptide Synthesizer (Perkin-Elmer). Various fragments of HTMPN may be synthesized separately and then combined to produce the full length molecule.

THERAPEUTICS

25 Chemical and structural similarity, e.g., in the context of sequences and motifs, exists between regions of HTMPN and human transmembrane proteins. In addition, the expression of HTMPN is closely associated with tissue involved in inflammation and the immune response and with cell proliferative conditions including cancer, and in reproductive, gastrointestinal, fetal, smooth muscle, cardiovascular, developmental, and
30 nervous tissue. Therefore, HTMPN appears to play a role in immune, reproductive, smooth muscle, neurological, gastrointestinal, developmental, and cell proliferative disorders. In the treatment of immune, reproductive, smooth muscle, neurological,

gastrointestinal, developmental, and cell proliferative disorders associated with increased HTMPN expression or activity, it is desirable to decrease the expression or activity of HTMPN. In the treatment of the above conditions associated with decreased HTMPN expression or activity, it is desirable to increase the expression or activity of HTMPN.

5 Therefore, in one embodiment, HTMPN or a fragment or derivative thereof may be administered to a subject to treat or prevent a disorder associated with decreased expression or activity of HTMPN. Examples of such disorders include, but are not limited to, an immune disorder such as acquired immunodeficiency syndrome (AIDS), Addison's disease, adult respiratory distress syndrome, allergies, ankylosing spondylitis, amyloidosis, 10 anemia, asthma, atherosclerosis, autoimmune hemolytic anemia, autoimmune thyroiditis, autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED), bronchitis, cholecystitis, contact dermatitis, Crohn's disease, atopic dermatitis, dermatomyositis, diabetes mellitus, emphysema, episodic lymphopenia with lymphocytotoxins, erythroblastosis fetalis, erythema nodosum, atrophic gastritis, 15 glomerulonephritis, Goodpasture's syndrome, gout, Graves' disease, Hashimoto's thyroiditis, hypereosinophilia, irritable bowel syndrome, multiple sclerosis, myasthenia gravis, myocardial or pericardial inflammation, osteoarthritis, osteoporosis, pancreatitis, polymyositis, psoriasis, Reiter's syndrome, rheumatoid arthritis, scleroderma, Sjögren's syndrome, systemic anaphylaxis, systemic lupus erythematosus, systemic sclerosis, 20 thrombocytopenic purpura, ulcerative colitis, uveitis, Werner syndrome, complications of cancer, hemodialysis, and extracorporeal circulation, viral, bacterial, fungal, parasitic, protozoal, and helminthic infections, and trauma; a reproductive disorder such as a disorder of prolactin production; infertility, including tubal disease, ovulatory defects, and endometriosis; a disruption of the estrous cycle, a disruption of the menstrual cycle, 25 polycystic ovary syndrome, ovarian hyperstimulation syndrome, endometrial and ovarian tumors, uterine fibroids, autoimmune disorders, ectopic pregnancies, and teratogenesis; cancer of the breast, fibrocystic breast disease, and galactorrhea; disruptions of spermatogenesis, abnormal sperm physiology, cancer of the testis, cancer of the prostate, benign prostatic hyperplasia, prostatitis, Peyronie's disease, impotence, carcinoma of the 30 male breast, and gynecomastia; a smooth muscle disorder such as angina, anaphylactic shock, arrhythmias, asthma, cardiovascular shock, Cushing's syndrome, hypertension, hypoglycemia, myocardial infarction, migraine, and pheochromocytoma, and myopathies

including cardiomyopathy, encephalopathy, epilepsy, Kearns-Sayre syndrome, lactic acidosis, myoclonic disorder, and ophthalmoplegia; a neurological disorder such as epilepsy, ischemic cerebrovascular disease, stroke, cerebral neoplasms, Alzheimer's disease, Pick's disease, Huntington's disease, dementia, Parkinson's disease and other
5 extrapyramidal disorders, amyotrophic lateral sclerosis and other motor neuron disorders, progressive neural muscular atrophy, retinitis pigmentosa, hereditary ataxias, multiple sclerosis and other demyelinating diseases, bacterial and viral meningitis, brain abscess, subdural empyema, epidural abscess, suppurative intracranial thrombophlebitis, myelitis and radiculitis, viral central nervous system disease; prion diseases including kuru,
10 Creutzfeldt-Jakob disease, and Gerstmann-Straussler-Scheinker syndrome; fatal familial insomnia, nutritional and metabolic diseases of the nervous system, neurofibromatosis, tuberous sclerosis, cerebelloretinal hemangioblastomatosis, encephalotrigeminal syndrome, mental retardation and other developmental disorders of the central nervous system, cerebral palsy, neuroskeletal disorders, autonomic nervous system disorders,
15 cranial nerve disorders, spinal cord diseases, muscular dystrophy and other neuromuscular disorders, peripheral nervous system disorders, dermatomyositis and polymyositis; inherited, metabolic, endocrine, and toxic myopathies; myasthenia gravis, periodic paralysis; mental disorders including mood, anxiety, and schizophrenic disorders; akathisia, amnesia, catatonia, diabetic neuropathy, tardive dyskinesia, dystonias, paranoid
20 psychoses, postherpetic neuralgia, and Tourette's disorder; a gastrointestinal disorder such as dysphagia, peptic esophagitis, esophageal spasm, esophageal stricture, esophageal carcinoma, dyspepsia, indigestion, gastritis, gastric carcinoma, anorexia, nausea, emesis, gastroparesis, antral or pyloric edema, abdominal angina, pyrosis, gastroenteritis, intestinal obstruction, infections of the intestinal tract, peptic ulcer, cholelithiasis, cholecystitis,
25 cholestasis, pancreatitis, pancreatic carcinoma, biliary tract disease, hepatoma, infectious colitis, ulcerative colitis, ulcerative proctitis, Crohn's disease, Whipple's disease, Mallory-Weiss syndrome, colonic carcinoma, colonic obstruction, irritable bowel syndrome, short bowel syndrome, diarrhea, constipation, gastrointestinal hemorrhage, and acquired immunodeficiency syndrome (AIDS) enteropathy, cirrhosis, jaundice, cholestasis,
30 hereditary hyperbilirubinemia, hepatic encephalopathy, hepatorenal syndrome, hepatitis, hepatic steatosis, hemochromatosis, Wilson's disease, α_1 -antitrypsin deficiency, Reye's syndrome, primary sclerosing cholangitis, liver infarction, portal vein obstruction and

thrombosis, passive congestion, centrilobular necrosis, peliosis hepatis, hepatic vein thrombosis, veno-occlusive disease, preeclampsia, eclampsia, acute fatty liver of pregnancy, intrahepatic cholestasis of pregnancy, and hepatic tumors including nodular hyperplasias, adenomas, and carcinomas; a cell proliferative disorder such as actinic
5 keratosis, arteriosclerosis, atherosclerosis, bursitis, cirrhosis, hepatitis, mixed connective tissue disease (MCTD), myelofibrosis, paroxysmal nocturnal hemoglobinuria, polycythemia vera, psoriasis, primary thrombocythemia, and cancers including adenocarcinoma, leukemia, lymphoma, melanoma, myeloma, sarcoma, teratocarcinoma, and, in particular, cancers of the adrenal gland, bladder, bone, bone marrow, brain, breast,
10 cervix, gall bladder, ganglia, gastrointestinal tract, heart, kidney, liver, lung, muscle, ovary, pancreas, parathyroid, penis, prostate, salivary glands, skin, spleen, testis, thymus, thyroid, and uterus; and a developmental disorder including, but not limited to, those listed above.

In another embodiment, a vector capable of expressing HTMPN or a fragment or derivative thereof may be administered to a subject to treat or prevent a disorder associated
15 with decreased expression or activity of HTMPN including, but not limited to, those described above.

In a further embodiment, a pharmaceutical composition comprising a substantially purified HTMPN in conjunction with a suitable pharmaceutical carrier may be administered to a subject to treat or prevent a disorder associated with decreased
20 expression or activity of HTMPN including, but not limited to, those provided above.

In still another embodiment, an agonist which modulates the activity of HTMPN may be administered to a subject to treat or prevent a disorder associated with decreased expression or activity of HTMPN including, but not limited to, those listed above.

In a further embodiment, an antagonist of HTMPN may be administered to a
25 subject to treat or prevent a disorder associated with increased expression or activity of HTMPN. Examples of such disorders include, but are not limited to, those described above. In one aspect, an antibody which specifically binds HTMPN may be used directly as an antagonist or indirectly as a targeting or delivery mechanism for bringing a pharmaceutical agent to cells or tissue which express HTMPN.

30 In an additional embodiment, a vector expressing the complement of the polynucleotide encoding HTMPN may be administered to a subject to treat or prevent a disorder associated with increased expression or activity of HTMPN including, but not

limited to, those described above.

In other embodiments, any of the proteins, antagonists, antibodies, agonists, complementary sequences, or vectors of the invention may be administered in combination with other appropriate therapeutic agents. Selection of the appropriate agents for use in
5 combination therapy may be made by one of ordinary skill in the art, according to conventional pharmaceutical principles. The combination of therapeutic agents may act synergistically to effect the treatment or prevention of the various disorders described above. Using this approach, one may be able to achieve therapeutic efficacy with lower dosages of each agent, thus reducing the potential for adverse side effects.

10 An antagonist of HTMPN may be produced using methods which are generally known in the art. In particular, purified HTMPN may be used to produce antibodies or to screen libraries of pharmaceutical agents to identify those which specifically bind HTMPN. Antibodies to HTMPN may also be generated using methods that are well known in the art. Such antibodies may include, but are not limited to, polyclonal,
15 monoclonal, chimeric, and single chain antibodies, Fab fragments, and fragments produced by a Fab expression library. Neutralizing antibodies (i.e., those which inhibit dimer formation) are especially preferred for therapeutic use.

For the production of antibodies, various hosts including goats, rabbits, rats, mice, humans, and others may be immunized by injection with HTMPN or with any fragment or
20 oligopeptide thereof which has immunogenic properties. Depending on the host species, various adjuvants may be used to increase immunological response. Such adjuvants include, but are not limited to, Freund's, mineral gels such as aluminum hydroxide, and surface active substances such as lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, KLH, and dinitrophenol. Among adjuvants used in humans, BCG (bacilli
25 Calmette-Guerin) and Corynebacterium parvum are especially preferable.

It is preferred that the oligopeptides, peptides, or fragments used to induce antibodies to HTMPN have an amino acid sequence consisting of at least about 5 amino acids, and, more preferably, of at least about 10 amino acids. It is also preferable that these oligopeptides, peptides, or fragments are identical to a portion of the amino acid
30 sequence of the natural protein and contain the entire amino acid sequence of a small, naturally occurring molecule. Short stretches of HTMPN amino acids may be fused with those of another protein, such as KLH, and antibodies to the chimeric molecule may be

produced.

Monoclonal antibodies to HTMPN may be prepared using any technique which provides for the production of antibody molecules by continuous cell lines in culture.

These include, but are not limited to, the hybridoma technique, the human B-cell

5 hybridoma technique, and the EBV-hybridoma technique. (See, e.g., Kohler, G. et al. (1975) *Nature* 256:495-497; Kozbor, D. et al. (1985) *J. Immunol. Methods* 81:31-42; Cote, R.J. et al. (1983) *Proc. Natl. Acad. Sci.* 80:2026-2030; and Cole, S.P. et al. (1984) *Mol. Cell Biol.* 62:109-120.)

In addition, techniques developed for the production of "chimeric antibodies," such
10 as the splicing of mouse antibody genes to human antibody genes to obtain a molecule with appropriate antigen specificity and biological activity, can be used. (See, e.g., Morrison, S.L. et al. (1984) *Proc. Natl. Acad. Sci.* 81:6851-6855; Neuberger, M.S. et al. (1984) *Nature* 312:604-608; and Takeda, S. et al. (1985) *Nature* 314:452-454.)

Alternatively, techniques described for the production of single chain antibodies may be
15 adapted, using methods known in the art, to produce HTMPN-specific single chain antibodies. Antibodies with related specificity, but of distinct idiotypic composition, may be generated by chain shuffling from random combinatorial immunoglobulin libraries. (See, e.g., Burton D.R. (1991) *Proc. Natl. Acad. Sci.* 88:10134-10137.)

Antibodies may also be produced by inducing in vivo production in the
20 lymphocyte population or by screening immunoglobulin libraries or panels of highly specific binding reagents as disclosed in the literature. (See, e.g., Orlandi, R. et al. (1989) *Proc. Natl. Acad. Sci.* 86: 3833-3837; Winter, G. et al. (1991) *Nature* 349:293-299.)

Antibody fragments which contain specific binding sites for HTMPN may also be generated. For example, such fragments include, but are not limited to, F(ab')₂ fragments
25 produced by pepsin digestion of the antibody molecule and Fab fragments generated by reducing the disulfide bridges of the F(ab')₂ fragments. Alternatively, Fab expression libraries may be constructed to allow rapid and easy identification of monoclonal Fab fragments with the desired specificity. (See, e.g., Huse, W.D. et al. (1989) *Science* 246:1275-1281.)

30 Various immunoassays may be used for screening to identify antibodies having the desired specificity. Numerous protocols for competitive binding or immunoradiometric assays using either polyclonal or monoclonal antibodies with established specificities are

well known in the art. Such immunoassays typically involve the measurement of complex formation between HTMPN and its specific antibody. A two-site, monoclonal-based immunoassay utilizing monoclonal antibodies reactive to two non-interfering HTMPN epitopes is preferred, but a competitive binding assay may also be employed (Pound, 5 supra).

Various methods such as Scatchard analysis in conjunction with radioimmunoassay techniques may be used to assess the affinity of antibodies for HTMPN. Affinity is expressed as an association constant, K_a , which is defined as the molar concentration of HTMPN-antibody complex divided by the molar concentrations of free antigen and free 10 antibody under equilibrium conditions. The K_a determined for a preparation of polyclonal antibodies, which are heterogeneous in their affinities for multiple HTMPN epitopes, represents the average affinity, or avidity, of the antibodies for HTMPN. The K_a determined for a preparation of monoclonal antibodies, which are monospecific for a particular HTMPN epitope, represents a true measure of affinity. High-affinity antibody 15 preparations with K_a ranging from about 10^9 to 10^{12} L/mole are preferred for use in immunoassays in which the HTMPN-antibody complex must withstand rigorous manipulations. Low-affinity antibody preparations with K_a ranging from about 10^6 to 10^7 L/mole are preferred for use in immunopurification and similar procedures which ultimately require dissociation of HTMPN, preferably in active form, from the antibody 20 (Catty, D. (1988) Antibodies, Volume I: A Practical Approach, IRL Press, Washington, DC; Liddell, J. E. and Cryer, A. (1991) A Practical Guide to Monoclonal Antibodies, John Wiley & Sons, New York NY).

The titer and avidity of polyclonal antibody preparations may be further evaluated to determine the quality and suitability of such preparations for certain downstream 25 applications. For example, a polyclonal antibody preparation containing at least 1-2 mg specific antibody/ml, preferably 5-10 mg specific antibody/ml, is preferred for use in procedures requiring precipitation of HTMPN-antibody complexes. Procedures for evaluating antibody specificity, titer, and avidity, and guidelines for antibody quality and usage in various applications, are generally available. (See, e.g., Catty, supra, and Coligan 30 et al. supra.)

In another embodiment of the invention, the polynucleotides encoding HTMPN, or any fragment or complement thereof, may be used for therapeutic purposes. In one aspect,

the complement of the polynucleotide encoding HTMPN may be used in situations in which it would be desirable to block the transcription of the mRNA. In particular, cells may be transformed with sequences complementary to polynucleotides encoding HTMPN. Thus, complementary molecules or fragments may be used to modulate HTMPN activity, or to achieve regulation of gene function. Such technology is now well known in the art, and sense or antisense oligonucleotides or larger fragments can be designed from various locations along the coding or control regions of sequences encoding HTMPN.

Expression vectors derived from retroviruses, adenoviruses, or herpes or vaccinia viruses, or from various bacterial plasmids, may be used for delivery of nucleotide sequences to the targeted organ, tissue, or cell population. Methods which are well known to those skilled in the art can be used to construct vectors to express nucleic acid sequences complementary to the polynucleotides encoding HTMPN. (See, e.g., Sambrook, supra; Ausubel, 1995, supra.)

Genes encoding HTMPN can be turned off by transforming a cell or tissue with expression vectors which express high levels of a polynucleotide, or fragment thereof, encoding HTMPN. Such constructs may be used to introduce untranslatable sense or antisense sequences into a cell. Even in the absence of integration into the DNA, such vectors may continue to transcribe RNA molecules until they are disabled by endogenous nucleases. Transient expression may last for a month or more with a non-replicating vector, and may last even longer if appropriate replication elements are part of the vector system.

As mentioned above, modifications of gene expression can be obtained by designing complementary sequences or antisense molecules (DNA, RNA, or PNA) to the control, 5', or regulatory regions of the gene encoding HTMPN. Oligonucleotides derived from the transcription initiation site, e.g., between about positions -10 and +10 from the start site, are preferred. Similarly, inhibition can be achieved using triple helix base-pairing methodology. Triple helix pairing is useful because it causes inhibition of the ability of the double helix to open sufficiently for the binding of polymerases, transcription factors, or regulatory molecules. Recent therapeutic advances using triplex DNA have been described in the literature. (See, e.g., Gee, J.E. et al. (1994) in Huber, B.E. and B.I. Carr, Molecular and Immunologic Approaches, Futura Publishing, Mt. Kisco NY, pp. 163-177.) A complementary sequence or antisense molecule may also be designed to block

translation of mRNA by preventing the transcript from binding to ribosomes.

Ribozymes, enzymatic RNA molecules, may also be used to catalyze the specific cleavage of RNA. The mechanism of ribozyme action involves sequence-specific hybridization of the ribozyme molecule to complementary target RNA, followed by
5 endonucleolytic cleavage. For example, engineered hammerhead motif ribozyme molecules may specifically and efficiently catalyze endonucleolytic cleavage of sequences encoding HTMPN.

Specific ribozyme cleavage sites within any potential RNA target are initially identified by scanning the target molecule for ribozyme cleavage sites, including the
10 following sequences: GUA, GUU, and GUC. Once identified, short RNA sequences of between 15 and 20 ribonucleotides, corresponding to the region of the target gene containing the cleavage site, may be evaluated for secondary structural features which may render the oligonucleotide inoperable. The suitability of candidate targets may also be evaluated by testing accessibility to hybridization with complementary oligonucleotides
15 using ribonuclease protection assays.

Complementary ribonucleic acid molecules and ribozymes of the invention may be prepared by any method known in the art for the synthesis of nucleic acid molecules. These include techniques for chemically synthesizing oligonucleotides such as solid phase phosphoramidite chemical synthesis. Alternatively, RNA molecules may be generated by
20 in vitro and in vivo transcription of DNA sequences encoding HTMPN. Such DNA sequences may be incorporated into a wide variety of vectors with suitable RNA polymerase promoters such as T7 or SP6. Alternatively, these cDNA constructs that synthesize complementary RNA, constitutively or inducibly, can be introduced into cell lines, cells, or tissues.

25 RNA molecules may be modified to increase intracellular stability and half-life. Possible modifications include, but are not limited to, the addition of flanking sequences at the 5' and/or 3' ends of the molecule, or the use of phosphorothioate or 2' O-methyl rather than phosphodiesterase linkages within the backbone of the molecule. This concept is inherent in the production of PNAs and can be extended in all of these molecules by the
30 inclusion of nontraditional bases such as inosine, queosine, and wybutosine, as well as acetyl-, methyl-, thio-, and similarly modified forms of adenine, cytidine, guanine, thymine, and uridine which are not as easily recognized by endogenous endonucleases.

Many methods for introducing vectors into cells or tissues are available and equally suitable for use in vivo, in vitro, and ex vivo. For ex vivo therapy, vectors may be introduced into stem cells taken from the patient and clonally propagated for autologous transplant back into that same patient. Delivery by transfection, by liposome injections, or
5 by polycationic amino polymers may be achieved using methods which are well known in the art. (See, e.g., Goldman, C.K. et al. (1997) Nature Biotechnology 15:462-466.)

Any of the therapeutic methods described above may be applied to any subject in need of such therapy, including, for example, mammals such as dogs, cats, cows, horses, rabbits, monkeys, and most preferably, humans.

10 An additional embodiment of the invention relates to the administration of a pharmaceutical or sterile composition, in conjunction with a pharmaceutically acceptable carrier, for any of the therapeutic effects discussed above. Such pharmaceutical compositions may consist of HTMPN, antibodies to HTMPN, and mimetics, agonists, antagonists, or inhibitors of HTMPN. The compositions may be administered alone or in
15 combination with at least one other agent, such as a stabilizing compound, which may be administered in any sterile, biocompatible pharmaceutical carrier including, but not limited to, saline, buffered saline, dextrose, and water. The compositions may be administered to a patient alone, or in combination with other agents, drugs, or hormones.

The pharmaceutical compositions utilized in this invention may be administered by
20 any number of routes including, but not limited to, oral, intravenous, intramuscular, intra-arterial, intramedullary, intrathecal, intraventricular, transdermal, subcutaneous, intraperitoneal, intranasal, enteral, topical, sublingual, or rectal means.

In addition to the active ingredients, these pharmaceutical compositions may contain suitable pharmaceutically-acceptable carriers comprising excipients and auxiliaries
25 which facilitate processing of the active compounds into preparations which can be used pharmaceutically. Further details on techniques for formulation and administration may be found in the latest edition of Remington's Pharmaceutical Sciences (Maack Publishing, Easton PA).

Pharmaceutical compositions for oral administration can be formulated using
30 pharmaceutically acceptable carriers well known in the art in dosages suitable for oral administration. Such carriers enable the pharmaceutical compositions to be formulated as tablets, pills, dragees, capsules, liquids, gels, syrups, slurries, suspensions, and the like, for

ingestion by the patient.

Pharmaceutical preparations for oral use can be obtained through combining active compounds with solid excipient and processing the resultant mixture of granules (optionally, after grinding) to obtain tablets or dragee cores. Suitable auxiliaries can be added, if desired. Suitable excipients include carbohydrate or protein fillers, such as sugars, including lactose, sucrose, mannitol, and sorbitol; starch from corn, wheat, rice, potato, or other plants; cellulose, such as methyl cellulose, hydroxypropylmethyl-cellulose, or sodium carboxymethylcellulose; gums, including arabic and tragacanth; and proteins, such as gelatin and collagen. If desired, disintegrating or solubilizing agents may be added, such as the cross-linked polyvinyl pyrrolidone, agar, and alginic acid or a salt thereof, such as sodium alginate.

Dragee cores may be used in conjunction with suitable coatings, such as concentrated sugar solutions, which may also contain gum arabic, talc, polyvinylpyrrolidone, carbopol gel, polyethylene glycol, and/or titanium dioxide, lacquer solutions, and suitable organic solvents or solvent mixtures. Dyestuffs or pigments may be added to the tablets or dragee coatings for product identification or to characterize the quantity of active compound, i.e., dosage.

Pharmaceutical preparations which can be used orally include push-fit capsules made of gelatin, as well as soft, sealed capsules made of gelatin and a coating, such as glycerol or sorbitol. Push-fit capsules can contain active ingredients mixed with fillers or binders, such as lactose or starches, lubricants, such as talc or magnesium stearate, and, optionally, stabilizers. In soft capsules, the active compounds may be dissolved or suspended in suitable liquids, such as fatty oils, liquid, or liquid polyethylene glycol with or without stabilizers.

Pharmaceutical formulations suitable for parenteral administration may be formulated in aqueous solutions, preferably in physiologically compatible buffers such as Hanks' solution, Ringer's solution, or physiologically buffered saline. Aqueous injection suspensions may contain substances which increase the viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol, or dextran. Additionally, suspensions of the active compounds may be prepared as appropriate oily injection suspensions. Suitable lipophilic solvents or vehicles include fatty oils, such as sesame oil, or synthetic fatty acid esters, such as ethyl oleate, triglycerides, or liposomes. Non-lipid polycationic amino

polymers may also be used for delivery. Optionally, the suspension may also contain suitable stabilizers or agents to increase the solubility of the compounds and allow for the preparation of highly concentrated solutions.

For topical or nasal administration, penetrants appropriate to the particular barrier
5 to be permeated are used in the formulation. Such penetrants are generally known in the art.

The pharmaceutical compositions of the present invention may be manufactured in a manner that is known in the art, e.g., by means of conventional mixing, dissolving, granulating, dragee-making, levigating, emulsifying, encapsulating, entrapping, or
10 lyophilizing processes.

The pharmaceutical composition may be provided as a salt and can be formed with many acids, including but not limited to, hydrochloric, sulfuric, acetic, lactic, tartaric, malic, and succinic acid. Salts tend to be more soluble in aqueous or other protonic solvents than are the corresponding free base forms. In other cases, the preferred
15 preparation may be a lyophilized powder which may contain any or all of the following: 1 mM to 50 mM histidine, 0.1% to 2% sucrose, and 2% to 7% mannitol, at a pH range of 4.5 to 5.5, that is combined with buffer prior to use.

After pharmaceutical compositions have been prepared, they can be placed in an appropriate container and labeled for treatment of an indicated condition. For
20 administration of HTMPN, such labeling would include amount, frequency, and method of administration.

Pharmaceutical compositions suitable for use in the invention include compositions wherein the active ingredients are contained in an effective amount to achieve the intended purpose. The determination of an effective dose is well within the capability of those
25 skilled in the art.

For any compound, the therapeutically effective dose can be estimated initially either in cell culture assays, e.g., of neoplastic cells or in animal models such as mice, rats, rabbits, dogs, or pigs. An animal model may also be used to determine the appropriate concentration range and route of administration. Such information can then be used to
30 determine useful doses and routes for administration in humans.

A therapeutically effective dose refers to that amount of active ingredient, for example HTMPN or fragments thereof, antibodies of HTMPN, and agonists, antagonists

or inhibitors of HTMPN, which ameliorates the symptoms or condition. Therapeutic efficacy and toxicity may be determined by standard pharmaceutical procedures in cell cultures or with experimental animals, such as by calculating the ED_{50} (the dose therapeutically effective in 50% of the population) or LD_{50} (the dose lethal to 50% of the population) statistics. The dose ratio of toxic to therapeutic effects is the therapeutic index, and it can be expressed as the LD_{50}/ED_{50} ratio. Pharmaceutical compositions which exhibit large therapeutic indices are preferred. The data obtained from cell culture assays and animal studies are used to formulate a range of dosage for human use. The dosage contained in such compositions is preferably within a range of circulating concentrations that includes the ED_{50} with little or no toxicity. The dosage varies within this range depending upon the dosage form employed, the sensitivity of the patient, and the route of administration.

The exact dosage will be determined by the practitioner, in light of factors related to the subject requiring treatment. Dosage and administration are adjusted to provide sufficient levels of the active moiety or to maintain the desired effect. Factors which may be taken into account include the severity of the disease state, the general health of the subject, the age, weight, and gender of the subject, time and frequency of administration, drug combination(s), reaction sensitivities, and response to therapy. Long-acting pharmaceutical compositions may be administered every 3 to 4 days, every week, or biweekly depending on the half-life and clearance rate of the particular formulation.

Normal dosage amounts may vary from about $0.1 \mu g$ to $100,000 \mu g$, up to a total dose of about 1 gram, depending upon the route of administration. Guidance as to particular dosages and methods of delivery is provided in the literature and generally available to practitioners in the art. Those skilled in the art will employ different formulations for nucleotides than for proteins or their inhibitors. Similarly, delivery of polynucleotides or polypeptides will be specific to particular cells, conditions, locations, etc.

DIAGNOSTICS

In another embodiment, antibodies which specifically bind HTMPN may be used for the diagnosis of disorders characterized by expression of HTMPN, or in assays to monitor patients being treated with HTMPN or agonists, antagonists, or inhibitors of HTMPN. Antibodies useful for diagnostic purposes may be prepared in the same manner

as described above for therapeutics. Diagnostic assays for HTMPN include methods which utilize the antibody and a label to detect HTMPN in human body fluids or in extracts of cells or tissues. The antibodies may be used with or without modification, and may be labeled by covalent or non-covalent attachment of a reporter molecule. A wide
5 variety of reporter molecules, several of which are described above, are known in the art and may be used.

A variety of protocols for measuring HTMPN, including ELISAs, RIAs, and FACS, are known in the art and provide a basis for diagnosing altered or abnormal levels of HTMPN expression. Normal or standard values for HTMPN expression are established
10 by combining body fluids or cell extracts taken from normal mammalian subjects, preferably human, with antibody to HTMPN under conditions suitable for complex formation. The amount of standard complex formation may be quantitated by various methods, preferably by photometric means. Quantities of HTMPN expressed in subject, control, and disease samples from biopsied tissues are compared with the standard values.
15 Deviation between standard and subject values establishes the parameters for diagnosing disease.

In another embodiment of the invention, the polynucleotides encoding HTMPN may be used for diagnostic purposes. The polynucleotides which may be used include oligonucleotide sequences, complementary RNA and DNA molecules, and PNAs. The
20 polynucleotides may be used to detect and quantitate gene expression in biopsied tissues in which expression of HTMPN may be correlated with disease. The diagnostic assay may be used to determine absence, presence, and excess expression of HTMPN, and to monitor regulation of HTMPN levels during therapeutic intervention.

In one aspect, hybridization with PCR probes which are capable of detecting
25 polynucleotide sequences, including genomic sequences, encoding HTMPN or closely related molecules may be used to identify nucleic acid sequences which encode HTMPN. The specificity of the probe, whether it is made from a highly specific region, e.g., the 5' regulatory region, or from a less specific region, e.g., a conserved motif, and the stringency of the hybridization or amplification (maximal, high, intermediate, or low), will determine
30 whether the probe identifies only naturally occurring sequences encoding HTMPN, allelic variants, or related sequences.

Probes may also be used for the detection of related sequences, and should

preferably have at least 50% sequence identity to any of the HTMPN encoding sequences. The hybridization probes of the subject invention may be DNA or RNA and may be derived from the sequence of SEQ ID NO:80-158 or from genomic sequences including promoters, enhancers, and introns of the HTMPN gene.

- 5 Means for producing specific hybridization probes for DNAs encoding HTMPN include the cloning of polynucleotide sequences encoding HTMPN or HTMPN derivatives into vectors for the production of mRNA probes. Such vectors are known in the art, are commercially available, and may be used to synthesize RNA probes in vitro by means of the addition of the appropriate RNA polymerases and the appropriate labeled nucleotides.
- 10 Hybridization probes may be labeled by a variety of reporter groups, for example, by radionuclides such as ^{32}P or ^{35}S , or by enzymatic labels, such as alkaline phosphatase coupled to the probe via avidin/biotin coupling systems, and the like.

Polynucleotide sequences encoding HTMPN may be used for the diagnosis of disorders associated with expression of HTMPN. Examples of such disorders include, but

15 are not limited to, an immune disorder such as acquired immunodeficiency syndrome (AIDS), Addison's disease, adult respiratory distress syndrome, allergies, ankylosing spondylitis, amyloidosis, anemia, asthma, atherosclerosis, autoimmune hemolytic anemia, autoimmune thyroiditis, autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED), bronchitis, cholecystitis, contact dermatitis, Crohn's disease, atopic

20 dermatitis, dermatomyositis, diabetes mellitus, emphysema, episodic lymphopenia with lymphocytotoxins, erythroblastosis fetalis, erythema nodosum, atrophic gastritis, glomerulonephritis, Goodpasture's syndrome, gout, Graves' disease, Hashimoto's thyroiditis, hypereosinophilia, irritable bowel syndrome, multiple sclerosis, myasthenia gravis, myocardial or pericardial inflammation, osteoarthritis, osteoporosis, pancreatitis,

25 polymyositis, psoriasis, Reiter's syndrome, rheumatoid arthritis, scleroderma, Sjögren's syndrome, systemic anaphylaxis, systemic lupus erythematosus, systemic sclerosis, thrombocytopenic purpura, ulcerative colitis, uveitis, Werner syndrome, complications of cancer, hemodialysis, and extracorporeal circulation, viral, bacterial, fungal, parasitic, protozoal, and helminthic infections, and trauma; a reproductive disorder such as a

30 disorder of prolactin production; infertility, including tubal disease, ovulatory defects, and endometriosis; a disruption of the estrous cycle, a disruption of the menstrual cycle, polycystic ovary syndrome, ovarian hyperstimulation syndrome, endometrial and ovarian

tumors, uterine fibroids, autoimmune disorders, ectopic pregnancies, and teratogenesis; cancer of the breast, fibrocystic breast disease, and galactorrhea; disruptions of spermatogenesis, abnormal sperm physiology, cancer of the testis, cancer of the prostate, benign prostatic hyperplasia, prostatitis, Peyronie's disease, impotence, carcinoma of the male breast, and gynecomastia; a smooth muscle disorder such as angina, anaphylactic shock, arrhythmias, asthma, cardiovascular shock, Cushing's syndrome, hypertension, hypoglycemia, myocardial infarction, migraine, and pheochromocytoma, and myopathies including cardiomyopathy, encephalopathy, epilepsy, Kearns-Sayre syndrome, lactic acidosis, myoclonic disorder, and ophthalmoplegia; a neurological disorder such as epilepsy, ischemic cerebrovascular disease, stroke, cerebral neoplasms, Alzheimer's disease, Pick's disease, Huntington's disease, dementia, Parkinson's disease and other extrapyramidal disorders, amyotrophic lateral sclerosis and other motor neuron disorders, progressive neural muscular atrophy, retinitis pigmentosa, hereditary ataxias, multiple sclerosis and other demyelinating diseases, bacterial and viral meningitis, brain abscess, subdural empyema, epidural abscess, suppurative intracranial thrombophlebitis, myelitis and radiculitis, viral central nervous system disease; prion diseases including kuru, Creutzfeldt-Jakob disease, and Gerstmann-Straussler-Scheinker syndrome; fatal familial insomnia, nutritional and metabolic diseases of the nervous system, neurofibromatosis, tuberous sclerosis, cerebelloretinal hemangioblastomatosis, encephalotrigeminal syndrome, mental retardation and other developmental disorders of the central nervous system, cerebral palsy, neuroskeletal disorders, autonomic nervous system disorders, cranial nerve disorders, spinal cord diseases, muscular dystrophy and other neuromuscular disorders, peripheral nervous system disorders, dermatomyositis and polymyositis; inherited, metabolic, endocrine, and toxic myopathies; myasthenia gravis, periodic paralysis; mental disorders including mood, anxiety, and schizophrenic disorders; akathisia, amnesia, catatonia, diabetic neuropathy, tardive dyskinesia, dystonias, paranoid psychoses, postherpetic neuralgia, and Tourette's disorder; a gastrointestinal disorder such as dysphagia, peptic esophagitis, esophageal spasm, esophageal stricture, esophageal carcinoma, dyspepsia, indigestion, gastritis, gastric carcinoma, anorexia, nausea, emesis, gastroparesis, antral or pyloric edema, abdominal angina, pyrosis, gastroenteritis, intestinal obstruction, infections of the intestinal tract, peptic ulcer, cholelithiasis, cholecystitis, cholestasis, pancreatitis, pancreatic carcinoma, biliary tract disease, hepatoma, infectious

- colitis, ulcerative colitis, ulcerative proctitis, Crohn's disease, Whipple's disease, Mallory-Weiss syndrome, colonic carcinoma, colonic obstruction, irritable bowel syndrome, short bowel syndrome, diarrhea, constipation, gastrointestinal hemorrhage, and acquired immunodeficiency syndrome (AIDS) enteropathy, cirrhosis, jaundice, cholestasis,
- 5 hereditary hyperbilirubinemia, hepatic encephalopathy, hepatorenal syndrome, hepatitis, hepatic steatosis, hemochromatosis, Wilson's disease, α_1 -antitrypsin deficiency, Reye's syndrome, primary sclerosing cholangitis, liver infarction, portal vein obstruction and thrombosis, passive congestion, centrilobular necrosis, peliosis hepatis, hepatic vein thrombosis, veno-occlusive disease, preeclampsia, eclampsia, acute fatty liver of
- 10 pregnancy, intrahepatic cholestasis of pregnancy, and hepatic tumors including nodular hyperplasias, adenomas, and carcinomas; a cell proliferative disorder such as actinic keratosis, arteriosclerosis, atherosclerosis, bursitis, cirrhosis, hepatitis, mixed connective tissue disease (MCTD), myelofibrosis, paroxysmal nocturnal hemoglobinuria, polycythemia vera, psoriasis, primary thrombocythemia, and cancers including
- 15 adenocarcinoma, leukemia, lymphoma, melanoma, myeloma, sarcoma, teratocarcinoma, and, in particular, cancers of the adrenal gland, bladder, bone, bone marrow, brain, breast, cervix, gall bladder, ganglia, gastrointestinal tract, heart, kidney, liver, lung, muscle, ovary, pancreas, parathyroid, penis, prostate, salivary glands, skin, spleen, testis, thymus, thyroid, and uterus; and a developmental disorder including, but not limited to, those listed above.
- 20 The polynucleotide sequences encoding HTMPN may be used in Southern or northern analysis, dot blot, or other membrane-based technologies; in PCR technologies; in dipstick, pin, and multiformat ELISA-like assays; and in microarrays utilizing fluids or tissues from patients to detect altered HTMPN expression. Such qualitative or quantitative methods are well known in the art.
- 25 In a particular aspect, the nucleotide sequences encoding HTMPN may be useful in assays that detect the presence of associated disorders, particularly those mentioned above. The nucleotide sequences encoding HTMPN may be labeled by standard methods and added to a fluid or tissue sample from a patient under conditions suitable for the formation of hybridization complexes. After a suitable incubation period, the sample is washed and
- 30 the signal is quantitated and compared with a standard value. If the amount of signal in the patient sample is significantly altered in comparison to a control sample then the presence of altered levels of nucleotide sequences encoding HTMPN in the sample indicates the

presence of the associated disorder. Such assays may also be used to evaluate the efficacy of a particular therapeutic treatment regimen in animal studies, in clinical trials, or to monitor the treatment of an individual patient.

In order to provide a basis for the diagnosis of a disorder associated with
5 expression of HTMPN, a normal or standard profile for expression is established. This may be accomplished by combining body fluids or cell extracts taken from normal subjects, either animal or human, with a sequence, or a fragment thereof, encoding HTMPN, under conditions suitable for hybridization or amplification. Standard hybridization may be quantified by comparing the values obtained from normal subjects
10 with values from an experiment in which a known amount of a substantially purified polynucleotide is used. Standard values obtained in this manner may be compared with values obtained from samples from patients who are symptomatic for a disorder. Deviation from standard values is used to establish the presence of a disorder.

Once the presence of a disorder is established and a treatment protocol is initiated,
15 hybridization assays may be repeated on a regular basis to determine if the level of expression in the patient begins to approximate that which is observed in the normal subject. The results obtained from successive assays may be used to show the efficacy of treatment over a period ranging from several days to months.

With respect to cancer, the presence of an abnormal amount of transcript (either
20 under- or overexpressed) in biopsied tissue from an individual may indicate a predisposition for the development of the disease, or may provide a means for detecting the disease prior to the appearance of actual clinical symptoms. A more definitive diagnosis of this type may allow health professionals to employ preventative measures or aggressive treatment earlier thereby preventing the development or further progression of
25 the cancer.

Additional diagnostic uses for oligonucleotides designed from the sequences encoding HTMPN may involve the use of PCR. These oligomers may be chemically synthesized, generated enzymatically, or produced in vitro. Oligomers will preferably contain a fragment of a polynucleotide encoding HTMPN, or a fragment of a
30 polynucleotide complementary to the polynucleotide encoding HTMPN, and will be employed under optimized conditions for identification of a specific gene or condition. Oligomers may also be employed under less stringent conditions for detection or

quantitation of closely related DNA or RNA sequences.

Methods which may also be used to quantitate the expression of HTMPN include radiolabeling or biotinylating nucleotides, coamplification of a control nucleic acid, and interpolating results from standard curves. (See, e.g., Melby, P.C. et al. (1993) J.

5 Immunol. Methods 159:235-244; Duplaa, C. et al. (1993) Anal. Biochem. 212:229-236.)

The speed of quantitation of multiple samples may be accelerated by running the assay in an ELISA format where the oligomer of interest is presented in various dilutions and a spectrophotometric or colorimetric response gives rapid quantitation.

In further embodiments, oligonucleotides or longer fragments derived from any of
10 the polynucleotide sequences described herein may be used as targets in a microarray. The microarray can be used to monitor the expression level of large numbers of genes simultaneously and to identify genetic variants, mutations, and polymorphisms. This information may be used to determine gene function, to understand the genetic basis of a disorder, to diagnose a disorder, and to develop and monitor the activities of therapeutic
15 agents.

Microarrays may be prepared, used, and analyzed using methods known in the art. (See, e.g., Brennan, T.M. et al. (1995) U.S. Patent No. 5,474,796; Schena, M. et al. (1996) Proc. Natl. Acad. Sci. 93:10614-10619; Baldeschweiler et al. (1995) PCT application WO95/251116; Shalon, D. et al. (1995) PCT application WO95/35505; Heller, R.A. et al.
20 (1997) Proc. Natl. Acad. Sci. 94:2150-2155; and Heller, M.J. et al. (1997) U.S. Patent No. 5,605,662.)

In another embodiment of the invention, nucleic acid sequences encoding HTMPN may be used to generate hybridization probes useful in mapping the naturally occurring genomic sequence. The sequences may be mapped to a particular chromosome, to a
25 specific region of a chromosome, or to artificial chromosome constructions, e.g., human artificial chromosomes (HACs), yeast artificial chromosomes (YACs), bacterial artificial chromosomes (BACs), bacterial P1 constructions, or single chromosome cDNA libraries. (See, e.g., Harrington, J.J. et al. (1997) Nat Genet. 15:345-355; Price, C.M. (1993) Blood Rev. 7:127-134; and Trask, B.J. (1991) Trends Genet. 7:149-154.)

30 Fluorescent in situ hybridization (FISH) may be correlated with other physical chromosome mapping techniques and genetic map data. (See, e.g., Heinz-Ulrich, et al. (1995) in Meyers, supra, pp. 965-968.) Examples of genetic map data can be found in

various scientific journals or at the Online Mendelian Inheritance in Man (OMIM) site. Correlation between the location of the gene encoding HTMPN on a physical chromosomal map and a specific disorder, or a predisposition to a specific disorder, may help define the region of DNA associated with that disorder. The nucleotide sequences of
5 the invention may be used to detect differences in gene sequences among normal, carrier, and affected individuals.

In situ hybridization of chromosomal preparations and physical mapping techniques, such as linkage analysis using established chromosomal markers, may be used for extending genetic maps. Often the placement of a gene on the chromosome of another
10 mammalian species, such as mouse, may reveal associated markers even if the number or arm of a particular human chromosome is not known. New sequences can be assigned to chromosomal arms by physical mapping. This provides valuable information to investigators searching for disease genes using positional cloning or other gene discovery techniques. Once the disease or syndrome has been crudely localized by genetic linkage to
15 a particular genomic region, e.g., ataxia-telangiectasia to 11q22-23, any sequences mapping to that area may represent associated or regulatory genes for further investigation. (See, e.g., Gatti, R.A. et al. (1988) Nature 336:577-580.) The nucleotide sequence of the subject invention may also be used to detect differences in the chromosomal location due to translocation, inversion, etc., among normal, carrier, or affected individuals.

20 In another embodiment of the invention, HTMPN, its catalytic or immunogenic fragments, or oligopeptides thereof can be used for screening libraries of compounds in any of a variety of drug screening techniques. The fragment employed in such screening may be free in solution, affixed to a solid support, borne on a cell surface, or located intracellularly. The formation of binding complexes between HTMPN and the agent being
25 tested may be measured.

Another technique for drug screening provides for high throughput screening of compounds having suitable binding affinity to the protein of interest. (See, e.g., Geysen, et al. (1984) PCT application WO84/03564.) In this method, large numbers of different small test compounds are synthesized on a solid substrate. The test compounds are reacted
30 with HTMPN, or fragments thereof, and washed. Bound HTMPN is then detected by methods well known in the art. Purified HTMPN can also be coated directly onto plates for use in the aforementioned drug screening techniques. Alternatively, non-neutralizing

antibodies can be used to capture the peptide and immobilize it on a solid support.

In another embodiment, one may use competitive drug screening assays in which neutralizing antibodies capable of binding HTMPN specifically compete with a test compound for binding HTMPN. In this manner, antibodies can be used to detect the
5 presence of any peptide which shares one or more antigenic determinants with HTMPN.

In additional embodiments, the nucleotide sequences which encode HTMPN may be used in any molecular biology techniques that have yet to be developed, provided the new techniques rely on properties of nucleotide sequences that are currently known, including, but not limited to, such properties as the triplet genetic code and specific base
10 pair interactions.

Without further elaboration, it is believed that one skilled in the art can, using the preceding description, utilize the present invention to its fullest extent. The following preferred specific embodiments are, therefore, to be construed as merely illustrative, and not limitative of the remainder of the disclosure in any way whatsoever.

15 The entire disclosure of all applications, patents, and publications, cited above and below, and of US provisional applications 60/087,260 (filed May 29, 1998), 60/091,674 (filed July 2, 1998), 60/102,954 (filed October 2, 1998), and 60/109,869 (filed November 24, 1998) is hereby incorporated by reference.

EXAMPLES

20 I. Construction of cDNA Libraries

RNA was purchased from Clontech or isolated from tissues described in Table 4. Some tissues were homogenized and lysed in guanidinium isothiocyanate, while others were homogenized and lysed in phenol or in a suitable mixture of denaturants, such as TRIZOL (Life Technologies), a monophasic solution of phenol and guanidine
25 isothiocyanate. The resulting lysates were centrifuged over CsCl cushions or extracted with chloroform. RNA was precipitated from the lysates with either isopropanol or sodium acetate and ethanol, or by other routine methods.

Phenol extraction and precipitation of RNA were repeated as necessary to increase RNA purity. In some cases, RNA was treated with DNase. For most libraries, poly(A+) RNA was isolated using oligo d(T)-coupled paramagnetic particles (Promega),
30 OLIGOTEX latex particles (QIAGEN, Valencia CA), or an OLIGOTEX mRNA purification kit (QIAGEN). Alternatively, RNA was isolated directly from tissue lysates

using other RNA isolation kits, e.g., the POLY(A)PURE mRNA purification kit (Ambion, Austin TX).

In some cases, Stratagene was provided with RNA and constructed the corresponding cDNA libraries. Otherwise, cDNA was synthesized and cDNA libraries
5 were constructed with the UNIZAP vector system (Stratagene) or SUPERScript plasmid system (Life Technologies), using the recommended procedures or similar methods known in the art. (See, e.g., Ausubel, 1997, supra, units 5.1-6.6). Reverse transcription was initiated using oligo d(T) or random primers. Synthetic oligonucleotide adapters were ligated to double stranded cDNA, and the cDNA was digested with the appropriate
10 restriction enzyme or enzymes. For most libraries, the cDNA was size-selected (300-1000 bp) using SEPHACRYL S1000, SEPHAROSE CL2B, or SEPHAROSE CL4B column chromatography (Amersham Pharmacia Biotech) or preparative agarose gel electrophoresis. cDNAs were ligated into compatible restriction enzyme sites of the polylinker of a suitable plasmid, e.g., PBLUEScript plasmid (Stratagene), pSPORT1
15 plasmid (Life Technologies), or pINCY (Incyte Pharmaceuticals, Palo Alto CA). Recombinant plasmids were transformed into competent *E. coli* cells including XL1-Blue, XL1-BlueMRF, or SOLR from Stratagene or DH5 α , DH10B, or ElectroMAX DH10B from Life Technologies.

II. Isolation of cDNA Clones

20 Plasmids were recovered from host cells by in vivo excision, using the UNIZAP vector system (Stratagene) or cell lysis. Plasmids were purified using at least one of the following: a Magic or WIZARD Minipreps DNA purification system (Promega); an AGTC Miniprep purification kit (Edge Biosystems, Gaithersburg MD); and QIAWELL 8 Plasmid, QIAWELL 8 Plus Plasmid, QIAWELL 8 Ultra Plasmid purification systems or
25 the REAL Prep 96 plasmid kit from QIAGEN. Following precipitation, plasmids were resuspended in 0.1 ml of distilled water and stored, with or without lyophilization, at 4°C.

Alternatively, plasmid DNA was amplified from host cell lysates using direct link PCR in a high-throughput format (Rao, V.B. (1994) Anal. Biochem. 216:1-14). Host cell lysis and thermal cycling steps were carried out in a single reaction mixture. Samples
30 were processed and stored in 384-well plates, and the concentration of amplified plasmid DNA was quantified fluorometrically using PICOGREEN dye (Molecular Probes, Eugene OR) and a Fluoroskan II fluorescence scanner (Labsystems Oy, Helsinki, Finland).

III. Sequencing and Analysis

The cDNAs were prepared for sequencing using the ABI CATALYST 800 (Perkin-Elmer) or the HYDRA microdispenser (Robbins Scientific) or MICROLAB 2200 (Hamilton) systems in combination with the PTC-200 thermal cyclers (MJ Research). The cDNAs were sequenced using the ABI PRISM 373 or 377 sequencing systems (Perkin-Elmer) and standard ABI protocols, base calling software, and kits. In one alternative, cDNAs were sequenced using the MEGABACE 1000 DNA sequencing system (Molecular Dynamics). In another alternative, the cDNAs were amplified and sequenced using the ABI PRISM BIGDYE Terminator cycle sequencing ready reaction kit (Perkin-Elmer). In yet another alternative, cDNAs were sequenced using solutions and dyes from Amersham Pharmacia Biotech. Reading frames for the ESTs were determined using standard methods (reviewed in Ausubel, 1997, supra, unit 7.7). Some of the cDNA sequences were selected for extension using the techniques disclosed in Example V.

The polynucleotide sequences derived from cDNA, extension, and shotgun sequencing were assembled and analyzed using a combination of software programs which utilize algorithms well known to those skilled in the art. Table 5 summarizes the software programs, descriptions, references, and threshold parameters used. The first column of Table 5 shows the tools, programs, and algorithms used, the second column provides a brief description thereof, the third column presents the references which are incorporated by reference herein, and the fourth column presents, where applicable, the scores, probability values, and other parameters used to evaluate the strength of a match between two sequences (the higher the probability the greater the homology). Sequences were analyzed using MACDNASIS PRO software (Hitachi Software Engineering, South San Francisco CA) and LASERGENE software (DNASTAR).

The polynucleotide sequences were validated by removing vector, linker, and polyA sequences and by masking ambiguous bases, using algorithms and programs based on BLAST, dynamic programming, and dinucleotide nearest neighbor analysis. The sequences were then queried against a selection of public databases such as GenBank primate, rodent, mammalian, vertebrate, and eukaryote databases, and BLOCKS to acquire annotation, using programs based on BLAST, FASTA, and BLIMPS. The sequences were assembled into full length polynucleotide sequences using programs based on Phred, Phrap, and Consed, and were screened for open reading frames using programs based on

GeneMark, BLAST, and FASTA. The full length polynucleotide sequences were translated to derive the corresponding full length amino acid sequences, and these full length sequences were subsequently analyzed by querying against databases such as the GenBank databases (described above), SwissProt, BLOCKS, PRINTS, Prosite, and

5 Hidden Markov Model (HMM)-based protein family databases such as PFAM. HMM is a probabilistic approach which analyzes consensus primary structures of gene families. (See, e.g., Eddy, S.R. (1996) *Cur. Opin. Str. Biol.* 6:361-365.)

The programs described above for the assembly and analysis of full length polynucleotide and amino acid sequences were also used to identify polynucleotide

10 sequence fragments from SEQ ID NO:80-158. Fragments from about 20 to about 4000 nucleotides which are useful in hybridization and amplification technologies were described in The Invention section above.

IV. Northern Analysis

Northern analysis is a laboratory technique used to detect the presence of a

15 transcript of a gene and involves the hybridization of a labeled nucleotide sequence to a membrane on which RNAs from a particular cell type or tissue have been bound. (See, e.g., Sambrook, *supra*, ch. 7; Ausubel, 1995, *supra*, ch. 4 and 16.)

Analogous computer techniques applying BLAST were used to search for identical or related molecules in nucleotide databases such as GenBank or LIFESEQ database

20 (Incyte Pharmaceuticals). This analysis is much faster than multiple membrane-based hybridizations. In addition, the sensitivity of the computer search can be modified to determine whether any particular match is categorized as exact or similar. The basis of the search is the product score, which is defined as:

$$\frac{\% \text{ sequence identity} \times \% \text{ maximum BLAST score}}{100}$$

25

The product score takes into account both the degree of similarity between two sequences and the length of the sequence match. For example, with a product score of 40, the match will be exact within a 1% to 2% error, and, with a product score of 70, the match will be exact. Similar molecules are usually identified by selecting those which show product

30 scores between 15 and 40, although lower scores may identify related molecules.

The results of northern analyses are reported as a percentage distribution of libraries in which the transcript encoding HTMPN occurred. Analysis involved the

categorization of cDNA libraries by organ/tissue and disease. The organ/tissue categories included cardiovascular, dermatologic, developmental, endocrine, gastrointestinal, hematopoietic/immune, musculoskeletal, nervous, reproductive, and urologic. The disease/condition categories included cancer, inflammation/trauma, cell proliferation, neurological, and pooled. For each category, the number of libraries expressing the sequence of interest was counted and divided by the total number of libraries across all categories. Percentage values of tissue-specific and disease- or condition-specific expression are reported in Table 3.

V. Extension of HTMPN Encoding Polynucleotides

Full length nucleic acid sequences of SEQ ID NOs:80-120 were produced by extension of the component fragments described in Table 1, column 5, using oligonucleotide primers based on these fragments. For each nucleic acid sequence, one primer was synthesized to initiate extension of an antisense polynucleotide, and the other was synthesized to initiate extension of a sense polynucleotide. Primers were used to facilitate the extension of the known sequence "outward" generating amplicons containing new unknown nucleotide sequence for the region of interest. The initial primers were designed from the cDNA using OLIGO™ 4.06 (National Biosciences, Plymouth, MN), or another appropriate program, to be about 22 to 30 nucleotides in length, to have a GC content of about 50% or more, and to anneal to the target sequence at temperatures of about 68°C to about 72°C. Any stretch of nucleotides which would result in hairpin structures and primer-primer dimerizations was avoided.

Selected human cDNA libraries (GIBCO BRL) were used to extend the sequence. If more than one extension is necessary or desired, additional sets of primers are designed to further extend the known region.

High fidelity amplification was obtained by following the instructions for the XL-PCR™ kit (The Perkin-Elmer Corp., Norwalk, CT) and thoroughly mixing the enzyme and reaction mix. PCR was performed using the PTC-200 thermal cycler (MJ Research, Inc., Watertown, MA), beginning with 40 pmol of each primer and the recommended concentrations of all other components of the kit, with the following parameters:

Step 1	94° C for 1 min (initial denaturation)
Step 2	65° C for 1 min
Step 3	68° C for 6 min
Step 4	94° C for 15 sec

	Step 5	65° C for 1 min
	Step 6	68° C for 7 min
	Step 7	Repeat steps 4 through 6 for an additional 15 cycles
	Step 8	94° C for 15 sec
5	Step 9	65° C for 1 min
	Step 10	68° C for 7:15 min
	Step 11	Repeat steps 8 through 10 for an additional 12 cycles
	Step 12	72° C for 8 min
10	Step 13	4° C (and holding)

A 5 μ l to 10 μ l aliquot of the reaction mixture was analyzed by electrophoresis on a low concentration (about 0.6% to 0.8%) agarose mini-gel to determine which reactions were successful in extending the sequence. Bands thought to contain the largest products were excised from the gel, purified using QIAQUICK™ (QIAGEN Inc.), and trimmed of overhangs using Klenow enzyme to facilitate religation and cloning.

After ethanol precipitation, the products were redissolved in 13 μ l of ligation buffer. 1 μ l T4-DNA ligase (15 units) and 1 μ l T4 polynucleotide kinase were added, and the mixture was incubated at room temperature for 2 to 3 hours, or overnight at 16° C. Competent *E. coli* cells (in 40 μ l of appropriate media) were transformed with 3 μ l of ligation mixture and cultured in 80 μ l of SOC medium. (See, e.g., Sambrook, *supra*, Appendix A, p. 2.) After incubation for one hour at 37° C, the *E. coli* mixture was plated on Luria Bertani (LB) agar (See, e.g., Sambrook, *supra*, Appendix A, p. 1) containing carbenicillin (2x carb). The following day, several colonies were randomly picked from each plate and cultured in 150 μ l of liquid LB/2x carb medium placed in an individual well of an appropriate commercially-available sterile 96-well microtiter plate. The following day, 5 μ l of each overnight culture was transferred into a non-sterile 96-well plate and, after dilution 1:10 with water, 5 μ l from each sample was transferred into a PCR array.

For PCR amplification, 18 μ l of concentrated PCR reaction mix (3.3x) containing 4 units of rTth DNA polymerase, a vector primer, and one or both of the gene specific primers used for the extension reaction were added to each well. Amplification was performed using the following conditions:

	Step 1	94° C for 60 sec
	Step 2	94° C for 20 sec
	Step 3	55° C for 30 sec
35	Step 4	72° C for 90 sec
	Step 5	Repeat steps 2 through 4 for an additional 29 cycles
	Step 6	72° C for 180 sec

Step 7 4° C (and holding)

Aliquots of the PCR reactions were run on agarose gels together with molecular weight markers. The sizes of the PCR products were compared to the original partial cDNAs, and appropriate clones were selected, ligated into plasmid, and sequenced.

The full length nucleic acid sequences of SEQ ID NO:121-158 were produced by extension of an appropriate fragment of the full length molecule using oligonucleotide primers designed from this fragment. One primer was synthesized to initiate 5' extension of the known fragment, and the other primer, to initiate 3' extension of the known fragment. The initial primers were designed using OLIGO 4.06 software (National Biosciences), or another appropriate program, to be about 22 to 30 nucleotides in length, to have a GC content of about 50% or more, and to anneal to the target sequence at temperatures of about 68°C to about 72°C. Any stretch of nucleotides which would result in hairpin structures and primer-primer dimerizations was avoided.

Selected human cDNA libraries were used to extend the sequence. If more than one extension was necessary or desired, additional or nested sets of primers were designed.

High fidelity amplification was obtained by PCR using methods well known in the art. PCR was performed in 96-well plates using the PTC-200 thermal cycler (MJ Research, Inc.). The reaction mix contained DNA template, 200 nmol of each primer, reaction buffer containing Mg^{2+} , $(NH_4)_2SO_4$, and β -mercaptoethanol, Taq DNA polymerase (Amersham Pharmacia Biotech), ELONGASE enzyme (Life Technologies), and Pfu DNA polymerase (Stratagene), with the following parameters for primer pair PCI A and PCI B: Step 1: 94°C, 3 min; Step 2: 94°C, 15 sec; Step 3: 60°C, 1 min; Step 4: 68°C, 2 min; Step 5: Steps 2, 3, and 4 repeated 20 times; Step 6: 68°C, 5 min; Step 7: storage at 4°C. In the alternative, the parameters for primer pair T7 and SK+ were as follows: Step 1: 94°C, 3 min; Step 2: 94°C, 15 sec; Step 3: 57°C, 1 min; Step 4: 68°C, 2 min; Step 5: Steps 2, 3, and 4 repeated 20 times; Step 6: 68°C, 5 min; Step 7: storage at 4°C.

The concentration of DNA in each well was determined by dispensing 100 μ l PICOGREEN quantitation reagent (0.25% (v/v) PICOGREEN; Molecular Probes, Eugene OR) dissolved in 1X TE and 0.5 μ l of undiluted PCR product into each well of an opaque fluorimeter plate (Corning Costar, Acton MA), allowing the DNA to bind to the reagent. The plate was scanned in a Fluoroskan II (Labsystems Oy, Helsinki, Finland) to measure

the fluorescence of the sample and to quantify the concentration of DNA. A 5 μ l to 10 μ l aliquot of the reaction mixture was analyzed by electrophoresis on a 1 % agarose mini-gel to determine which reactions were successful in extending the sequence.

The extended nucleotides were desalted and concentrated, transferred to 384-well
5 plates, digested with CviII cholera virus endonuclease (Molecular Biology Research,
Madison WI), and sonicated or sheared prior to religation into pUC 18 vector (Amersham
Pharmacia Biotech). For shotgun sequencing, the digested nucleotides were separated on
low concentration (0.6 to 0.8%) agarose gels, fragments were excised, and agar digested
with Agar ACE (Promega). Extended clones were religated using T4 ligase (New England
10 Biolabs, Beverly MA) into pUC 18 vector (Amersham Pharmacia Biotech), treated with
Pfu DNA polymerase (Stratagene) to fill-in restriction site overhangs, and transfected into
competent *E. coli* cells. Transformed cells were selected on antibiotic-containing media,
individual colonies were picked and cultured overnight at 37°C in 384-well plates in
LB/2x carb liquid media.

15 The cells were lysed, and DNA was amplified by PCR using Taq DNA
polymerase (Amersham Pharmacia Biotech) and Pfu DNA polymerase (Stratagene) with
the following parameters: Step 1: 94°C, 3 min; Step 2: 94°C, 15 sec; Step 3: 60°C, 1 min;
Step 4: 72°C, 2 min; Step 5: steps 2, 3, and 4 repeated 29 times; Step 6: 72°C, 5 min; Step
7: storage at 4°C. DNA was quantified by PICOGREEN reagent (Molecular Probes) as
20 described above. Samples with low DNA recoveries were reamplified using the same
conditions as described above. Samples were diluted with 20% dimethylsulphoxide (1:2,
v/v), and sequenced using DYENAMIC energy transfer sequencing primers and the
DYENAMIC DIRECT kit (Amersham Pharmacia Biotech) or the ABI PRISM BIGDYE
Terminator cycle sequencing ready reaction kit (Perkin-Elmer).

25 In like manner, the nucleotide sequences of SEQ ID NO:80-158 are used to obtain
5' regulatory sequences using the procedure above, oligonucleotides designed for such
extension, and an appropriate genomic library.

VI. Labeling and Use of Individual Hybridization Probes

Hybridization probes derived from SEQ ID NO:80-158 are employed to screen
30 cDNAs, genomic DNAs, or mRNAs. Although the labeling of oligonucleotides,
consisting of about 20 base pairs, is specifically described, essentially the same procedure
is used with larger nucleotide fragments. Oligonucleotides are designed using state-of-the-

art software such as OLIGO 4.06 software (National Biosciences) and labeled by combining 50 pmol of each oligomer, 250 μ Ci of [γ - 32 P] adenosine triphosphate (Amersham Pharmacia Biotech), and T4 polynucleotide kinase (DuPont NEN, Boston MA). The labeled oligonucleotides are substantially purified using a SEPHADEX G-25
5 superfine size exclusion dextran bead column (Amersham Pharmacia Biotech). An aliquot containing 10^7 counts per minute of the labeled probe is used in a typical membrane-based hybridization analysis of human genomic DNA digested with one of the following endonucleases: Ase I, Bgl II, Eco RI, Pst I, Xba I, or Pvu II (DuPont NEN).

The DNA from each digest is fractionated on a 0.7% agarose gel and transferred to
10 nylon membranes (Nytran Plus, Schleicher & Schuell, Durham NH). Hybridization is carried out for 16 hours at 40°C. To remove nonspecific signals, blots are sequentially washed at room temperature under increasingly stringent conditions up to 0.1 x saline sodium citrate and 0.5% sodium dodecyl sulfate. After XOMAT-AR film (Eastman Kodak, Rochester NY) is exposed to the blots to film for several hours, hybridization
15 patterns are compared visually.

VII. Microarrays

A chemical coupling procedure and an ink jet device can be used to synthesize array elements on the surface of a substrate. (See, e.g., Baldeschweiler, *supra*.) An array analogous to a dot or slot blot may also be used to arrange and link elements to the surface
20 of a substrate using thermal, UV, chemical, or mechanical bonding procedures. A typical array may be produced by hand or using available methods and machines and contain any appropriate number of elements. After hybridization, nonhybridized probes are removed and a scanner used to determine the levels and patterns of fluorescence. The degree of complementarity and the relative abundance of each probe which hybridizes to an element
25 on the microarray may be assessed through analysis of the scanned images.

Full-length cDNAs, Expressed Sequence Tags (ESTs), or fragments thereof may comprise the elements of the microarray. Fragments suitable for hybridization can be selected using software well known in the art such as LASERGENE software (DNASTAR). Full-length cDNAs, ESTs, or fragments thereof corresponding to one of the
30 nucleotide sequences of the present invention, or selected at random from a cDNA library relevant to the present invention, are arranged on an appropriate substrate, e.g., a glass slide. The cDNA is fixed to the slide using, e.g., UV cross-linking followed by thermal

and chemical treatments and subsequent drying. (See, e.g., Schena, M. et al. (1995) Science 270:467-470; Shalon, D. et al. (1996) Genome Res. 6:639-645.) Fluorescent probes are prepared and used for hybridization to the elements on the substrate. The substrate is analyzed by procedures described above.

5 VIII. Complementary Polynucleotides

Sequences complementary to the HTMPN-encoding sequences, or any parts thereof, are used to detect, decrease, or inhibit expression of naturally occurring HTMPN. Although use of oligonucleotides comprising from about 15 to 30 base pairs is described, essentially the same procedure is used with smaller or with larger sequence fragments.

- 10 Appropriate oligonucleotides are designed using OLIGO 4.06 software (National Biosciences) and the coding sequence of HTMPN. To inhibit transcription, a complementary oligonucleotide is designed from the most unique 5' sequence and used to prevent promoter binding to the coding sequence. To inhibit translation, a complementary oligonucleotide is designed to prevent ribosomal binding to the HTMPN-encoding
15 transcript.

IX. Expression of HTMPN

- Expression and purification of HTMPN is achieved using bacterial or virus-based expression systems. For expression of HTMPN in bacteria, cDNA is subcloned into an appropriate vector containing an antibiotic resistance gene and an inducible promoter that
20 directs high levels of cDNA transcription. Examples of such promoters include, but are not limited to, the *trp-lac* (*tac*) hybrid promoter and the T5 or T7 bacteriophage promoter in conjunction with the *lac* operator regulatory element. Recombinant vectors are transformed into suitable bacterial hosts, e.g., BL21(DE3). Antibiotic resistant bacteria express HTMPN upon induction with isopropyl beta-D-thiogalactopyranoside (IPTG).
- 25 Expression of HTMPN in eukaryotic cells is achieved by infecting insect or mammalian cell lines with recombinant Autographica californica nuclear polyhedrosis virus (AcMNPV), commonly known as baculovirus. The nonessential polyhedrin gene of baculovirus is replaced with cDNA encoding HTMPN by either homologous recombination or bacterial-mediated transposition involving transfer plasmid
30 intermediates. Viral infectivity is maintained and the strong polyhedrin promoter drives high levels of cDNA transcription. Recombinant baculovirus is used to infect Spodoptera frugiperda (Sf9) insect cells in most cases, or human hepatocytes, in some cases. Infection

of the latter requires additional genetic modifications to baculovirus. (See Engelhard, E. K. et al. (1994) Proc. Natl. Acad. Sci. USA 91:3224-3227; Sandig, V. et al. (1996) Hum. Gene Ther. 7:1937-1945.)

In most expression systems, HTMPN is synthesized as a fusion protein with, e.g.,
5 glutathione S-transferase (GST) or a peptide epitope tag, such as FLAG or 6-His, permitting rapid, single-step, affinity-based purification of recombinant fusion protein from crude cell lysates. GST, a 26-kilodalton enzyme from Schistosoma japonicum, enables the purification of fusion proteins on immobilized glutathione under conditions that maintain protein activity and antigenicity (Amersham Pharmacia Biotech). Following
10 purification, the GST moiety can be proteolytically cleaved from HTMPN at specifically engineered sites. FLAG, an 8-amino acid peptide, enables immunoaffinity purification using commercially available monoclonal and polyclonal anti-FLAG antibodies (Eastman Kodak). 6-His, a stretch of six consecutive histidine residues, enables purification on metal-chelate resins (QIAGEN). Methods for protein expression and purification are
15 discussed in Ausubel (1995, supra, ch 10 and 16). Purified HTMPN obtained by these methods can be used directly in the following activity assay.

X. Demonstration of HTMPN Activity

Given the chemical and structural similarity between the HTMPN and other members of the transmembrane protein families, HTMPN is identified as a new member of
20 the membrane spanning proteins and is presumed to be involved in the regulation of cell growth. To demonstrate that increased levels of HTMPN expression correlates with decreased cell motility and increased cell proliferation, expression vectors encoding HTMPN are electroporated into highly motile cell lines, such as U-937 (ATCC CRL 1593), HEL 92.1.7 (ATCC TIB 180) and MAC10, and the motility of the electroporated
25 and control cells are compared. Methods for the design and construction of an expression vector capable of expressing HTMPN in the desired mammalian cell line(s) chosen are well known to the art. Assays for examining the motility of cells in culture are known to the art (cf Miyake, M. et al. (1991) J. Exp. Med. 174:1347-1354 and Ikeyama, S. et al. (1993) J. Exp. Med. 177:1231-1237). Increasing the level of HTMPN in highly motile cell
30 lines by transfection with an HTMPN expression vector inhibits or reduces the motility of these cell lines, and the amount of this inhibition is proportional to the activity of HTMPN in the assay.

Alternatively, the activity of HTMPN may be measured using an assay based upon the property of MPs to support in vitro proliferation of fibroblasts and tumor cells under serum-free conditions. (Chiquet-Ehrismann, R. et al. (1986) Cell 47:131-139.) Wells in 96 well cluster plates (Falcon, Fisher Scientific, Santa Clara, CA) are coated with HTMPN by
5 incubation with solutions at 50-100 µg HTMPN/ml for 15 min at ambient temperature. The coating solution is aspirated, and the wells washed with Dulbecco's medium before cells are plated. Rat fibroblast cultures or rat mammary tumor cells are prepared as described. (Chiquet-Ehrismann, R. et al. supra.) and plated at a density of 10^4 - 10^5 cells/ml in Dulbecco's medium supplemented with 10% fetal calf serum.

10 After three days the medium is removed, and the cells washed three times with phosphate-buffered saline (PBS), pH 7.0, before addition of serum-free Dulbecco's medium containing 0.25 mg/ml bovine serum albumin (BSA, Fraction V, Sigma Chemical Company, St. Louis, MO). After 2 days the medium is aspirated, and 100 µl of [³H]thymidine (NEN) at 2 µCi/ml in fresh Dulbecco's medium containing 0.25 mg/ml
15 BSA is added. Parallel plates are fixed and stained to determine cell numbers. After 16 hr, the medium is aspirated, the cell layer washed with PBS, and the 10% trichloroacetic acid-precipitable radioactivity in the cell layer determined by liquid scintillation counting (normalized to relative cell numbers; Chiquet-Ehrismann, R. et al. supra). The amount of radioisotope-labeled DNA incorporated into chromatin under serum-free conditions is
20 proportional to the activity of HTMPN.

Alternatively, HTMPN, or biologically active fragments thereof, are labeled with ¹²⁵I Bolton-Hunter reagent (See, e.g., Bolton et al. (1973) Biochem. J. 133:529). Candidate molecules previously arrayed in the wells of a multi-well plate are incubated with the labeled HTMPN, washed, and any wells with labeled HTMPN complex are assayed. Data
25 obtained using different concentrations of HTMPN are used to calculate values for the number, affinity, and association of HTMPN with the candidate molecules.

XI. Functional Assays

HTMPN function is assessed by expressing the sequences encoding HTMPN at physiologically elevated levels in mammalian cell culture systems. cDNA is subcloned
30 into a mammalian expression vector containing a strong promoter that drives high levels of cDNA expression. Vectors of choice include pCMV SPORT (Life Technologies) and pCR3.1 (Invitrogen, Carlsbad CA), both of which contain the cytomegalovirus promoter.

5-10 μ g of recombinant vector are transiently transfected into a human cell line, preferably of endothelial or hematopoietic origin, using either liposome formulations or electroporation. 1-2 μ g of an additional plasmid containing sequences encoding a marker protein are co-transfected. Expression of a marker protein provides a means to distinguish transfected cells from nontransfected cells and is a reliable predictor of cDNA expression from the recombinant vector. Marker proteins of choice include, e.g., Green Fluorescent Protein (GFP; Clontech), CD64, or a CD64-GFP fusion protein. Flow cytometry (FCM), an automated, laser optics-based technique, is used to identify transfected cells expressing GFP or CD64-GFP, and to evaluate properties, for example, their apoptotic state. FCM detects and quantifies the uptake of fluorescent molecules that diagnose events preceding or coincident with cell death. These events include changes in nuclear DNA content as measured by staining of DNA with propidium iodide; changes in cell size and granularity as measured by forward light scatter and 90 degree side light scatter; down-regulation of DNA synthesis as measured by decrease in bromodeoxyuridine uptake; alterations in expression of cell surface and intracellular proteins as measured by reactivity with specific antibodies; and alterations in plasma membrane composition as measured by the binding of fluorescein-conjugated Annexin V protein to the cell surface. Methods in flow cytometry are discussed in Ormerod, M. G. (1994) Flow Cytometry, Oxford, New York NY.

The influence of HTMPN on gene expression can be assessed using highly purified populations of cells transfected with sequences encoding HTMPN and either CD64 or CD64-GFP. CD64 and CD64-GFP are expressed on the surface of transfected cells and bind to conserved regions of human immunoglobulin G (IgG). Transfected cells are efficiently separated from nontransfected cells using magnetic beads coated with either human IgG or antibody against CD64 (DYNAL, Lake Success NY). mRNA can be purified from the cells using methods well known by those of skill in the art. Expression of mRNA encoding HTMPN and other genes of interest can be analyzed by northern analysis or microarray techniques.

XII. Production of HTMPN Specific Antibodies

HTMPN substantially purified using polyacrylamide gel electrophoresis (PAGE; see, e.g., Harrington, M.G. (1990) *Methods Enzymol.* 182:488-495), or other purification techniques, is used to immunize rabbits and to produce antibodies using standard

protocols.

Alternatively, the HTMPN amino acid sequence is analyzed using LASERGENE software (DNASTAR) to determine regions of high immunogenicity, and a corresponding oligopeptide is synthesized and used to raise antibodies by means known to those of skill
5 in the art. Methods for selection of appropriate epitopes, such as those near the C-terminus or in hydrophilic regions are well described in the art. (See, e.g., Ausubel, 1995, supra, ch. 11.)

Typically, oligopeptides 15 residues in length are synthesized using an ABI 431A Peptide Synthesizer (Perkin-Elmer) using fmoc-chemistry and coupled to KLH (Sigma-
10 Aldrich, St. Louis MO) by reaction with N-maleimidobenzoyl-N-hydroxysuccinimide ester (MBS) to increase immunogenicity. (See, e.g., Ausubel, 1995, supra.) Rabbits are immunized with the oligopeptide-KLH complex in complete Freund's adjuvant. Resulting antisera are tested for antipeptide activity by, for example, binding the peptide to plastic, blocking with 1% BSA, reacting with rabbit antisera, washing, and reacting with radio-
15 iodinated goat anti-rabbit IgG.

XIII. Purification of Naturally Occurring HTMPN Using Specific Antibodies

Naturally occurring or recombinant HTMPN is substantially purified by immunoaffinity chromatography using antibodies specific for HTMPN. An immunoaffinity column is constructed by covalently coupling anti-HTMPN antibody to an
20 activated chromatographic resin, such as CNBr-activated SEPHAROSE (Amersham Pharmacia Biotech). After the coupling, the resin is blocked and washed according to the manufacturer's instructions.

Media containing HTMPN are passed over the immunoaffinity column, and the column is washed under conditions that allow the preferential absorbance of HTMPN (e.g.,
25 high ionic strength buffers in the presence of detergent). The column is eluted under conditions that disrupt antibody/HTMPN binding (e.g., a buffer of pH 2 to pH 3, or a high concentration of a chaotrope, such as urea or thiocyanate ion), and HTMPN is collected.

XIV. Identification of Molecules Which Interact with HTMPN

HTMPN, or biologically active fragments thereof, are labeled with ¹²⁵I Bolton-Hunter reagent (See, e.g., Bolton et al. (1973) Biochem. J. 133:529). Candidate
30 molecules previously arrayed in the wells of a multi-well plate are incubated with the labeled HTMPN, washed, and any wells with labeled HTMPN complex are assayed. Data

obtained using different concentrations of HTMPN are used to calculate values for the number, affinity, and association of HTMPN with the candidate molecules.

Various modifications and variations of the described methods and systems of the invention will be apparent to those skilled in the art without departing from the scope and
5 spirit of the invention. Although the invention has been described in connection with specific preferred embodiments, it should be understood that the invention as claimed should not be unduly limited to such specific embodiments. Indeed, various modifications of the described modes for carrying out the invention which are obvious to those skilled in molecular biology or related fields are intended to be within the scope of the following
10 claims.

Table I

Protein SEQ ID NO:	Nucleotide SEQ ID NO:	Clone ID	Library	Fragments
1	80	153831	THP1P1B02	153831 (THP1P1B02), 2700741111 (COVAR111110), 881348R1 (H1YRNO102), 185658816 (PROSNO118)
2	81	350629	LVENNO101	350629 and 35062916 (LVENNO101), 3499109H1 (PROSTUT113)
3	82	729171	LUNGNO103	729171 and 729171R6 (LUNGNO103), 1645343H1 (HEARFE101), 680519X2 and 680519X1 (UTRSNO102), 625051R6 (PGANNO101), 1459466F1 (COLNFE102), 1225759T1 (COLNNO101), 2590526H1 (LUNGNOT22), 2807811H1 (BLADTUT08)
4	83	1273641	TESTTUT02	1273641 and 1273641F6 (TESTTUT02), 1308181F6 and 1308181F1 (COLNFE102), 1427606F1 (SINTBST01), 756171H1 (BRAITUT02), 2416518F6 (HNT3AZ101), 4242346H1 (SYNWDIT01)
5	84	1427389	SINTBST01	1427389 (SINTBST01), 3097151H1 (CERVNOT03), 723779R1 (SYNNOOAT01)
6	85	1458357	COLNFE102	1458357 (COLNFE102), SAOA01955F1, SAOA03146F1, SAOA03356F1, SAOA00213F1
7	86	1482837	CORPNOT02	1482837 and 1482837T6 (CORPNOT02), 869453H1 (LUNGAST01), 3564972F6 (SKINNO105), 663983H1 (SCORNOT01), 1315073F6 (BLADTUT102), 3809242H1 (CONTTUT01), 31145916 (LUNGNOT02), 1798893F6 (COLNNOT27)
8	87	1517434	PANCTUT01	1517434 (PANCTUT01), 2848842H1 (BRSTTUT13), 586843X1 (UTRSNOT01), 1261245R1 (SYNORAT05), 1554505F1 (BLADTUT04)
9	88	1536052	SPLNNO104	1536052 and 1531447T6 (SPLNNOT04), 1729124T6 (BRSTTUT08)
10	89	1666118	BRSTNO109	1666118 (BRSTNOT09), 907075R2 (COLNNO108), 1524914H1 (UCMC15101), 128345916 (COLNNO116)
11	90	1675560	BLADNO105	1675560 and 1675560T6 (BLADNOT05)
12	91	1687323	PROSTUT10	1687323 and 1687323F6 (PROSTUT10), 2292356R3 (BRAINON01)
13	92	1692236	PROSTUT10	1692236 (PROSTUT10), 2786557F6 (BRSTNO113), 602869R6 and 602869T6 (BRSTTUT01), 2258230H1 (OVARTUT01), 780083T1 (MYOMNO101), 2057230T6 (BEPINOT01), 288105R1 (EOSHET02)
14	93	1720847	BLADNO106	1720847, 1722250F6, and 1722250T6 (BLADNO106)

Table 1 (cont.)

Protein SEQ ID NO:	Nucleotide SEQ ID NO:	Clone ID	Library	Fragments
15	94	1752821	LIVR1U101	1752821 (LIVR1U101), 3180328H1 (H1YINOT01), 1969457T6 (BRSTNOT04), 2608504H11 (BONTNO101), 2455688T6 and 2455688T6 (ENDANO101), 1816354F6 (PROSNOT20)
16	95	1810923	PROSTU112	1810923 and 1810923T6 (PROSTU112), 3221260H1 (COLNNO103)
17	96	1822315	GBLA1U101	1822315 (GBLA1U101), 1841726H1 (COLNNO107), 1598582T6 (BLADNO103), 1264125R1 (SYNORAT05), 645048H1 (BRSTTUT02), 1474782H1 (LUNG1U103), 352739F1 (LVENNOT01), 876001R1 (LUNGAST01)
18	97	1877777	LEUKNO103	1877777 (LEUKNOT03), 1219656H1 (NEUTGMT01), 1471553T1 (LUNG1U103)
19	98	1879819	LEUKNOT03	1879819 (LEUKNOT03), 1734538H1 (COLNNO122), 1428615F6 (SINTBST01), 3558710H1 (LUNGNO131), 1996096R6 (BRSTTUT03)
20	99	1932945	COLNNOT16	1932945 (COLNNOT16), 2383333H1 (ISL1NOT01), 2706050F6 (PONSAT01), 2061026 (OVARNO103)
21	100	2061026	OVARNO103	2061026 (OVARNO103)
22	101	2096687	BRAITUT02	2096687 (BRAITUT02), 2204640H1 (SPI1NFE102)
23	102	2100530	BRAITUT02	2100530 (BRAITUT02), 2740969F6 (BRSTTUT14)
24	103	2357636	LUNGNO120	2357636 (LUNGNO120), 2693537H1 (LUNGNO123), 1794235T6 (PROSTU105), 235425R6 (SINTNO102), 760091R1 (BRAITUT02), 887877R1 (PANCNO105)
25	104	2365230	ADRENOT07	2365230 (ADRENOT07), 2921195H1 (SININOT04)
26	105	2455121	ENDANO101	2455121 and 2455121F6 (ENDANO101)
27	106	2472514	THP1NOT03	2472514 (THP1NOT03), 3212904H1 (BLADNOT08)
28	107	2543486	UTRSNOT11	2543486 (UTRSNOT11), 2374764H1 (ISL1NOT01), 1359576F1 (LUNGNO112), 1357170H1 (LUNGNO109)
29	108	2778171	OVARUT03	2778171 (OVARUT03), 1822045H1 (GBLA1U101), 1692535F6 (COLNNO123), 1905275F6 (OVARNO107)

Table 1 (cont.)

Protein SEQ ID NO:	Nucleotide SEQ ID NO:	Clone ID	Library	Fragments
30	109	2799575	PLNCNO101	2799575 (PLNCNO101), 874115H1 (LUNGAS101), 967837R1 (BRSINO105), 323524816 and 3235248F6 (COLNUC103)
31	110	2804955	BLADTUT08	2804955 (BLADTUT08), 732534H1 (LUNGNOT03), 402168R1 (TMLR3DJ101), 3481814H1 (KIDNNOT31), 1485989F1 (CORPNO102)
32	111	2806395	BLADTUT08	2806395 (BLADTUT08), 1579109H1 (DUODNOT01), 1533572F1 (SPLNNO104), 1889837F6 and 1889837I6 (BLADTUT07), 2414178F6 (HNT3AZ101)
33	112	2836858	TYMNOT03	2836858 and 2836858CT1 (TYMNOT03), 2127516H1 (KIDNNOT05)
34	113	2844513	DRGLNOT01	2844513 and 2844513I6 (DRGLNOT01), 388885T6 (HYMNOT02), 287344F1 (E-OSIH102), 3867626H1 (BMARNOT03)
35	114	3000380	TYMNOT06	3000380 (TYMNOT06), 1930658H1 (COLNUT03), 2395295F6 (HIP1AZ101), 1242456R6 (LUNGNOT03)
36	115	182532	PLACNOB01	062374H1, 062962R6, 064457R6, and 182532H1 (PLACNOB01), 3144248XI2F1 (HNT2AZS07)
37	116	239589	HIPONOT01	239589H1 and 239589X13 (HIPONOT01), 264805R6 (HNT2AG101), 552683X17 (SCORNO101), 1595053F1 (BRAINOT14)
38	117	1671302	BMARNOT03	399804H1 (PITUNOT02), 1458549H1 (COLNFE102), 1671302F6 and 1671302H1 (BMARNOT03), 2093453R6 (PANCNOT04), 2498385F6 and 2498385T6 (ADRETUT05)
39	118	2041858	HIPONON02	063184R1 (PLACNOB01), 1294823F1 (PGANNO103), 1303974F1 (PLACNO102), 1648770F6 (PROSTUT09), 2041858H1 (HIPONON02)
40	119	2198863	SPLNFE102	1880470F6 (LEUKNOT03), 1888946F6 (BLADTUT07), 2198863F6 and 2198863H1 (SPLNFE102)
41	120	3250703	SEMVNOT03	1317728H1, 1318433H1, 1319354H1, 1319380F1, 1320494H1, and 1320812F1 (BLADNO104), 3247874H1, 3249188H1, 3249385H1, and 3250703H1 (SEMVNOT03)
42	121	350287	LVENNOT01	062018F1 (PLACNOB01), 350287H1 (LVENNO101), 869320R1 (LUNGAS101), 1416927F6 (BRAINOT12), 3083789H1 (OVARFUN01)
43	122	1618171	BRAITUT12	1618171F6 and 1618171H1 (BRAITUT12), 3316315F6 (PROSBPT03)

Table 1 (cont.)

Protein SEQ ID NO:	Nucleotide SEQ ID NO:	Clone ID	Library	Fragments
44	123	1625863	COLNPO101	1625863H1 and 1625863T6 (COLNPO101), 2100364R6 (BRAHUT02)
45	124	1638353	UTRSNO106	1638353H1 (UTRSNO106), 3733085H1 (SMCUNOS01), 3882774T6 (SPLNNO11), 1626195T6 (COLNPO101), 1495745H1 (PROSNON01)
46	125	1726843	PROSN0114	826000T1 (PROSN0106), 1726843F6 and 1726843H1 (PROSN0114), 2225762F6 (SEMVNO101), 2480248H1 (SMCANOT01), 2600692F6 (UTRSNOT10), 2728257F6 (OVARUT05)
47	126	1754506	LIVRTU101	907854R2 (COLNNO109), 1354345F1 (LUNGNOT09), 1359472F1 (LUNGNOT12), 1397284F1 (BRAITUT08), 1557921F1 (BLAD1U104), 1754506F6 and 1754506H1 (LIVRTUT01)
48	127	1831378	THPIAZ101	441541R1 (MPHGN0103), 712292R6 (SYNORA104), 1311835F1 (COLNFET02), 1555765F6 (BLADTUT04), 1831378H1 (THPIAZ101), 1865502F6 (PROSNOT19), 3077521H1 (BONEUNT01), 3555043H1 (SYNNO101), 3774618H1 (BRSTNOT25)
49	128	1864943	PROSN0119	714070F1 (PROSTUT01), 736327R1 (TONSNOT01), 1864943H1 (PROSN0119), 2672921F6 (KIDNNOT19)
50	129	1911316	CONNTUT01	777070F1 (COLNNO105), 1911316H1 and 1911316T6 (CONNTUT01)
51	130	1943120	HIPONOT01	1516263F1 (PANCUTUT01), 1943120H1 (HIPONOT01), 2469009F6 (THYRNO108), 2522459F6 (BRAITUT21), 3202972F6 (PENCNO102), 4383679H1 (BRAVUT02)
52	131	2314236	NGANNO101	2314236H1 (NGANNO101), 2812085F6 (OVARNO110), 3949704T6 (DRGCNO101)
53	132	2479409	SMCANO101	2479409F6 and 2479409H1 (SMCANOT01)
54	133	2683149	SINIUCT01	760389H1 (BRAITUT02), 1634372F6 (COLNNO119), 1695052F6 (COLNNO123), 1736429F6 (COLNNO122), 2048429F6 (LIVRFET02), 2683149H1 (SINIUCT01), 3282234F6 (STOMFET02)
55	134	2774051	PANCNO115	1852505F6 (LUNGFET03), 2774051F6 and 2774051H1 (PANCNO115)
56	135	2869038	THYRNO110	536017R6 (ADRENOT03), 2770632F6 (COLANOT02), 2795420F6 (NIPOLNO101), 2869038F6 and 2869038H1 (THYRNOT10), 3323992H1 (PTHYNO103)
57	136	2918334	THYMFET03	2918334H1 (THYMFET03), SBNA01788F1

Table 1 (cont.)

Protein SEQ ID NO:	Nucleotide SEQ ID NO:	Clone ID	Library	Fragments
58	137	2949916	KIDNFE101	2949916H1 (KIDNFE101), SBMA007381F1
59	138	2989375	KIDNFE102	437481R6 and 437481T6 (THYRNO101), 2989375H1 (KIDNFE102)
60	139	3316764	PROSBP103	1328462F1 (PANCNOT07), 1691807T6 (PROS1U110), 1851237T6 (LUNGFE103), 3316764H1 (PROSBP103), 5092348H1 (UTRSTMR01)
61	140	3359559	PROSTUT16	943684 and 943564 (ADRENOT03), 1697079F6 (COLNNO123), 2717735H1 (THYRNOT09), 2792705H1 (COLNTUT16), 3359559H1 (PROSTUT16)
62	141	4289208	BRABDIR01	3990421R6 (LUNGNON03), 4289208H1 (BRABDIR01)
63	142	2454013	ENDANOT01	014571R1 (THIPLB01), 1303790T1 (PLACNO102), 1342791T1 (COLNTUT03), 1351680F1 (LATRTUT02), 1359607T1 (LUNGNOT12), 2454013F6 and 2454013H1 (ENDANOT01)
64	143	2454048	ENDANOT01	551329R1 and 2056675R6 (BEPINOT01), 819281R1 (KERANO102), 2454048H1 (ENDANOT01), 3143588H1 (HNT2AZS07)
65	144	2479282	SMCANOT01	873307R1 (LUNGAST01), 2479282H1 and 2479282T6 (SMCANOT01), 2610082F6 (COLNTUT15), SANA03636F1
66	145	2483432	SMCANOT01	940455T1 (ADRENOT03), 1863558T6 (PROSNOT19), 2483432H1 (SMCANOT01), 2641345H1 (LUNG1UT08), 3245089T6 (BRAINOT19), SBCA02765F1
67	146	2493824	ADRETUT05	489685F1 (HNT2AGT01), 530794H1 (BRAINOT03), 735826R1 (TONSNOT01), 2056809R6 (BEPINOT01), 2493824H1 (ADRETUT05), 2763162F6 (BRSTNOT12), 2812426H1 (OVARNOT10)
68	147	2555823	THYMINOT03	1266972F6 (BRAINOT09), 1335461T1 (COLNNOT13), 1900947F6 (BLAD1UT06), 194225616 (HIPONOT01), 2555823H1 (THYMINOT03), SARB01019F1, SARB01303F1
69	148	2598242	OVAR1UT02	320268F1 (EOSHET02), 738915R1 (PANCNOT04), 1250161F1 (LUNGFE103), 2598242F6 and 2598242H1 (OVAR1UT02), 5020793H1 (OVARNON03), SASA00178F1
70	149	2634120	COLNTUT15	1398694F1 (BRA1TUT08), 1506594F1 (BRA1TUT07), 2120954F6 (BRSTNOT07), 2634120F6 and 2634120H1 (COLNTUT15), 2761586H1 (BRAINOS12), 2806841F6 (BLAD1UT08)

Table 1 (cont.)

Protein SEQ ID NO:	Nucleotide SEQ ID NO:	Clone ID	Library	Fragments
71	150	2765411	BRSTNO112	27652361f6 and 27654111H1 (BRSTNO112), 4058218H1 (SP1 NNO113)
72	151	2769412	COLANO102	1715480F6 (UCMCNO102), 2769412H1 (COLANO102), SBDA04076F1
73	152	2842779	DRGLNO101	1262711R1 (SYNGRAT05), 1710449T6 (PROSNO116), 2842779F6 (DRGLNO101), 2842779H1 (DRGLNO101), 2850941F6 (BRSTTU113), 3123378H1 (LNO105), 3457873H1 (2931F1101), SBGA04623F1, SAOA02667F1
74	153	2966260	SCORNO104	5302421H1 (BRAINO103), 2113607H1 (BRAITU103), 2125619F6 (BRSTNO107), 2155349H1 and 2156022H1 (BRAINO109), 2966260F6, 2966260H1, and 2966260T6 (SCORNO104), 3270731H1 (BRAINO120), 3272328F6 (PROSBPT06)
75	154	2993326	KIDNFE102	190217F1 (SYNORAB01), 815990R1 and 815990T1 (OVARIUT01), 2993326H1 (KIDNFE102), 3629860H1 (COLNNO138)
76	155	3001124	TYMNNO106	2123347T6 (BRSTNO107), 3001124H1 (TYMNNO106), SBEA07088F3
77	156	3120070	LUNGTUT13	021565F1 (ADENINB01), 144798R1 (TYMNNO101), 1216676H1 (BRSTTUT01), 2024357H1 (KERANO102), 2616322H1 (GBLANO101), 2742604H1 (BRSTTUT14), 2746025H1 (LUNGTUT11), 2924884H1 (SININOT04), 3120070H1 (LUNGTUT13)
78	157	3133035	SMCCNO101	1478001F1 and 1482667H1 (CORPNO102), 2812193F6 and 2812193T6 (OVARNOT10), 3133035H1 and 3133035T6 (SMCCNO101), 5025075F6 (OVARNON03)
79	158	3436879	PENCNO105	3323031F6 (PTHYNO103), 3436879F6 and 3436879H1 (PENCNO105), 4247733H1 (BRABDIT01)

Table 2

SEQ ID NO:	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequence	Identification	Analytical Methods
1	240	S233 S159 T194 I43 I77 I129 T134 S171	N73 N101 N167	S33-G36 L198-L219	Somatostatin receptor tyrosine kinase	BLAST, BLOCKS, HMM
2	100	S6 S64			Meningioma-expressed antigen 11	BLAST, PRINTS, HMM
3	416	S14 S62 T109 T177 T340 S365 S380 S6 I7 T205 S327 T331 Y56	N144 N277		PMP-22/FMP/MP20 family	BLOCKS, PRINTS, HMM
4	224	T31 T57 S86 S173 S214			B cell growth factor	BLAST
5	247	S103 T60 S113 S235			5-hydroxytryptamine receptor	PRINTS
6	72				Fizzled protein	PRINTS, HMM
7	106	S97 S9 S24 T31			Dopamine 2 receptor	BLAST, PRINTS, HMM
8	239	S233	N230		PB39 protein	BLAST, HMM
9	150	S53 S111 T127			CD44 antigen precursor	PRINTS, HMM
10	110	S12	N92		Anion exchanger	BLOCKS, PRINTS, HMM
11	58		N5 N9		Neurofibromatosis type 2	BLAST, PRINTS, HMM
12	221	S35 S178 S60 S183			mitsugumin 23	BLAST, HMM

Table 2 (cont.)

SEQ ID NO:	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequence	Identification	Analytical Methods
13	262	T33 S94 S150 T225 T245 T14 S22 T30 T57 S137 T201 S207 T230	N104		C5a-anaphylatoxin receptor	PRINTS, HMM
14	90	S67 T52			Frizzled protein	PRINTS, HMM
15	208	T119 T123 T132 S56 S142	N121		Rieske iron-sulphur protein	BLOCKS, PRINTS, HMM
16	97	S61 T2			Endothelin B receptor	PRINTS, HMM
17	243	S82 T104 S168 T181 S6 S99 T195 Y24			Thromboxane receptor	PRINTS, HMM
18	162	S26	N6		G protein-couple receptor	BLOCKS, PRINTS, HMM
19	470	S285 S29 T136 S145 T167 T168 S199 S236 S249 T401 S172 S209 S254 T264 S335 T385	N118 N298 N466	R306-D308	Molluscan rhodopsin C-terminus	PRINTS, HMM
20	144	S42 S21 T72	N30 N36		Lysosome-associated membrane protein	PRINTS, HMM
21	221	S75 T82		S151-G154	Glycoprotein hormone receptor	BLAST, PRINTS, HMM
22	688	T60 T186 T103 T298 S405 S484 S488 S492 S494 S498 S499 S503 S584 S601 S611 S647 T663 T109 T188 T284 T315 S324 S347 T402 T573 S643 T658 T681 Y118	N198 N576 N577 N582	S5-G8 A80-N140	Ring3	BLAST, PRINTS

Table 2 (cont.)

SEQ ID NO:	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequence	Identification	Analytical Methods
23	439	I75 I257 S397 S424 S210 S435	N227	S365-G368	Prostanoid EP3 receptor	BLOCKS, PRINTS
24	192	S20 S44	N68		PMP-22/EMP/MP20 family	BLOCKS, PRINTS, HMM
25	175	T171 I43 S136 T7			Progesterone receptor	PRINTS
26	91	S34 S19 S29			Similar to mouse disvelled-3(Dvl-3)	BLAST, BLOCKS, PRINTS, HMM
27	214	T34 S83 T118 T152 S17			Somatostatin receptor tyrosine kinase	BLOCKS, PRINTS, HMM
28	250	S64 S132 T154			Sec22 homolog	BLAST, HMM
29	84	T80 T3 S76			DPM2 protein	BLAST, HMM
30	277	T140 S217 S19 S85 T129			Somatomedin B domain protein	BLOCKS, PRINTS, HMM
31	273	S64 S4 S114 S179 S256 S14 T167 T218	N187		Anion exchanger family	BLOCKS, PRINTS, HMM
32	524	T190 S5 T131 S148 S171 S262 S275 I302 S356 S404 S473 S177 S207 T492	N152 N471 N501 N513	I46-I67	G protein-coupled receptor	BLOCKS, PRINTS, HMM
33	257	S48 S52 S55 T64 S82 T90 S96 T97 S123 T129 T144 S192 S224 T227 S250	N98 N187		Nucleoporin p62 homolog	BLAST
34	274	S16 I84 S249 S56 S113	N234		Molluscan rhodopsin C-terminus	PRINTS

Table 2 (cont.)

SEQ ID NO.	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequence	Identification	Analytical Methods
35	281	S52 T150 S165 S263 L48 S116 T167 T226 T241		G125-S132 S185-G188	ABC 2 type transport protein	BLOCKS, PRINTS, HMM
36	335	S96 T113 T131 T308 T14 T146 T292 S302 S312 T317 Y258	N104 N111	E296 to A307 R127 to G129	pregnancy-specific beta 1-glycoprotein-4 precursor	Blast, BLOCKS, PRINTS, Motifs
37	280	T41 S102 T135 S148	N35 N53 N127	T56 to Y70	lysosomal membrane glycoprotein-type A precursor	Blast, BLOCKS, PRINTS, Motifs
38	210	S50 S143 S151 S63 S107 S153			Butyrophilin	Blast
39	279	T90	N66 N171		Plasma membrane glycoprotein C1G30	Blast
40	154	T75 S121 S48 S58 T112 Y84 Y90		G101 to G122 V115 to F130	Pathogenesis-related protein PR-1	Blast, BLOCKS, PRINTS
41	582	S160 S255 T256 S291 S292 S316 S351 S352 S411 S412 S471 S472 T485 S533 T559 S79 T93 S96 S151 S231		G520 to S527	semenogelin II	Blast, Motifs
42	71	S17 T45 T50		M1 to T50 P5 to C29	Integral membrane protein	BLOCKS, PRINTS
43	102	T44 S33 T75		S6 to L24 S33 to G36 I49 to I74 A2 to S29	TM4SF	BLOCKS, PRINTS, HMM
44	226	S60 T3 T4 S85 T169	N46 N82 N83	I184 to R205 G128 to Q152 Y179 to Y201	Cation-dependant mannose transporter protein	PRINTS, HMM

Table 2 (cont.)

C ₁ Q HD NO	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequence	Identification	Analytical Methods
45	154	T145 T148 S33 T134 T141 S152		M1 to A22 P56 to M78 P58 to M82 L91 to S110 L109 to L125	Fizzled protein	PRINTS, HMM
46	167	S154 S3 T25 T29 T126 S140		E72 to F103	GPCR	BLOCKS, PRINTS, HMM
47	545	T257 S513 S10 T11 S47 S166 S408 S495	N8 N406	E376 to K410	Human secreted protein K640 variant	Blast, BLOCKS, PRINTS, HMM
48	570	T529 S128 S130 T184 T235 T161 S293 Y199	N27 N61 N75 N87 N264	V296 to C309 F321 to F332	GPCR	Blast, BLOCKS, PRINTS, HMM
49	127	S24 T118		N10 to G30	Anion exchanger	PRINTS, HMM
50	152	T49 S16		L78 to L99 L85 to L106 V47 to Y63 Y45 to V94	TM4SF GNS1/SUR4 family	BLOCKS, HMM, Motifs
51	777	T48 S66 S162 T268 S272 T322 T355 S393 S471 S559 S574 S624 S660 S700 T742 S750 S11 T12 S196 S346 T400 S423 T493 T579 T582 S599 S723	N64 N205 N470 N706	T20 to D34 R122 to L132 L598 to L619 D331 to L349 R565 to T582	pecanex protein	Blast, PRINTS, Motifs
52	108	S52 T31 T105		L76 to Y92	GNS1/SUR4 family	BLOCKS, PRINTS, PROTESCAN
53	66	S4 S35	N2	F22 to G58	NF2 protein	Blast, BLOCKS, PRINTS, HMM

Table 2 (cont.)

SEQ ID NO:	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequence	Identification	Analytical Methods
54	540	S135 S149 I527 I82 I94 I177 S441	N50 N92 N160 N334 N395	S115 to G118 L295 to L308 L490 to L518	IIV-1 protein	Blast, PRINTS, HMM, Motifs
55	87	T4 S13 S37 S68 S69		I46 to L82	calyculin	BLOCKS, HMM
56	100	S94		I7 to N34 G8 to F21 K65 to N91 T78 to C97	ammonium ion transporters	BLOCKS, PRINTS, HMM
57	58	T43			shox protein	BLAST, HMM
58	61	S51 S58 S42		R2 to L23	carboxyl ester lipase	Blast, PRINTS, HMM
59	50	S9		C33 to W45 C11 to L40	Lipoxygenase; growth factor and cytokines receptor family	BLOCKS, PRINTS, HMM, Motifs
60	310	T46 T156 S301 T81 S108 S166 S305		A153 to S166	C4 methyl-sterol oxidase	Blast, PRINTS, HMM
61	160	S114		L71 to W84 Y143 to T154	C5A-anaphylatoxin receptor	Blast, BLOCKS, PRINTS, HMM
62	35			K11 to M34	steroid hormone receptor	PRINTS
63	323	T92 S105 S182 T263 S301 S271	N90	M1-G31 Signal Peptide M1-A27 Signal Peptide L234-L254 TM Protein	Signal Peptide Containing Transmembrane Protein	Motifs SPScan HMM

Table 2 (cont.)

SEQ ID NO:	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequence	Identification	Analytical Methods
64	129	T112 T117 S5 S54		M1-G27 Signal Peptide M1-G27 Signal Peptide I81-V100 TM Prot	Signal Peptide Containing Transmembrane Protein	Motifs SPScan HMM
65	461	I56 I41 S47 I56 T127 S146 S147 S197 S198 T407 S8 S47 T51 T284 T341 T407	N193 N236		Signal Peptide Containing Transmembrane Protein	Motifs
66	264	S243 T264 S33 T211 S260 S22 S243 S260	N172 N250	M1-A17 Signal Peptide M1-S22 Signal Peptide I173-Y195 TM Prot M1-L21 TM Prot L25-R30 Prot. Splicing	Protein Splicing Protein	Motifs SPScan HMM BLOCKS
67	339	T99 S119 S157 S166 S321 T54 S55 T77 S149 S211 S279 T336 Y105	N172	M1-G30 Signal Peptide M1-G26 Signal Peptide L176-L194 TM. Prot.	Signal Peptide Containing Transmembrane Protein	Motifs SPScan HMM
68	397	S104 T148 T166 T259 S303 S317 T127 T191 S302		G202-S209 AIP GTP binding L10-L31 Leucine zipper D106-L108 Ca binding S367-L384 Signal Peptide M1-G29 Transmembr Prot.	Gene Regulatory Protein	Motifs SPScan BLOCKS HMM
69	301	T7 S52 S100 S133 S239 T155 T206	N162 N211	V12-A32 TM. Prot. V282-G300 TM. Prot. L59-V64 aatRNA ligase	Aminoacyl tRNA ligase	Motifs HMM BLOCKS
70	217	S8 S142 T112 T197		W73-199 TM. Prot.	Cell Proliferation Protein	Motifs HMM

Table 2 (cont.)

SEQ ID NO:	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequence	Identification	Analytical Methods
71	143	S81 T120 S139 S116		M1-C26 Signal Peptide M1-R25 Signal Peptide M1-V22 TM Prot.	Signal Peptide Containing Transmembrane Protein	Motifs SPScan HMM
72	186	I50 S132 I151 S116 Y43	N29 N104	M1-S25 Signal Peptide M1-S31 Signal Peptide F9-F28 TM Prot. A27-G89 T-cell receptor interacting molecule	T-cell Receptor Interacting Molecule	Motifs SPScan HMM BLAST
73	364	S172 S213 S243 S302	N229	L234-L255 Leucine zipper M1-G28 Signal Peptide L151-L170 TM. Prot. L72-E92 TM Prot.	Gene Regulatory Protein	Motifs SPScan HMM
74	605	S46 T54 S108 S129 S195 S220 S231 T254 T261 S316 S440 S472 S536 S560 T124	N106 N193 N395 N480	M1-A32 Signal Peptide V494-I515 TM. Prot. I17-E36 TM Prot.	2-Membrane Spanning Signal Peptide Containing Transmembrane Protein	Motifs SPScan HMM
75	97	T2 S87		M1-G26 Signal Peptide M1-G23 Signal Peptide V35-M54 TM. Prot. I11-I34 TM Prot.	2-Membrane Spanning Signal Peptide Containing Transmembrane Protein	Motifs SPScan HMM
76	247	S160 T204 S165		F72-L90 Transmembr. Prot. L45-T64 Transmembr. Prot.	2-Membrane Spanning Signal Peptide Containing Transmembrane Protein	Motifs HMM

Table 2 (cont.)

SEQ ID NO:	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequence	Identification	Analytical Methods
77	193	S60 S67		M1-D26 Signal Peptide M1-A31 Signal Peptide M80-M104 TM Prot. R109-Y129 TM Prot. S67-L108 PMP-22 Y149-Y176 PMP-22 N150-A159 Trehalase	Peripheral Myelin Protein 22	Motifs SPScan HMM BLOCKS
78	128	S30 S30 S50	N71 N84 N91	N126-L128 microbodies targeting motif	Microbody Protein	Motifs
79	115	S109		M1-S16 Signal Peptide M1-T24 Signal Peptide M1-W19 TM Prot. V27-Y46 TM Prot. V5-V15 G Prot. Receptor	G Protein Receptor	Motifs SPScan HMM PRINTS

Table 3

Nucleotide SEQ ID NO:	Tissue Expression (Fraction of Total)	Disease Class (Fraction of Total)	Vector
80	Reproductive (0.321) Cardiovascular (0.143) Gastrointestinal (0.134)	Cancer (0.527) Inflammation (0.232) Fetal (0.170)	pBLUESCRIPT
81	Cardiovascular (0.500) Gastrointestinal (0.250) Other (0.250)	Cancer (0.500) Fetal (0.250) Other (0.250)	pBLUESCRIPT
82	Reproductive (0.260) Cardiovascular (0.220) Gastrointestinal (0.120)	Cancer (0.500) Inflammation (0.180) Fetal (0.160)	pSPORT 1
83	Nervous (0.400) Gastrointestinal (0.300) Developmental (0.100)	Cancer (0.500) Inflammation (0.300) Fetal (0.200)	pINCY 1
84	Reproductive (0.266) Gastrointestinal (0.141) Cardiovascular (0.125)	Cancer (0.469) Inflammation (0.250) Fetal (0.195)	pINCY 1
85	Reproductive (0.750) Developmental (0.250)	Cancer (0.750) Fetal (0.250)	pINCY 1
86	Reproductive (0.250) Cardiovascular (0.143) Nervous (0.143)	Inflammation (0.321) Trauma (0.286) Cancer (0.250)	pINCY 1
87	Reproductive (0.368) Developmental (0.158) Cardiovascular (0.105)	Cancer (0.421) Fetal (0.368) Inflammation (0.211)	pINCY 1
88	Hematopoietic/Immune (0.417) Cardiovascular (0.250) Reproductive (0.167)	Inflammation (0.417) Cancer (0.333) Fetal (0.167)	pINCY 1
89	Cardiovascular (0.220) Nervous (0.171) Reproductive (0.122)	Cancer (0.463) Inflammation (0.195) Trauma (0.171)	pINCY 1
90	Gastrointestinal (0.200) Reproductive (0.200) Urologic (0.200)	Cancer (0.500) Inflammation (0.300) Other (0.100)	pINCY 1

Table 3 (cont.)

Nucleotide SEQ ID NO:	Tissue Expression (Fraction of Total)	Disease Class (Fraction of Total)	Vector
91	Reproductive (0.306) Cardiovascular (0.204) Nervous (0.122)	Cancer (0.510) Inflammation (0.204) Fetal (0.143)	pINCY1
92	Reproductive (0.227) Hematopoietic/Immune (0.182) Cardiovascular (0.136)	Cancer (0.432) Fetal (0.273) Inflammation (0.273)	pINCY1
93	Gastrointestinal (0.375) Reproductive (0.188) Cardiovascular (0.125)	Cancer (0.500) Inflammation (0.250) Trauma (0.125)	pINCY1
94	Reproductive (0.333) Cardiovascular (0.214) Gastrointestinal (0.143)	Cancer (0.548) Inflammation (0.167) Fetal (0.143)	pINCY1
95	Cardiovascular (0.231) Gastrointestinal (0.231) Reproductive (0.192)	Cancer (0.500) Inflammation (0.231) Fetal (0.154)	pINCY1
96	Gastrointestinal (0.208) Cardiovascular (0.167) Reproductive (0.167)	Cancer (0.542) Inflammation (0.292) Other (0.083)	pINCY1
97	Hematopoietic/Immune (0.341) Reproductive (0.268) Cardiovascular (0.122)	Cancer (0.415) Inflammation (0.415) Fetal (0.195)	pINCY1
98	Gastrointestinal (0.346) Reproductive (0.231) Hematopoietic/Immune (0.154)	Inflammation (0.462) Cancer (0.385) Fetal (0.115)	pSPORT1
99	Gastrointestinal (0.400) Developmental (0.200) Nervous (0.200)	Cancer (0.400) Fetal (0.200) Neurological (0.200)	pSPORT1
100	Reproductive (0.231) Nervous (0.168) Cardiovascular (0.140)	Cancer (0.441) Inflammation (0.231) Fetal (0.133)	pSPORT1
101	Hematopoietic/Immune (0.225) Reproductive (0.225) Gastrointestinal (0.125)	Cancer (0.475) Inflammation (0.325) Fetal (0.175)	pINCY1
102	Reproductive (0.333) Gastrointestinal (0.185) Nervous (0.148)	Cancer (0.630) Fetal (0.185) Inflammation (0.111)	pINCY1

Table 3 (cont.)

Nucleotide SEQ ID NO:	Tissue Expression (Fraction of Total)	Disease Class (Fraction of Total)	Vector
103	Gastrointestinal (0.242) Reproductive (0.182) Developmental (0.121)	Cancer (0.455) Inflammation (0.364) Fetal (0.182)	pINCY 1
104	Gastrointestinal (0.188) Hematopoietic/Immune (0.188) Urologic (0.188)	Inflammation (0.438) Cancer (0.281) Fetal (0.250)	pINCY 1
105	Urologic (0.250) Cardiovascular (0.167) Gastrointestinal (0.167)	Fetal (0.500) Cancer (0.417) Inflammation (0.333)	pINCY 1
106	Hematopoietic/Immune (0.333) Urologic (0.333)	Cancer (0.333) Fetal (0.333) Inflammation (0.333)	pINCY 1
107	Reproductive (0.286) Cardiovascular (0.204) Nervous (0.184)	Cancer (0.592) Fetal (0.143) Inflammation (0.143)	pINCY 1
108	Reproductive (0.231) Gastrointestinal (0.215) Hematopoietic/Immune (0.154)	Cancer (0.462) Inflammation (0.292) Fetal (0.185)	pINCY 1
109	Reproductive (0.304) Cardiovascular (0.261) Gastrointestinal (0.130)	Cancer (0.609) Inflammation (0.174) Trauma (0.087)	pINCY 1
110	Reproductive (0.256) Gastrointestinal (0.186) Hematopoietic/Immune (0.186)	Cancer (0.558) Inflammation (0.349) Trauma (0.070)	pINCY 1
111	Nervous (0.200) Reproductive (0.200) Gastrointestinal (0.175)	Cancer (0.550) Fetal (0.175) Inflammation (0.150)	pINCY 1
112	Developmental (0.222) Endocrine (0.222) Hematopoietic/Immune (0.222)	Cancer (0.222) Inflammation (0.222) Fetal (0.222)	pINCY 1
113	Hematopoietic/Immune (0.267) Nervous (0.200) Gastrointestinal (0.133)	Cancer (0.467) Trauma (0.267) Inflammation (0.200)	pINCY 1
114	Hematopoietic/Immune (0.304) Gastrointestinal (0.130) Nervous (0.130)	Inflammation (0.391) Cancer (0.304) Fetal (0.130)	pINCY 1

Table 3 (cont.)

Nucleotide SEQ ID NO.	Tissue Expression (Fraction of Total)	Disease Class (Fraction of Total)	Vector
115	Developmental (0.333) Cardiovascular (0.167) Dermatologic (0.167)	Fetal (0.667) Inflammation (0.500)	pBIUE-SCRIPT
116	Nervous (0.478) Gastrointestinal (0.130) Hematopoietic/Immune (0.130)	Cancer (0.565) Fetal (0.217) Inflammation (0.217)	pBIUE-SCRIPT
117	Reproductive (0.222) Hematopoietic/Immune (0.200) Nervous (0.156)	Cancer (0.422) Inflammation (0.311) Fetal (0.178)	pINCY
118	Reproductive (0.256) Gastrointestinal (0.148) Nervous (0.125)	Cancer (0.430) Inflammation (0.259) Fetal (0.196)	pSPOR11
119	Reproductive (0.190) Nervous (0.167) Developmental (0.143)	Cancer (0.381) Inflammation (0.333) Fetal (0.262)	pINCY
120	Reproductive (0.800) Urologic (0.100)	Cancer (0.900) Trauma (0.100)	pINCY
121	Reproductive (0.295) Nervous (0.182) Cardiovascular (0.159)	Cancer (0.455) Inflammation (0.182) Cell Proliferation (0.159)	pBIUE-SCRIPT
122	Developmental (0.250) Musculoskeletal (0.250) Nervous (0.250)	Cancer (0.500) Cell Proliferation (0.250) Inflammation (0.250)	pINCY
123	Gastrointestinal (0.786) Developmental (0.071) Nervous (0.071)	Cancer (0.500) Inflammation (0.429) Cell Proliferation (0.071)	pINCY
124	Reproductive (0.348) Cardiovascular (0.159) Hematopoietic/Immune (0.130)	Cancer (0.493) Inflammation (0.246) Cell Proliferation (0.145)	pINCY
125	Nervous (0.405) Reproductive (0.324) Cardiovascular (0.108)	Cancer (0.459) Proliferation (0.189) Inflammation (0.108)	pINCY
126	Reproductive (0.275) Nervous (0.231) Gastrointestinal (0.154)	Cancer (0.549) Inflammation (0.220) Cell Proliferation (0.154)	pINCY

Table 3 (cont.)

Nucleotide SEQ ID NO:	Tissue Expression (Fraction of Total)	Disease Class (Fraction of Total)	Vector
127	Reproductive (0.250) Nervous (0.150) Cardiovascular (0.133)	Cancer (0.517) Cell Proliferation (0.350) Inflammation (0.233)	pINCY
128	Nervous (0.333) Reproductive (0.333) Hematopoietic/Immune (0.111)	Cancer (0.593) Inflammation (0.259) Neurological (0.111)	pINCY
129	Hematopoietic/Immune (0.304) Gastrointestinal (0.214) Reproductive (0.196)	Cancer (0.446) Inflammation (0.446) Cell Proliferation (0.161)	pINCY
130	Nervous (0.400) Reproductive (0.300) Endocrine (0.100)	Cancer (0.300) Inflammation (0.300) Cell Proliferation (0.200)	pBLUESCRIPT
131	Reproductive (0.364) Cardiovascular (0.227) Nervous (0.227)	Cancer (0.545) Inflammation (0.318) Cell Proliferation (0.091)	pSPORT1
132	Cardiovascular (0.667) Nervous (0.333)	Cell Proliferation (1.000) Cancer (0.333)	pINCY
133	Gastrointestinal (0.750) Developmental (0.125) Reproductive (0.083)	Cancer (0.375) Cell Proliferation (0.292) Inflammation (0.250)	pINCY
134	Cardiovascular (0.250) Developmental (0.250) Gastrointestinal (0.250)	Cancer (0.500) Cell Proliferation (0.500) Inflammation (0.250)	pINCY
135	Reproductive (0.250) Nervous (0.208) Endocrine (0.167)	Inflammation (0.417) Cancer (0.208) Trauma (0.167)	pINCY
136	Developmental (0.500) Reproductive (0.500)	Cancer (0.500) Cell Proliferation (0.500)	pINCY
137	Developmental (1.000)	Cell Proliferation (1.000)	pINCY
138	Developmental (0.333) Endocrine (0.333) Gastrointestinal (0.333)	Cancer (0.666) Fetal (0.333)	pINCY
139	Reproductive (0.538) Developmental (0.154) Gastrointestinal (0.154)	Cancer (0.462) Inflammation (0.231) Cell Proliferation (0.154)	pINCY

Table 3 (cont.)

Nucleotide SEQ ID NO:	Tissue Expression (Fraction of Total)	Disease Class (Fraction of Total)	Vector
140	Gastrointestinal (0.385) Endocrine (0.231) Reproductive (0.231)	Cancer (0.308) Inflammation (0.308) Cell Proliferation (0.077)	pINCY
141	Nervous (0.500) Cardiovascular (0.167) Gastrointestinal (0.167)	Cancer (0.333) Trauma (0.333) Neurological (0.167)	pINCY
142	Reproductive (0.220) Gastrointestinal (0.155) Nervous (0.152)	Cell Proliferation (0.637) Inflammation (0.312)	pBLUFESCRIP1
143	Cardiovascular (0.202) Reproductive (0.190) Gastrointestinal (0.179)	Cell Proliferation (0.583) Inflammation (0.322)	pBLUFESCRIP1
144	Reproductive (0.242) Nervous (0.158) Gastrointestinal (0.116)	Cell Proliferation (0.632) Inflammation (0.379)	pINCY
145	Cardiovascular (0.238) Reproductive (0.238) Nervous (0.143)	Cell Proliferation (0.619) Inflammation (0.476)	pINCY
146	Reproductive (0.235) Nervous (0.189) Hematopoietic/Immune (0.131)	Cell Proliferation (0.625) Inflammation (0.348)	pINCY
147	Reproductive (0.191) Hematopoietic/Immune (0.173) Nervous (0.145)	Cell Proliferation (0.582) Inflammation (0.455)	pINCY
148	Reproductive (0.279) Hematopoietic/Immune (0.140) Nervous (0.128)	Cell Proliferation (0.674) Inflammation (0.232)	pINCY
149	Reproductive (0.286) Nervous (0.214) Cardiovascular (0.095)	Cell Proliferation (0.834) Inflammation (0.215)	pINCY
150	Hematopoietic/Immune (0.400) Endocrine (0.200) Gastrointestinal (0.200)	Cell Proliferation (0.200) Inflammation (0.800)	pINCY
151	Hematopoietic/Immune (0.667) Gastrointestinal (0.167) Musculoskeletal (0.167)	Cell Proliferation (0.167) Inflammation (0.667)	pINCY

Table 3 (cont.)

Nucleotide SEQ ID NO:	Tissue Expression (Fraction of Total)	Disease Class (Fraction of Total)	Vector
152	Reproductive (0.240) Nervous (0.173) Hematopoietic/Immune (0.133)	Cell Proliferation (0.546) Inflammation (0.360)	pINCY
153	Reproductive (0.308) Nervous (0.231) Gastrointestinal (0.115)	Cell Proliferation (0.885) Inflammation (0.154)	pINCY
154	Nervous (0.455) Reproductive (0.182) Developmental (0.136)	Cell Proliferation (0.682) Inflammation (0.181)	pINCY
155	Reproductive (0.286) Urologic (0.286) Cardiovascular (0.143)	Cell Proliferation (0.857) Inflammation (0.429)	pINCY
156	Reproductive (0.299) Gastrointestinal (0.216) Cardiovascular (0.120)	Cell Proliferation (0.767) Inflammation (0.246)	pINCY
157	Nervous (0.222) Reproductive (0.222)	Cell Proliferation (0.333) Inflammation (0.222)	pINCY
158	Reproductive (0.429) Nervous (0.357)	Cell Proliferation (0.286) Inflammation (0.357)	pINCY

Table 4

Nucleotide SEQ ID NO:	Clone ID	Library	Library Comment
80	153831	THP1P1B02	The THP1P1B02 library was constructed by reamplification of THP1P1B01, which was made using RNA isolated from THP-1 cells cultured for 48 hours with 100 ng/ml phorbol ester (PMA), followed by a 4-hour culture in media containing 1 g/ml LPS. THP-1 (ATCC TIB 202) is a human promonocyte line derived from the peripheral blood of a 1-year-old male with acute monocytic leukemia (ref. Int. J. Cancer (1980) 26:171).
81	350629	LVENNOT01	The LVENNOT01 library was constructed using RNA isolated from the left ventricle of a 51-year-old Caucasian female, who died from an intracranial bleed.
82	729171	LUNGNOT03	The LUNGNOT03 library was constructed using polyA RNA isolated from nontumorous lung tissue of a 79-year-old Caucasian male. Tissue had been removed from the upper and lower left lobes of the lung, superior (left paratracheal) and inferior (subclavian) mediastinal lymph nodes, and the right paratracheal region. Pathology for the associated tumor tissue indicated grade 4 carcinoma. Patient history included a benign prostate neoplasm, atherosclerosis, benign hypertension, and tobacco use.
83	1273641	TESTTUT02	The TESTTUT02 library was constructed using polyA RNA isolated from a testicular tumor removed from a 31-year-old Caucasian male during unilateral orchiectomy. Pathology indicated embryonal carcinoma forming a largely necrotic mass involving the entire testicle. Rare foci of residual testicle showed intralobular germ cell neoplasia and tumor was identified at the spermatic cord margin.
84	1427389	SINTBST01	The SINTBST01 library was constructed using polyA RNA isolated from the ileum tissue of an 18-year-old Caucasian female with irritable bowel syndrome (IBS). Pathology indicated Crohn's disease of the ileum, involving 15 cm of the small bowel. Patient history included osteoporosis of the vertebra and abnormal blood chemistry. Family history included cerebrovascular disease and atherosclerotic coronary artery disease.
85	1458357	COLNFEI02	The COLNFEI02 library was constructed using RNA isolated from the colon tissue of a Caucasian female fetus, who died at 20 weeks' gestation from fetal demise. Serology was negative.
86	1482837	CORPNOT02	The CORPNOT02 library was constructed using polyA RNA isolated from diseased corpus callosum tissue removed from the brain of a 74-year-old Caucasian male, who died from Alzheimer's disease. Serologies were negative.

Table 4 (cont.)

Protein SEQ ID NO:	Clone ID	Library	Library Comment
87	1517434	PANCTU101	The PANCTU101 library was constructed using polyA RNA isolated from pancreatic tumor tissue removed from a 65-year-old Caucasian female during radical subtotal pancreatectomy. Pathology indicated an invasive grade 2 adenocarcinoma. Patient history included osteoarthritis, benign hypertension, atherosclerotic coronary artery disease, an acute myocardial infarction, benign neoplasm in the large bowel, and a cataract disorder. Family history included benign hypertension and atherosclerotic coronary artery disease. Type II diabetes, impaired renal function, and stomach cancer.
88	1536052	SPLNNO104	The SPLNNO104 library was constructed using polyA RNA isolated from the spleen tissue of a 2-year-old Hispanic male, who died from cerebral anoxia. Past medical history and serologies were negative.
89	1666118	BRSTNOT09	The BRSTNOT09 library was constructed using polyA RNA isolated from nontumor breast tissue removed from a 45-year-old Caucasian female during unilateral extended simple mastectomy. Pathology for the associated tumor tissue indicated invasive nuclear grade 2-3 adenocarcinoma in the same breast, with 3 of 23 lymph nodes positive for metastatic disease. There were also positive estrogen/progesterone receptors and uninvolved tissue showing proliferative changes. Patient history included valvuloplasty of mitral valve without replacement, rheumatic mitral insufficiency, rheumatic heart disease, and tobacco use. Family history included acute myocardial infarction, atherosclerotic coronary artery disease, and Type II diabetes.
90	1675560	BLADNOT05	The BLADNOT05 library was constructed using polyA RNA isolated from nontumorous bladder tissue removed from a 60-year-old Caucasian male during a radical cystectomy, prostatectomy, and vasectomy. Pathology for the associated tumor tissue indicated grade 3 transitional cell carcinoma. The patient presented with dysuria. Family history included Type I diabetes, a malignant neoplasm of the stomach, atherosclerotic coronary artery disease, and an acute myocardial infarction.
91	1687323	PROSTUT10	The PROSTUT10 library was constructed using polyA RNA isolated from prostatic tumor tissue removed from a 66-year-old Caucasian male during radical prostatectomy and regional lymph node excision. Pathology indicated an adenocarcinoma (Gleason grade 2+3). Adenofibromatous hyperplasia was also present. The patient presented with elevated prostate specific antigen (PSA). Family history included prostate cancer, secondary bone cancer, and benign hypertension.

Table 4 (cont.)

Protein SEQ ID NO:	Clone ID	Library	Library Comment
92	1692236	PROSTUT10	The PROSTUT10 library was constructed using polyA RNA isolated from prostatic tumor tissue removed from a 66-year-old Caucasian male during radical prostatectomy and regional lymph node excision. Pathology indicated an adenocarcinoma (Gleason grade 2+3). Adenofibromatous hyperplasia was also present. The patient presented with elevated prostate specific antigen (PSA). Family history included prostate cancer, secondary bone cancer, and benign hypertension.
93	1720847	BLADNOT06	The BLADNOT06 library was constructed using polyA RNA isolated from the posterior wall bladder tissue removed from a 66-year-old Caucasian male during a radical prostatectomy, radical cystectomy, and urinary diversion. Pathology for the associated tumor tissue indicated grade 3 transitional cell carcinoma. The patient presented with prostatic inflammatory disease. Family history included a malignant breast neoplasm, benign hypertension, cerebrovascular disease, atherosclerotic coronary artery disease, and lung cancer.
94	1752821	LIVRTUT01	The LIVRTUT01 library was constructed using polyA RNA isolated from liver tumor tissue removed from a 51-year-old Caucasian female during a hepatic lobectomy. Pathology indicated metastatic grade 3 adenocarcinoma consistent with colon cancer. Patient history included thrombophlebitis and pure hypercholesterolemia. Patient medications included Premarin and Provera. The patient had also received 8 cycles of fluorouracil and leucovorin in the two years prior to surgery. Family history included a malignant neoplasm of the liver.
95	1810923	PROSTUT12	The PROSTUT12 library was constructed using polyA RNA isolated from prostate tumor tissue removed from a 65-year-old Caucasian male during a radical prostatectomy. Pathology indicated an adenocarcinoma (Gleason grade 2+2). Adenofibromatous hyperplasia was also present. The patient presented with elevated prostate specific antigen (PSA).
96	1822315	GBLATUT01	The GBLATUT01 library was constructed using polyA RNA isolated from gallbladder tumor tissue removed from a 78-year-old Caucasian female during a cholecystectomy. Pathology indicated invasive grade 3 transitional cell carcinoma. The patient was taking Indural (propranolol hydrochloride) for hypertension. Family history included a cholecystectomy, atherosclerosis, hyperlipidemia, and benign hypertension.
97	1877777	LEUKNOT03	The LEUKNOT03 library was constructed using polyA RNA isolated from white blood cells of a 27-year-old female with blood type A+. The donor tested negative for cytomegalovirus (CMV).
98	1879819	LEUKNOT03	The LEUKNOT03 library was constructed using polyA RNA isolated from white blood cells of a 27-year-old female with blood type A+. The donor tested negative for cytomegalovirus (CMV).

Table 4 (cont.)

Protein SFQ ID NO.	Clone ID	Library	Library Comment
99	1932945	COI NNO116	The COI NNO116 library was constructed using polyA RNA isolated from nontumorous sigmoid colon tissue removed from a 62-year-old Caucasian male during a sigmoidectomy and permanent colostomy. Pathology for the associated tumor tissue indicated invasive grade 2 adenocarcinoma. Family history included benign hypertension, atherosclerotic coronary artery disease, hyperlipidemia, breast cancer, and prostate cancer.
100	2061026	OVARNOT03	The OVARNOT03 library was constructed using polyA RNA isolated from nontumorous ovarian tissue removed from a 43-year-old Caucasian female during a bilateral salpingo-oophorectomy. Pathology for the associated tumor tissue indicated grade 2 mucinous cystadenocarcinoma. Family history included atherosclerotic coronary artery disease, pancreatic cancer, stress reaction, cerebrovascular disease, breast cancer, and uterine cancer.
101	2096687	BRAITUT02	The BRAITUT02 library was constructed using polyA RNA isolated from brain tumor tissue removed from the frontal lobe of a 58-year-old Caucasian male during excision of a cerebral meningeal lesion. Pathology indicated a grade 2 metastatic hypernephroma. Patient history included a grade 2 renal cell carcinoma, insomnia, and chronic airway obstruction. Previous surgeries included a nephroureterectomy. Patient medications included Decadron (dexamethasone) and Dilantin (phenytoin). Family history included a malignant neoplasm of the kidney.
102	2100530	BRAITUT02	The BRAITUT02 library was constructed using polyA RNA isolated from brain tumor tissue removed from the frontal lobe of a 58-year-old Caucasian male during excision of a cerebral meningeal lesion. Pathology indicated a grade 2 metastatic hypernephroma. Patient history included a grade 2 renal cell carcinoma, insomnia, and chronic airway obstruction. Previous surgeries included a nephroureterectomy. Patient medications included Decadron (dexamethasone) and Dilantin (phenytoin). Family history included a malignant neoplasm of the kidney.
103	2357636	LUNGNOT20	The LUNGNOT20 library was constructed using polyA RNA isolated from lung tissue removed from the right upper lobe of a 61-year-old Caucasian male during a segmental lung resection. Pathology indicated pancreatic emphysema. Family history included a subdural hemorrhage, cancer at an unidentified site, benign hypertension, atherosclerotic coronary artery disease, pneumonia, and an unspecified muscle disorder.

Table 4 (cont.)

Protein SEQ ID NO:	Clone ID	Library	Library Comment
104	2365230	ADREN0107	The ADREN0107 library was constructed using polyA RNA isolated from adrenal tissue removed from a 61-year-old female during a bilateral adrenalectomy. Patient history included an unspecified disorder of the adrenal glands, depressive disorder, benign hypertension, vocal cord paralysis, hemiplegia, subarachnoid hemorrhage, communicating hydrocephalus, neoplasm of uncertain behavior of pituitary gland, hyperlipidemia, Type II diabetes, a benign neoplasm of the colon, osteoarthritis, Meckel's diverticulum, and tobacco use. Previous surgeries included total excision of the pituitary gland and a unilateral thyroid lobectomy. Patient medications included Calderol and Premarin (conjugated estrogen). Family history included prostate cancer, benign hypertension, myocardial infarction, atherosclerotic coronary artery disease, congestive heart failure, hyperlipidemia, depression, anxiety disorder, colon cancer, and gas gangrene.
105	2455121	ENDANOT01	The ENDANOT01 library was constructed using polyA RNA isolated from aortic endothelial cell tissue from an explanted heart removed from a male during a heart transplant.
106	2472514	THPINO103	The THPINO103 library was constructed using polyA RNA isolated from untreated THP-1 cells. THP-1 (ATCC TIB 202) is a human promonocyte line derived from the peripheral blood of a 1-year-old Caucasian male with acute monocytic leukemia (ref: Int. J. Cancer (1980) 26:171).
107	2543486	UTRSNOT11	The UTRSNOT11 library was constructed using polyA RNA isolated from uterine myometrial tissue removed from a 43-year-old female during a vaginal hysterectomy and salpingo-oophorectomy. The endometrium was in proliferative phase. Family history included benign hypertension, hyperlipidemia, colon cancer, Type II diabetes, and atherosclerotic coronary artery disease.
108	2778171	OVARTUT03	The OVARTUT03 library was constructed using polyA RNA isolated from ovarian tumor tissue removed from the left ovary of a 52-year-old mixed ethnicity female during a total abdominal hysterectomy, bilateral salpingo-oophorectomy, peritoneal and lymphatic structure biopsy, regional lymph node excision, and peritoneal tissue destruction. Pathology indicated an invasive grade 3 (of 4) seroanaplastic carcinoma. Pathology also indicated a metastatic grade 3 seroanaplastic carcinoma. Patient history included breast cancer, chronic peptic ulcer, joint pain, and a normal delivery. Family history included colon cancer, cerebrovascular disease, breast cancer, Type II diabetes, esophagus cancer, and depressive disorder.
109	2799575	PENCNO101	The PENCNO101 library was constructed using polyA RNA isolated from penis corpus cavernosum tissue removed from a 53-year-old male. Patient history included an untreated penile carcinoma.

Table 4 (cont.)

Protein SEQ ID NO:	Clone ID	Library	Library Comment
110	2804955	BLADTUT08	The BLADTUT08 library was constructed using polyA RNA isolated from bladder tumor tissue removed from a 72-year-old Caucasian male during a radical cystectomy and prostatectomy. Pathology indicated an invasive grade 3 (of 3) transitional cell carcinoma. Family history included myocardial infarction, cerebrovascular disease, and brain cancer.
111	2806395	BLADTUT08	The BLADTUT08 library was constructed using polyA RNA isolated from bladder tumor tissue removed from a 72-year-old Caucasian male during a radical cystectomy and prostatectomy. Pathology indicated an invasive grade 3 (of 3) transitional cell carcinoma. Family history included myocardial infarction, cerebrovascular disease, and brain cancer.
112	2836858	TLYMNOT03	The TLYMNOT03 library was constructed using polyA RNA isolated from nonactivated Th1 cells. These cells were differentiated from umbilical cord CD4 T cells with IL-12 and B7-transfected COS cells.
113	2844513	DRGLNOT01	The DRGLNOT01 library was constructed using polyA RNA isolated from dorsal root ganglion tissue removed from the low thoracic/high lumbar region of a 32-year-old Caucasian male, who died from acute pulmonary edema, acute bronchopneumonia, bilateral pleural effusions, pericardial effusion, and malignant lymphoma (natural killer cell type). Patient medications included Diflucan (fluconazole), Deliasone (prednisone), hydrocodone, Loratab, Alprazolam, Reazodone, Cytabom, Etoposide, Cisplatin, Cytarabine, and dexamethasone. The patient received radiation therapy and multiple blood transfusions.
114	3000380	TLYMNOT06	The TLYMNOT06 library was constructed using polyA RNA isolated from activated Th2 cells. These cells were differentiated from umbilical cord CD4 T cells with IL-4 in the presence of anti-IL-12 antibodies and B7-transfected COS cells, and then activated for six hours with anti-CD3 and anti-CD28 antibodies.
115	182532	PLACNOB01	The PLACNOB01 library was constructed using RNA isolated from placenta.
116	239589	HIPONOT01	The HIPONOT01 library was constructed using RNA isolated from the hippocampus tissue of a 72-year-old Caucasian female who died from an intracranial bleed. Patient history included nose cancer, hypertension, and arthritis.
117	1671302	BMARNOT03	The BMARNOT03 library was constructed using RNA isolated from the left tibial bone marrow tissue of a 16-year-old Caucasian male during a partial left tibial osteotomy with free skin graft. Patient history included an abnormality of the red blood cells. Family history included osteoarthritis.

Table 4 (cont.)

Protein SEQ ID NO:	Clone ID	Library	Library Comment
118	2041858	HIPONON02	This normalized hippocampus library was constructed from 1.13M independent clones from HIPONON01 library. RNA was isolated from the hippocampus tissue of a 72-year-old Caucasian female who died from an intracranial bleed. Patient history included nose cancer, hypertension, and arthritis. The normalization and hybridization conditions were adapted from Soares et al. (PNAS (1994) 91:9928)
119	2198863	SPLNFET02	The SPLNFET02 library was constructed using RNA isolated from spleen tissue removed from a Caucasian male fetus, who died at 23 weeks gestation.
120	3250703	SEMVNOT03	The SEMVNOT03 library was constructed using RNA isolated from seminal vesicle tissue removed from a 56-year-old male during a radical prostatectomy. Pathology for the associated tumor tissue indicated adenocarcinoma (Gleason grade 3+3).
121	350287	LVENNOT01	The LVENNOT01 library was constructed using RNA isolated from the left ventricle of a 51-year-old Caucasian female who died from intracranial bleeding.
122	1618171	BRAITUT12	The BRAITUT12 library was constructed using RNA isolated from brain tumor tissue removed from the left frontal lobe of a 40-year-old Caucasian female during excision of a cerebral meningeal lesion. Pathology indicated grade 4 gemistocytic astrocytoma. Medications included dexamethasone and phenytoin sodium.
123	1625863	COLNPOT01	The COLNPOT01 library was constructed using RNA isolated from colon polyp tissue removed from a 40-year-old Caucasian female during a total colectomy. Pathology indicated an inflammatory pseudopolyp; this tissue was associated with a focally invasive grade 2 adenocarcinoma and multiple tubovillous adenomas. Patient history included a benign neoplasm of the bowel. Medications included Zantac, betamethasone, furosemide, and amiodarone.
124	1638353	UTRSNOT06	The UTRSNOT06 library was constructed using RNA isolated from myometrial tissue removed from a 50 year old Caucasian female during a vaginal hysterectomy. Pathology indicated residual atypical complex endometrial hyperplasia. Pathology for the associated tissue removed during dilation and curettage indicated fragments of atypical complex hyperplasia and a single microscopic focus suspicious for grade 1 adenocarcinoma. Patient history included benign breast neoplasm, hypothyroid disease, polypectomy, and arthralgia.

Table 4 (cont.)

Protein SEQ ID NO:	Clone ID	Library	Library Comment
125	1726843	PROSNOT14	The PROSNOT14 library was constructed using RNA isolated from diseased prostate tissue removed from a 60-year-old Caucasian male during radical prostatectomy and regional lymph node excision. Pathology indicated adenofibromatous hyperplasia. Pathology for the associated tumor tissue indicated an adenocarcinoma (Gleason grade 3+4). The patient presented with elevated prostate specific antigen (PSA). Patient history included a kidney cyst and hematuria. Family history included benign hypertension, cerebrovascular disease, and arteriosclerotic coronary artery disease.
126	1754506	LIVRTUT01	The LIVRTUT01 library was constructed using RNA isolated from liver tumor tissue removed from a 51-year-old Caucasian female during a hepatic lobectomy. Pathology indicated metastatic grade 3 adenocarcinoma consistent with colon cancer. Medications included Premarin, Provera, and earlier, fluorouracil, and leucovorin. Family history included a malignant neoplasm of the liver.
127	1831378	THIP1AZT01	The THIP1AZT01 library was constructed using RNA isolated from THP-1 promonocyte cells treated for 3 days with 0.8 micromolar 5-aza-2'-deoxycytidine. THP-1 (ATCC TIB 202) is a human promonocyte line derived from peripheral blood of a one-year-old Caucasian male with acute monocytic leukemia (Int. J. Cancer (1980) 26:171).
128	1864943	PROSNOT19	The PROSNOT19 library was constructed using RNA isolated from diseased prostate tissue removed from a 59-year-old Caucasian male during a radical prostatectomy with regional lymph node excision. Pathology indicated adenofibromatous hyperplasia. Pathology for the associated tumor tissue indicated an adenocarcinoma (Gleason grade 3+3). The patient presented with elevated prostate-specific antigen (PSA). Family history included benign hypertension, multiple myeloma, hyperlipidemia, and rheumatoid arthritis.
129	1911316	CONNTUT01	The CONNTUT01 library was constructed using RNA isolated from a soft tissue tumor removed from the clival area of the skull of a 30-year-old Caucasian female. Pathology indicated chondroid chordoma with neoplastic cells reactive for keratin. Medications included medroxyprogesterone acetate.
130	1943120	HIPONOT01	The HIPONOT01 library was constructed using RNA isolated from the hippocampus tissue of a 72-year-old Caucasian female who died from intracranial bleeding. Patient history included nose cancer, hypertension, and arthritis.
131	2314236	NGANNO T01	The NGANNO T01 library was constructed using RNA isolated from tumorous neuroganglion tissue removed from a 9-year-old Caucasian male during a soft tissue excision of the chest wall. Pathology indicated a ganglioneuroma forming an encapsulated lobulated mass. The tissue from the medial aspect pleura surrounding the tumor showed fibrotic tissue with chronic inflammation. Family history included asthma.

Table 4 (cont.)

Protein SEQ ID NO:	Clone ID	Library	Library Comment
132	2479409	SMCANO101	The SMCANO101 library was constructed using RNA isolated from an aortic smooth muscle cell line derived from the explanted heart of a male during a heart transplant.
133	2683149	SINIUCT01	The SINIUCT01 library was constructed using RNA isolated from ileum tissue obtained from a 42 year-old Caucasian male during a total intra-abdominal colectomy and endoscopic jejunostomy. Previous surgeries included polypectomy, colonoscopy, and spinal canal exploration. Medications included Prednisone, mesalamine, and Deltasone. Family history included cerebrovascular disease, benign hypertension, atherosclerotic coronary artery disease, and type II diabetes.
134	2774051	PANCNO115	The PANCNO115 library was constructed using RNA isolated from diseased pancreatic tissue removed from a 15-year-old Caucasian male during an exploratory laparotomy with distal pancreatectomy and total splenectomy. Pathology indicated islet cell hyperplasia. A single pancreatic lymph node was negative. Family history included prostate cancer and cardiovascular disease.
135	2869038	THYRNOT10	The THYRNOT10 library was constructed using RNA isolated from the diseased left thyroid tissue removed from a 30-year-old Caucasian female during a unilateral thyroid lobectomy and parathyroid reimplantation. Pathology indicated lymphocytic thyroiditis. Pathology for the associated tumor indicated grade 1 (of 4) papillary carcinoma of the right thyroid gland, follicular variant. Multiple perithyroidal and other lymph nodes were negative. Patient history included hyperlipidemia and benign ovary neoplasm. Medications included Premarin, Provera, and Anaprox.
136	2918334	THYMFET03	The THYMFET03 library was constructed using RNA isolated from thymus tissue removed from a Caucasian male fetus who died at premature birth. Serology was negative.
137	2949916	KIDNFET01	The KIDNFET01 library was constructed using RNA isolated from kidney tissue removed from a Caucasian female fetus, who died at 17 weeks gestation from anencephalus. Serology was negative.
138	2989375	KIDNFET02	The KIDNFET02 library was constructed using RNA isolated from kidney tissue removed from a Caucasian male fetus who was stillborn with a hypoplastic left heart at 23 weeks gestation. Serology was negative.

Table 4 (cont.)

Protein SEQ ID NO:	Clone ID	Library	Library Comment
139	3316764	PROSBPT03	The PROSBPT03 library was constructed using RNA isolated from diseased prostate tissue removed from a 59-year-old Caucasian male during a radical prostatectomy and regional lymph node excision. Pathology indicated benign prostatic hyperplasia. Pathology for the associated tumor indicated adenocarcinoma, Gleason grade 3+3. The patient presented with elevated prostate specific antigen (PSA), benign hypertension, and hyperlipidemia. Medications included Lotensin and Pravachol. Family history included cerebrovascular disease, benign hypertension, and prostate cancer.
140	3359559	PROSTUT16	The PROSTUT16 library was constructed using RNA isolated from prostate tumor tissue removed from a 55-year-old Caucasian male. Pathology indicated adenocarcinoma, Gleason grade 5+4. Adenofibromatous hyperplasia was also present. The patient presented with elevated prostate specific antigen (PSA). Patient history included calculus of the kidney. Family history included lung cancer and breast cancer.
141	4289208	BRABDIR01	The BRABDIR01 library was constructed using RNA isolated from diseased cerebellum tissue removed from the brain of a 57-year-old Caucasian male who died from a cerebrovascular accident. Patient history included Huntington's disease, emphysema, and long-term tobacco use.
142	2454013	ENDANO101	The ENDANO101 library was constructed using RNA isolated from aortic endothelial cell tissue from an explanted heart removed from a male during a heart transplant.
143	2454048	ENDANO101	The ENDANO101 library was constructed using RNA isolated from aortic endothelial cell tissue from an explanted heart removed from a male during a heart transplant.
144	2479282	SMCANOT01	The SMCANOT01 library was constructed using RNA isolated from an aortic smooth muscle cell line derived from the explanted heart of a male during a heart transplant.
145	2483432	SMCANOT01	The SMCANOT01 library was constructed using RNA isolated from an aortic smooth muscle cell line derived from the explanted heart of a male during a heart transplant.
146	2493824	ADRETUT05	The ADRETUT05 library was constructed using RNA isolated from adrenal tumor tissue removed from a 52-year-old Caucasian female during a unilateral adrenalectomy. Pathology indicated a pheochromocytoma.

Table 4 (cont.)

Protein SEQ ID NO:	Clone ID	Library	Library Comment
147	2555823	THYMNO103	The THYMNO103 library was constructed using 0.5 micrograms of polyA RNA isolated from thymus tissue removed from a 21-year-old Caucasian male during a thymectomy. Pathology indicated an unremarkable thymus and a benign parathyroid adenoma in the right inferior parathyroid. Patient history included atopic dermatitis, a benign neoplasm of the parathyroid, and tobacco use. Patient medications included multivitamins. Family history included atherosclerotic coronary artery disease and benign hypertension.
148	2598242	OVARTUT02	The OVARTUT02 library was constructed using RNA isolated from ovarian tumor tissue removed from a 51-year-old Caucasian female during an exploratory laparotomy, total abdominal hysterectomy, salpingo-oophorectomy, and an incidental appendectomy. Pathology indicated mucinous cystadenoma presenting as a multiloculated neoplasm involving the entire left ovary. The right ovary contained a follicular cyst and a hemorrhagic corpus luteum. The uterus showed proliferative endometrium and a single intramural leiomyoma. The peritoneal biopsy indicated benign glandular inclusions consistent with endosalpingiosis. Family history included atherosclerotic coronary artery disease, benign hypertension, breast cancer, and uterine cancer.
149	2634120	COLNTUT15	The COLNTUT15 library was constructed using RNA isolated from colon tumor tissue obtained from a 64-year-old Caucasian female during a right hemicolectomy with ileostomy and bilateral salpingo-oophorectomy (removal of the fallopian tubes and ovaries). Pathology indicated an invasive grade 3 adenocarcinoma. Patient history included hypothyroidism, depression, and anemia. Family history included colon cancer and uterine cancer.
150	2765411	BRSTNOT12	The BRSTNOT12 library was constructed using RNA isolated from diseased breast tissue removed from a 32-year-old Caucasian female during a bilateral reduction mammoplasty. Pathology indicated nonproliferative fibrocystic disease. Family history included benign hypertension and atherosclerotic coronary artery disease.
151	2769412	COLANO102	The COLANO102 library was constructed using RNA isolated from diseased ascending colon tissue removed from a 25-year-old Caucasian female during a multiple segmental resection of the large bowel. Pathology indicated moderately to severely active chronic ulcerative colitis, involving the entire colectomy specimen and sparing 2 cm of the attached ileum. Grossly, the specimen showed continuous involvement from the rectum proximally; marked mucosal atrophy and no skip areas were identified. Microscopically, the specimen showed dense, predominantly mucosal inflammation and crypt abscesses. Patient history included benign large bowel neoplasm.

Table 4 (cont.)

Protein SEQ ID NO:	Clone ID	Library	Library Comment
152	2842779	DRGI NO101	The DRGI NO101 library was constructed using RNA isolated from dorsal root ganglion tissue removed from the low thoracic/high lumbar region of a 32-year-old Caucasian male who died from acute pulmonary edema and bronchopneumonia, bilateral pleural and pericardial effusions, and malignant lymphoma (natural killer cell type). Patient history included probable cytomegalovirus, infection, hepatic congestion and steatosis, splenomegaly, hemorrhagic cystitis, thyroid hemorrhage, and Bell's palsy.
153	2966260	SCORNOT04	The SCORNOT04 library was constructed using RNA isolated from cervical spinal cord tissue removed from a 32-year-old Caucasian male who died from acute pulmonary edema and bronchopneumonia, bilateral pleural and pericardial effusions, and malignant lymphoma (natural killer cell type). Patient history included probable cytomegalovirus, infection, hepatic congestion and steatosis, splenomegaly, hemorrhagic cystitis, thyroid hemorrhage, and Bell's palsy.
154	2993326	KIDNFE102	The KIDNFE102 library was constructed using RNA isolated from kidney tissue removed from a Caucasian male fetus, who was stillborn with a hypoplastic left heart and died at 23 weeks' gestation.
155	3001124	TYMNOT06	The TYMNOT06 library was constructed using 0.5 micrograms of polyA RNA isolated from activated Th2 cells. These cells were differentiated from umbilical cord CD4 T cells with IL-4 in the presence of anti-IL-12 antibodies and B7-transfected COS cells, and then activated for six hours with anti-CD3 and anti-CD28 antibodies.
156	3120070	LUNGTUT13	The LUNGTUT13 library was constructed using RNA isolated from tumorous lung tissue removed from the right upper lobe of a 47-year-old Caucasian male during a segmental lung resection. Pathology indicated invasive grade 3 (of 4) adenocarcinoma. Family history included atherosclerotic coronary artery disease, and type II diabetes.
157	3133035	SMCCNOT01	The SMCCNOT01 library was constructed using RNA isolated from smooth muscle cells removed from the coronary artery of a 3-year-old Caucasian male.
158	3436879	PENCNOT05	The PENCNOT05 library was constructed using RNA isolated from penis left corpus cavernosum tissue.

Table 5

Program	Description	Reference	Parameter Threshold
AMFAC/URA	A program that removes vector sequences and masks ambiguous bases in nucleic acid sequences.	Perkin-Elmer Applied Biosystems, Foster City, CA.	
AM/PARACEL FDF	A Fast Data Finder useful in comparing and annotating amino acid or nucleic acid sequences.	Perkin-Elmer Applied Biosystems, Foster City, CA; Paracel Inc., Pasadena, CA.	Mismatch <50%
ABI AutoAssembler	A program that assembles nucleic acid sequences.	Perkin-Elmer Applied Biosystems, Foster City, CA.	
BLAST	A Basic Local Alignment Search Tool useful in sequence similarity search for amino acid and nucleic acid sequences. BLAST includes five functions: blastp, blastn, blastx, tblastn, and tblastx.	Altschul, S.F. et al. (1990) <i>J. Mol. Biol.</i> 215:403-410; Altschul, S.F. et al. (1997) <i>Nucleic Acids Res.</i> 25: 3389-3402.	ESTs: Probability value = 1.0E-8 or less Full Length sequences: Probability value = 1.0E-10 or less
FASTA	A Pearson and Lipman algorithm that searches for similarity between a query sequence and a group of sequences of the same type. FASTA comprises at least five functions: fasta, tfasta, fastx, tfastx, and ssearch.	Pearson, W.R. and D.J. Lipman (1988) <i>Proc. Natl. Acad. Sci.</i> 85:2444-2448; Pearson, W.R. (1990) <i>Methods Enzymol.</i> 183: 63-98; and Smith, T.F. and M. S. Waterman (1981) <i>Adv. Appl. Math.</i> 2:482-489.	ESTs: fasta E value = 1.0E-6 Assembled ESTs: fasta Identity = 95% or greater and Match length = 200 bases or greater; fastx E value = 1.0E-8 or less Full Length sequences: fastx score = 100 or greater
BLIMPS	A BLocks IMProved Searcher that matches a sequence against those in BLOCKS and PRINTS databases to search for gene families, sequence homology, and structural fingerprint regions	Henikoff, S. and J.G. Henikoff, <i>Nucl. Acid Res.</i> , 19:6565-72, 1991. J.G. Henikoff and S. Henikoff (1996) <i>Methods Enzymol.</i> 266:88-105; and Attwood, T.K. et al. (1997) <i>J. Chem. Inf. Comput. Sci.</i> 37: 417-424.	Score = 1000 or greater; Ratio of Score/Strength = 0.75 or larger; and Probability value = 1.0E-3 or less
PI/AM	A Hidden Markov Models-based application useful for protein family search.	Krogh, A. et al. (1994) <i>J. Mol. Biol.</i> , 235:1501-1531; Sonnhammer, E.L.L. et al. (1988) <i>Nucleic Acids Res.</i> 26:320-322.	Score = 10-50 bits, depending on individual protein families

Table 5 cont.

Program	Description	Reference	Parameter Threshold
ProfileScan	An algorithm that searches for structural and sequence motifs in protein sequences that match sequence patterns defined in Prosite.	Gribskov, M. et al. (1988) CABIOS 4:61-66; Gribskov, et al. (1989) Methods Enzymol. 183:146-159; Bairoch, A. et al. (1997) Nucleic Acids Res. 25: 217-221.	Score= 4.0 or greater
Phred	A base-calling algorithm that examines automated sequencer traces with high sensitivity and probability.	Ewing, B. et al. (1998) Genome Res. 8:175-185; Ewing, B. and P. Green (1998) Genome Res. 8:186-194.	
Phrap	A Phils Revised Assembly Program including SWAT and CrossMatch, programs based on efficient implementation of the Smith-Waterman algorithm, useful in searching sequence homology and assembling DNA sequences.	Smith, T.F. and M. S. Waterman (1981) Adv. Appl. Math. 2:482-489; Smith, T.F. and M. S. Waterman (1981) J. Mol. Biol. 147:195-197; and Green, P., University of Washington, Seattle, WA.	Score= 120 or greater; Match length= 56 or greater
Consed	A graphical tool for viewing and editing Phrap assemblies	Gordon, D. et al. (1998) Genome Res. 8:195-202.	
SPScan	A weight matrix analysis program that scans protein sequences for the presence of secretory signal peptides.	Nielson, H. et al. (1997) Protein Engineering 10:1-6; Claverie, J.M. and S. Audic (1997) CABIOS 12: 431-439.	Score=5 or greater
Motifs	A program that searches amino acid sequences for patterns that matched those defined in Prosite.	Bairoch et al. <u>supra</u> ; Wisconsin Package Program Manual, version 9, page M51-59, Genetics Computer Group, Madison, WI.	

What is claimed is:

1. A substantially purified polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:31, SEQ ID NO:32, SEQ ID NO:33, SEQ ID NO:34, SEQ ID NO:35, SEQ ID NO:36, SEQ ID NO:37, SEQ ID NO:38, SEQ ID NO:39, SEQ ID NO:40, SEQ ID NO:41, SEQ ID NO:42, SEQ ID NO:43, SEQ ID NO:44, SEQ ID NO:45, SEQ ID NO:46, SEQ ID NO:47, SEQ ID NO:48, SEQ ID NO:49, SEQ ID NO:50, SEQ ID NO:51, SEQ ID NO:52, SEQ ID NO:53, SEQ ID NO:54, SEQ ID NO:55, SEQ ID NO:56, SEQ ID NO:57, SEQ ID NO:58, SEQ ID NO:59, SEQ ID NO:60, SEQ ID NO:61, SEQ ID NO:62, SEQ ID NO:63, SEQ ID NO:64, SEQ ID NO:65, SEQ ID NO:66, SEQ ID NO:67, SEQ ID NO:68, SEQ ID NO:69, SEQ ID NO:70, SEQ ID NO:71, SEQ ID NO:72, SEQ ID NO:73, SEQ ID NO:74, SEQ ID NO:75, SEQ ID NO:76, SEQ ID NO:77, SEQ ID NO:78, and SEQ ID NO:79 and fragments thereof.
2. A substantially purified variant having at least 90% amino acid sequence identity to the amino acid sequence of claim 1.
3. An isolated and purified polynucleotide encoding the polypeptide of claim 1.
4. An isolated and purified polynucleotide variant having at least 90% polynucleotide sequence identity to the polynucleotide of claim 3.
5. An isolated and purified polynucleotide which hybridizes under stringent conditions to the polynucleotide of claim 3.
6. An isolated and purified polynucleotide having a sequence which is complementary to the polynucleotide of claim 3.
7. A method for detecting a polynucleotide, the method comprising the steps of:
 - (a) hybridizing the polynucleotide of claim 6 to at least one nucleic acid

in a sample, thereby forming a hybridization complex; and

(b) detecting the hybridization complex, wherein the presence of the hybridization complex correlates with the presence of the polynucleotide in the sample.

5 8. The method of claim 7 further comprising amplifying the polynucleotide prior to hybridization.

9. An isolated and purified polynucleotide comprising a polynucleotide sequence selected from the group consisting of SEQ ID NO:80, SEQ ID NO:81, SEQ ID NO:82, SEQ ID NO:83, SEQ ID NO:84, SEQ ID NO:85, SEQ ID NO:86, SEQ ID NO:87, 10 SEQ ID NO:88, SEQ ID NO:89, SEQ ID NO:90, SEQ ID NO:91, SEQ ID NO:92, SEQ ID NO:93, SEQ ID NO:94, SEQ ID NO:95, SEQ ID NO:96, SEQ ID NO:97, SEQ ID NO:98, SEQ ID NO:99, SEQ ID NO:100, SEQ ID NO:101, SEQ ID NO:102, SEQ ID NO:103, SEQ ID NO:104, SEQ ID NO:105, SEQ ID NO:106, SEQ ID NO:107, SEQ ID NO:108, SEQ ID NO:109, SEQ ID NO:110, SEQ ID NO:111, SEQ ID NO:112, SEQ ID 15 NO:113, SEQ ID NO:114, SEQ ID NO:115, SEQ ID NO:116, SEQ ID NO:117, SEQ ID NO:118, SEQ ID NO:119, SEQ ID NO:120, SEQ ID NO:121, SEQ ID NO:122, SEQ ID NO:123, SEQ ID NO:124, SEQ ID NO:125, SEQ ID NO:126, SEQ ID NO:127, SEQ ID NO:128, SEQ ID NO:129, SEQ ID NO:130, SEQ ID NO:131, SEQ ID NO:132, SEQ ID NO:133, SEQ ID NO:134, SEQ ID NO:135, SEQ ID NO:136, SEQ ID NO:137, SEQ ID 20 NO:138, SEQ ID NO:139, SEQ ID NO:140, SEQ ID NO:141, SEQ ID NO:142, SEQ ID NO:143, SEQ ID NO:144, SEQ ID NO:145, SEQ ID NO:146, SEQ ID NO:147, SEQ ID NO:148, SEQ ID NO:149, SEQ ID NO:150, SEQ ID NO:151, SEQ ID NO:152, SEQ ID NO:153, SEQ ID NO:154, SEQ ID NO:155, SEQ ID NO:156, SEQ ID NO:157, and SEQ ID NO:158 and fragments thereof.

25 10. An isolated and purified polynucleotide variant having at least 90% polynucleotide sequence identity to the polynucleotide of claim 9.

11. An isolated and purified polynucleotide having a sequence which is complementary to the polynucleotide of claim 9.

12. An expression vector comprising at least a fragment of the polynucleotide 30 of claim 3.

13. A host cell comprising the expression vector of claim 12.

14. A method for producing a polypeptide, the method comprising the steps of:

a) culturing the host cell of claim 13 under conditions suitable for the expression of the polypeptide; and

b) recovering the polypeptide from the host cell culture.

15. A pharmaceutical composition comprising the polypeptide of claim 1 in
5 conjunction with a suitable pharmaceutical carrier.

16. A purified antibody which specifically binds to the polypeptide of claim 1.

17. A purified agonist of the polypeptide of claim 1.

18. A purified antagonist of the polypeptide of claim 1.

19. A method for treating or preventing a disorder associated with decreased
10 expression or activity of HTMPN, the method comprising administering to a subject in
need of such treatment an effective amount of the pharmaceutical composition of claim 15.

20. A method for treating or preventing a disorder associated with increased
expression or activity of HTMPN, the method comprising administering to a subject in
need of such treatment an effective amount of the antagonist of claim 18.

15

SEQUENCE LISTING

<110> INCYTE PHARMACEUTICALS, INC.

TANG, Y. Tom

LAL, Preeti

HILLMAN, Jennifer L.

YUE, Henry

GUEGLER, Karl J.

CORLEY, Neil C.

BANDMAN, Olga

PATTERSON, Chandra

GORGONE, Gina A.

KASER, Matthew R.

BAUGHEN, Mariah R.

AU-YOUNG, Janice

<120> HUMAN TRANSMEMBRANE PROTEINS

<130> PF-0526 PCT

<140> To Be Assigned

<141> Herewith

<150> 60/087,260; 60/091,674; 60/102,954; 60/109,869

<151> 1998-05-29; 1998-07-02; 1998-10-02; 1998-11-24

<160> 158

<170> PERL Program

<210> 1

<211> 240

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte Clone No: 153831

<400> 1

Met	Gly	Asn	Cys	Gln	Ala	Gly	His	Asn	Leu	His	Leu	Cys	Leu	Ala	
1				5					10					15	
His	His	Pro	Pro	Leu	Val	Cys	Ala	Thr	Leu	Ile	Leu	Leu	Leu	Leu	
				20					25					30	
Gly	Leu	Ser	Gly	Leu	Gly	Leu	Gly	Ser	Phe	Leu	Leu	Thr	His	Arg	
				35					40					45	
Thr	Gly	Leu	Arg	Ser	Pro	Asp	Ile	Pro	Gln	Asp	Trp	Val	Ser	Phe	
				50					55					60	
Leu	Arg	Ser	Phe	Gly	Gln	Leu	Thr	Leu	Cys	Pro	Arg	Asn	Gly	Thr	
				65					70					75	
Val	Thr	Gly	Lys	Trp	Arg	Gly	Ser	His	Val	Val	Gly	Leu	Leu	Thr	
				80					85					90	
Thr	Leu	Asn	Phe	Gly	Asp	Gly	Pro	Asp	Arg	Asn	Lys	Thr	Arg	Thr	
				95					100					105	
Phe	Gln	Ala	Thr	Val	Leu	Gly	Ser	Gln	Met	Gly	Leu	Lys	Gly	Ser	
				110					115					120	

Ser	Ala	Gly	Gln	Leu	Val	Leu	Ile	Thr	Ala	Arg	Val	Thr	Thr	Glu
				125					130					135
Arg	Thr	Ala	Gly	Thr	Cys	Leu	Tyr	Phe	Ser	Ala	Val	Pro	Gly	Ile
				140					145					150
Leu	Pro	Ser	Ser	Gln	Pro	Pro	Ile	Ser	Cys	Ser	Glu	Glu	Gly	Ala
				155					160					165
Gly	Asn	Ala	Thr	Leu	Ser	Pro	Arg	Met	Gly	Glu	Glu	Cys	Val	Ser
				170					175					180
Val	Trp	Ser	His	Glu	Gly	Leu	Val	Leu	Thr	Lys	Leu	Leu	Thr	Ser
				185					190					195
Glu	Glu	Leu	Ala	Leu	Cys	Gly	Ser	Arg	Leu	Leu	Val	Leu	Gly	Ser
				200					205					210
Phe	Leu	Leu	Leu	Phe	Cys	Gly	Leu	Leu	Cys	Cys	Val	Thr	Ala	Met
				215					220					225
Cys	Phe	His	Pro	Arg	Arg	Glu	Ser	His	Trp	Ser	Arg	Thr	Arg	Leu
				230					235					240

<210> 2

<211> 100

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte Clone No: 350629

<400> 2

Met	Glu	Gly	Leu	Arg	Ser	Ser	Val	Glu	Leu	Asp	Pro	Glu	Leu	Thr
1				5					10					15
Pro	Gly	Lys	Leu	Asp	Glu	Glu	Met	Val	Gly	Leu	Pro	Pro	His	Asp
				20					25					30
Ala	Ser	Pro	Gln	Val	Thr	Phe	His	Ser	Leu	Asp	Gly	Lys	Thr	Val
				35					40					45
Val	Cys	Pro	His	Phe	Met	Gly	Leu	Leu	Leu	Gly	Leu	Leu	Leu	Leu
				50					55					60
Leu	Thr	Leu	Ser	Val	Arg	Asn	Gln	Leu	Cys	Val	Arg	Gly	Glu	Arg
				65					70					75
Gln	Leu	Ala	Glu	Thr	Leu	His	Ser	Gln	Val	Lys	Glu	Lys	Ser	Gln
				80					85					90
Leu	Ile	Gly	Lys	Lys	Thr	Asp	Cys	Arg	Asp					
				95					100					

<210> 3

<211> 416

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte Clone No: 729171

<400> 3

Met	Ser	Gly	His	Arg	Ser	Thr	Arg	Lys	Arg	Cys	Gly	Asp	Ser	His
1				5					10					15
Pro	Glu	Ser	Pro	Val	Gly	Phe	Gly	His	Met	Ser	Thr	Thr	Gly	Cys
				20					25					30
Val	Leu	Asn	Lys	Leu	Phe	Gln	Leu	Pro	Thr	Pro	Pro	Leu	Ser	Arg
				35					40					45
His	Gln	Leu	Lys	Arg	Leu	Glu	Glu	His	Arg	Tyr	Gln	Ser	Ala	Gly
				50					55					60
Arg	Ser	Leu	Leu	Glu	Pro	Leu	Val	Gln	Gly	Tyr	Trp	Glu	Trp	Leu
				65					70					75
Val	Arg	Arg	Val	Pro	Ser	Trp	Ile	Ala	Pro	Asn	Leu	Ile	Thr	Ile
				80					85					90
Ile	Gly	Leu	Ser	Ile	Asn	Ile	Cys	Thr	Thr	Ile	Leu	Leu	Val	Phe
				95					100					105
Tyr	Cys	Pro	Thr	Ala	Thr	Glu	Gln	Ala	Pro	Leu	Trp	Ala	Tyr	Ile
				110					115					120
Ala	Cys	Ala	Cys	Gly	Leu	Phe	Ile	Tyr	Gln	Ser	Leu	Asp	Ala	Ile
				125					130					135
Gly	Gly	Lys	Gln	Ala	Arg	Arg	Thr	Asn	Ser	Ser	Ser	Pro	Leu	Gly
				140					145					150
Glu	Leu	Phe	Asp	His	Gly	Cys	Asp	Ser	Leu	Ser	Thr	Val	Phe	Val
				155					160					165
Val	Leu	Gly	Thr	Cys	Ile	Ala	Val	Gln	Leu	Gly	Thr	Asn	Pro	Asp
				170					175					180
Trp	Met	Phe	Phe	Cys	Cys	Phe	Ala	Gly	Thr	Phe	Met	Phe	Tyr	Cys
				185					190					195
Ala	His	Trp	Gln	Thr	Tyr	Val	Ser	Gly	Thr	Leu	Arg	Phe	Gly	Ile
				200					205					210
Ile	Asp	Val	Thr	Glu	Val	Gln	Ile	Phe	Ile	Ile	Ile	Met	His	Leu
				215					220					225
Leu	Ala	Val	Met	Gly	Gly	Pro	Pro	Phe	Trp	Gln	Ser	Met	Ile	Pro
				230					235					240
Val	Leu	Asn	Ile	Gln	Met	Lys	Ile	Phe	Pro	Ala	Leu	Cys	Thr	Val
				245					250					255
Ala	Gly	Thr	Ile	Phe	Pro	Val	Thr	Asn	Tyr	Phe	Arg	Val	Ile	Phe
				260					265					270
Thr	Gly	Gly	Val	Gly	Lys	Asn	Gly	Ser	Thr	Ile	Ala	Gly	Thr	Ser
				275					280					285
Val	Leu	Ser	Pro	Phe	Leu	His	Ile	Gly	Ser	Val	Ile	Thr	Leu	Ala
				290					295					300
Ala	Met	Ile	Tyr	Lys	Lys	Ser	Ala	Val	Gln	Leu	Phe	Glu	Lys	His
				305					310					315
Pro	Cys	Leu	Tyr	Ile	Leu	Thr	Phe	Gly	Phe	Val	Ser	Ala	Lys	Ile
				320					325					330
Thr	Asn	Lys	Leu	Val	Val	Ala	His	Met	Thr	Lys	Ser	Glu	Met	His
				335					340					345
Leu	His	Asp	Thr	Ala	Phe	Ile	Gly	Pro	Ala	Leu	Leu	Phe	Leu	Asp
				350					355					360
Gln	Tyr	Phe	Asn	Ser	Phe	Ile	Asp	Glu	Tyr	Ile	Val	Leu	Trp	Ile
				365					370					375
Ala	Leu	Val	Phe	Ser	Phe	Phe	Asp	Leu	Ile	Arg	Tyr	Cys	Val	Ser
				380					385					390
Val	Cys	Asn	Gln	Ile	Ala	Ser	His	Leu	His	Ile	His	Val	Phe	Arg
				395					400					405
Ile	Lys	Val	Ser	Thr	Ala	His	Ser	Asn	His	His				

410

415

<210> 4
 <211> 224
 <212> PRT
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte Clone No: 1273641

<400> 4
 Met Thr Ile Thr Ser Phe Tyr Ala Val Cys Phe Tyr Leu Leu Met
 1 5 10 15
 Leu Val Met Val Glu Gly Phe Gly Gly Lys Glu Ala Val Leu Arg
 20 25 30
 Thr Leu Arg Asp Thr Pro Met Met Val His Thr Gly Pro Cys Cys
 35 40 45
 Cys Cys Cys Pro Cys Cys Gln Arg Leu Leu Leu Thr Arg Lys Lys
 50 55 60
 Leu Gln Leu Leu Met Leu Gly Pro Phe Gln Tyr Ala Phe Leu Lys
 65 70 75
 Ile Thr Leu Thr Trp Trp Ala Leu Phe Ser Ser Pro Thr Glu Ser
 80 85 90
 Tyr Asp Pro Ala Asp Ile Ser Glu Gly Ser Thr Ala Leu Trp Ile
 95 100 105
 Asn Thr Phe Leu Gly Val Ser Thr Leu Leu Ala Leu Trp Thr Leu
 110 115 120
 Gly Ile Ile Ser Arg Gln Ala Arg Leu His Leu Gly Glu Gln Asn
 125 130 135
 Met Gly Ala Lys Phe Ala Leu Phe Gln Val Leu Leu Ile Leu Thr
 140 145 150
 Ala Leu Gln Pro Ser Ile Phe Ser Val Leu Ala Asn Gly Gly Gln
 155 160 165
 Ile Ala Cys Ser Pro Pro Tyr Ser Ser Lys Thr Arg Ser Gln Val
 170 175 180
 Met Asn Cys His Leu Leu Ile Leu Glu Thr Phe Leu Met Thr Val
 185 190 195
 Leu Thr Arg Met Tyr Tyr Arg Arg Lys Asp His Lys Val Gly Tyr
 200 205 210
 Glu Thr Phe Ser Ser Pro Asp Leu Asp Leu Asn Leu Lys Ala
 215 220

<210> 5
 <211> 247
 <212> PRT
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte Clone No: 1427389

<400> 5


```

Met Gly Ala Ala Val Phe Phe Gly Cys Thr Phe Val Ala Phe Gly
 1          5          10          15
Pro Ala Phe Ala Leu Phe Leu Ile Thr Val Ala Gly Asp Pro Leu
          20          25          30
Arg Val Ile Ile Leu Val Ala Gly Ala Phe Phe Trp Leu Val Ser
          35          40          45
Leu Leu Leu Ala Ser Val Val Trp Phe Ile Leu Val His Val Thr
          50          55          60
Asp Arg Ser Asp Ala Arg Leu Gln Tyr Gly Leu Leu Ile Phe Gly
          65          70          75
Ala Ala Val Ser Val Leu Leu Gln Glu Val Phe Arg Phe Ala Tyr
          80          85          90
Tyr Lys Leu Leu Lys Lys Ala Asp Glu Gly Leu Ala Ser Leu Ser
          95          100          105
Glu Asp Gly Arg Ser Pro Ile Ser Ile Arg Gln Met Ala Tyr Val
          110          115          120
Ser Gly Leu Ser Phe Gly Ile Ile Ser Gly Val Phe Ser Val Ile
          125          130          135
Asn Ile Leu Ala Asp Ala Leu Gly Pro Gly Val Val Gly Ile His
          140          145          150
Gly Asp Ser Pro Tyr Tyr Phe Leu Thr Ser Ala Phe Leu Thr Ala
          155          160          165
Ala Ile Ile Leu Leu His Thr Phe Trp Gly Val Val Phe Phe Asp
          170          175          180
Ala Cys Glu Arg Arg Arg Tyr Trp Ala Leu Gly Leu Val Val Gly
          185          190          195
Ser His Leu Leu Thr Ser Gly Leu Thr Phe Leu Asn Pro Trp Tyr
          200          205          210
Glu Ala Ser Leu Leu Pro Ile Tyr Ala Val Thr Val Ser Met Gly
          215          220          225
Leu Trp Ala Phe Ile Thr Ala Gly Gly Ser Leu Arg Ser Ile Gln
          230          235          240
Arg Ser Leu Leu Cys Lys Asp
          245

```

<210> 6

<211> 72

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte Clone No: 1458357

<400> 6

```

Met Tyr Trp Leu His Gln Asp Met Phe Trp Leu Leu Val Leu Ile
 1          5          10          15
Leu Ile Cys Leu Val Thr His Leu Ile Thr Arg Glu Thr Ile Tyr
          20          25          30
Val Lys Ser Leu Phe Tyr Phe Lys Ile Leu Phe Val Tyr Leu Glu
          35          40          45
Ser Lys Pro Ala His Cys Asn Leu Cys Leu Tyr Ala Lys Glu Leu
          50          55          60

```

Asp Phe Phe Val Phe Val Leu Phe Phe Lys Leu Leu
 65 70

<210> 7
 <211> 106
 <212> PRT
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte Clone No: 1482837

<400> 7
 Met His Tyr Gly Phe Leu Leu Trp Ser Gly Lys Lys Arg Gly Leu
 1 5 10 15
 Ala Gly Pro Gln Gly Ile Cys Lys Ser Gln Lys Thr Val Phe Leu
 20 25 30
 Thr Ala Arg Cys His Ser Thr Leu Val Gly Lys Glu Glu Lys Lys
 35 40 45
 Ile Lys Leu Phe His Arg Thr Ser Trp Pro Pro His Ser His Ala
 50 55 60
 Leu Pro Thr Gln Pro Gly Pro Leu Pro Ala Pro Phe Ile Lys Ala
 65 70 75
 Glu Arg Val Glu Leu Ile Phe Thr Asn Cys Asn Ile Phe Val Val
 80 85 90
 Ser Val Ser Ser Phe Val Ser Ser Ala Glu Pro Cys Pro Phe Leu
 95 100 105
 Leu

<210> 8
 <211> 239
 <212> PRT
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte Clone No: 1517434

<400> 8
 Met Cys Val Thr Gln Leu Arg Leu Ile Phe Tyr Met Gly Ala Met
 1 5 10 15
 Asn Asn Ile Leu Lys Phe Leu Val Ser Gly Asp Gln Lys Thr Val
 20 25 30
 Gly Leu Tyr Thr Ser Ile Phe Gly Val Leu Gln Leu Leu Cys Leu
 35 40 45
 Leu Thr Ala Pro Val Ile Gly Tyr Ile Met Asp Trp Arg Leu Lys
 50 55 60
 Glu Cys Glu Asp Ala Ser Glu Glu Pro Glu Glu Lys Asp Ala Asn
 65 70 75
 Gln Gly Glu Lys Lys Lys Lys Lys Arg Asp Arg Gln Ile Gln Lys
 80 85 90
 Ile Thr Asn Ala Met Arg Ala Phe Ala Phe Thr Asn Leu Leu Leu
 95 100 105

Val Gly Phe Gly	Val Thr Cys Leu Ile	Pro Asn Leu Pro Leu Gln
110	115	120
Ile Leu Ser Phe	Ile Leu His Thr Ile	Val Arg Gly Phe Ile His
125	130	135
Ser Ala Val Gly	Gly Leu Tyr Ala Ala	Val Tyr Pro Ser Thr Gln
140	145	150
Phe Gly Ser Leu	Thr Gly Leu Gln Ser	Leu Ile Ser Ala Leu Phe
155	160	165
Ala Leu Leu Gln	Gln Pro Leu Phe Leu	Ala Met Met Gly Pro Leu
170	175	180
Gln Gly Asp Pro	Leu Trp Val Asn Val	Gly Leu Leu Leu Leu Ser
185	190	195
Leu Leu Gly Phe	Cys Leu Pro Leu Tyr	Leu Ile Cys Tyr Arg Arg
200	205	210
Gln Leu Glu Arg	Gln Leu Gln Gln Arg	Gln Glu Asp Asp Lys Leu
215	220	225
Phe Leu Lys Ile	Asn Gly Ser Ser Asn	Gln Glu Ala Phe Val
230	235	

<210> 9

<211> 150

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte Clone No: 1536052

<400> 9

Met Trp Leu Pro	Trp Ala Leu Leu Leu	Leu Trp Val Pro Ala Ser
1	5	10
Thr Ser Met Thr	Pro Ala Ser Ile Thr	Ala Ala Lys Thr Ser Thr
20	25	30
Ile Thr Thr Ala	Phe Pro Pro Val Ser	Ser Thr Thr Leu Phe Ala
35	40	45
Val Gly Ala Thr	His Ser Ala Ser Ile	Gln Glu Glu Thr Glu Glu
50	55	60
Val Val Asn Ser	Gln Leu Pro Leu Leu	Leu Ser Leu Leu Ala Leu
65	70	75
Leu Leu Leu Leu	Leu Val Gly Ala Ser	Leu Leu Ala Trp Arg Met
80	85	90
Phe Gln Lys Trp	Ile Lys Ala Gly Asp	His Ser Glu Leu Ser Gln
95	100	105
Asn Pro Lys Gln	Ala Ser Pro Arg Glu	Glu Leu His Tyr Ala Ser
110	115	120
Val Val Phe Asp	Ser Asn Thr Asn Arg	Ile Ala Ala Gln Arg Pro
125	130	135
Arg Glu Glu Glu	Pro Asp Ser Asp Tyr	Ser Val Ile Arg Lys Thr
140	145	150

<210> 10

<211> 110

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte Clone No: 1666118

<400> 10

Met	Pro	Ala	Cys	Ile	Leu	Glu	Asp	Val	Glu	Ile	Ser	Phe	Arg	Gln
1			5						10					15
Lys	Trp	Ser	Ile	Asn	Ser	Asp	Thr	Leu	Leu	Gly	Cys	Leu	Thr	Leu
			20						25					30
Phe	Ile	Ser	Ala	Phe	Phe	Ala	Ser	Glu	Thr	Trp	Gln	Lys	Leu	Val
			35						40					45
Ser	Gln	Ser	Thr	Ala	Phe	Leu	Thr	Met	Cys	Gly	Val	Thr	Tyr	Ala
			50						55					60
Trp	Tyr	Met	Pro	Leu	Leu	Leu	Leu	Lys	Phe	Tyr	Ser	Leu	Leu	Leu
			65						70					75
Ala	Gln	Val	Leu	Leu	Asn	Pro	Phe	Leu	Met	Cys	Thr	Gly	Trp	Arg
			80						85					90
Lys	Asn	Tyr	Ser	Gln	His	Phe	Glu	Arg	Lys	Val	Phe	Arg	Asn	Asn
			95						100					105
Ile	Asn	Trp	His	Tyr										
			110											

<210> 11

<211> 58

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte Clone No: 1675560

<400> 11

Met	Leu	Val	Thr	Asn	Ile	Thr	Val	Asn	Arg	Ser	Leu	Leu	His	Ala
1				5					10					15
Lys	Asp	Gln	Cys	Asp	Leu	Trp	Met	Glu	Met	Ile	Val	Met	Lys	Phe
			20						25					30
Leu	Phe	His	Gly	Ala	Val	Phe	Leu	Phe	Ile	Ser	Leu	Gly	Ser	Arg
			35						40					45
Phe	Ser	Glu	Ala	Val	Arg	Cys	Cys	Cys	Cys	Gly	Phe	Leu		
			50						55					

<210> 12

<211> 221

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte Clone No: 1687323

<400> 12

```

Met Ala Ala Ser Ser Ile Ser Ser Pro Trp Gly Lys His Val Phe
 1           5           10           15
Lys Ala Ile Leu Met Val Leu Val Ala Leu Ile Leu Leu His Ser
           20           25           30
Ala Leu Ala Gln Ser Arg Arg Asp Phe Ala Pro Pro Gly Gln Gln
           35           40           45
Lys Arg Glu Ala Pro Val Asp Val Leu Thr Gln Ile Gly Arg Ser
           50           55           60
Val Arg Gly Thr Leu Asp Ala Trp Ile Gly Pro Glu Thr Met His
           65           70           75
Leu Val Ser Glu Ser Ser Ser Gln Val Leu Trp Ala Ile Ser Ser
           80           85           90
Ala Ile Ser Val Ala Phe Phe Ala Leu Ser Gly Ile Ala Ala Gln
           95          100          105
Leu Leu Asn Ala Leu Gly Leu Ala Gly Asp Tyr Leu Ala Gln Gly
          110          115          120
Leu Lys Leu Ser Pro Gly Gln Val Gln Thr Phe Leu Leu Trp Gly
          125          130          135
Ala Gly Ala Leu Val Val Tyr Trp Leu Leu Ser Leu Leu Leu Gly
          140          145          150
Leu Val Leu Ala Leu Leu Gly Arg Ile Leu Trp Gly Leu Lys Leu
          155          160          165
Val Ile Phe Leu Ala Gly Phe Val Ala Leu Met Arg Ser Val Pro
          170          175          180
Asp Pro Ser Thr Arg Ala Leu Leu Leu Leu Ala Leu Leu Ile Leu
          185          190          195
Tyr Ala Leu Leu Ser Arg Leu Thr Gly Ser Arg Ala Ser Gly Ala
          200          205          210
Gln Leu Glu Ala Lys Val Arg Gly Leu Glu Arg
          215          220

```

<210> 13

<211> 262

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte Clone No: 1692236

<400> 13

```

Met Ala Leu Gly Leu Lys Cys Phe Arg Met Val His Pro Thr Phe
 1           5           10           15
Arg Asn Tyr Leu Ala Ala Ser Ile Arg Pro Val Ser Glu Val Thr
           20           25           30
Leu Lys Thr Val His Glu Arg Gln His Gly His Arg Gln Tyr Met
           35           40           45
Ala Tyr Ser Ala Val Pro Val Arg His Phe Ala Thr Lys Lys Ala
           50           55           60
Lys Ala Lys Gly Lys Gly Gln Ser Gln Thr Arg Val Asn Ile Asn
           65           70           75
Ala Ala Leu Val Glu Asp Ile Ile Asn Leu Glu Glu Val Asn Glu
           80           85           90

```

```

Glu Met Lys Ser Val Ile Glu Ala Leu Lys Asp Asn Phe Asn Leu
      95                      100                      105
Thr Leu Asn Ile Arg Ala Ser Pro Gly Ser Leu Asp Lys Ile Ala
      110                      115                      120
Val Val Thr Ala Asp Gly Lys Leu Ala Leu Asn Gln Ile Ser Gln
      125                      130                      135
Ile Ser Met Lys Ser Pro Gln Leu Ile Leu Val Asn Met Ala Ser
      140                      145                      150
Phe Pro Glu Cys Thr Ala Ala Ala Ile Lys Ala Ile Arg Glu Ser
      155                      160                      165
Gly Met Asn Leu Asn Pro Glu Val Glu Gly Thr Leu Ile Arg Val
      170                      175                      180
Pro Ile Pro Gln Val Thr Arg Glu His Arg Glu Met Leu Val Lys
      185                      190                      195
Leu Ala Lys Gln Asn Thr Asn Lys Ala Lys Asp Ser Leu Arg Lys
      200                      205                      210
Val Arg Thr Asn Ser Met Asn Lys Leu Lys Lys Ser Lys Asp Thr
      215                      220                      225
Val Ser Glu Asp Thr Ile Arg Leu Ile Glu Lys Gln Ile Ser Gln
      230                      235                      240
Met Ala Asp Asp Thr Val Ala Glu Leu Asp Arg His Leu Ala Val
      245                      250                      255
Lys Thr Lys Glu Leu Leu Gly
      260

```

<210> 14

<211> 90

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte Clone No: 1720847

<400> 14

```

Met Glu Ala Ala Met Glu Trp Glu Gly Gly Ala Ile Arg His Pro
  1                      5                      10                      15
Ser Thr Glu Leu Gly Ile Met Gly Ser Trp Phe Tyr Leu Phe Leu
      20                      25                      30
Ala Pro Leu Phe Lys Gly Leu Ala Gly Ser Leu Pro Phe Gly Cys
      35                      40                      45
Leu Ser Leu Leu Gln Pro Thr Glu Lys Thr Ala Leu Gln Arg Trp
      50                      55                      60
Arg Val Phe Met Lys His Ser Cys Gln Glu Pro Arg His Arg Ala
      65                      70                      75
Gly Gly Leu Glu Lys Gly Gly His Thr Gly Gly Gly Arg Ser Trp
      80                      85                      90

```

<210> 15

<211> 208

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte Clone No: 1752821

<400> 15

```

Met Ala Ser Ser Leu Leu Ala Gly Glu Arg Leu Val Arg Ala Leu
  1              5              10              15
Gly Pro Gly Gly Glu Leu Glu Pro Glu Arg Leu Pro Arg Lys Leu
              20              25              30
Arg Ala Glu Leu Glu Ala Ala Leu Gly Lys Lys His Lys Gly Gly
              35              40              45
Asp Ser Ser Ser Gly Pro Gln Arg Leu Val Ser Phe Arg Leu Ile
              50              55              60
Arg Asp Leu His Gln His Leu Arg Glu Arg Asp Ser Lys Leu Tyr
              65              70              75
Leu His Glu Leu Leu Glu Gly Ser Glu Ile Tyr Leu Pro Glu Val
              80              85              90
Val Lys Pro Pro Arg Asn Pro Glu Leu Val Ala Arg Leu Glu Lys
              95              100             105
Ile Lys Ile Gln Leu Ala Asn Glu Glu Tyr Lys Arg Ile Thr Arg
              110             115             120
Asn Val Thr Cys Gln Asp Thr Arg His Gly Gly Thr Leu Ser Asp
              125             130             135
Leu Gly Lys Gln Val Arg Ser Leu Lys Ala Leu Val Ile Thr Ile
              140             145             150
Phe Asn Phe Ile Val Thr Val Val Ala Ala Phe Val Cys Thr Tyr
              155             160             165
Leu Gly Ser Gln Tyr Ile Phe Thr Glu Met Ala Ser Arg Val Leu
              170             175             180
Ala Ala Leu Ile Val Ala Ser Val Val Gly Leu Ala Glu Leu Tyr
              185             190             195
Val Met Val Arg Ala Met Glu Gly Glu Leu Gly Glu Leu
              200             205

```

<210> 16

<211> 97

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte Clone No: 1810923

<400> 16

```

Met Thr Lys Lys Lys Arg Glu Asn Leu Gly Val Ala Leu Glu Ile
  1              5              10              15
Asp Gly Leu Glu Glu Lys Leu Ser Gln Cys Arg Arg Asp Leu Glu
              20              25              30
Ala Val Asn Ser Arg Leu His Ser Arg Glu Leu Ser Pro Glu Ala
              35              40              45
Arg Arg Ser Leu Glu Lys Glu Lys Asn Ser Leu Met Asn Lys Ala
              50              55              60

```

```

Ser Asn Tyr Glu Lys Glu Leu Lys Phe Leu Arg Gln Glu Asn Arg
      65              70              75
Lys Asn Met Leu Leu Ser Val Ala Ile Phe Ile Leu Leu Thr Leu
      80              85              90
Val Tyr Ala Tyr Trp Thr Met
      95

```

```

<210> 17
<211> 243
<212> PRT
<213> Homo sapiens

```

```

<220>
<221> misc_feature
<223> Incyte Clone No: 1822315

```

```

<400> 17
Met Phe Phe Leu Ser Ser Ser Lys Leu Thr Lys Trp Lys Gly Glu
  1              5              10              15
Val Lys Lys Arg Leu Asp Ser Glu Tyr Lys Glu Gly Gly Gln Arg
      20              25              30
Asn Trp Val Gln Val Phe Cys Asn Gly Ala Val Pro Thr Glu Leu
      35              40              45
Ala Leu Leu Tyr Met Ile Glu Asn Gly Pro Gly Glu Ile Pro Val
      50              55              60
Asp Phe Ser Lys Gln Tyr Ser Ala Ser Trp Met Cys Leu Ser Leu
      65              70              75
Leu Ala Ala Leu Ala Cys Ser Ala Gly Asp Thr Trp Ala Ser Glu
      80              85              90
Val Gly Pro Val Leu Ser Lys Ser Ser Pro Arg Leu Ile Thr Thr
      95              100             105
Trp Glu Lys Val Pro Val Gly Thr Asn Gly Gly Val Thr Val Val
      110             115             120
Gly Leu Val Ser Ser Leu Leu Gly Gly Thr Phe Val Gly Ile Ala
      125             130             135
Tyr Phe Leu Thr Gln Leu Ile Phe Val Asn Asp Leu Asp Ile Ser
      140             145             150
Ala Pro Gln Trp Pro Ile Ile Ala Phe Gly Gly Leu Ala Gly Leu
      155             160             165
Leu Gly Ser Ile Val Asp Ser Tyr Leu Gly Ala Thr Met Gln Tyr
      170             175             180
Thr Gly Leu Asp Glu Ser Thr Gly Met Val Val Asn Ser Pro Thr
      185             190             195
Asn Lys Ala Arg His Ile Ala Gly Lys Pro Ile Leu Asp Asn Asn
      200             205             210
Ala Trp Ile Cys Phe Leu Leu Phe Leu Leu Pro Ser Cys Ser Gln
      215             220             225
Leu Leu Leu Gly Val Phe Gly Pro Gly Gly Glu Leu Tyr Phe Ile
      230             235             240
Ser Thr Gly

```

```

<210> 18
<211> 162

```


<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte Clone No: 1877777

<400> 18

```

Met Leu Gln Thr Ser Asn Tyr Ser Leu Val Leu Ser Leu Gln Phe
  1                      5                      10                      15
Leu Leu Leu Ser Tyr Asp Leu Phe Val Asn Ser Phe Ser Glu Leu
                      20                      25                      30
Leu Gln Lys Thr Pro Val Ile Gln Leu Val Leu Phe Ile Ile Gln
                      35                      40                      45
Asp Ile Ala Val Leu Phe Asn Ile Ile Ile Ile Phe Leu Met Phe
                      50                      55                      60
Phe Asn Thr Phe Val Phe Gln Ala Gly Leu Val Asn Leu Leu Phe
                      65                      70                      75
His Lys Phe Lys Gly Thr Ile Ile Leu Thr Ala Val Tyr Phe Ala
                      80                      85                      90
Leu Ser Ile Ser Leu His Val Trp Val Met Asn Leu Arg Trp Lys
                      95                      100                     105
Asn Ser Asn Ser Phe Ile Trp Thr Asp Gly Leu Gln Met Leu Phe
                      110                     115                     120
Val Phe Gln Arg Leu Ala Ala Val Leu Tyr Cys Tyr Phe Tyr Lys
                      125                     130                     135
Arg Thr Ala Val Arg Leu Gly Asp Pro His Phe Tyr Gln Asp Ser
                      140                     145                     150
Leu Trp Leu Arg Lys Glu Phe Met Gln Val Arg Arg
                      155                     160

```

<210> 19

<211> 470

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte Clone No: 1879819

<400> 19

```

Met Leu Ser Pro Ser Pro Gly Lys Gly Pro Pro Pro Ala Val Ala
  1                      5                      10                      15
Pro Arg Pro Lys Ala Pro Leu Gln Leu Gly Pro Ser Ser Ser Ile
                      20                      25                      30
Lys Glu Lys Gln Gly Pro Leu Leu Asp Leu Phe Gly Gln Lys Leu
                      35                      40                      45
Pro Ile Ala His Thr Pro Pro Pro Pro Pro Ala Pro Pro Leu Pro
                      50                      55                      60
Leu Pro Glu Asp Pro Gly Thr Leu Ser Ala Glu Arg Arg Cys Leu
                      65                      70                      75
Thr Gln Pro Val Glu Asp Gln Gly Val Ser Thr Gln Leu Leu Ala

```

	80		85		90
Pro Ser Gly Ser	Val Cys Phe Ser Tyr	Thr Gly Thr Pro Trp Lys			
	95	100		105	
Leu Phe Leu Arg	Lys Glu Val Phe Tyr	Pro Arg Glu Asn Phe Ser			
	110	115		120	
His Pro Tyr Tyr	Leu Arg Leu Leu Cys	Glu Gln Ile Leu Arg Asp			
	125	130		135	
Thr Phe Ser Glu	Ser Cys Ile Arg Ile	Ser Gln Asn Glu Arg Arg			
	140	145		150	
Lys Met Lys Asp	Leu Leu Gly Gly Leu	Glu Val Asp Leu Asp Ser			
	155	160		165	
Leu Thr Thr Thr	Glu Asp Ser Val Lys	Lys Arg Ile Val Val Ala			
	170	175		180	
Ala Arg Asp Asn	Trp Ala Asn Tyr Phe	Ser Arg Phe Phe Pro Val			
	185	190		195	
Ser Gly Glu Ser	Gly Ser Asp Val Gln	Leu Leu Ala Val Ser His			
	200	205		210	
Arg Gly Leu Arg	Leu Leu Lys Val Thr	Gln Gly Pro Gly Leu Arg			
	215	220		225	
Pro Asp Gln Leu	Lys Ile Leu Cys Ser	Tyr Ser Phe Ala Glu Val			
	230	235		240	
Leu Gly Val Glu	Cys Arg Gly Gly Ser	Thr Leu Glu Leu Ser Leu			
	245	250		255	
Lys Ser Glu Gln	Leu Val Leu His Thr	Ala Arg Ala Arg Ala Ile			
	260	265		270	
Glu Ala Leu Val	Glu Leu Phe Leu Asn	Glu Leu Lys Lys Asp Ser			
	275	280		285	
Gly Tyr Val Ile	Ala Leu Arg Ser Tyr	Ile Thr Asp Asn Cys Ser			
	290	295		300	
Leu Leu Ser Phe	His Arg Gly Asp Leu	Ile Lys Leu Leu Pro Val			
	305	310		315	
Cys His Pro Gly	Ala Arg Leu Ala Val	Trp Leu Cys Arg Gly Pro			
	320	325		330	
Phe Arg Thr Leu	Ser Cys Arg His Ser	Ala Ala Gly Cys Arg Ser			
	335	340		345	
Arg Leu Phe Leu	Leu Gln Gly Ala Glu	Glu Trp Leu Ala Gln Gly			
	350	355		360	
Ser Ala Val Gln	Arg Gly Thr Arg Ala	Gly Ser Val Gly Gln Gly			
	365	370		375	
Leu Arg Gly Glu	Glu Asp Gly Arg Gly	Thr Ser Arg Gly Lys Ala			
	380	385		390	
Cys Leu Arg Leu	Arg Lys Glu Arg Gly	Leu Thr Thr Pro Glu Ala			
	395	400		405	
Ala Met Arg Trp	Asp His Pro Ala Val	Arg Leu Leu Trp Leu Pro			
	410	415		420	
Leu Cys Pro Leu	Leu Met Ala Arg Leu	Val Ser Pro Ala Arg Leu			
	425	430		435	
Cys Thr Pro Cys	Arg Gln Gly Leu Gly	Trp Met Leu Leu Leu Cys			
	440	445		450	
Pro Thr Trp Tyr	Leu Val Gln Gly Cys	Pro Ser Arg Cys Leu Ile			
	455	460		465	
Asn Ser Ser Ser	Leu				
	470				

<210> 20

<211> 144

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte Clone No: 1932945

<400> 20

```

Met Glu Arg Glu Gly Ser Gly Gly Ser Gly Gly Ser Ala Gly Leu
 1          5          10          15
Leu Gln Gln Ile Leu Ser Leu Lys Val Val Pro Arg Val Gly Asn
          20          25          30
Gly Thr Leu Cys Pro Asn Ser Thr Ser Leu Cys Ser Phe Pro Glu
          35          40          45
Met Trp Tyr Gly Val Phe Leu Trp Ala Leu Val Ser Ser Leu Phe
          50          55          60
Phe His Val Pro Ala Gly Leu Leu Ala Leu Phe Thr Leu Arg His
          65          70          75
His Lys Tyr Gly Arg Phe Met Ser Val Ser Ile Leu Leu Met Gly
          80          85          90
Ile Val Gly Pro Ile Thr Ala Gly Ile Leu Thr Ser Ala Ala Ile
          95          100          105
Ala Gly Val Tyr Arg Ala Ala Gly Lys Glu Met Ile Pro Phe Glu
          110          115          120
Ala Leu Thr Leu Gly Thr Gly Gln Thr Phe Cys Val Leu Val Val
          125          130          135
Ser Phe Leu Arg Ile Leu Ala Thr Leu
          140

```

<210> 21

<211> 221

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte Clone No: 2061026

<400> 21

```

Met Ala Leu Ala Leu Ala Ala Leu Ala Ala Val Glu Pro Ala Cys
 1          5          10          15
Gly Ser Arg Tyr Gln Gln Leu Gln Asn Glu Glu Glu Ser Gly Glu
          20          25          30
Pro Glu Gln Ala Ala Gly Asp Ala Pro Pro Pro Tyr Ser Ser Ile
          35          40          45
Ser Ala Glu Ser Ala Ala Tyr Phe Asp Tyr Lys Asp Glu Ser Gly
          50          55          60
Phe Pro Lys Pro Pro Ser Tyr Asn Val Ala Thr Thr Leu Pro Ser
          65          70          75
Tyr Asp Glu Ala Glu Arg Thr Lys Ala Glu Ala Thr Ile Pro Leu
          80          85          90
Val Pro Gly Arg Asp Glu Asp Phe Val Gly Arg Asp Asp Phe Asp
          95          100          105
Asp Ala Asp Gln Leu Arg Ile Gly Asn Asp Gly Ile Phe Met Leu

```

	110		115		120
Thr Phe Phe Met	Ala Phe Leu Phe Asn	Trp Ile Gly Phe Phe	Leu		
	125		130		135
Ser Phe Cys Leu	Thr Thr Ser Ala Ala	Gly Arg Tyr Gly Ala	Ile		
	140		145		150
Ser Gly Phe Gly	Leu Ser Leu Ile Lys	Trp Ile Leu Ile Val	Arg		
	155		160		165
Phe Ser Thr Tyr	Phe Pro Gly Tyr Phe	Asp Gly Gln Tyr Trp	Leu		
	170		175		180
Trp Trp Val Phe	Leu Val Leu Gly Phe	Leu Leu Phe Leu Arg	Gly		
	185		190		195
Phe Ile Asn Tyr	Ala Lys Val Arg Lys	Met Pro Glu Thr Phe	Ser		
	200		205		210
Asn Leu Pro Arg	Thr Arg Val Leu Phe	Ile Tyr			
	215		220		

<210> 22

<211> 688

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte Clone No: 2096687

<400> 22

Met Ser Ala Glu Ser Gly Pro Gly Thr Arg Leu Arg Asn Leu Pro		
1	5	10
Val Met Gly Asp Gly Leu Glu Thr Ser Gln Met Ser Thr Thr Gln		
	20	25
Ala Gln Ala Gln Pro Gln Pro Ala Asn Ala Ala Ser Thr Asn Pro		
	35	40
Pro Pro Pro Glu Thr Ser Asn Pro Asn Lys Pro Lys Arg Gln Thr		
	50	55
Asn Gln Leu Gln Tyr Leu Leu Arg Val Val Leu Lys Thr Leu Trp		
	65	70
Lys His Gln Phe Ala Trp Pro Phe Gln Gln Pro Val Asp Ala Val		
	80	85
Lys Leu Asn Leu Pro Asp Tyr Tyr Lys Ile Ile Lys Thr Pro Met		
	95	100
Asp Met Gly Thr Ile Lys Lys Arg Leu Glu Asn Asn Tyr Tyr Trp		
	110	115
Asn Ala Gln Glu Cys Ile Gln Asp Phe Asn Thr Met Phe Thr Asn		
	125	130
Cys Tyr Ile Tyr Asn Lys Pro Gly Asp Asp Ile Val Leu Met Ala		
	140	145
Glu Ala Leu Glu Lys Leu Phe Leu Gln Lys Ile Asn Glu Leu Pro		
	155	160
Thr Glu Glu Thr Glu Ile Met Ile Val Gln Ala Lys Gly Arg Gly		
	170	175
Arg Gly Arg Lys Glu Thr Gly Thr Ala Lys Pro Gly Val Ser Thr		
	185	190
Val Pro Asn Thr Thr Gln Ala Ser Thr Pro Pro Gln Thr Gln Thr		

	200		205		210
Pro Gln Pro Asn	Pro Pro Pro Val Gln	Ala Thr Pro His Pro	Phe		
	215		220		225
Pro Ala Val Thr	Pro Asp Leu Ile Val	Gln Thr Pro Val Met	Thr		
	230		235		240
Val Val Pro Pro	Gln Pro Leu Gln Thr	Pro Pro Pro Val Pro	Pro		
	245		250		255
Gln Pro Gln Pro	Pro Pro Ala Pro Ala	Pro Gln Pro Val Gln	Ser		
	260		265		270
His Pro Pro Ile	Ile Ala Ala Thr Pro	Gln Pro Val Lys Thr	Lys		
	275		280		285
Lys Gly Val Lys	Arg Lys Ala Asp Thr	Thr Thr Pro Thr Thr	Ile		
	290		295		300
Asp Pro Ile His	Glu Pro Pro Ser Leu	Pro Pro Glu Pro Lys	Thr		
	305		310		315
Thr Lys Leu Gly	Gln Arg Arg Glu Ser	Ser Arg Pro Val Lys	Pro		
	320		325		330
Pro Lys Lys Asp	Val Pro Asp Ser Gln	Gln His Pro Ala Pro	Glu		
	335		340		345
Lys Ser Ser Lys	Val Ser Glu Gln Leu	Lys Cys Cys Ser Gly	Ile		
	350		355		360
Leu Lys Glu Met	Phe Ala Lys Lys His	Ala Ala Tyr Ala Trp	Pro		
	365		370		375
Phe Tyr Lys Pro	Val Asp Val Glu Ala	Leu Gly Leu His Asp	Tyr		
	380		385		390
Cys Asp Ile Ile	Lys His Pro Met Asp	Met Ser Thr Ile Lys	Ser		
	395		400		405
Lys Leu Glu Ala	Arg Glu Tyr Arg Asp	Ala Gln Glu Phe Gly	Ala		
	410		415		420
Asp Val Arg Leu	Met Phe Ser Asn Cys	Tyr Lys Tyr Asn Pro	Pro		
	425		430		435
Asp His Glu Val	Val Ala Met Ala Arg	Lys Leu Gln Asp Val	Phe		
	440		445		450
Glu Met Arg Phe	Ala Lys Met Pro Asp	Glu Pro Glu Glu Pro	Val		
	455		460		465
Val Ala Val Ser	Ser Pro Ala Val Pro	Pro Pro Thr Lys Val	Val		
	470		475		480
Ala Pro Pro Ser	Ser Ser Asp Ser Ser	Ser Asp Ser Ser Ser	Asp		
	485		490		495
Ser Asp Ser Ser	Thr Asp Asp Ser Glu	Glu Glu Arg Ala Gln	Arg		
	500		505		510
Leu Ala Glu Leu	Gln Glu Gln Leu Lys	Ala Val His Glu Gln	Leu		
	515		520		525
Ala Ala Leu Ser	Gln Pro Gln Gln Asn	Lys Pro Lys Lys Lys	Glu		
	530		535		540
Lys Asp Lys Lys	Glu Lys Lys Lys Glu	Lys His Lys Arg Lys	Glu		
	545		550		555
Glu Val Glu Glu	Asn Lys Lys Ser Lys	Ala Lys Glu Pro Pro	Pro		
	560		565		570
Lys Lys Thr Lys	Lys Asn Asn Ser Ser	Asn Ser Asn Val Ser	Lys		
	575		580		585
Lys Glu Pro Ala	Pro Met Lys Ser Lys	Pro Pro Pro Thr Tyr	Glu		
	590		595		600
Ser Glu Glu Glu	Asp Lys Cys Lys Pro	Met Ser Tyr Glu Glu	Lys		
	605		610		615
Arg Gln Leu Ser	Leu Asp Ile Asn Lys	Leu Pro Gly Glu Lys	Leu		
	620		625		630

Gly	Arg	Val	Val	His	Ile	Ile	Gln	Ser	Arg	Glu	Pro	Ser	Leu	Lys
				635					640					645
Asn	Ser	Asn	Pro	Asp	Glu	Ile	Glu	Ile	Asp	Phe	Glu	Thr	Leu	Lys
				650					655					660
Pro	Ser	Thr	Leu	Arg	Glu	Leu	Gly	Ala	Leu	Cys	His	Leu	Leu	Phe
				665					670					675
Ala	Glu	Glu	Lys	Glu	Thr	Phe	Lys	Leu	Arg	Lys	Leu	Met		
				680					685					

<210> 23

<211> 439

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte Clone No: 2100530

<400> 23

Met	Gly	Ser	Gln	Glu	Val	Leu	Gly	His	Ala	Ala	Arg	Leu	Ala	Ser
1				5					10					15
Ser	Gly	Leu	Leu	Leu	Gln	Val	Leu	Phe	Arg	Leu	Ile	Thr	Phe	Val
				20					25					30
Leu	Asn	Ala	Phe	Ile	Leu	Arg	Phe	Leu	Ser	Lys	Glu	Ile	Val	Gly
				35					40					45
Val	Val	Asn	Val	Arg	Leu	Thr	Leu	Leu	Tyr	Ser	Thr	Thr	Leu	Phe
				50					55					60
Leu	Ala	Arg	Glu	Ala	Phe	Arg	Arg	Ala	Cys	Leu	Ser	Gly	Gly	Thr
				65					70					75
Gln	Arg	Asp	Trp	Ser	Gln	Thr	Leu	Asn	Leu	Leu	Trp	Leu	Thr	Val
				80					85					90
Pro	Leu	Gly	Val	Phe	Trp	Ser	Leu	Phe	Leu	Gly	Trp	Ile	Trp	Leu
				95					100					105
Gln	Leu	Leu	Glu	Val	Pro	Asp	Pro	Asn	Val	Val	Pro	His	Tyr	Ala
				110					115					120
Thr	Gly	Val	Val	Leu	Phe	Gly	Leu	Ser	Ala	Val	Val	Glu	Leu	Leu
				125					130					135
Gly	Glu	Pro	Phe	Trp	Val	Leu	Ala	Gln	Ala	His	Met	Phe	Val	Lys
				140					145					150
Leu	Lys	Val	Ile	Ala	Glu	Ser	Leu	Ser	Val	Ile	Leu	Lys	Ser	Val
				155					160					165
Leu	Thr	Ala	Phe	Leu	Val	Leu	Trp	Leu	Pro	His	Trp	Gly	Leu	Tyr
				170					175					180
Ile	Phe	Ser	Leu	Ala	Gln	Leu	Phe	Tyr	Thr	Thr	Val	Leu	Val	Leu
				185					190					195
Cys	Tyr	Val	Ile	Tyr	Phe	Thr	Lys	Leu	Leu	Gly	Ser	Pro	Glu	Ser
				200					205					210
Thr	Lys	Leu	Gln	Thr	Leu	Pro	Val	Ser	Arg	Ile	Thr	Asp	Leu	Leu
				215					220					225
Pro	Asn	Ile	Thr	Arg	Asn	Gly	Ala	Phe	Ile	Asn	Trp	Lys	Glu	Ala

	230		235		240
Lys Leu Thr Trp	Ser Phe Phe Lys Gln	Ser Phe Leu Lys Gln	Ile		
	245		250		255
Leu Thr Glu Gly	Glu Arg Tyr Val Met	Thr Phe Leu Asn Val	Leu		
	260		265		270
Asn Phe Gly Asp	Gln Gly Val Tyr Asp	Ile Val Asn Asn Leu	Gly		
	275		280		285
Ser Leu Val Ala	Arg Leu Ile Phe Gln	Pro Ile Glu Glu Ser	Phe		
	290		295		300
Tyr Ile Phe Phe	Ala Lys Val Leu Glu	Arg Gly Lys Asp Ala	Thr		
	305		310		315
Leu Gln Lys Gln	Glu Asp Val Ala Val	Ala Ala Ala Val Leu	Glu		
	320		325		330
Ser Leu Leu Lys	Leu Ala Leu Leu Ala	Gly Leu Thr Ile Thr	Val		
	335		340		345
Phe Gly Phe Ala	Tyr Ser Gln Leu Ala	Leu Asp Ile Tyr Gly	Gly		
	350		355		360
Thr Met Leu Ser	Ser Gly Ser Gly Pro	Val Leu Leu Arg Ser	Tyr		
	365		370		375
Cys Leu Tyr Val	Leu Leu Leu Ala Ile	Asn Gly Val Thr Glu	Cys		
	380		385		390
Phe Thr Phe Ala	Ala Met Ser Lys Glu	Glu Val Asp Arg Tyr	Ser		
	395		400		405
Ser Ala Val Ser	Arg Ala Gly Gln Pro	Asp Trp His Thr Leu	Leu		
	410		415		420
Trp Gly Pro Ser	Val Trp Glu Gln Leu	Ser Gly Gln His Xaa	Ser		
	425		430		435
Gln Arg Pro Ser					

<210> 24

<211> 192

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte Clone No: 2357636

<400> 24

Met Thr Ala Val	Gly Val Gln Ala Gln	Arg Pro Leu Gly Gln	Arg
1	5	10	15
Gln Pro Arg Arg	Ser Phe Phe Glu Ser	Phe Ile Arg Thr Leu	Ile
	20	25	30
Ile Thr Cys Val	Ala Leu Ala Val Val	Leu Ser Ser Val Ser	Ile
	35	40	45
Cys Asp Gly His	Trp Leu Leu Ala Glu	Asp Arg Leu Phe Gly	Leu
	50	55	60
Trp His Phe Cys	Thr Thr Asn Gln Ser	Val Pro Ile Cys Phe	
	65	70	75
Arg Asp Leu Gly	Gln Ala His Val Pro	Gly Leu Ala Val Gly	Met
	80	85	90
Gly Leu Val Arg	Ser Val Gly Ala Leu	Ala Val Val Ala Ala	Ile
	95	100	105
Phe Gly Leu Glu	Phe Leu Met Val Ser	Gln Leu Cys Glu Asp	Lys

	110		115		120
His Ser Gln Cys	Lys Trp Val Met Gly	Ser Ile Leu Leu Leu	Val		
	125		130		135
Ser Phe Val Leu	Ser Ser Gly Gly Leu	Leu Gly Phe Val Ile	Leu		
	140		145		150
Leu Arg Asn Gln	Val Thr Leu Ile Gly	Phe Thr Leu Met Phe	Trp		
	155		160		165
Cys Glu Phe Thr	Ala Ser Phe Leu Leu	Phe Leu Asn Ala Ile	Ser		
	170		175		180
Gly Leu His Ile	Asn Ser Ile Thr His	Pro Trp Glu			
	185		190		

<210> 25

<211> 175

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte Clone No: 2365230

<400> 25

Met Lys Glu Val	Thr Arg Thr Trp Lys	Ile Val Gly Gly Val	Thr
1	5	10	15
His Ala Asn Ser	Tyr Tyr Lys Asn Gly	Trp Ile Val Met Ile	Ala
	20	25	30
Ile Gly Trp Ala	Arg Gly Ala Gly Gly	Thr Ile Ile Thr Asn	Phe
	35	40	45
Glu Arg Leu Val	Lys Gly Asp Trp Lys	Pro Glu Gly Asp Glu	Trp
	50	55	60
Leu Lys Met Ser	Tyr Pro Ala Lys Val	Thr Leu Leu Gly Ser	Val
	65	70	75
Ile Phe Thr Phe	Gln His Thr Gln His	Leu Ala Ile Ser Lys	His
	80	85	90
Asn Leu Met Phe	Leu Tyr Thr Ile Phe	Ile Val Ala Thr Lys	Ile
	95	100	105
Thr Met Met Thr	Thr Gln Thr Ser Thr	Met Thr Phe Ala Pro	Phe
	110	115	120
Glu Asp Thr Leu	Ser Trp Met Leu Phe	Gly Trp Gln Gln Pro	Phe
	125	130	135
Ser Ser Cys Glu	Lys Lys Ser Glu Ala	Lys Ser Pro Ser Asn	Gly
	140	145	150
Val Gly Ser Leu	Ala Ser Lys Pro Val	Asp Val Ala Ser Asp	Asn
	155	160	165
Val Lys Lys Lys	His Thr Lys Lys Asn	Glu	
	170	175	

<210> 26

<211> 91

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte Clone No: 2455121

<400> 26

```

Met Tyr Pro Pro Pro Pro Pro Pro Pro His Arg Asp Phe Ile Ser
 1          5          10          15
Val Thr Leu Ser Phe Gly Glu Ser Tyr Asp Asn Ser Lys Ser Trp
          20          25          30
Arg Arg Arg Ser Cys Trp Arg Lys Trp Lys Gln Leu Ser Arg Leu
          35          40          45
Gln Arg Asn Met Ile Leu Phe Leu Leu Ala Phe Leu Leu Phe Cys
          50          55          60
Gly Leu Leu Phe Tyr Ile Asn Leu Ala Asp His Trp Lys Ala Leu
          65          70          75
Ala Phe Arg Leu Gly Glu Glu Gln Lys Met Arg Pro Glu Ile Ala
          80          85          90
Gly

```

<210> 27

<211> 214

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte Clone No: 2472514

<400> 27

```

Met Gln Pro Thr Ser Trp Ala Val Ser Cys Gly Leu Arg Pro Leu
 1          5          10          15
Pro Ser Trp Lys Pro Gln Gly Gly Glu Gly Arg Gly Gly Glu Glu
          20          25          30
Arg Arg Gly Thr Val Met Gly Pro Trp Ser Arg Val Arg Val Ala
          35          40          45
Lys Cys Gln Met Leu Val Thr Cys Phe Phe Ile Leu Leu Leu Gly
          50          55          60
Leu Ser Val Ala Thr Met Val Thr Leu Thr Tyr Phe Gly Ala His
          65          70          75
Phe Ala Val Ile Arg Arg Ala Ser Leu Glu Lys Asn Pro Tyr Gln
          80          85          90
Ala Val His Gln Trp Ala Phe Ser Ala Gly Leu Ser Leu Val Gly
          95          100          105
Leu Leu Thr Leu Gly Ala Val Leu Ser Ala Ala Ala Thr Val Arg
          110          115          120
Glu Ala Gln Gly Leu Met Ala Gly Gly Phe Leu Cys Phe Ser Leu
          125          130          135
Ala Phe Cys Ala Gln Val Gln Val Val Phe Trp Arg Leu His Ser
          140          145          150
Pro Thr Gln Val Glu Asp Ala Met Leu Asp Thr Tyr Asp Leu Val
          155          160          165
Tyr Glu Gln Ala Met Lys Gly Thr Ser His Val Arg Arg Gln Glu
          170          175          180
Leu Ala Ala Ile Gln Asp Val Val Ser Val Gly Thr Ala Gly Trp
          185          190          195
Gln Gly Gly Gln Leu Leu Leu Gly Leu Gln Phe Arg Glu Gln Ala

```

Gln Gly Gly Gln 200 205 210

<210> 28
 <211> 250
 <212> PRT
 <213> Homo sapiens
 <220>
 <221> misc_feature
 <223> Incyte Clone No: 2543486

<400> 28
 Met Ser Val Ile Phe Phe Ala Cys Val Val Arg Val Arg Asp Gly
 1 5 10 15
 Leu Pro Leu Ser Ala Ser Thr Asp Phe Tyr His Thr Gln Asp Phe
 20 25 30
 Leu Glu Trp Arg Arg Arg Leu Lys Ser Leu Ala Leu Arg Leu Ala
 35 40 45
 Gln Tyr Pro Gly Arg Gly Ser Ala Glu Gly Cys Asp Phe Ser Ile
 50 55 60
 His Phe Ser Ser Phe Gly Asp Val Ala Cys Met Ala Ile Cys Ser
 65 70 75
 Cys Gln Cys Pro Ala Ala Met Ala Phe Cys Phe Leu Glu Thr Leu
 80 85 90
 Trp Trp Glu Phe Thr Ala Ser Tyr Asp Thr Thr Cys Ile Gly Leu
 95 100 105
 Ala Ser Arg Pro Tyr Ala Phe Leu Glu Phe Asp Ser Ile Ile Gln
 110 115 120
 Lys Val Lys Trp His Phe Asn Tyr Val Ser Ser Ser Gln Met Glu
 125 130 135
 Cys Ser Leu Glu Lys Ile Gln Glu Glu Leu Lys Leu Gln Pro Pro
 140 145 150
 Ala Val Leu Thr Leu Glu Asp Thr Asp Val Ala Asn Gly Val Met
 155 160 165
 Asn Gly His Thr Pro Met His Leu Glu Pro Ala Pro Asn Phe Arg
 170 175 180
 Met Glu Pro Val Thr Ala Leu Gly Ile Leu Ser Leu Ile Leu Asn
 185 190 195
 Ile Met Cys Ala Ala Leu Asn Leu Ile Arg Gly Val His Leu Ala
 200 205 210
 Glu His Ser Leu Gln Val Ala His Glu Glu Ile Gly Asn Ile Leu
 215 220 225
 Ala Phe Leu Val Pro Phe Val Ala Cys Ile Phe Gln Asp Pro Arg
 230 235 240
 Ser Trp Phe Cys Trp Leu Asp Gln Thr Ser
 245 250

<210> 29
 <211> 84
 <212> PRT
 <213> Homo sapiens
 <220>

<221> misc_feature

<223> Incyte Clone No: 2778171

<400> 29

```

Met Ala Thr Gly Thr Asp Gln Val Val Gly Leu Gly Leu Val Ala
 1              5              10              15
Val Ser Leu Ile Ile Phe Thr Tyr Tyr Thr Ala Trp Val Ile Leu
              20              25              30
Leu Pro Phe Ile Asp Ser Gln His Val Ile His Lys Tyr Phe Leu
              35              40              45
Pro Arg Ala Tyr Ala Val Ala Ile Pro Leu Ala Ala Gly Leu Leu
              50              55              60
Leu Leu Leu Phe Val Gly Leu Phe Ile Ser Tyr Val Met Leu Lys
              65              70              75
Ser Lys Arg Val Thr Lys Lys Ala Gln
              80

```

<210> 30

<211> 277

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte Clone No: 2799575

<400> 30

```

Met Ala Ser Ala Glu Leu Asp Tyr Thr Ile Glu Ile Pro Asp Gln
 1              5              10              15
Pro Cys Trp Ser Gln Lys Asn Ser Pro Ser Pro Gly Gly Lys Glu
              20              25              30
Ala Glu Thr Arg Gln Pro Val Val Ile Leu Leu Gly Trp Gly Gly
              35              40              45
Cys Lys Asp Lys Asn Leu Ala Lys Tyr Ser Ala Ile Tyr His Lys
              50              55              60
Arg Gly Cys Ile Val Ile Arg Tyr Thr Ala Pro Trp His Met Val
              65              70              75
Phe Phe Ser Glu Ser Leu Gly Ile Pro Ser Leu Arg Val Leu Ala
              80              85              90
Gln Lys Leu Leu Glu Leu Leu Phe Asp Tyr Glu Ile Glu Lys Glu
              95              100             105
Pro Leu Leu Phe His Val Phe Ser Asn Gly Gly Val Met Leu Tyr
              110             115             120
Arg Tyr Val Leu Glu Leu Leu Gln Thr Arg Arg Phe Cys Arg Leu
              125             130             135
Arg Val Val Gly Thr Ile Phe Asp Ser Ala Pro Gly Asp Ser Asn
              140             145             150
Leu Val Gly Ala Leu Arg Ala Leu Ala Ala Ile Leu Glu Arg Arg
              155             160             165
Ala Ala Met Leu Arg Leu Leu Leu Leu Val Ala Phe Ala Leu Val
              170             175             180
Val Val Leu Phe His Val Leu Leu Ala Pro Ile Thr Ala Leu Phe
              185             190             195
His Thr His Phe Tyr Asp Arg Leu Gln Asp Ala Gly Ser Arg Trp

```

	200		205		210
Pro Glu Leu Tyr	Leu Tyr Ser Arg Ala	Asp Glu Val Val Leu Ala			
	215		220		225
Arg Asp Ile Glu	Arg Met Val Glu Ala	Arg Leu Ala Arg Arg Val			
	230		235		240
Leu Ala Arg Ser	Val Asp Phe Val Ser	Ser Ala His Val Ser His			
	245		250		255
Leu Arg Asp Tyr	Pro Thr Tyr Tyr Thr	Ser Leu Cys Val Asp Phe			
	260		265		270
Met Arg Asn Cys	Val Arg Cys				
	275				

<210> 31

<211> 273

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte Clone No: 2804955

<400> 31

Met Ser Gly Ser	Gln Ser Glu Val Ala	Pro Ser Pro Gln Ser Pro	
1	5	10	15
Arg Ser Pro Glu	Met Gly Arg Asp Leu	Arg Pro Gly Ser Arg Val	
	20	25	30
Leu Leu Leu Leu	Leu Leu Leu Leu	Val Tyr Leu Thr Gln Pro	
	35	40	45
Gly Asn Gly Asn	Glu Gly Ser Val Thr	Gly Ser Cys Tyr Cys Gly	
	50	55	60
Lys Arg Ile Ser	Ser Asp Ser Pro Pro	Ser Val Gln Phe Met Asn	
	65	70	75
Arg Leu Arg Lys	His Leu Arg Ala Tyr	His Arg Cys Leu Tyr Tyr	
	80	85	90
Thr Arg Phe Gln	Leu Leu Ser Trp Ser	Val Cys Gly Gly Asn Lys	
	95	100	105
Asp Pro Trp Val	Gln Glu Leu Met Ser	Cys Leu Asp Leu Lys Glu	
	110	115	120
Cys Gly His Ala	Tyr Ser Gly Ile Val	Ala His Gln Lys His Leu	
	125	130	135
Leu Pro Thr Ser	Pro Pro Ile Ser Gln	Ala Ser Glu Gly Ala Ser	
	140	145	150
Ser Asp Ile His	Thr Pro Ala Gln Met	Leu Leu Ser Thr Leu Gln	
	155	160	165
Ser Thr Gln Arg	Pro Thr Leu Pro Val	Gly Ser Leu Ser Ser Asp	
	170	175	180
Lys Glu Leu Thr	Arg Pro Asn Glu Thr	Thr Ile His Thr Ala Gly	
	185	190	195
His Ser Leu Ala	Ala Gly Pro Glu Ala	Gly Glu Asn Gln Lys Gln	
	200	205	210
Pro Glu Lys Asn	Ala Gly Pro Thr Ala	Arg Thr Ser Ala Thr Val	
	215	220	225
Pro Val Leu Cys	Leu Leu Ala Ile Ile	Phe Ile Leu Thr Ala Ala	

	230		235		240
Leu Ser Tyr Val	Leu Cys Lys Arg Arg	Arg Gly Gln Ser Pro	Gln		
	245		250		255
Ser Ser Pro Asp	Leu Pro Val His Tyr	Ile Pro Val Ala Pro	Asp		
	260		265		270
Ser Asn Thr					

<210> 32
 <211> 524
 <212> PRT
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte Clone No: 2806395

<400> 32

Met Ser Gln Gly Ser Pro Gly Asp Trp Ala Pro Leu Asp Pro Thr		
1	5	10 15
Pro Gly Pro Pro Ala Ser Pro Asn Pro Phe Val His Glu Leu His		
	20	25 30
Leu Ser Arg Leu Gln Arg Val Lys Phe Cys Leu Leu Gly Ala Leu		
	35	40 45
Leu Ala Pro Ile Arg Val Leu Leu Ala Phe Ile Val Leu Phe Leu		
	50	55 60
Leu Trp Pro Phe Ala Trp Leu Gln Val Ala Gly Leu Ser Glu Glu		
	65	70 75
Gln Leu Gln Glu Pro Ile Thr Gly Trp Arg Lys Thr Val Cys His		
	80	85 90
Asn Gly Val Leu Gly Leu Ser Arg Leu Leu Phe Phe Leu Leu Gly		
	95	100 105
Phe Leu Arg Ile Arg Val Arg Gly Gln Arg Ala Ser Arg Leu Gln		
	110	115 120
Ala Pro Val Leu Val Ala Ala Pro His Ser Thr Phe Phe Asp Pro		
	125	130 135
Ile Val Leu Leu Pro Cys Asp Leu Pro Lys Val Val Ser Arg Ala		
	140	145 150
Glu Asn Leu Ser Val Pro Val Ile Gly Ala Leu Leu Arg Phe Asn		
	155	160 165
Gln Ala Ile Leu Val Ser Arg His Asp Pro Ala Ser Arg Arg Arg		
	170	175 180
Val Val Glu Glu Val Arg Arg Arg Ala Thr Ser Gly Gly Lys Trp		
	185	190 195
Pro Gln Val Leu Phe Phe Pro Glu Gly Thr Cys Ser Asn Lys Lys		
	200	205 210
Ala Leu Leu Lys Phe Lys Pro Gly Ala Phe Ile Ala Gly Val Pro		
	215	220 225
Val Gln Pro Val Leu Ile Arg Tyr Pro Asn Ser Leu Asp Thr Thr		
	230	235 240
Ser Trp Ala Trp Arg Gly Pro Gly Val Leu Lys Val Leu Trp Leu		
	245	250 255
Thr Ala Ser Gln Pro Cys Ser Ile Val Asp Val Glu Phe Leu Pro		
	260	265 270
Val Tyr His Pro Ser Pro Glu Glu Ser Arg Asp Pro Thr Leu Tyr		
	275	280 285

Ala Asn Asn Val	Gln Arg Val Met Ala	Gln Ala Leu Gly Ile Pro
290		295 300
Ala Thr Glu Cys	Glu Phe Val Gly Ser	Leu Pro Val Ile Val Val
305		310 315
Gly Arg Leu Lys	Val Ala Leu Glu Pro	Gln Leu Trp Glu Leu Gly
320		325 330
Lys Val Leu Arg	Lys Ala Gly Leu Ser	Ala Gly Tyr Val Asp Ala
335		340 345
Gly Ala Glu Pro	Gly Arg Ser Arg Met	Ile Ser Gln Glu Glu Phe
350		355 360
Ala Arg Gln Leu	Gln Leu Ser Asp Pro	Gln Thr Val Ala Gly Ala
365		370 375
Phe Gly Tyr Phe	Gln Gln Asp Thr Lys	Gly Leu Val Asp Phe Arg
380		385 390
Asp Val Ala Leu	Ala Leu Ala Ala Leu	Asp Gly Gly Arg Ser Leu
395		400 405
Glu Glu Leu Thr	Arg Leu Ala Phe Glu	Leu Phe Ala Glu Glu Gln
410		415 420
Ala Glu Gly Pro	Asn Arg Leu Leu Tyr	Lys Asp Gly Phe Ser Thr
425		430 435
Ile Leu His Leu	Leu Leu Gly Ser Pro	His Pro Ala Ala Thr Ala
440		445 450
Leu His Ala Glu	Leu Cys Gln Ala Gly	Ser Ser Gln Gly Leu Ser
455		460 465
Leu Cys Gln Phe	Gln Asn Phe Ser Leu	His Asp Pro Leu Tyr Gly
470		475 480
Lys Leu Phe Ser	Thr Tyr Leu Arg Pro	Pro His Thr Ser Arg Gly
485		490 495
Thr Ser Gln Thr	Pro Asn Ala Ser Ser	Pro Gly Asn Pro Thr Ala
500		505 510
Leu Ala Asn Gly	Thr Val Gln Ala Pro	Lys Gln Lys Gly Asp
515		520

<210> 33

<211> 257

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte Clone No: 2836858

<400> 33

Met Asp Phe Ser	Arg Leu His Met Tyr Ser	Pro Pro Gln Cys Val
1	5	10 15
Pro Glu Asn Thr	Gly Tyr Thr Tyr Ala Leu	Ser Ser Ser Tyr Ser
20		25 30
Ser Asp Ala Leu	Asp Phe Glu Thr Glu His	Lys Leu Asp Pro Val
35		40 45
Phe Asp Ser Pro	Arg Met Ser Arg Arg Ser	Leu Arg Leu Ala Thr
50		55 60
Thr Ala Cys Thr	Leu Gly Asp Gly Glu Ala	Val Gly Ala Asp Ser
65		70 75
Gly Thr Ser Ser	Ala Val Ser Leu Lys Asn	Arg Ala Ala Arg Thr
80		85 90

```

Thr Lys Gln Arg Arg Ser Thr Asn Lys Ser Ala Phe Ser Ile Asn
      95      100      105
His Val Ser Arg Gln Val Thr Ser Ser Gly Val Ser His Gly Gly
      110      115      120
Thr Val Ser Leu Gln Asp Ala Val Thr Arg Arg Pro Pro Val Leu
      125      130      135
Asp Glu Ser Trp Ile Arg Glu Gln Thr Thr Val Asp His Phe Trp
      140      145      150
Gly Leu Asp Asp Asp Gly Asp Leu Lys Gly Gly Asn Lys Ala Ala
      155      160      165
Ile Gln Gly Asn Gly Asp Val Gly Ala Ala Ala Ala Thr Ala His
      170      175      180
Asn Gly Phe Ser Cys Ser Asn Cys Ser Met Leu Ser Glu Arg Lys
      185      190      195
Asp Val Leu Thr Ala His Pro Ala Ala Pro Gly Pro Val Ser Arg
      200      205      210
Val Tyr Ser Arg Asp Arg Asn Gln Lys Cys Lys Ser Gln Ser Phe
      215      220      225
Lys Thr Gln Lys Lys Val Cys Phe Pro Asn Leu Ile Phe Pro Phe
      230      235      240
Cys Lys Ser Gln Cys Leu His Tyr Leu Ser Trp Arg Leu Lys Ile
      245      250      255
Ile Pro

```

<210> 34

<211> 274

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte Clone No: 2844513

<400> 34

```

Met Arg Ala Ala Gly Val Gly Leu Val Asp Cys His Cys His Leu
  1      5      10      15
Ser Ala Pro Asp Phe Asp Arg Asp Leu Asp Asp Val Leu Glu Lys
      20      25      30
Ala Lys Lys Ala Asn Val Val Ala Leu Val Ala Val Ala Glu His
      35      40      45
Ser Gly Glu Phe Glu Lys Ile Met Gln Leu Ser Glu Arg Tyr Asn
      50      55      60
Gly Phe Val Leu Pro Cys Leu Gly Val His Pro Val Gln Gly Leu
      65      70      75
Pro Pro Glu Asp Gln Arg Ser Val Thr Leu Lys Asp Leu Asp Val
      80      85      90
Ala Leu Pro Ile Ile Glu Asn Tyr Lys Asp Arg Leu Leu Ala Ile
      95      100      105
Gly Glu Val Gly Leu Asp Phe Ser Pro Arg Phe Ala Gly Thr Gly
      110      115      120
Glu Gln Lys Glu Glu Gln Arg Gln Val Leu Ile Arg Gln Ile Gln
      125      130      135
Leu Ala Lys Arg Leu Asn Leu Pro Val Asn Val His Ser Arg Ser
      140      145      150
Ala Gly Arg Pro Thr Ile Asn Leu Leu Gln Glu Gln Gly Ala Glu

```

	155		160		165
Lys Val Leu Leu His Ala Phe Asp Gly Arg Pro Ser Val Ala Met					
	170		175		180
Glu Gly Val Arg Ala Gly Tyr Phe Phe Ser Ile Pro Pro Ser Ile					
	185		190		195
Ile Arg Ser Gly Gln Lys Gln Lys Leu Val Lys Gln Leu Pro Leu					
	200		205		210
Thr Ser Ile Cys Leu Glu Thr Asp Ser Pro Ala Leu Gly Pro Glu					
	215		220		225
Lys Gln Val Arg Asn Glu Pro Trp Asn Ile Ser Ile Ser Ala Glu					
	230		235		240
Tyr Ile Ala Gln Val Lys Gly Ile Ser Val Glu Glu Val Ile Glu					
	245		250		255
Val Thr Thr Gln Asn Ala Leu Lys Leu Phe Pro Lys Leu Arg His					
	260		265		270
Leu Leu Gln Lys					

<210> 35

<211> 281

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte Clone No: 3000380

<400> 35

Met Ser Glu Pro Gln Pro Asp Leu Glu Pro Pro Gln His Gly Leu		
1	5	10
Tyr Met Leu Phe Leu Leu Val Leu Val Phe Phe Leu Met Gly Leu		
	20	25
Val Gly Phe Met Ile Cys His Val Leu Lys Lys Lys Gly Tyr Arg		
	35	40
Cys Arg Thr Ser Arg Gly Ser Glu Pro Asp Asp Ala Gln Leu Gln		
	50	55
Pro Pro Glu Asp Asp Asp Met Asn Glu Asp Thr Val Glu Arg Ile		
	65	70
Val Arg Cys Ile Ile Gln Asn Glu Val Trp Met Pro Pro Pro Ala		
	80	85
Cys Arg Thr Glu Pro Pro Pro Ile Ile Thr Gln Cys Thr Trp Ala		
	95	100
Leu Gln Pro Leu Ala Val His Cys Ser Arg Ser Lys Arg Pro Pro		
	110	115
Leu Val Arg Gln Gly Arg Ser Lys Glu Gly Lys Ser Arg Pro Arg		
	125	130
Thr Gly Glu Thr Thr Val Phe Ser Val Gly Arg Phe Arg Val Thr		
	140	145
His Ile Glu Lys Arg Tyr Gly Leu His Glu His Arg Asp Gly Ser		
	155	160
Pro Thr Asp Arg Ser Trp Gly Ser Arg Gly Gly Gln Asp Pro Gly		
	170	175
Gly Gly Gln Gly Ser Gly Gly Gly His Pro Lys Ala Gly Met Leu		
	185	190

Pro	Trp	Arg	Gly	Cys	Pro	Pro	Glu	Arg	Pro	Gln	Pro	Gln	Val	Leu
				200					205					210
Ala	Ser	Pro	Pro	Val	Gln	Asn	Gly	Gly	Leu	Arg	Asp	Ser	Ser	Leu
				215					220					225
Thr	Pro	Arg	Ala	Leu	Glu	Gly	Asn	Pro	Arg	Ala	Ser	Ala	Glu	Pro
				230					235					240
Thr	Leu	Arg	Ala	Gly	Gly	Arg	Gly	Pro	Ser	Pro	Gly	Leu	Pro	Thr
				245					250					255
Gln	Glu	Ala	Asn	Gly	Gln	Pro	Ser	Lys	Pro	Asp	Thr	Ser	Asp	His
				260					265					270
Gln	Val	Ser	Leu	Pro	Gln	Gly	Ala	Gly	Ser	Met				
				275					280					

<210> 36

<211> 335

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte Clone No: 182532

<400> 36

Met	Gly	Pro	Leu	Ser	Ala	Pro	Pro	Cys	Thr	His	Leu	Ile	Thr	Trp
1				5					10					15
Lys	Gly	Val	Leu	Leu	Thr	Ala	Ser	Leu	Leu	Asn	Phe	Trp	Asn	Pro
				20					25					30
Pro	Thr	Thr	Ala	Gln	Val	Thr	Ile	Glu	Ala	Gln	Pro	Pro	Lys	Val
				35					40					45
Ser	Glu	Gly	Lys	Asp	Val	Leu	Leu	Leu	Val	His	Asn	Leu	Pro	Gln
				50					55					60
Asn	Leu	Ala	Gly	Tyr	Ile	Trp	Tyr	Lys	Gly	Gln	Met	Thr	Tyr	Val
				65					70					75
Tyr	His	Tyr	Ile	Ile	Ser	Tyr	Ile	Val	Asp	Gly	Lys	Ile	Ile	Ile
				80					85					90
Tyr	Gly	Pro	Ala	Tyr	Ser	Gly	Arg	Glu	Arg	Val	Tyr	Ser	Asn	Ala
				95					100					105
Ser	Leu	Leu	Ile	Gln	Asn	Val	Thr	Gln	Glu	Asp	Ala	Gly	Ser	Tyr
				110					115					120
Thr	Leu	His	Ile	Ile	Lys	Arg	Gly	Asp	Gly	Thr	Arg	Gly	Glu	Thr
				125					130					135
Gly	His	Phe	Thr	Phe	Thr	Leu	Tyr	Leu	Glu	Thr	Pro	Lys	Pro	Ser
				140					145					150
Ile	Ser	Ser	Ser	Asn	Leu	Tyr	Pro	Arg	Glu	Asp	Met	Glu	Ala	Val
				155					160					165
Ser	Leu	Thr	Cys	Asp	Pro	Glu	Thr	Pro	Asp	Ala	Ser	Tyr	Leu	Trp
				170					175					180
Trp	Met	Asn	Gly	Gln	Ser	Leu	Pro	Met	Thr	His	Ser	Leu	Gln	Leu
				185					190					195
Ser	Lys	Asn	Lys	Arg	Thr	Leu	Phe	Leu	Phe	Gly	Val	Thr	Lys	Tyr
				200					205					210
Thr	Ala	Gly	Pro	Tyr	Glu	Cys	Glu	Ile	Arg	Asn	Pro	Val	Ser	Gly
				215					220					225
Ile	Arg	Ser	Asp	Pro	Val	Thr	Leu	Asn	Val	Leu	Tyr	Gly	Pro	Asp
				230					235					240

```

Leu Pro Ser Ile Tyr Pro Ser Phe Thr Tyr Tyr Arg Ser Gly Glu
      245                      250                      255
Asn Leu Tyr Leu Ser Cys Phe Ala Glu Ser Asn Pro Arg Ala Gln
      260                      265                      270
Tyr Ser Trp Thr Ile Asn Gly Lys Phe Gln Leu Ser Gly Gln Lys
      275                      280                      285
Leu Phe Ile Pro Gln Ile Thr Thr Lys His Ser Gly Leu Tyr Ala
      290                      295                      300
Cys Ser Val Arg Asn Ser Ala Thr Gly Met Glu Ser Ser Lys Ser
      305                      310                      315
Met Thr Val Lys Val Ser Ala Pro Ser Gly Thr Gly His Leu Pro
      320                      325                      330
Gly Leu Asn Pro Leu
      335

```

<210> 37

<211> 280

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte Clone No: 239589

<400> 37

```

Met Asp Leu Gln Gly Arg Gly Val Pro Ser Ile Asp Arg Leu Arg
  1          5          10          15
Val Leu Leu Met Leu Phe His Thr Met Ala Gln Ile Met Ala Glu
      20          25          30
Gln Glu Val Glu Asn Leu Ser Gly Leu Ser Thr Asn Pro Glu Lys
      35          40          45
Asp Ile Phe Val Val Arg Glu Asn Gly Thr Thr Cys Leu Met Ala
      50          55          60
Glu Phe Ala Ala Lys Phe Ile Val Pro Tyr Asp Val Trp Ala Ser
      65          70          75
Asn Tyr Val Asp Leu Ile Thr Glu Gln Ala Asp Ile Ala Leu Thr
      80          85          90
Arg Gly Ala Glu Val Lys Gly Arg Cys Gly His Ser Gln Ser Glu
      95          100         105
Leu Gln Val Phe Trp Val Asp Arg Ala Tyr Ala Leu Lys Met Leu
      110         115         120
Phe Val Lys Glu Ser His Asn Met Ser Lys Gly Pro Glu Ala Thr
      125         130         135
Trp Arg Leu Ser Lys Val Gln Phe Val Tyr Asp Ser Ser Glu Lys
      140         145         150
Thr His Phe Lys Asp Ala Val Ser Ala Gly Lys His Thr Ala Asn
      155         160         165
Ser His His Leu Ser Ala Leu Val Thr Pro Ala Gly Lys Ser Tyr
      170         175         180
Glu Cys Gln Ala Gln Gln Thr Ile Ser Leu Ala Ser Ser Asp Pro
      185         190         195
Gln Lys Thr Val Thr Met Ile Leu Ser Ala Val His Ile Gln Pro
      200         205         210
Phe Asp Ile Ile Ser Asp Phe Val Phe Ser Glu Glu His Lys Cys
      215         220         225

```

Pro Val Asp Glu Arg Glu Gln Leu Glu Glu Thr Leu Pro Leu Ile	
	230 235 240
Leu Gly Leu Ile Leu Gly Leu Val Ile Met Val Thr Leu Ala Ile	
	245 250 255
Tyr His Val His His Lys Met Thr Ala Asn Gln Val Gln Ile Pro	
	260 265 270
Arg Asp Arg Ser Gln Tyr Lys His Met Gly	
	275 280

<210> 38

<211> 210

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte Clone No: 1671302

<400> 38

Met Ser Arg Met Phe Cys Gln Ala Ala Arg Val Asp Leu Thr Leu	
1 5 10 15	
Asp Pro Asp Thr Ala His Pro Ala Leu Met Leu Ser Pro Asp Arg	
20 25 30	
Arg Gly Val Arg Leu Ala Glu Arg Arg Gln Glu Val Ala Asp His	
35 40 45	
Pro Lys Arg Phe Ser Ala Asp Cys Cys Val Leu Gly Ala Gln Gly	
50 55 60	
Phe Arg Ser Gly Arg His Tyr Trp Glu Val Glu Val Gly Gly Arg	
65 70 75	
Arg Gly Trp Ala Val Gly Ala Ala Arg Glu Ser Thr His His Lys	
80 85 90	
Glu Lys Val Gly Pro Gly Gly Ser Ser Val Gly Ser Gly Asp Ala	
95 100 105	
Ser Ser Ser Arg His His His Arg Arg Arg Arg Leu His Leu Pro	
110 115 120	
Gln Gln Pro Leu Leu Gln Arg Glu Val Trp Cys Val Gly Thr Asn	
125 130 135	
Gly Lys Arg Tyr Gln Ala Gln Ser Ser Thr Glu Gln Thr Leu Leu	
140 145 150	
Ser Pro Ser Glu Lys Pro Arg Arg Phe Gly Val Tyr Leu Asp Tyr	
155 160 165	
Glu Ala Gly Arg Leu Gly Phe Tyr Asn Ala Glu Thr Leu Ala His	
170 175 180	
Val His Thr Phe Ser Ala Ala Phe Leu Gly Glu Arg Val Phe Pro	
185 190 195	
Phe Phe Arg Val Leu Ser Lys Gly Thr Arg Ile Lys Leu Cys Pro	
200 205 210	

<210> 39

<211> 279

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte Clone No: 2041858

<400> 39

```

Met Glu Ala Val Val Asn Leu Tyr Gln Glu Val Met Lys His Ala
 1              5              10              15
Asp Pro Arg Ile Gln Gly Tyr Pro Leu Met Gly Ser Pro Leu Leu
      20              25              30
Met Thr Ser Ile Leu Leu Thr Tyr Val Tyr Phe Val Leu Ser Leu
      35              40              45
Gly Pro Arg Ile Met Ala Asn Arg Lys Pro Phe Gln Leu Arg Gly
      50              55              60
Phe Met Ile Val Tyr Asn Phe Ser Leu Val Ala Leu Ser Leu Tyr
      65              70              75
Ile Val Tyr Glu Phe Leu Met Ser Gly Trp Leu Ser Thr Tyr Thr
      80              85              90
Trp Arg Cys Asp Pro Val Asp Tyr Ser Asn Ser Pro Glu Ala Leu
      95             100             105
Arg Met Val Arg Val Ala Trp Leu Phe Leu Phe Ser Lys Phe Ile
     110             115             120
Glu Leu Met Asp Thr Val Ile Phe Ile Leu Arg Lys Lys Asp Gly
     125             130             135
Gln Val Thr Phe Leu His Val Phe His His Ser Val Leu Pro Trp
     140             145             150
Ser Trp Trp Trp Gly Val Lys Ile Ala Pro Gly Gly Met Gly Ser
     155             160             165
Phe His Ala Met Ile Asn Ser Ser Val His Val Ile Met Tyr Leu
     170             175             180
Tyr Tyr Gly Leu Ser Ala Phe Gly Pro Val Ala Gln Pro Tyr Leu
     185             190             195
Trp Trp Lys Lys His Met Thr Ala Ile Gln Leu Ile Gln Phe Val
     200             205             210
Leu Val Ser Leu His Ile Ser Gln Tyr Tyr Phe Met Ser Ser Cys
     215             220             225
Asn Tyr Gln Tyr Pro Val Ile Ile His Leu Ile Trp Met Tyr Gly
     230             235             240
Thr Ile Phe Phe Met Leu Phe Ser Asn Phe Trp Tyr His Ser Tyr
     245             250             255
Thr Lys Gly Lys Arg Leu Pro Arg Ala Leu Gln Gln Asn Gly Ala
     260             265             270
Pro Gly Ile Ala Lys Val Lys Ala Asn
     275

```

<210> 40

<211> 154

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte Clone No: 2198863

<400> 40

```

Met Gly Lys Ser Ala Ser Lys Gln Phe His Asn Glu Val Leu Lys

```

1	5	10	15
Ala His Asn Glu Tyr Arg Gln Lys His Gly Val Pro Pro Leu Lys			
	20	25	30
Leu Cys Lys Asn Leu Asn Arg Glu Ala Gln Gln Tyr Ser Glu Ala			
	35	40	45
Leu Ala Ser Thr Arg Ile Leu Lys His Ser Pro Glu Ser Ser Arg			
	50	55	60
Gly Gln Cys Gly Glu Asn Leu Ala Trp Ala Ser Tyr Asp Gln Thr			
	65	70	75
Gly Lys Glu Val Ala Asp Arg Trp Tyr Ser Glu Ile Lys Asn Tyr			
	80	85	90
Asn Phe Gln Gln Pro Gly Phe Thr Ser Gly Thr Gly His Phe Thr			
	95	100	105
Ala Met Val Trp Lys Asn Thr Lys Lys Met Gly Val Gly Lys Ala			
	110	115	120
Ser Ala Ser Asp Gly Ser Ser Phe Val Val Ala Arg Tyr Phe Pro			
	125	130	135
Ala Gly Asn Val Val Asn Glu Gly Phe Phe Glu Glu Asn Val Leu			
	140	145	150
Pro Pro Lys Lys			

<210> 41

<211> 582

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte Clone No: 3250703

<400> 41

Met Lys Pro Asn Ile Ile Phe Val Leu Ser Leu Leu Leu Ile Leu		
1	5	10
Glu Lys Gln Ala Ala Val Met Gly Gln Lys Gly Gly Ser Lys Gly		
	20	25
Arg Leu Pro Ser Glu Phe Ser Gln Phe Pro His Gly Gln Lys Gly		
	35	40
Gln His Tyr Ser Gly Gln Lys Gly Lys Gln Gln Thr Glu Ser Lys		
	50	55
Gly Ser Phe Ser Ile Gln Tyr Thr Tyr His Val Asp Ala Asn Asp		
	65	70
His Asp Gln Ser Arg Lys Ser Gln Gln Tyr Asp Leu Asn Ala Leu		
	80	85
His Lys Thr Thr Lys Ser Gln Arg His Leu Gly Gly Ser Gln Gln		
	95	100
Leu Leu His Asn Lys Gln Glu Gly Arg Asp His Asp Lys Ser Lys		
	110	115
Gly His Phe His Arg Val Val Ile His His Lys Gly Gly Lys Ala		
	125	130
His Arg Gly Thr Gln Asn Pro Ser Gln Asp Gln Gly Asn Ser Pro		
	140	145
Ser Gly Lys Gly Ile Ser Ser Gln Tyr Ser Asn Thr Glu Glu Arg		
	155	160
		165

Leu Trp Val His	Gly Leu Ser Lys Glu Gln Thr Ser Val Ser Gly	170	175	180
Ala Gln Lys Gly	Arg Lys Gln Gly Gly Ser Gln Ser Ser Tyr Val	185	190	195
Leu Gln Thr Glu	Glu Leu Val Ala Asn Lys Gln Gln Arg Glu Thr	200	205	210
Lys Asn Ser His	Gln Asn Lys Gly His Tyr Gln Asn Val Val Glu	215	220	225
Val Arg Glu Glu	His Ser Ser Lys Val Gln Thr Ser Leu Cys Pro	230	235	240
Ala His Gln Asp	Lys Leu Gln His Gly Ser Lys Asp Ile Phe Ser	245	250	255
Thr Gln Asp Glu	Leu Leu Val Tyr Asn Lys Asn Gln His Gln Thr	260	265	270
Lys Asn Leu Asn	Gln Asp Gln Gln His Gly Arg Lys Ala Asn Lys	275	280	285
Ile Ser Tyr Gln	Ser Ser Ser Thr Glu Glu Arg Arg Leu His Tyr	290	295	300
Gly Glu Asn Gly	Val Gln Lys Asp Val Ser Gln Ser Ser Ile Tyr	305	310	315
Ser Gln Thr Glu	Glu Lys Ile His Gly Lys Ser Gln Asn Gln Val	320	325	330
Thr Ile His Ser	Gln Asp Gln Glu His Gly His Lys Glu Asn Lys	335	340	345
Ile Ser Tyr Gln	Ser Ser Ser Thr Glu Glu Arg His Leu Asn Cys	350	355	360
Gly Glu Lys Gly	Ile Gln Lys Gly Val Ser Lys Gly Ser Ile Ser	365	370	375
Ile Gln Thr Glu	Glu Gln Ile His Gly Lys Ser Gln Asn Gln Val	380	385	390
Arg Ile Pro Ser	Gln Ala Gln Glu Tyr Gly His Lys Glu Asn Lys	395	400	405
Ile Ser Tyr Gln	Ser Ser Ser Thr Glu Glu Arg Arg Leu Asn Ser	410	415	420
Gly Glu Lys Asp	Val Gln Lys Gly Val Ser Lys Gly Ser Ile Ser	425	430	435
Ile Gln Thr Glu	Glu Lys Ile His Gly Lys Ser Gln Asn Gln Val	440	445	450
Thr Ile Pro Ser	Gln Asp Gln Glu His Gly His Lys Glu Asn Lys	455	460	465
Met Ser Tyr Gln	Ser Ser Ser Thr Glu Glu Arg Arg Leu Asn Tyr	470	475	480
Gly Gly Lys Ser	Thr Gln Lys Asp Val Ser Gln Ser Ser Ile Ser	485	490	495
Phe Gln Ile Glu	Lys Leu Val Glu Gly Lys Ser Gln Ile Gln Thr	500	505	510
Pro Asn Pro Asn	Gln Asp Gln Trp Ser Gly Gln Asn Ala Lys Gly	515	520	525
Lys Ser Gly Gln	Ser Ala Asp Ser Lys Gln Asp Leu Leu Ser His	530	535	540
Glu Gln Lys Gly	Arg Tyr Lys Gln Glu Ser Ser Glu Ser His Asn	545	550	555
Ile Val Ile Thr	Glu His Glu Val Ala Gln Asp Asp His Leu Thr	560	565	570
Gln Gln Tyr Asn	Glu Asp Arg Asn Pro Ile Ser Thr	575	580	

<210> 42
 <211> 71
 <212> PRT
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte Clone No: 350287

<400> 42
 Met Phe Thr Ala Pro Leu Phe Phe Phe Phe Phe Phe Glu Ile Ile
 1 5 10 15
 Asn Ser Met Arg Asn Leu Gly Leu Asn Ile Cys Leu Leu Cys Leu
 20 25 30
 Leu Ile Glu His His Ser Arg Pro Ser Val Cys Leu Pro Phe Thr
 35 40 45
 Pro Lys Ile Phe Thr Lys Lys Ile Leu Arg Gln Gln Val Thr Ile
 50 55 60
 Tyr Arg Cys Leu Asn Asp Phe Leu Ile Phe Ile
 65 70

<210> 43
 <211> 102
 <212> PRT
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte Clone No: 1618171

<400> 43
 Met Ala Val Leu Pro Ser Val Leu Leu Val Tyr Ser Leu Phe Phe
 1 5 10 15
 Cys Leu Arg Phe Cys Met Leu Leu Leu Leu Pro Ser Tyr Ser His
 20 25 30
 Ser Arg Ser Gly Arg Gly Pro Gly Arg Tyr Gly His Ile Thr Leu
 35 40 45
 Ile Asp Val Ile His Val Ser Val Tyr Trp Phe Phe Glu Ala Leu
 50 55 60
 Ser Thr Phe Gln Ile Phe Tyr Tyr Cys Ile Thr Arg Thr Ile Thr
 65 70 75
 Val Arg Lys Gly Ile Val Val Ser Arg His Val Asn Glu Ala Gly
 80 85 90
 Val Ser Phe Val Ser Tyr Leu Cys Ile Asn Phe Lys
 95 100

<210> 44
 <211> 226
 <212> PRT
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte Clone No: 1625863

<400> 44

```

Met Pro Thr Thr Lys Lys Thr Leu Met Phe Leu Ser Ser Phe Phe
 1           5           10           15
Thr Ser Leu Gly Ser Phe Ile Val Ile Cys Ser Ile Leu Gly Thr
          20           25           30
Gln Ala Trp Ile Thr Ser Thr Ile Ala Val Arg Asp Ser Ala Ser
          35           40           45
Asn Gly Ser Ile Phe Ile Thr Tyr Gly Leu Phe Arg Gly Glu Ser
          50           55           60
Ser Glu Glu Leu Ser His Gly Leu Ala Glu Pro Lys Lys Lys Phe
          65           70           75
Ala Val Leu Glu Ile Leu Asn Asn Ser Ser Gln Lys Thr Leu His
          80           85           90
Ser Val Thr Ile Leu Phe Leu Val Leu Ser Leu Ile Thr Ser Leu
          95          100          105
Leu Ser Ser Gly Phe Thr Phe Tyr Asn Ser Ile Ser Asn Pro Tyr
          110          115          120
Gln Thr Phe Leu Gly Pro Thr Gly Val Tyr Thr Trp Asn Gly Leu
          125          130          135
Gly Ala Ser Phe Val Phe Val Thr Met Ile Leu Phe Val Ala Asn
          140          145          150
Thr Gln Ser Asn Gln Leu Ser Glu Glu Leu Phe Gln Met Leu Tyr
          155          160          165
Pro Ala Thr Thr Ser Lys Gly Thr Thr His Ser Tyr Gly Tyr Ser
          170          175          180
Phe Trp Leu Ile Leu Leu Val Ile Leu Leu Asn Ile Val Thr Val
          185          190          195
Thr Ile Ile Ile Phe Tyr Gln Lys Ala Arg Tyr Gln Arg Lys Gln
          200          205          210
Glu Gln Arg Lys Pro Met Glu Tyr Ala Pro Arg Asp Gly Ile Leu
          215          220          225
Phe

```

<210> 45

<211> 154

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte Clone No: 1638353

<400> 45

```

Met Ala Leu Leu Leu Ser Val Leu Arg Val Leu Leu Gly Gly Phe
 1           5           10           15
Phe Ala Leu Val Gly Leu Ala Lys Leu Ser Glu Glu Ile Ser Ala
          20           25           30
Pro Val Ser Glu Arg Met Asn Ala Leu Phe Val Gln Phe Ala Glu
          35           40           45
Val Phe Pro Leu Lys Val Phe Gly Tyr Gln Pro Asp Pro Leu Asn
          50           55           60
Tyr Gln Ile Ala Val Gly Phe Leu Glu Leu Leu Ala Gly Leu Leu
          65           70           75

```



```

Leu Val Met Gly Pro Pro Met Leu Gln Glu Ile Ser Asn Leu Phe
      80                      85                      90
Leu Ile Leu Leu Met Met Gly Ala Ile Phe Thr Leu Ala Ala Leu
      95                      100                     105
Lys Glu Ser Leu Ser Thr Cys Ile Pro Ala Ile Val Cys Leu Gly
      110                     115                     120
Phe Leu Leu Leu Leu Asn Val Gly Gln Leu Leu Ala Gln Thr Lys
      125                     130                     135
Lys Val Val Arg Pro Thr Arg Lys Lys Thr Leu Ser Thr Phe Lys
      140                     145                     150
Glu Ser Trp Lys

```

```

<210> 46
<211> 167
<212> PRT
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte Clone No: 1726843

```

```

<400> 46
Met Ala Ser Pro Arg Thr Val Thr Ile Val Ala Leu Ser Val Ala
  1          5          10          15
Leu Gly Leu Phe Phe Val Phe Met Gly Thr Ile Lys Leu Thr Pro
      20          25          30
Arg Leu Ser Lys Asp Ala Tyr Ser Glu Met Lys Arg Ala Tyr Lys
      35          40          45
Ser Tyr Val Arg Ala Leu Pro Leu Leu Lys Lys Met Gly Ile Asn
      50          55          60
Ser Ile Leu Leu Arg Lys Ser Ile Gly Ala Leu Glu Val Ala Cys
      65          70          75
Gly Ile Val Met Thr Leu Val Pro Gly Arg Pro Lys Asp Val Ala
      80          85          90
Asn Phe Phe Leu Leu Leu Val Leu Ala Val Leu Phe Phe His
      95         100         105
Gln Leu Val Gly Asp Pro Leu Lys Arg Tyr Ala His Ala Leu Val
      110         115         120
Phe Gly Ile Leu Leu Thr Cys Arg Leu Leu Ile Ala Arg Lys Pro
      125         130         135
Glu Asp Arg Ser Ser Glu Lys Lys Pro Leu Pro Gly Asn Ala Glu
      140         145         150
Glu Gln Pro Ser Leu Tyr Glu Lys Ala Pro Gln Gly Lys Val Lys
      155         160         165
Val Ser

```

```

<210> 47
<211> 545
<212> PRT
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte Clone No: 1754506

```

<400> 47

Met	Ala	Gly	Ala	Ile	Ile	Glu	Asn	Met	Ser	Thr	Lys	Lys	Leu	Cys
1				5					10					15
Ile	Val	Gly	Gly	Ile	Leu	Leu	Val	Phe	Gln	Ile	Ile	Ala	Phe	Leu
				20					25					30
Val	Gly	Gly	Leu	Ile	Ala	Pro	Gly	Pro	Thr	Thr	Ala	Val	Ser	Tyr
				35					40					45
Met	Ser	Val	Lys	Cys	Val	Asp	Ala	Arg	Lys	Asn	His	His	Lys	Thr
				50					55					60
Lys	Trp	Phe	Val	Pro	Trp	Gly	Pro	Asn	His	Cys	Asp	Lys	Ile	Arg
				65					70					75
Asp	Ile	Glu	Glu	Ala	Ile	Pro	Arg	Glu	Ile	Glu	Ala	Asn	Asp	Ile
				80					85					90
Val	Phe	Ser	Val	His	Ile	Pro	Leu	Pro	His	Met	Glu	Met	Ser	Pro
				95					100					105
Trp	Phe	Gln	Phe	Met	Leu	Phe	Ile	Leu	Gln	Leu	Asp	Ile	Ala	Phe
				110					115					120
Lys	Leu	Asn	Asn	Gln	Ile	Arg	Glu	Asn	Ala	Glu	Val	Ser	Met	Asp
				125					130					135
Val	Ser	Leu	Ala	Tyr	Arg	Asp	Asp	Ala	Phe	Ala	Glu	Trp	Thr	Glu
				140					145					150
Met	Ala	His	Glu	Arg	Val	Pro	Arg	Lys	Leu	Lys	Cys	Thr	Phe	Thr
				155					160					165
Ser	Pro	Lys	Thr	Pro	Glu	His	Glu	Gly	Arg	Tyr	Tyr	Glu	Cys	Asp
				170					175					180
Val	Leu	Pro	Phe	Met	Glu	Ile	Gly	Ser	Val	Ala	His	Lys	Phe	Tyr
				185					190					195
Leu	Leu	Asn	Ile	Arg	Leu	Pro	Val	Asn	Glu	Lys	Lys	Lys	Ile	Asn
				200					205					210
Val	Gly	Ile	Gly	Glu	Ile	Lys	Asp	Ile	Arg	Leu	Val	Gly	Ile	His
				215					220					225
Gln	Asn	Gly	Gly	Phe	Thr	Lys	Val	Trp	Phe	Ala	Met	Lys	Thr	Phe
				230					235					240
Leu	Thr	Pro	Ser	Ile	Phe	Ile	Ile	Met	Val	Trp	Tyr	Trp	Arg	Arg
				245					250					255
Ile	Thr	Met	Met	Ser	Arg	Pro	Pro	Val	Leu	Leu	Glu	Lys	Val	Ile
				260					265					270
Phe	Ala	Leu	Gly	Ile	Ser	Met	Thr	Phe	Ile	Asn	Ile	Pro	Val	Glu
				275					280					285
Trp	Phe	Ser	Ile	Gly	Phe	Asp	Trp	Thr	Trp	Met	Leu	Leu	Phe	Gly
				290					295					300
Asp	Ile	Arg	Gln	Gly	Ile	Phe	Tyr	Ala	Met	Leu	Leu	Ser	Phe	Trp
				305					310					315
Ile	Ile	Phe	Cys	Gly	Glu	His	Met	Met	Asp	Gln	His	Glu	Arg	Asn
				320					325					330
His	Ile	Ala	Gly	Tyr	Trp	Lys	Gln	Val	Gly	Pro	Ile	Ala	Val	Gly
				335					340					345
Ser	Phe	Cys	Leu	Phe	Ile	Phe	Asp	Met	Cys	Glu	Arg	Gly	Val	Gln
				350					355					360
Leu	Thr	Asn	Pro	Phe	Tyr	Ser	Ile	Trp	Thr	Thr	Asp	Ile	Gly	Thr
				365					370					375
Glu	Leu	Ala	Met	Ala	Phe	Ile	Ile	Val	Ala	Gly	Ile	Cys	Leu	Cys
				380					385					390
Leu	Tyr	Phe	Leu	Phe	Leu	Cys	Phe	Met	Val	Phe	Gln	Val	Phe	Arg
				395					400					405
Asn	Ile	Ser	Gly	Lys	Gln	Ser	Ser	Leu	Pro	Ala	Met	Ser	Lys	Val

410	415	420
Arg Arg Leu His Tyr Glu Gly Leu Ile	Phe Arg Phe Lys Phe Leu	
425	430	435
Met Leu Ile Thr Leu Ala Cys Ala Ala	Met Thr Val Ile Phe Phe	
440	445	450
Ile Val Ser Gln Val Thr Glu Gly His	Trp Lys Trp Gly Gly Val	
455	460	465
Thr Val Gln Val Asn Ser Ala Phe Phe	Thr Gly Ile Tyr Gly Met	
470	475	480
Trp Asn Leu Tyr Val Phe Ala Leu Met	Phe Leu Tyr Ala Pro Ser	
485	490	495
His Lys Asn Tyr Gly Glu Asp Gln Ser	Asn Gly Met Gln Leu Pro	
500	505	510
Cys Lys Ser Arg Glu Asp Cys Ala Leu	Phe Val Ser Glu Leu Tyr	
515	520	525
Gln Glu Leu Phe Ser Ala Ser Lys Tyr	Ser Phe Ile Asn Asp Asn	
530	535	540
Ala Ala Ser Gly Ile		
545		

<210> 48

<211> 570

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte Clone No: 1831378

<400> 48

Met Gly Phe Leu Gln Leu Leu Val Val	Ala Val Leu Ala Ser Glu
1 5	10 15
His Arg Val Ala Gly Ala Ala Glu Val	Phe Gly Asn Ser Ser Glu
20	25 30
Gly Leu Ile Glu Phe Ser Val Gly Lys	Phe Arg Tyr Phe Glu Leu
35	40 45
Asn Arg Pro Phe Pro Glu Glu Ala Ile	Leu His Asp Ile Ser Ser
50	55 60
Asn Val Thr Phe Leu Ile Phe Gln Ile	His Ser Gln Tyr Gln Asn
65	70 75
Thr Thr Val Ser Phe Ser Pro Thr Leu	Leu Ser Asn Ser Ser Glu
80	85 90
Thr Gly Thr Ala Ser Gly Leu Val Phe	Ile Leu Arg Pro Glu Gln
95	100 105
Ser Thr Cys Thr Trp Tyr Leu Gly Thr	Ser Gly Ile Gln Pro Val
110	115 120
Gln Asn Met Ala Ile Leu Leu Ser Tyr	Ser Glu Arg Asp Pro Val
125	130 135
Pro Gly Gly Cys Asn Leu Glu Phe Asp	Leu Asp Ile Asp Pro Asn
140	145 150
Ile Tyr Leu Glu Tyr Asn Phe Phe Glu	Thr Thr Ile Lys Phe Ala
155	160 165
Pro Ala Asn Leu Gly Tyr Ala Arg Gly	Val Asp Pro Pro Pro Cys
170	175 180
Asp Ala Gly Thr Asp Gln Asp Ser Arg	Trp Arg Leu Gln Tyr Asp

	185		190		195
Val Tyr Gln Tyr	Phe Leu Pro Glu Asn Asp	Leu Thr Glu Glu Met			
	200		205		210
Leu Leu Lys His	Leu Gln Arg Met Val Ser	Val Pro Gln Val Lys			
	215		220		225
Ala Ser Ala Leu	Lys Val Val Thr Leu Thr	Ala Asn Asp Lys Thr			
	230		235		240
Ser Val Ser Phe	Ser Ser Leu Pro Gly Gln	Gly Val Ile Tyr Asn			
	245		250		255
Val Ile Val Trp	Asp Pro Phe Leu Asn Thr	Ser Ala Ala Tyr Ile			
	260		265		270
Pro Ala His Thr	Tyr Ala Cys Ser Phe Glu	Ala Gly Glu Gly Ser			
	275		280		285
Cys Ala Ser Leu	Gly Arg Val Ser Ser Lys	Val Phe Phe Thr Leu			
	290		295		300
Phe Ala Leu Leu	Gly Phe Phe Ile Cys Phe	Phe Gly His Arg Phe			
	305		310		315
Trp Lys Thr Glu	Leu Phe Phe Ile Gly Phe	Ile Ile Met Gly Phe			
	320		325		330
Phe Phe Tyr Ile	Leu Ile Thr Arg Leu Thr	Pro Ile Lys Tyr Asp			
	335		340		345
Val Asn Leu Ile	Leu Thr Ala Val Thr Gly	Ser Val Gly Gly Met			
	350		355		360
Phe Leu Val Ala	Val Trp Trp Arg Phe Gly	Ile Leu Ser Ile Cys			
	365		370		375
Met Leu Cys Val	Gly Leu Val Leu Gly Phe	Leu Ile Ser Ser Val			
	380		385		390
Thr Phe Phe Thr	Pro Leu Gly Asn Leu Lys	Ile Phe His Asp Asp			
	395		400		405
Gly Val Phe Trp	Val Thr Phe Ser Cys Ile	Ala Ile Leu Ile Pro			
	410		415		420
Val Val Phe Met	Gly Cys Leu Arg Ile Leu	Asn Ile Leu Thr Cys			
	425		430		435
Gly Val Ile Gly	Ser Tyr Ser Val Val Leu	Ala Ile Asp Ser Tyr			
	440		445		450
Trp Ser Thr Ser	Leu Ser Tyr Ile Thr Leu	Asn Val Leu Lys Arg			
	455		460		465
Ala Leu Asn Lys	Asp Phe His Arg Ala Phe	Thr Asn Val Pro Phe			
	470		475		480
Gln Thr Asn Asp	Phe Ile Ile Leu Ala Val	Trp Gly Met Leu Ala			
	485		490		495
Val Ser Gly Ile	Thr Leu Gln Ile Arg Arg	Glu Arg Gly Arg Pro			
	500		505		510
Phe Phe Pro Pro	His Pro Tyr Lys Leu Trp	Lys Gln Glu Arg Glu			
	515		520		525
Arg Arg Val Thr	Asn Ile Leu Asp Pro Ser	Tyr His Ile Pro Pro			
	530		535		540
Leu Arg Glu Arg	Leu Tyr Gly Arg Leu Thr	Gln Ile Lys Gly Leu			
	545		550		555
Phe Gln Lys Glu	Gln Pro Ala Gly Glu Arg	Thr Pro Leu Leu Leu			
	560		565		570

<210> 49

<211> 127

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte Clone No: 1864943

<400> 49

```

Met Arg Arg Arg Phe Trp Gly Val Phe Asn Cys Leu Cys Ala Gly
 1           5           10           15
Ala Phe Gly Ala Leu Ala Ala Ala Ser Ala Lys Leu Ala Phe Gly
           20           25           30
Ser Glu Val Ser Met Gly Leu Cys Val Leu Gly Ile Ile Val Met
           35           40           45
Ala Ser Thr Asn Ser Leu Met Trp Thr Phe Phe Ser Arg Gly Leu
           50           55           60
Ser Phe Ser Met Ser Ser Ala Ile Ala Ser Val Thr Val Thr Phe
           65           70           75
Ser Asn Ile Leu Ser Ser Ala Phe Leu Gly Tyr Val Leu Tyr Gly
           80           85           90
Glu Cys Gln Glu Val Leu Trp Trp Gly Gly Val Phe Leu Ile Leu
           95          100          105
Cys Gly Leu Thr Leu Ile His Arg Lys Leu Pro Pro Thr Trp Lys
          110          115          120
Pro Leu Pro His Lys Gln Gln
          125

```

<210> 50

<211> 152

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte Clone No: 1911316

<400> 50

```

Met Asp Asn Val Gln Pro Lys Ile Lys His Arg Pro Phe Cys Phe
 1           5           10           15
Ser Val Lys Gly His Val Lys Met Leu Arg Leu Ala Leu Thr Val
           20           25           30
Thr Ser Met Thr Phe Phe Ile Ile Ala Gln Ala Pro Glu Pro Tyr
           35           40           45
Ile Val Ile Thr Gly Phe Glu Val Thr Val Ile Leu Phe Phe Ile
           50           55           60
Leu Leu Tyr Val Leu Arg Leu Asp Arg Leu Met Lys Trp Leu Phe
           65           70           75
Trp Pro Leu Leu Asp Ile Ile Asn Ser Leu Val Thr Thr Val Phe
           80           85           90
Met Leu Ile Val Ser Val Leu Ala Leu Ile Pro Glu Thr Thr Thr
           95          100          105
Leu Thr Val Gly Gly Gly Val Phe Ala Leu Val Thr Ala Val Cys
          110          115          120
Cys Leu Ala Asp Gly Ala Leu Ile Tyr Arg Lys Leu Leu Phe Asn
          125          130          135
Pro Ser Gly Pro Tyr Gln Lys Lys Pro Val His Glu Lys Lys Glu
          140          145          150
Val Leu

```

<210> 51
 <211> 777
 <212> PRT
 <213> Homo sapiens

 <220>
 <221> misc_feature
 <223> Incyte Clone No: 1943120

<400> 51
 Met Thr Phe Tyr Pro Phe Val Ala Ser Ser Ser Thr Arg Arg Val
 1 5 10 15
 Asp Asn Ser Asn Thr Arg Leu Ala Val Gln Ile Glu Arg Asp Pro
 20 25 30
 Gly Asn Asp Asp Asn Asn Leu Asn Ser Ile Phe Tyr Glu His Leu
 35 40 45
 Thr Arg Thr Leu Leu Glu Ser Leu Cys Gly Asp Leu Val Leu Gly
 50 55 60
 Arg Trp Gly Asn Tyr Ser Ser Gly Asp Cys Phe Ile Leu Ala Ser
 65 70 75
 Asp Asp Leu Asn Ala Phe Val His Leu Ile Glu Ile Gly Asn Gly
 80 85 90
 Leu Val Thr Phe Gln Leu Arg Gly Leu Glu Phe Arg Gly Thr Tyr
 95 100 105
 Cys Gln Gln Arg Glu Val Glu Ala Ile Met Glu Gly Asp Glu Glu
 110 115 120
 Asp Arg Gly Cys Cys Cys Cys Lys Pro Gly His Leu Pro His Leu
 125 130 135
 Leu Ser Arg Asn Ala Ala Phe His Leu Arg Trp Leu Thr Trp Glu
 140 145 150
 Ile Thr Gln Thr Gln Tyr Ile Leu Glu Gly Tyr Ser Ile Leu Asp
 155 160 165
 Asn Asn Ala Ala Thr Met Leu Gln Val Phe Asp Leu Arg Arg Ile
 170 175 180
 Leu Ile Arg Tyr Tyr Ile Lys Ser Ile Ile Tyr Tyr Met Val Thr
 185 190 195
 Ser Pro Lys Leu Leu Ser Trp Ile Lys Asn Glu Ser Leu Leu Lys
 200 205 210
 Ser Leu Gln Pro Phe Ala Lys Trp His Tyr Ile Glu Arg Asp Leu
 215 220 225
 Ala Met Phe Asn Ile Asn Ile Asp Asp Asp Tyr Val Pro Cys Leu
 230 235 240
 Gln Gly Ile Thr Arg Ala Ser Phe Cys Asn Val Tyr Leu Glu Trp
 245 250 255
 Ile Gln His Cys Ala Arg Lys Arg Gln Glu Pro Ser Thr Thr Leu
 260 265 270
 Asp Ser Asp Glu Asp Ser Pro Leu Val Thr Leu Ser Phe Ala Leu
 275 280 285
 Cys Thr Leu Gly Arg Arg Ala Leu Gly Thr Ala Ala His Asn Met
 290 295 300
 Ala Ile Ser Leu Asp Ser Phe Leu Tyr Gly Leu His Val Leu Phe
 305 310 315
 Lys Gly Asp Phe Arg Ile Thr Ala Arg Asp Glu Trp Val Phe Ala
 320 325 330
 Asp Met Asp Leu Leu His Lys Val Val Ala Pro Ala Ile Arg Met

	335		340		345
Ser Leu Lys Leu His Gln Asp Gln Phe Thr Cys Pro Asp Glu Tyr					
	350		355		360
Glu Asp Pro Ala Val Leu Tyr Glu Ala Ile Gln Ser Phe Glu Lys					
	365		370		375
Lys Val Val Ile Cys His Glu Gly Asp Pro Ala Trp Arg Gly Ala					
	380		385		390
Val Leu Ser Asn Lys Glu Glu Leu Leu Thr Leu Arg His Val Val					
	395		400		405
Asp Glu Gly Ala Asp Glu Tyr Lys Val Ile Met Leu His Arg Ser					
	410		415		420
Phe Leu Ser Phe Lys Val Ile Lys Val Asn Lys Glu Cys Val Arg					
	425		430		435
Gly Leu Trp Ala Gly Gln Gln Gln Glu Leu Ile Phe Leu Arg Asn					
	440		445		450
Arg Asn Pro Glu Arg Gly Ser Ile Gln Asn Asn Lys Gln Val Leu					
	455		460		465
Arg Asn Leu Ile Asn Ser Ser Cys Asp Gln Pro Leu Gly Tyr Pro					
	470		475		480
Met Tyr Val Ser Pro Leu Thr Thr Ser Tyr Leu Gly Thr His Arg					
	485		490		495
Gln Leu Lys Asn Ile Trp Gly Gly Pro Ile Thr Leu Asp Arg Ile					
	500		505		510
Arg Thr Trp Phe Trp Thr Lys Trp Val Arg Met Arg Lys Asp Cys					
	515		520		525
Asn Ala Arg Gln His Ser Gly Gly Asn Ile Glu Asp Val Asp Gly					
	530		535		540
Gly Gly Ala Pro Thr Thr Gly Gly Asn Asn Ala Pro Asn Gly Gly					
	545		550		555
Ser Gln Glu Ser Ser Ala Glu Gln Pro Arg Lys Gly Gly Ala Gln					
	560		565		570
His Gly Val Ser Ser Cys Glu Gly Thr Gln Arg Thr Gly Arg Arg					
	575		580		585
Lys Gly Arg Ser Gln Ser Val Gln Ala His Ser Ala Leu Ser Gln					
	590		595		600
Arg Pro Pro Met Leu Ser Ser Ser Gly Pro Ile Leu Glu Ser Arg					
	605		610		615
Gln Thr Phe Leu Gln Thr Ser Thr Ser Val His Glu Leu Ala Gln					
	620		625		630
Arg Leu Ser Gly Ser Arg Leu Ser Leu His Ala Ser Ala Thr Ser					
	635		640		645
Leu His Ser Gln Pro Pro Pro Val Thr Thr Thr Gly His Leu Ser					
	650		655		660
Val Arg Glu Arg Ala Glu Ala Leu Ile Arg Ser Ser Leu Gly Ser					
	665		670		675
Ser Thr Ser Ser Thr Leu Ser Phe Leu Phe Gly Lys Arg Ser Phe					
	680		685		690
Ser Ser Ala Leu Val Ile Ser Gly Leu Ser Ala Ala Glu Gly Gly					
	695		700		705
Asn Thr Ser Asp Thr Gln Ser Ser Ser Ser Val Asn Ile Val Met					
	710		715		720
Gly Pro Ser Ala Arg Ala Ala Ser Gln Ala Thr Arg Val Arg Gly					
	725		730		735
Trp Ala Gly Leu Thr Arg Thr Gly Trp Asp Gly Gly Thr Gly Ser					
	740		745		750
Trp Pro Glu Arg Gly Thr Cys Leu Ala Phe Pro Pro Phe Cys Leu					
	755		760		765

Gln Asn Pro Ile Pro Phe Ser Met Gly Leu Pro Glu
 770 775

<210> 52
 <211> 108
 <212> PRT
 <213> Homo sapiens
 <220>
 <221> misc_feature
 <223> Incyte Clone No: 2314236

<400> 52
 Met Phe Lys His Glu Leu Glu Glu Leu Arg Thr Thr Ile Met Tyr
 1 5 10 15
 Arg Asp Ser His Ser Val Leu Ala Leu Asn Trp Lys Val Val Ala
 20 25 30
 Thr Leu Lys Tyr Phe Leu Leu Tyr Val Ile Ile Leu Tyr Asn Leu
 35 40 45
 Glu Arg Asp Asn Gly His Ser Asn Tyr Glu Asn Tyr Glu Leu Gly
 50 55 60
 Asp Lys Ser Leu Asn Leu Leu Leu Phe Tyr Asn Ser Met Tyr Lys
 65 70 75
 Leu Val Phe Pro Tyr Ile Phe Thr Phe Ser Ser Phe Leu Ile Ser
 80 85 90
 Ser Tyr Thr Ser Ile Leu Tyr Lys Met Phe Tyr Ile Gln Arg Thr
 95 100 105
 Val Lys Ser

<210> 53
 <211> 66
 <212> PRT
 <213> Homo sapiens
 <220>
 <221> misc_feature
 <223> Incyte Clone No: 2479409

<400> 53
 Met Asn Leu Ser Lys Lys Ser Ile Leu Leu Thr Gln Val Ile Lys
 1 5 10 15
 Phe Val Asp Ile Arg Leu Phe Ile Met Val Pro Ser Tyr Pro Phe
 20 25 30
 Asn Val Phe Arg Ser Cys Val Asp Asn Phe Leu Phe Ile Met Ile
 35 40 45
 Leu Val Ile Ser Val Leu Thr Phe Leu Ile Arg Leu Gly Arg Gly
 50 55 60
 Leu Ser Val Leu Leu Ile
 65

<210> 54

<211> 540
 <212> PRT
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte Clone No: 2683149

<400> 54
 Met Met Gly Ser Pro Val Ser His Leu Leu Ala Gly Phe Cys Val
 5 10 15
 Trp Val Val Leu Gly Trp Val Gly Gly Ser Val Pro Asn Leu Gly
 20 25 30
 Pro Ala Glu Gln Glu Gln Asn His Tyr Leu Ala Gln Leu Phe Gly
 35 40 45
 Leu Tyr Gly Glu Asn Gly Thr Leu Thr Ala Gly Gly Leu Ala Arg
 50 55 60
 Leu Leu His Ser Leu Gly Leu Gly Arg Val Gln Gly Leu Arg Leu
 65 70 75
 Gly Gln His Gly Pro Leu Thr Gly Arg Ala Ala Ser Pro Ala Ala
 80 85 90
 Asp Asn Ser Thr His Arg Pro Gln Asn Pro Glu Leu Ser Val Asp
 95 100 105
 Val Trp Ala Gly Met Pro Leu Gly Pro Ser Gly Trp Gly Asp Leu
 110 115 120
 Glu Glu Ser Lys Ala Pro His Leu Pro Arg Gly Pro Ala Pro Ser
 125 130 135
 Gly Leu Asp Leu Leu His Arg Leu Leu Leu Leu Asp His Ser Leu
 140 145 150
 Ala Asp His Leu Asn Glu Asp Cys Leu Asn Gly Ser Gln Leu Leu
 155 160 165
 Val Asn Phe Gly Leu Ser Pro Ala Ala Pro Leu Thr Pro Arg Gln
 170 175 180
 Phe Ala Leu Leu Cys Pro Ala Leu Leu Tyr Gln Ile Asp Ser Arg
 185 190 195
 Val Cys Ile Gly Ala Pro Ala Pro Ala Pro Pro Gly Asp Leu Leu
 200 205 210
 Ser Ala Leu Leu Gln Ser Ala Leu Ala Val Leu Leu Leu Ser Leu
 215 220 225
 Pro Ser Pro Leu Ser Leu Leu Leu Leu Arg Leu Leu Gly Pro Arg
 230 235 240
 Leu Leu Arg Pro Leu Leu Gly Phe Leu Gly Ala Leu Ala Val Gly
 245 250 255
 Thr Leu Cys Gly Asp Ala Leu Leu His Leu Leu Pro His Ala Gln
 260 265 270
 Glu Gly Arg His Ala Gly Pro Gly Gly Leu Pro Glu Lys Asp Leu
 275 280 285
 Gly Pro Gly Leu Ser Val Leu Gly Gly Leu Phe Leu Leu Phe Val
 290 295 300
 Leu Glu Asn Met Leu Gly Leu Leu Arg His Arg Gly Leu Arg Pro
 305 310 315
 Arg Cys Cys Arg Arg Lys Arg Arg Asn Leu Glu Thr Arg Asn Leu
 320 325 330
 Asp Pro Glu Asn Gly Ser Gly Met Ala Leu Gln Pro Leu Gln Ala
 335 340 345
 Ala Pro Glu Pro Gly Ala Gln Gly Gln Arg Glu Lys Asn Ser Gln

350	355	360
His Pro Pro Ala	Leu Ala Pro Pro Gly	His Gln Gly His Ser His
365	370	375
Gly His Gln Gly	Gly Thr Asp Ile Thr	Trp Met Val Leu Leu Gly
380	385	390
Asp Gly Leu His	Asn Leu Thr Asp Gly	Leu Ala Ile Gly Ala Ala
395	400	405
Phe Ser Asp Gly	Phe Ser Ser Gly Leu	Ser Thr Thr Leu Ala Val
410	415	420
Phe Cys His Glu	Leu Pro His Glu Leu	Gly Asp Phe Ala Met Leu
425	430	435
Leu Gln Ser Gly	Leu Ser Phe Arg Arg	Leu Leu Leu Leu Ser Leu
440	445	450
Val Ser Gly Ala	Leu Gly Leu Gly Gly	Ala Val Leu Gly Val Gly
455	460	465
Leu Ser Leu Gly	Pro Val Pro Leu Thr	Pro Trp Val Phe Gly Val
470	475	480
Thr Ala Gly Val	Phe Leu Tyr Val Ala	Leu Val Asp Met Leu Pro
485	490	495
Ala Leu Leu Arg	Pro Pro Glu Pro Leu	Pro Thr Pro His Val Leu
500	505	510
Leu Gln Gly Leu	Gly Leu Leu Leu Gly	Gly Gly Leu Met Leu Ala
515	520	525
Ile Thr Leu Leu	Glu Glu Arg Leu Leu	Pro Val Thr Thr Glu Gly
530	535	540

<210> 55

<211> 87

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte Clone No: 2774051

<400> 55

Met Pro Phe Thr Leu	Asp Asp Tyr Gly Ala Tyr Ser Ser Gln Lys
1	5 10 15
Gln Tyr Thr Cys Gln	Phe Pro Ser Thr Ile Ala Ile His Ala Glu
20	25 30
Asp Lys Arg Pro Pro	Gln Ser Arg Arg Gly Ile Val Leu Gly Pro
35	40 45
Ile Phe Leu Ile Val	Leu Lys Ile Ile Ile Arg Trp Thr Val Phe
50	55 60
Cys Glu Asp Phe Leu	Phe Pro Ser Ser Lys Lys Pro Cys Gly Lys
65	70 75
Asn Ser Leu Ile Thr	Val Leu Ile Phe Phe Phe Phe
80	85

<210> 56

<211> 100

<212> PRT

<213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte Clone No: 2869038

<400> 56
 Met Ile Met Ala Gln Lys Ile Gly Gly Leu Thr Trp Trp Ala Ile
 1 5 10 15
 Met Phe Ile Ile Leu Phe Glu Ile Thr Gly Thr Ser Ser Ser Phe
 20 25 30
 Leu Arg Ile Asn Ala Leu Pro His Phe Ser Met Asn Arg Cys Gly
 35 40 45
 Glu Ala Tyr Phe Pro Phe Ser Tyr Leu Tyr Thr Ser Leu Gln Lys
 50 55 60
 Gln Phe Leu Met Lys Val Ser Gly Ile Val Lys Asn Leu Arg Gly
 65 70 75
 Met Met Thr Gly Gly Val Trp Gly Phe Phe Leu Tyr Ser Phe Phe
 80 85 90
 Asn Glu Lys Ser Phe Lys Cys Ser Thr Gly
 95 100

<210> 57
 <211> 58
 <212> PRT
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte Clone No: 2918334

<400> 57
 Met Asp Leu Leu Tyr Glu Ile Leu Leu Ala Leu Tyr Tyr Asn Ile
 1 5 10 15
 Cys Tyr Asp Ile Pro Phe Ile Phe Phe Asn Leu Asn Met Met Phe
 20 25 30
 Tyr Ile Val Leu Asp Leu Arg Ile Val Phe Phe Arg Thr Ile Arg
 35 40 45
 Glu Tyr Leu Ser Pro Pro Ser Leu Ser Phe Tyr Ile Tyr
 50 55

<210> 58
 <211> 61
 <212> PRT
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte Clone No: 2949916

<400> 58
 Met Arg Arg Ile Ile Arg Leu Arg Leu Arg Phe Ser Asp Thr Phe

1	5	10	15
Met Ala Ala Phe	Leu Leu Cys Leu Gly	Phe Val Leu Met Leu	Phe
	20	25	30
Pro Ser Leu Leu	Arg Asp Gly Gly Ser	Ile Ser Ser Cys Arg	Asn
	35	40	45
Ser Cys Ser Ser	Pro Ser Ser Glu Glu	Arg His Phe Ser Asn	Leu
	50	55	60
Glu			

<210> 59
 <211> 50
 <212> PRT
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte Clone No: 2989375

<400> 59
Met Cys Leu Thr Pro His Arg Asp Ser Met Cys Glu Asp Ser Pro
1 5 10 15
Phe Thr His Gln Ile Ile Ser Met Ala Thr Ala Cys Ser Leu Leu
20 25 30
Leu Glu Cys Phe Val Leu Ala Ala Ser Leu Leu Val Cys Val Trp
35 40 45
Ser Glu Trp Arg Arg
50

<210> 60
 <211> 310
 <212> PRT
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte Clone No: 3316764

<400> 60
Met Arg Arg Thr Ala Phe Ile Leu Gly Ser Gly Leu Leu Ser Phe
1 5 10 15
Val Ala Phe Trp Asn Ser Val Thr Trp His Leu Gln Arg Phe Trp
20 25 30
Gly Ala Ser Gly Tyr Phe Trp Gln Ala Gln Trp Glu Arg Leu Leu
35 40 45
Thr Thr Phe Glu Gly Lys Glu Trp Ile Leu Phe Phe Ile Gly Ala
50 55 60
Ile Gln Val Pro Cys Leu Phe Phe Trp Ser Phe Asn Gly Leu Leu
65 70 75
Leu Val Val Asp Thr Thr Gly Lys Pro Asn Phe Ile Ser Arg Tyr
80 85 90
Arg Ile Gln Val Gly Lys Asn Glu Pro Val Asp Pro Val Lys Leu
95 100 105

```
<210> 61
<211> 160
<212> PRT
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte Clone No: 3359559
```

<400>	61														
Met	Ala	Pro	Ala	Leu	Trp	Arg	Ala	Cys	Asn	Gly	Leu	Met	Ala	Ala	
1				5					10					15	
Phe	Phe	Ala	Leu	Ala	Ala	Leu	Val	Gln	Val	Asn	Asp	Pro	Asp	Ala	
				20					25					30	
Glu	Val	Trp	Val	Val	Val	Tyr	Thr	Ile	Pro	Ala	Val	Leu	Thr	Leu	
				35					40					45	
Leu	Val	Gly	Leu	Asn	Pro	Glu	Val	Thr	Gly	Asn	Val	Ile	Trp	Lys	
				50					55					60	
Ser	Ile	Ser	Ala	Ile	His	Ile	Leu	Phe	Cys	Thr	Val	Trp	Ala	Val	
				65					70					75	
Gly	Leu	Ala	Ser	Tyr	Leu	Leu	His	Arg	Thr	Gln	Gln	Asn	Ile	Leu	
				80					85					90	
His	Glu	Glu	Glu	Gly	Arg	Glu	Leu	Ser	Gly	Leu	Val	Ile	Ile	Thr	
				95					100					105	
Ala	Trp	Ile	Ile	Leu	Cys	His	Ser	Ser	Ser	Lys	Asn	Pro	Val	Gly	
				110					115					120	

```

Gly Arg Ile Gln Leu Ala Ile Ala Ile Val Ile Thr Leu Phe Pro
      125                      130                      135
Phe Ile Ser Trp Val Tyr Ile Tyr Ile Asn Lys Glu Met Arg Ser
      140                      145                      150
Ser Trp Pro Thr His Cys Lys Thr Val Ile
      155                      160

```

```

<210> 62
<211> 35
<212> PRT
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte Clone No: 4289208

```

```

<400> 62
Met Ala Val Val Asp Ala Gly Asn Asn Gly Lys Val Leu Asp Arg
  1          5          10          15
Val Cys Val Arg Ser Val Pro Ala Leu Phe Leu Ser Lys Cys Ile
      20          25          30
Ser Leu Asp Met Glu
      35

```

```

<210> 63
<211> 323
<212> PRT
<213> Homo sapiens

```

```

<220>
<221> misc_feature
<223> Incyte Clone No: 2454013

```

```

<400> 63
Met Ala Ala Pro Lys Gly Ser Leu Trp Val Arg Thr Gln Leu Gly
  1          5          10          15
Leu Pro Pro Leu Leu Leu Leu Thr Met Ala Leu Ala Gly Gly Ser
      20          25          30
Gly Thr Ala Ser Ala Glu Ala Phe Asp Ser Val Leu Gly Asp Thr
      35          40          45
Ala Ser Cys His Arg Ala Cys Gln Leu Thr Tyr Pro Leu His Thr
      50          55          60
Tyr Pro Lys Glu Glu Glu Leu Tyr Ala Cys Gln Arg Gly Cys Arg
      65          70          75
Leu Phe Ser Ile Cys Gln Phe Val Asp Asp Gly Ile Asp Leu Asn
      80          85          90
Arg Thr Lys Leu Glu Cys Glu Ser Ala Cys Thr Glu Ala Tyr Ser
      95          100          105
Gln Ser Asp Glu Gln Tyr Ala Cys His Leu Gly Cys Gln Asn Gln
      110          115          120
Leu Pro Phe Ala Glu Leu Arg Gln Glu Gln Leu Met Ser Leu Met
      125          130          135
Pro Lys Met His Leu Leu Phe Pro Leu Thr Leu Val Arg Ser Phe

```

	140		145		150
Trp Ser Asp Met	Met Asp Ser Ala Gln	Phe Ile Thr Ser	Ser		
	155		160		165
Trp Thr Phe Tyr	Leu Gln Ala Asp Asp	Gly Lys Ile Val Ile	Phe		
	170		175		180
Gln Ser Lys Pro	Glu Ile Gln Tyr Ala	Pro His Leu Glu Gln	Glu		
	185		190		195
Pro Thr Asn Leu	Arg Glu Ser Ser Leu	Ser Lys Met Ser Tyr	Leu		
	200		205		210
Gln Met Arg Asn	Ser Gln Ala His Arg	Asn Phe Leu Glu Asp	Gly		
	215		220		225
Glu Ser Asp Gly	Phe Leu Arg Cys Leu	Ser Leu Asn Ser Gly	Trp		
	230		235		240
Ile Leu Thr Thr	Thr Leu Val Leu Ser	Val Met Val Leu Leu	Trp		
	245		250		255
Ile Cys Cys Ala	Thr Val Ala Thr Ala	Val Glu Gln Tyr Val	Pro		
	260		265		270
Ser Glu Lys Leu	Ser Ile Tyr Gly Asp	Leu Glu Phe Met Asn	Glu		
	275		280		285
Gln Lys Leu Asn	Arg Tyr Pro Ala Ser	Ser Leu Val Val Val	Arg		
	290		295		300
Ser Lys Thr Glu	Asp His Glu Glu Ala	Gly Pro Leu Pro Thr	Lys		
	305		310		315
Val Asn Leu Ala	His Ser Glu Ile				
	320				

<210> 64

<211> 129

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte Clone No: 2454048

<400> 64

Met Ala Arg Gly Ser Leu Arg Arg Leu Leu Arg Leu Leu Val Leu		
1	5	10 15
Gly Leu Trp Leu Ala Leu Leu Arg Ser Val Ala Gly Glu Gln Ala		
	20	25 30
Pro Gly Thr Ala Pro Cys Ser Arg Gly Ser Ser Trp Ser Ala Asp		
	35	40 45
Leu Asp Lys Cys Met Asp Cys Ala Ser Cys Arg Ala Arg Pro His		
	50	55 60
Ser Asp Phe Cys Leu Gly Cys Ala Ala Ala Pro Pro Ala Pro Phe		
	65	70 75
Arg Leu Leu Trp Pro Ile Leu Gly Gly Ala Leu Ser Leu Thr Phe		
	80	85 90
Val Leu Gly Leu Leu Ser Gly Phe Leu Val Trp Arg Arg Cys Arg		
	95	100 105
Arg Arg Glu Lys Phe Thr Thr Pro Ile Glu Glu Thr Gly Gly Glu		
	110	115 120
Gly Cys Pro Ala Val Ala Leu Ile Gln		
	125	

<210> 65
 <211> 461
 <212> PRT
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte Clone No: 2479282

<400> 65
 Met Ala Pro Gln Ser Leu Pro Ser Ser Arg Met Ala Pro Leu Gly
 1 5 10 15
 Met Leu Leu Gly Leu Leu Met Ala Ala Cys Phe Thr Phe Cys Leu
 20 25 30
 Ser His Gln Asn Leu Lys Glu Phe Ala Leu Thr Asn Pro Glu Lys
 35 40 45
 Ser Ser Thr Lys Glu Thr Glu Arg Lys Glu Thr Lys Ala Glu Glu
 50 55 60
 Glu Leu Asp Ala Glu Val Leu Glu Val Phe His Pro Thr His Glu
 65 70 75
 Trp Gln Ala Leu Gln Pro Gly Gln Ala Val Pro Ala Gly Ser His
 80 85 90
 Val Arg Leu Asn Leu Gln Thr Gly Glu Arg Glu Ala Lys Leu Gln
 95 100 105
 Tyr Glu Asp Lys Phe Arg Asn Asn Leu Lys Gly Lys Arg Leu Asp
 110 115 120
 Ile Asn Thr Asn Thr Tyr Thr Ser Gln Asp Leu Lys Ser Ala Leu
 125 130 135
 Ala Lys Phe Lys Glu Gly Ala Glu Met Glu Ser Ser Lys Glu Asp
 140 145 150
 Lys Ala Arg Gln Ala Glu Val Lys Arg Leu Phe Arg Pro Ile Glu
 155 160 165
 Glu Leu Lys Lys Asp Phe Asp Glu Leu Asn Val Val Ile Glu Thr
 170 175 180
 Asp Met Gln Ile Met Val Arg Leu Ile Asn Lys Phe Asn Ser Ser
 185 190 195
 Ser Ser Ser Leu Glu Glu Lys Ile Ala Ala Leu Phe Asp Leu Glu
 200 205 210
 Tyr Tyr Val His Gln Met Asp Asn Ala Gln Asp Leu Leu Ser Phe
 215 220 225
 Gly Gly Leu Gln Val Val Ile Asn Gly Leu Asn Ser Thr Glu Pro
 230 235 240
 Leu Val Lys Glu Tyr Ala Ala Phe Val Leu Gly Ala Ala Phe Ser
 245 250 255
 Ser Asn Pro Lys Val Gln Val Glu Ala Ile Glu Gly Gly Ala Leu
 260 265 270
 Gln Lys Leu Leu Val Ile Leu Ala Thr Glu Gln Pro Leu Thr Ala
 275 280 285
 Lys Lys Lys Val Leu Phe Ala Leu Cys Ser Leu Leu Arg His Phe
 290 295 300
 Pro Tyr Ala Gln Arg Gln Phe Leu Lys Leu Gly Gly Leu Gln Val
 305 310 315
 Leu Arg Thr Leu Val Gln Glu Lys Gly Thr Glu Val Leu Ala Val
 320 325 330
 Arg Val Val Thr Leu Leu Tyr Asp Leu Val Thr Glu Lys Met Phe
 335 340 345

Ala	Glu	Glu	Glu	Ala	Glu	Leu	Thr	Gln	Glu	Met	Ser	Pro	Glu	Lys
				350					355					360
Leu	Gln	Gln	Tyr	Arg	Gln	Val	His	Leu	Leu	Pro	Gly	Leu	Trp	Glu
				365					370					375
Gln	Gly	Trp	Cys	Glu	Ile	Thr	Ala	His	Leu	Leu	Ala	Leu	Pro	Glu
				380					385					390
His	Asp	Ala	Arg	Glu	Lys	Val	Leu	Gln	Thr	Leu	Gly	Val	Leu	Leu
				395					400					405
Thr	Thr	Cys	Arg	Asp	Arg	Tyr	Arg	Gln	Asp	Pro	Gln	Leu	Gly	Arg
				410					415					420
Thr	Leu	Ala	Ser	Leu	Gln	Ala	Glu	Tyr	Gln	Val	Leu	Ala	Ser	Leu
				425					430					435
Glu	Leu	Gln	Asp	Gly	Glu	Asp	Glu	Gly	Tyr	Phe	Gln	Glu	Leu	Leu
				440					445					450
Gly	Ser	Val	Asn	Ser	Leu	Leu	Lys	Glu	Leu	Arg				
				455					460					

<210> 66

<211> 264

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte Clone No: 2483432

<400> 66

Met	Arg	Pro	Leu	Leu	Gly	Leu	Leu	Leu	Val	Phe	Ala	Gly	Cys	Thr
1				5					10					15
Phe	Ala	Leu	Tyr	Leu	Leu	Ser	Thr	Arg	Leu	Pro	Arg	Gly	Arg	Arg
				20					25					30
Leu	Gly	Ser	Thr	Glu	Glu	Ala	Gly	Gly	Arg	Ser	Leu	Trp	Phe	Pro
				35					40					45
Ser	Asp	Leu	Ala	Glu	Leu	Arg	Glu	Leu	Ser	Glu	Val	Leu	Arg	Glu
				50					55					60
Tyr	Arg	Lys	Glu	His	Gln	Ala	Tyr	Val	Phe	Leu	Leu	Phe	Cys	Gly
				65					70					75
Ala	Tyr	Leu	Tyr	Lys	Gln	Gly	Phe	Ala	Ile	Pro	Gly	Ser	Ser	Phe
				80					85					90
Leu	Asn	Val	Leu	Ala	Gly	Ala	Leu	Phe	Gly	Pro	Trp	Leu	Gly	Leu
				95					100					105
Leu	Leu	Cys	Cys	Val	Leu	Thr	Ser	Val	Gly	Ala	Thr	Cys	Cys	Tyr
				110					115					120
Leu	Leu	Ser	Ser	Ile	Phe	Gly	Lys	Gln	Leu	Val	Val	Ser	Tyr	Phe
				125					130					135
Pro	Asp	Lys	Val	Ala	Leu	Leu	Gln	Arg	Lys	Val	Glu	Glu	Asn	Arg
				140					145					150
Asn	Ser	Leu	Phe	Phe	Phe	Leu	Leu	Phe	Leu	Arg	Leu	Phe	Pro	Met
				155					160					165
Thr	Pro	Asn	Trp	Phe	Leu	Asn	Leu	Ser	Ala	Pro	Ile	Leu	Asn	Ile
				170					175					180
Pro	Ile	Val	Gln	Phe	Phe	Phe	Ser	Val	Leu	Ile	Gly	Leu	Ile	Pro
				185					190					195
Tyr	Asn	Phe	Ile	Cys	Val	Gln	Thr	Gly	Ser	Ile	Leu	Ser	Thr	Leu
				200					205					210

Thr Ser Leu Asp Ala Leu Phe Ser Trp Asp Thr Val Phe Lys Leu
 215 220 225
 Leu Ala Ile Ala Met Val Ala Leu Ile Pro Gly Thr Leu Ile Lys
 230 235 240
 Lys Phe Ser Gln Lys His Leu Gln Leu Asn Glu Thr Ser Thr Ala
 245 250 255
 Asn His Ile His Ser Arg Lys Asp Thr
 260

<210> 67
 <211> 339
 <212> PRT
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte Clone No: 2493824

<400> 67
 Met Ala Ala Ala Cys Gly Pro Gly Ala Ala Gly Tyr Cys Leu Leu
 1 5 10 15
 Leu Gly Leu His Leu Phe Leu Leu Thr Ala Gly Pro Ala Leu Gly
 20 25 30
 Trp Asn Asp Pro Asp Arg Met Leu Leu Arg Asp Val Lys Ala Leu
 35 40 45
 Thr Leu His Tyr Asp Arg Tyr Thr Thr Ser Arg Arg Leu Asp Pro
 50 55 60
 Ile Pro Gln Leu Lys Cys Val Gly Gly Thr Ala Gly Cys Asp Ser
 65 70 75
 Tyr Thr Pro Lys Val Ile Gln Cys Gln Asn Lys Gly Trp Asp Gly
 80 85 90
 Tyr Asp Val Gln Trp Glu Cys Lys Thr Asp Leu Asp Ile Ala Tyr
 95 100 105
 Lys Phe Gly Lys Thr Val Val Ser Cys Glu Gly Tyr Glu Ser Ser
 110 115 120
 Glu Asp Gln Tyr Val Leu Arg Gly Ser Cys Gly Leu Glu Tyr Asn
 125 130 135
 Leu Asp Tyr Thr Glu Leu Gly Leu Gln Lys Leu Lys Glu Ser Gly
 140 145 150
 Lys Gln His Gly Phe Ala Ser Phe Ser Asp Tyr Tyr Tyr Lys Trp
 155 160 165
 Ser Ser Ala Asp Ser Cys Asn Met Ser Gly Leu Ile Thr Ile Val
 170 175 180
 Val Leu Leu Gly Ile Ala Phe Val Val Tyr Lys Leu Phe Leu Ser
 185 190 195
 Asp Gly Gln Tyr Ser Pro Pro Pro Tyr Ser Glu Tyr Pro Pro Phe
 200 205 210
 Ser His Arg Tyr Gln Arg Phe Thr Asn Ser Ala Gly Pro Pro Pro
 215 220 225
 Pro Gly Phe Lys Ser Glu Phe Thr Gly Pro Gln Asn Thr Gly His
 230 235 240
 Gly Ala Thr Ser Gly Phe Gly Ser Ala Phe Thr Gly Gln Gln Gly
 245 250 255

```

Tyr Glu Asn Ser Gly Pro Gly Phe Trp Thr Gly Leu Gly Thr Gly
      260                      265                      270
Gly Ile Leu Gly Tyr Leu Phe Gly Ser Asn Arg Ala Ala Thr Pro
      275                      280                      285
Phe Ser Asp Ser Trp Tyr Tyr Pro Ser Tyr Pro Pro Ser Tyr Pro
      290                      295                      300
Gly Thr Trp Asn Arg Ala Tyr Ser Pro Leu His Gly Gly Ser Gly
      305                      310                      315
Ser Tyr Ser Val Cys Ser Asn Ser Asp Thr Lys Thr Arg Thr Ala
      320                      325                      330
Ser Gly Tyr Gly Gly Thr Arg Arg Arg
      335

```

<210> 68

<211> 397

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte Clone No: 2555823

<400> 68

```

Met Val Arg Pro Gly Ala Arg Leu Cys Leu Gly Ser Val Gly Arg
  1                      5                      10                      15
Gly Leu Cys Leu Val Leu Pro Leu Leu Cys Leu Gly Ala Gly Phe
      20                      25                      30
Leu Phe Leu Asn Thr Leu Phe Ile Gln Arg Gly Arg His Glu Thr
      35                      40                      45
Thr Trp Thr Ile Leu Arg Arg Phe Gly Tyr Ser Asp Ala Leu Glu
      50                      55                      60
Leu Thr Ala Asp Tyr Leu Ser Pro Leu Ile His Val Pro Pro Gly
      65                      70                      75
Cys Ser Thr Glu Leu Asn His Leu Gly Tyr Gln Phe Val Gln Arg
      80                      85                      90
Val Phe Glu Lys His Asp Gln Asp Arg Asp Gly Ala Leu Ser Pro
      95                      100                     105
Val Glu Leu Gln Ser Leu Phe Ser Val Phe Pro Ala Ala Pro Trp
      110                     115                     120
Gly Pro Glu Leu Pro Arg Thr Val Arg Thr Glu Ala Gly Arg Leu
      125                     130                     135
Pro Leu His Gly Tyr Leu Cys Gln Trp Thr Leu Val Thr Tyr Leu
      140                     145                     150
Asp Val Arg Ser Cys Leu Gly His Leu Gly Tyr Leu Gly Tyr Pro
      155                     160                     165
Thr Leu Cys Glu Gln Asp Gln Ala His Ala Ile Thr Val Thr Arg
      170                     175                     180
Glu Lys Arg Leu Asp Gln Glu Lys Gly Gln Thr Gln Arg Ser Val
      185                     190                     195
Leu Leu Cys Lys Val Val Gly Ala Arg Gly Val Gly Lys Ser Ala
      200                     205                     210
Phe Leu Gln Ala Phe Leu Gly Arg Gly Leu Gly His Gln Asp Thr
      215                     220                     225
Arg Glu Gln Pro Pro Gly Tyr Ala Ile Asp Thr Val Gln Val Asn
      230                     235                     240

```

Gly Gln Glu Lys Tyr Leu Ile Leu Cys Glu Val Gly Thr Asp Gly
 245 250 255
 Leu Leu Ala Thr Ser Leu Asp Ala Thr Cys Asp Val Ala Cys Leu
 260 265 270
 Met Phe Asp Gly Ser Asp Pro Lys Ser Phe Ala His Cys Ala Ser
 275 280 285
 Val Tyr Lys His His Tyr Met Asp Gly Gln Thr Pro Cys Leu Phe
 290 295 300
 Val Ser Ser Lys Ala Asp Leu Pro Glu Gly Val Ala Val Ser Gly
 305 310 315
 Pro Ser Pro Ala Glu Phe Cys Arg Lys His Arg Leu Pro Ala Pro
 320 325 330
 Val Pro Phe Ser Cys Ala Gly Pro Ala Glu Pro Ser Thr Thr Ile
 335 340 345
 Phe Thr Gln Leu Ala Thr Met Ala Ala Phe Pro His Leu Val His
 350 355 360
 Ala Glu Leu His Pro Ser Ser Phe Trp Leu Arg Gly Leu Leu Gly
 365 370 375
 Val Val Gly Ala Ala Val Ala Ala Val Leu Ser Phe Ser Leu Tyr
 380 385 390
 Arg Val Leu Val Lys Ser Gln
 395

<210> 69

<211> 301

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte Clone No: 2598242

<400> 69

Met Glu Leu Ser Asp Val Thr Leu Ile Glu Gly Val Gly Asn Glu
 1 5 10 15
 Val Met Val Val Ala Gly Val Val Val Leu Ile Leu Ala Leu Val
 20 25 30
 Leu Ala Trp Leu Ser Thr Tyr Val Ala Asp Ser Gly Ser Asn Gln
 35 40 45
 Leu Leu Gly Ala Ile Val Ser Ala Gly Asp Thr Ser Val Leu His
 50 55 60
 Leu Gly His Val Asp His Leu Val Ala Gly Gln Gly Asn Pro Glu
 65 70 75
 Pro Thr Glu Leu Pro His Pro Ser Glu Gly Asn Asp Glu Lys Ala
 80 85 90
 Glu Glu Ala Gly Glu Gly Arg Gly Asp Ser Thr Gly Glu Ala Gly
 95 100 105
 Ala Gly Gly Gly Val Glu Pro Ser Leu Glu His Leu Leu Asp Ile
 110 115 120
 Gln Gly Leu Pro Lys Arg Gln Ala Gly Ala Gly Ser Ser Ser Pro
 125 130 135
 Glu Ala Pro Leu Arg Ser Glu Asp Ser Thr Cys Leu Pro Pro Ser
 140 145 150
 Pro Gly Leu Ile Thr Val Arg Leu Lys Phe Leu Asn Asp Thr Glu
 155 160 165

Glu	Leu	Ala	Val	Ala	Arg	Pro	Glu	Asp	Thr	Val	Gly	Ala	Leu	Lys
				170					175					180
Ser	Lys	Tyr	Phe	Pro	Gly	Gln	Glu	Ser	Gln	Met	Lys	Leu	Ile	Tyr
				185					190					195
Gln	Gly	Arg	Leu	Leu	Gln	Asp	Pro	Ala	Arg	Thr	Leu	Arg	Ser	Leu
				200					205					210
Asn	Ile	Thr	Asp	Asn	Cys	Val	Ile	His	Cys	His	Arg	Ser	Pro	Pro
				215					220					225
Gly	Ser	Ala	Val	Pro	Gly	Pro	Ser	Ala	Ser	Leu	Ala	Pro	Ser	Ala
				230					235					240
Thr	Glu	Pro	Pro	Ser	Leu	Gly	Val	Asn	Val	Gly	Ser	Leu	Met	Val
				245					250					255
Pro	Val	Phe	Val	Val	Leu	Leu	Gly	Val	Val	Trp	Tyr	Phe	Arg	Ile
				260					265					270
Asn	Tyr	Arg	Gln	Phe	Phe	Thr	Ala	Pro	Ala	Thr	Val	Ser	Leu	Val
				275					280					285
Gly	Val	Thr	Val	Phe	Phe	Ser	Phe	Leu	Val	Phe	Gly	Met	Tyr	Gly
				290					295					300

Arg

<210> 70

<211> 217

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte Clone No: 2634120

<400> 70

Met	Val	Glu	Val	Gln	Leu	Glu	Ser	Asp	His	Glu	Tyr	Pro	Pro	Gly
1				5					10					15
Leu	Leu	Val	Ala	Phe	Ser	Ala	Cys	Thr	Thr	Val	Leu	Val	Ala	Val
				20					25					30
His	Leu	Phe	Ala	Leu	Met	Val	Ser	Thr	Cys	Leu	Leu	Pro	His	Ile
				35					40					45
Glu	Ala	Val	Ser	Asn	Ile	His	Asn	Leu	Asn	Ser	Val	His	Gln	Ser
				50					55					60
Pro	His	Gln	Arg	Leu	His	Arg	Tyr	Val	Glu	Leu	Ala	Trp	Gly	Phe
				65					70					75
Ser	Thr	Ala	Leu	Gly	Thr	Phe	Leu	Phe	Leu	Ala	Glu	Val	Val	Leu
				80					85					90
Val	Gly	Trp	Val	Lys	Phe	Val	Pro	Ile	Gly	Ala	Pro	Leu	Asp	Thr
				95					100					105
Pro	Thr	Pro	Met	Val	Pro	Thr	Ser	Arg	Val	Pro	Gly	Thr	Leu	Ala
				110					115					120
Pro	Val	Ala	Thr	Ser	Leu	Ser	Pro	Ala	Ser	Asn	Leu	Pro	Arg	Ser
				125					130					135
Ser	Ala	Ser	Ala	Ala	Pro	Ser	Gln	Ala	Glu	Pro	Ala	Cys	Pro	Pro
				140					145					150
Arg	Gln	Ala	Cys	Gly	Gly	Gly	Gly	Ala	His	Gly	Pro	Gly	Trp	Gln
				155					160					165
Ala	Ala	Met	Ala	Ser	Thr	Ala	Ile	Met	Val	Pro	Val	Gly	Leu	Val
				170					175					180
Phe	Val	Ala	Phe	Ala	Leu	His	Phe	Tyr	Arg	Ser	Leu	Val	Ala	His

	185		190		195
Lys Thr Asp Arg Tyr Lys Gln Glu Leu		Glu Glu Leu Asn Arg Leu			
	200		205		210
Gln Gly Glu Leu Gln Ala Val					
	215				

<210> 71
 <211> 143
 <212> PRT
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte Clone No: 2765411

<400> 71
 Met Phe Pro Val Leu Gly Trp Ile Leu Ile Ala Val Val Ile Ile
 1 5 10 15
 Ile Leu Leu Ile Phe Thr Ser Val Thr Arg Cys Leu Ser Pro Val
 20 25 30
 Ser Phe Leu Gln Leu Lys Phe Trp Lys Ile Tyr Leu Glu Gln Glu
 35 40 45
 Gln Gln Ile Leu Lys Ser Lys Ala Thr Glu His Ala Thr Glu Leu
 50 55 60
 Ala Lys Glu Asn Ile Lys Cys Phe Phe Glu Gly Ser His Pro Lys
 65 70 75
 Glu Tyr Asn Thr Pro Ser Met Lys Glu Trp Gln Gln Ile Ser Ser
 80 85 90
 Leu Tyr Thr Phe Asn Pro Lys Gly Gln Tyr Tyr Ser Met Leu His
 95 100 105
 Lys Tyr Val Asn Arg Lys Glu Lys Thr His Ser Ile Arg Ser Thr
 110 115 120
 Glu Gly Asp Thr Val Ile Pro Val Leu Gly Phe Val Asp Ser Ser
 125 130 135
 Gly Ile Asn Ser Thr Pro Glu Leu
 140

<210> 72
 <211> 186
 <212> PRT
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte Clone No: 2769412

<400> 72
 Met Ser Gly Ile Ser Gly Cys Pro Phe Phe Leu Trp Gly Leu Leu
 1 5 10 15
 Ala Leu Leu Gly Leu Ala Leu Val Ile Ser Leu Ile Phe Asn Ile
 20 25 30

Ser	His	Tyr	Val	Glu	Lys	Gln	Arg	Gln	Asp	Lys	Met	Tyr	Ser	Tyr	
				35					40						45
Ser	Ser	Asp	His	Thr	Arg	Val	Asp	Glu	Tyr	Tyr	Ile	Glu	Asp	Thr	
				50					55						60
Pro	Ile	Tyr	Gly	Asn	Leu	Asp	Asp	Met	Ile	Ser	Glu	Pro	Met	Asp	
				65					70						75
Glu	Asn	Cys	Tyr	Glu	Gln	Met	Lys	Ala	Arg	Pro	Glu	Lys	Ser	Val	
				80					85						90
Asn	Lys	Met	Gln	Glu	Ala	Thr	Pro	Ser	Ala	Gln	Ala	Thr	Asn	Glu	
				95					100						105
Thr	Gln	Met	Cys	Tyr	Ala	Ser	Leu	Asp	His	Ser	Val	Lys	Gly	Lys	
				110					115						120
Arg	Arg	Lys	Pro	Arg	Lys	Gln	Asn	Thr	His	Phe	Ser	Asp	Lys	Asp	
				125					130						135
Gly	Asp	Glu	Gln	Leu	His	Ala	Ile	Asp	Ala	Ser	Val	Ser	Lys	Thr	
				140					145						150
Thr	Leu	Val	Asp	Ser	Phe	Ser	Pro	Glu	Ser	Gln	Ala	Val	Glu	Glu	
				155					160						165
Asn	Ile	His	Asp	Asp	Pro	Ile	Arg	Leu	Phe	Gly	Leu	Ile	Arg	Ala	
				170					175						180
Lys	Arg	Glu	Pro	Ile	Asn										
				185											

<210> 73

<211> 364

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte Clone No: 2842779

<400> 73

Met	Pro	Gly	Cys	Pro	Cys	Pro	Gly	Cys	Gly	Met	Ala	Gly	Pro	Arg	
1				5					10					15	
Leu	Leu	Phe	Leu	Thr	Ala	Leu	Ala	Leu	Glu	Leu	Leu	Gly	Arg	Ala	
				20					25					30	
Gly	Gly	Ser	Gln	Pro	Ala	Leu	Arg	Ser	Arg	Gly	Thr	Ala	Thr	Ala	
				35					40					45	
Cys	Arg	Leu	Asp	Asn	Lys	Glu	Ser	Glu	Ser	Trp	Gly	Ala	Leu	Leu	
				50					55					60	
Ser	Gly	Glu	Arg	Leu	Asp	Thr	Trp	Ile	Cys	Ser	Leu	Leu	Gly	Ser	
				65					70					75	
Leu	Met	Val	Gly	Leu	Ser	Gly	Val	Phe	Pro	Leu	Leu	Val	Ile	Pro	
				80					85					90	
Leu	Glu	Met	Gly	Thr	Met	Leu	Arg	Ser	Glu	Ala	Gly	Ala	Trp	Arg	
				95					100					105	
Leu	Lys	Gln	Leu	Leu	Ser	Phe	Ala	Leu	Gly	Gly	Leu	Leu	Gly	Asn	
				110					115					120	
Val	Phe	Leu	His	Leu	Leu	Pro	Glu	Ala	Trp	Ala	Tyr	Thr	Cys	Ser	
				125					130					135	
Ala	Ser	Pro	Gly	Gly	Glu	Gly	Gln	Ser	Leu	Gln	Gln	Gln	Gln	Gln	
				140					145					150	
Leu	Gly	Leu	Trp	Val	Ile	Ala	Gly	Ile	Leu	Thr	Phe	Leu	Ala	Leu	
				155					160					165	

Glu	Lys	Met	Phe	Leu	Asp	Ser	Lys	Glu	Glu	Gly	Thr	Ser	Gln	Ala	
				170					175					180	
Pro	Asn	Lys	Asp	Pro	Thr	Ala	Ala	Ala	Ala	Ala	Leu	Asn	Gly	Gly	
				185					190					195	
His	Cys	Leu	Ala	Gln	Pro	Ala	Ala	Glu	Pro	Gly	Leu	Gly	Ala	Val	
				200					205					210	
Val	Arg	Ser	Ile	Lys	Val	Ser	Gly	Tyr	Leu	Asn	Leu	Leu	Ala	Asn	
				215					220					225	
Thr	Ile	Asp	Asn	Phe	Thr	His	Gly	Leu	Ala	Val	Ala	Ala	Ser	Phe	
				230					235					240	
Leu	Val	Ser	Lys	Lys	Ile	Gly	Leu	Leu	Thr	Thr	Met	Ala	Ile	Leu	
				245					250					255	
Leu	His	Glu	Ile	Pro	His	Glu	Val	Gly	Asp	Phe	Ala	Ile	Leu	Leu	
				260					265					270	
Arg	Ala	Gly	Phe	Asp	Arg	Trp	Ser	Ala	Ala	Lys	Leu	Gln	Leu	Ser	
				275					280					285	
Thr	Ala	Leu	Gly	Gly	Leu	Leu	Gly	Ala	Gly	Phe	Ala	Ile	Cys	Thr	
				290					295					300	
Gln	Ser	Pro	Lys	Gly	Val	Glu	Glu	Thr	Ala	Ala	Trp	Val	Leu	Pro	
				305					310					315	
Phe	Thr	Ser	Gly	Gly	Phe	Leu	Tyr	Ile	Ala	Leu	Val	Asn	Val	Leu	
				320					325					330	
Pro	Asp	Leu	Leu	Glu	Glu	Glu	Asp	Pro	Trp	Arg	Ser	Leu	Gln	Gln	
				335					340					345	
Leu	Leu	Leu	Leu	Cys	Ala	Gly	Ile	Val	Val	Met	Val	Leu	Phe	Ser	
				350					355					360	
Leu	Phe	Val	Asp												

<210> 74

<211> 605

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte Clone No: 2966260

<400> 74

Met	Gly	Arg	Leu	Leu	Arg	Ala	Ala	Arg	Leu	Pro	Pro	Leu	Leu	Ser	
1				5					10					15	
Pro	Leu	Leu	Leu	Leu	Leu	Val	Gly	Gly	Ala	Phe	Leu	Gly	Ala	Cys	
				20					25					30	
Val	Ala	Gly	Ser	Asp	Glu	Pro	Gly	Pro	Glu	Gly	Leu	Thr	Ser	Thr	
				35					40					45	
Ser	Leu	Leu	Asp	Leu	Leu	Leu	Pro	Thr	Gly	Leu	Glu	Pro	Leu	Asp	
				50					55					60	
Ser	Glu	Glu	Pro	Ser	Glu	Thr	Met	Gly	Leu	Gly	Ala	Gly	Leu	Gly	
				65					70					75	
Ala	Pro	Gly	Ser	Gly	Phe	Pro	Ser	Glu	Glu	Asn	Glu	Glu	Ser	Arg	
				80					85					90	
Ile	Leu	Gln	Pro	Pro	Gln	Tyr	Phe	Trp	Glu	Glu	Glu	Glu	Glu	Leu	
				95					100					105	
Asn	Asp	Ser	Ser	Leu	Asp	Leu	Gly	Pro	Thr	Ala	Asp	Tyr	Val	Phe	
				110					115					120	

Pro Asp Leu Thr	Glu Lys Ala Gly Ser	Ile Glu Asp Thr Ser Gln
125	130	135
Ala Gln Glu Leu	Pro Asn Leu Pro Ser	Pro Leu Pro Lys Met Asn
140	145	150
Leu Val Glu Pro	Pro Trp His Met Pro	Pro Arg Glu Glu Glu Glu
155	160	165
Glu Glu Glu Glu	Glu Glu Glu Met Glu	Lys Glu Glu Val Glu Lys
170	175	180
Gln Asp Val Glu	Glu Glu Glu Glu Leu	Leu Pro Val Asn Gly Ser
185	190	195
Gln Glu Glu Ala	Lys Pro Gln Val Arg	Asp Phe Ser Leu Thr Ser
200	205	210
Ser Ser Gln Thr	Pro Gly Ala Thr Lys	Ser Arg His Glu Asp Ser
215	220	225
Gly Asp Gln Ala	Ser Ser Gly Val Glu	Val Glu Ser Ser Met Gly
230	235	240
Pro Ser Leu Leu	Leu Pro Ser Val Thr	Pro Thr Ile Val Thr Pro
245	250	255
Gly Asp Gln Asp	Ser Thr Ser Gln Glu	Ala Glu Ala Thr Val Leu
260	265	270
Pro Ala Ala Gly	Leu Gly Val Glu Phe	Glu Ala Pro Gln Glu Ala
275	280	285
Ser Glu Glu Ala	Thr Ala Gly Ala Ala	Gly Leu Ser Gly Gln His
290	295	300
Glu Glu Val Pro	Ala Leu Pro Ser Phe	Pro Gln Thr Thr Ala Pro
305	310	315
Ser Gly Ala Glu	His Pro Asp Glu Asp	Pro Leu Gly Ser Arg Thr
320	325	330
Ser Ala Ser Ser	Pro Leu Ala Pro Gly	Asp Met Glu Leu Thr Pro
335	340	345
Ser Ser Ala Thr	Leu Gly Gln Glu Asp	Leu Asn Gln Gln Leu Leu
350	355	360
Glu Gly Gln Ala	Ala Glu Ala Gln Ser	Arg Ile Pro Trp Asp Ser
365	370	375
Thr Gln Val Ile	Cys Lys Asp Trp Ser	Asn Leu Ala Gly Lys Asn
380	385	390
Tyr Ile Ile Leu	Asn Met Thr Glu Asn	Ile Asp Cys Glu Val Phe
395	400	405
Arg Gln His Arg	Gly Pro Gln Leu Leu	Ala Leu Val Glu Glu Val
410	415	420
Leu Pro Arg His	Gly Ser Gly His His	Gly Ala Trp His Ile Ser
425	430	435
Leu Ser Lys Pro	Ser Glu Lys Glu Gln	His Leu Leu Met Thr Leu
440	445	450
Val Gly Glu Gln	Gly Val Val Pro Thr	Gln Asp Val Leu Ser Met
455	460	465
Leu Gly Asp Ile	Arg Arg Ser Leu Glu	Glu Ile Gly Ile Gln Asn
470	475	480
Tyr Ser Thr Thr	Ser Ser Cys Gln Ala	Arg Ala Ser Gln Val Arg
485	490	495
Ser Asp Tyr Gly	Thr Leu Phe Val Val	Leu Val Val Ile Gly Ala
500	505	510
Ile Cys Ile Ile	Ile Ile Ala Leu Gly	Leu Leu Tyr Asn Cys Trp
515	520	525
Gln Arg Arg Leu	Pro Lys Leu Lys His	Val Ser His Gly Glu Glu
530	535	540
Leu Arg Phe Val	Glu Asn Gly Cys His	Asp Asn Pro Thr Leu Asp

	545		550		555									
Val	Ala	Ser	Asp	Ser	Gln	Ser	Glu	Met	Gln	Glu	Lys	His	Pro	Ser
	560		565		570									
Leu	Asn	Gly	Gly	Gly	Ala	Leu	Asn	Gly	Pro	Gly	Ser	Trp	Gly	Ala
	575		580		585									
Leu	Met	Gly	Gly	Lys	Arg	Asp	Pro	Glu	Asp	Ser	Asp	Val	Phe	Glu
	590		595		600									
Glu	Asp	Thr	His	Leu										
	605													

<210> 75

<211> 97

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte Clone No: 2993326

<400> 75

Met	Thr	Gly	Arg	Phe	Lys	Ala	Cys	Gln	Val	Ile	Leu	Gly	Leu	Leu
1				5					10					15
Val	Ala	Ile	Ser	Leu	Ala	Ala	Gly	Thr	Gly	Gly	Ala	Ala	Gly	Ala
				20					25					30
Ala	Leu	Val	Ile	Val	Phe	Ile	Gly	Ala	Phe	Leu	Val	Leu	Leu	Phe
				35					40					45
Leu	Gly	Arg	Leu	Thr	Thr	Gly	Gly	Ser	Met	Ala	Arg	Glu	Ser	Leu
				50					55					60
Val	Ala	Ala	Asn	Arg	Val	Cys	Ile	Ser	Arg	Thr	Leu	Ser	Ser	Ser
				65					70					75
Val	Val	Ser	Val	Cys	Ile	Ser	Gly	Gly	Lys	Gly	Ser	Pro	Arg	Leu
				80					85					90
Pro	Gly	Gly	Gly	Arg	Gly	Pro								
				95										

<210> 76

<211> 247

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte Clone No: 3001124

<400> 76

Met	Val	Thr	Leu	Val	Ser	Asp	Thr	Ala	Met	Thr	Pro	Ile	Ala	Ser
1				5					10					15
Val	Asp	Thr	Ile	Ala	Val	Cys	Leu	Phe	Ala	Gly	Ala	Trp	Gly	Gly
				20					25					30
Ala	Met	Val	Pro	Met	His	Leu	Leu	Gly	Arg	Leu	Glu	Lys	Pro	Leu
				35					40					45
Leu	Leu	Leu	Cys	Cys	Ala	Ser	Phe	Leu	Leu	Gly	Leu	Ala	Leu	Leu

	50		55		60
Gly Ile Lys Thr Asp Ile Thr Pro Val	Ala Tyr Phe Phe Leu Thr				
	65		70		75
Leu Gly Gly Phe Phe Leu Phe Ala Tyr	Leu Leu Val Arg Phe Leu				
	80		85		90
Glu Trp Gly Leu Arg Ser Gln Leu Gln	Ser Met Gln Thr Glu Ser				
	95		100		105
Pro Gly Pro Ser Gly Asn Ala Arg Asp	Asn Glu Ala Phe Glu Val				
	110		115		120
Pro Val Tyr Glu Glu Ala Val Val Gly	Leu Glu Ser Gln Cys Arg				
	125		130		135
Pro Gln Glu Leu Asp Gln Pro Pro Pro	Tyr Ser Thr Val Val Ile				
	140		145		150
Pro Pro Ala Pro Glu Glu Glu Gln Pro	Ser His Pro Glu Gly Ser				
	155		160		165
Arg Arg Ala Lys Leu Glu Gln Arg Arg	Met Ala Ser Glu Gly Ser				
	170		175		180
Met Ala Gln Glu Gly Ser Pro Gly Arg	Ala Pro Ile Asn Leu Arg				
	185		190		195
Leu Arg Gly Pro Arg Ala Val Ser Thr	Ala Pro Asp Leu Gln Ser				
	200		205		210
Leu Ala Ala Val Pro Thr Leu Glu Pro	Leu Thr Pro Pro Pro Ala				
	215		220		225
Tyr Asp Val Cys Phe Gly His Pro Asp	Asp Asp Ser Val Phe Tyr				
	230		235		240
Glu Asp Asn Trp Ala Pro Pro					
	245				

<210> 77

<211> 193

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte Clone No: 3120070

<400> 77

Met Ile Arg Cys Gly Leu Ala Cys Glu Arg	Cys Arg Trp Ile Leu		
1	5	10	15
Pro Leu Leu Leu Leu Ser Ala Ile Ala Phe	Asp Ile Ile Ala Leu		
	20	25	30
Ala Gly Arg Gly Trp Leu Gln Ser Ser Asp	His Gly Gln Thr Ser		
	35	40	45
Ser Leu Trp Trp Lys Cys Ser Gln Glu Gly	Gly Gly Ser Gly Ser		
	50	55	60
Tyr Glu Glu Gly Cys Gln Ser Leu Met Glu	Tyr Ala Trp Gly Arg		
	65	70	75
Ala Ala Ala Ala Met Leu Phe Cys Gly Phe	Ile Ile Leu Val Ile		
	80	85	90
Cys Phe Ile Leu Ser Phe Phe Ala Leu Cys	Gly Pro Gln Met Leu		
	95	100	105
Val Phe Leu Arg Val Ile Gly Gly Leu Leu	Ala Leu Ala Ala Val		
	110	115	120
Phe Gln Ile Ile Ser Leu Val Ile Tyr Pro	Val Lys Tyr Thr Gln		

				125					130				135	
Thr	Phe	Thr	Leu	His	Ala	Asn	Pro	Ala	Val	Thr	Tyr	Ile	Tyr	Asn
				140					145					150
Trp	Ala	Tyr	Gly	Phe	Gly	Trp	Ala	Ala	Thr	Ile	Ile	Leu	Ile	Gly
				155					160					165
Cys	Ala	Phe	Phe	Phe	Cys	Cys	Leu	Pro	Asn	Tyr	Glu	Asp	Asp	Leu
				170					175					180
Leu	Gly	Asn	Ala	Lys	Pro	Arg	Tyr	Phe	Tyr	Thr	Ser	Ala		
				185					190					

<210> 78

<211> 128

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte Clone No: 3133035

<400> 78

Met	Asn	Met	Lys	Gln	Lys	Ser	Val	Tyr	Gln	Gln	Thr	Lys	Ala	Leu
1			5						10					15
Leu	Cys	Lys	Asn	Phe	Leu	Lys	Lys	Trp	Arg	Met	Lys	Arg	Glu	Ser
			20						25					30
Leu	Leu	Glu	Trp	Gly	Leu	Ser	Ile	Leu	Leu	Gly	Leu	Cys	Ile	Ala
			35						40					45
Leu	Phe	Ser	Ser	Ser	Met	Arg	Asn	Val	Gln	Phe	Pro	Gly	Met	Ala
			50						55					60
Pro	Gln	Asn	Leu	Gly	Arg	Val	Asp	Lys	Phe	Asn	Ser	Ser	Ser	Leu
			65						70					75
Met	Val	Val	Tyr	Thr	Pro	Ile	Ser	Asn	Leu	Thr	Gln	Gln	Ile	Met
			80						85					90
Asn	Lys	Thr	Ala	Leu	Ala	Pro	Leu	Leu	Lys	Gly	Thr	Ser	Val	Ile
			95						100					105
Gly	Ala	Gln	Ile	Ile	His	Thr	Trp	Thr	Lys	Tyr	Phe	Trp	Lys	Ile
			110						115					120
Tyr	Ile	Cys	Tyr	Gly	Asn	His	Leu							
				125										

<210> 79

<211> 115

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte Clone No: 3436879

<400> 79

Met	Ala	Val	Ala	Val	Leu	Leu	Cys	Gly	Cys	Ile	Val	Ala	Thr	Val
1			5						10					15
Ser	Phe	Phe	Trp	Glu	Glu	Ser	Leu	Thr	Gln	His	Val	Ala	Gly	Leu
			20						25					30
Leu	Phe	Leu	Met	Thr	Gly	Ile	Phe	Cys	Thr	Ile	Ser	Leu	Cys	Thr

	35		40		45									
Tyr	Ala	Ala	Ser	Ile	Ser	Tyr	Asp	Leu	Asn	Arg	Leu	Pro	Lys	Leu
	50		55		60									
Ile	Tyr	Ser	Leu	Pro	Ala	Asp	Val	Glu	His	Gly	Tyr	Ser	Trp	Ser
	65		70		75									
Ile	Phe	Cys	Ala	Trp	Cys	Ser	Leu	Gly	Phe	Ile	Val	Ala	Ala	Gly
	80		85		90									
Gly	Leu	Cys	Ile	Ala	Tyr	Pro	Phe	Ile	Ser	Arg	Thr	Lys	Ile	Ala
	95		100		105									
Gln	Leu	Lys	Ser	Gly	Arg	Asp	Ser	Thr	Val					
	110		115											

<210> 80

<211> 1869

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte Clone No: 153831

<400> 80

```

gcgagcggct ggcggatccg acgcgcgaga ccgggagggg acgagggcgt tgcaatcggt 60
cggggcgggg gctttccggg gagggggtgc tcaggtgcac cagcggcggc ggaccctcag 120
actctgcctt cccctccctt taacccctt ccagccggac gggaggcggg gcagggctga 180
gcatttgtga cacctacatt tccgtggctc ccttcttttc ccccgacccc tgtttatctc 240
ttcgcttcc agaagttctt ttccatcagg cctgcgcacc ttgctgggga aggagcacc 300
cacttggaag caggaggcgg ggttcagatc ttggccctac cctcctgtg ttaaagtccg 360
cgagcctcag ttccctcac agtattttt gcctgcctt acccggtttt gaggatctgt 420
acgagaaaga gaaaggaagt ggacatttgt tgaattcctg catggccaaa taccacgcag 480
actgcttcat ccgccacgtt taatccttat tacttggtgt tctcagaact cccatttcat 540
ggattcttaa gctcacagag tcagtgaata acagaaaggg attcagatct agccgttttag 600
ctgcacagtg gagttcttct ccagagtctt ccttgtctg ggctctggct ggaactattc 660
ctcagcaaaa tctctgcccc agaacagtgc ttctgtttt tccagctgag aagtctccct 720
ttcagtttcc ttctccagc acggagtaca ctgctctgcc tccacttaga ttacttcaga 780
aatgaaatgc agcaaatatt tatccagcag tgcaggaggt tgaacttttg gagtcgggaa 840
ccttggaattc ttgttctggc tctgccactt actgtgtggc cttgggaagt cttttgtctt 900
ctctgagctt tcttttctct ttgcgtaaaa gcggtgctct tgtcccatc tccctccctg 960
tctccagca ggtctctccc ggaggctcag cccctctgc tcccatggg caactgccag 1020
gcagggcaca acctgcacct gtgtctggcc caccaccac ctctggctct tggcactttg 1080
atcctgctgc tccctggcct ctctggcctg ggcttggca gcttctcct caccacagg 1140
actggcctgc gcagccctga catccccag gactgggtct cttttttgag atcttttggc 1200
cagctgaccc tgtgtccag gaatgggaca gtcacaggga agtggcgagg gtctcacgtc 1260
gtgggcttgc tgaccacctt gaacttcgga gacggtccag acaggaacaa gaccgggaca 1320
ttccaggcca cagtcttggg aagtcagatg ggattgaaag gatcttctgc aggacaactg 1380
gtccttatca cagccagggt gaccacagaa aggactgcag gaacctgcct atattttagt 1440
gctgttccag gaatcctacc ctccagccag ccacccatat cctgctcaga ggagggggct 1500
ggaaatgcca cctgagccc tagaatgggt gaggaatgtg ttagtgtctg gagccatgaa 1560
ggccttgtgc tgaccaagct gctcacctcg gaggagctgg ctctgtgtgg ctccaggctg 1620
ctggcttgg gctccttctt gcttctcttc tgtggccttc tctgtgtgt cactgctatg 1680
tgcttccacc cgcgcgggga gtccactgg tctagaacct ggctctgagg gcactggcct 1740
agttcccgac ttgtttctca ggtgtgaatc aacttcttgg gccttggctc tgagttggaa 1800
aaggttttag aaaaagtga gagctggaat gtgggggaaa ataaaaagct tttttgcccc 1860
aaaaaaaaa

```

<210> 81
 <211> 1044
 <212> DNA
 <213> Homo sapiens
 <220>
 <221> misc_feature
 <223> Incyte Clone No: 350629

<400> 81
 tgcagttaac atctgcacac ttcactatat tttaagtttt tgtaaatata aaagaataag 60
 aaaacagaaa agtattactg ttaaacata atagagaaat gtatacttta ttacaaatt 120
 tctccctcta gctgatcata cagttgacca gttcaggggtg cccgctgctg gttggatgcc 180
 aggcggaatg tcagggtgtt ctctgggtgc tggtgtggct gtgggatcca cggttactgg 240
 ggggagcctg tgggtggctgt ggtgccatgg aggggctgcg atcttctgtg gagctggacc 300
 ctgagctgac tccagggaag ctggatgagg agatgggtggg gctgccaccc catgacgcga 360
 gtcctcaagt cactttccac agcctcgatg ggaagacagt ggtgtgtcca cacttcatgg 420
 gcttactgct ggggtctctta cttttattga ctttgtctgt taggaaccaa ctctgtgtaa 480
 gaggtgaaaag gcagcttgca gaaacactgc attcacaggt gaaggagaaa tcccagctca 540
 ttggcaagaa aacagattgt agagactgag gcattcttaa aagatgtcag ggtacagaaa 600
 aagtccttca acacccccgg ctttgtagat gcctacaaga aggtgaatag caccaacgag 660
 atgctgatgg agaaatttac caccctcgtt caagaactga aagaagagac atcctccaga 720
 ctctcctcaa tgggcgggtgc ctccaaatct aaagaatatg gaggtcctgg agcacaccaa 780
 gaaatgaggg actttttctt tgcagaaagt ttgaattctg tcttaatgag acagaatgcc 840
 atacttgagc acctcatctt ttgctcaaat tgaatgtca tcgaactgta tttctcaagt 900
 caatgggtctg taaatatgat ttatgtatta atctcctaag tgaacaattt atattttatc 960
 ctctacataa ttatcgtatt atgctttaaa tatatattta gtttatcaat aaagacattc 1020
 agtactcaat agcaaaaaaa aaaa 1044

<210> 82
 <211> 3079
 <212> DNA
 <213> Homo sapiens
 <220>
 <221> misc_feature
 <223> Incyte Clone No: 729171

<400> 82
 cggctcgagg tcggctggag tcggaggcga tatttctagg ggtgtacttg ttggggtcag 60
 ggtaagcacc agccacaaaa acctacaaaa gaagggaat tactgtcttt aaatattaaa 120
 aaaaaacaag atccatgagt gggcatcgat caacaaggaa aagatgtgga gattcccacc 180
 cggagtcccc agtgggcttc gggcatatga gtactacagg atgtgtatta aataaattgt 240
 ttcagttacc aacaccacca ttgtcaagac accaactaaa gcggttagaa gaacacagat 300
 atcaaagtgc tggacgggtc ctgcttgagc ccttagtgca agggatttgg gaatggctcg 360
 ttagaagagt tccctcctgg attgcccaa atctcatcac catcattgga ctgtcaataa 420
 acatctgtac aactatttta ttagtcttct actgccctac agctacagag caggcacctc 480
 tgtgggcata tattgcttgt gcctgtggcc ttttcattta ccagtcttg gatgctattg 540
 gtgggaaaca ggcaagaaga accaatagta gttctcctct gggagaactt tttgatcatg 600
 gctgtgattc actatcaaca gtttttgtgg ttcttggaac ttgtatagca gtgcagctgg 660
 ggacaaaccc tgattggatg ttttttgtt gttttgctgg gacatttatg ttctattgtg 720
 cgcactggca aacgtatgtt tctggaacat tgcgatttgg aataattgat gtgactgaag 780
 tgcaaatctt cataataatc atgcatttgc tggcagtgat gggaggacca cttttttggc 840

```

aatctatgat tccagtgcgt aatattcaaa tgaaaatttt tccctgcactt tgtactgtag 900
cagggaccat atttcctgta acaaattact tccgtgtaat cttcacaggt ggtggtggca 960
aaaatggatc aacaatagca ggaacaagtg tcccttctcc ttttctccat attggatcag 1020
tgattacatt agctgcaatg atctacaaga aatctgcagt tcagcttttt gaaaagcatc 1080
cctgtcttta tatactgaca tttgggtttt tgctgctaa aatcactaat aagcttgtgg 1140
ttgcacacat gacgaaaagt gaaatgcatt tgcatgacac agcattcata ggtccggcac 1200
ttttgtttct ggaccagtat tttaacagct ttattgatga atatatgtta ctttggattg 1260
ccctggtttt ctctttcttt gatttgatcc gctactgtgt cagtgtttgc aatcagattg 1320
cgtctcacct gcacatacat gtcttcagaa tcaaggcttc tacagctcat tctaatacat 1380
attaatgatg taattggtat ataggaacat catgttttct gcaggaaaga aagtaacata 1440
ttaaggagaa tgggggtgga taagaacaaa tataatttat aataatcaat gttgtataac 1500
ttttattctt tattattggt aacacgccct aactatcctg tgtgagaatg ggaatttcaa 1560
gtcccatctt gtaaatgtga tatgttgtca tgcagggttt gggccaagaa agcatgcaga 1620
aaaaaatgcc atgtgattgt aattatcctg gattcagaat aatactgtga tggggagcca 1680
gatccgcagt ggtggagagt tctaattgtg actgtttgca ggccaaaaga tgattgcttt 1740
ataattttaa caaatcattg tcttttagta acatccttgt ttagtgtctt ctcaagcttt 1800
ctttactgag gaattcagct tgtgacacag atacatccca ctagcttggt aggtggaact 1860
agtaataaag acctgaatt tggattgaaa agtttcctat ctttacattg ttgaggagt 1920
cctttttttt tttttttttt tttttaattg ctcaagaaat gattctctca caggcttggg 1980
aaatcctgtt agcatgcaga ataatgtggt aactttgtca atttccatt ttattttttt 2040
aaataaatat atgatctaaa agccaaacttt ttctcagttt tactcagtg aaagataaac 2100
taagttttaa tgttattttt ttaaatttaa gcaaaattta tttctgttct ttaataaata 2160
agaaaatgtg gtccactgca ttgttgtgat gtgtcttggt acatttctat ttgtagaaa 2220
ctttaaaaag gagaactatg ttcatttttc ctgtcaatgg tttttttgtg ttgtagtgt 2280
cacctgtgtg attatcaatc atttagaaat ctcataccct tcccctaaat tttcagcaag 2340
tgccctgggc tctctaagag gtcactttgt actctccttt tctggcagtc tctcttttg 2400
tatctgtact atcgtttgaa atgggaacca gatatgtttc cattttatac agataattca 2460
gttgcttgaa gaagagggac acaggagaaa agatttaaac tattggctaa aatgagggtg 2520
cttattattg attttcatct atatcttgct ccataatcag gaataaacag tagctacact 2580
gccttgatg gcagccagag cgtgcttgct ttgcactttt aatgattcca tcaataccat 2640
gtagattgaa ttagcaagga gaagtaaacc ttctatttct ttgccagact atattgggaa 2700
atgaaaatcc gtcattactt ttccttgcta gcaattgttc gaatatctgg gataaagaaa 2760
tacatacagg aaaatgttag ggcagaccaa gtattaaaag ctaggacaga gcaggacaaa 2820
ggaggaagga taattctact tgtttggcaa agttacatca gttgtcttac tgacacatca 2880
ggtactatct atagtggaaa ttgaggcccg gagagggtta atggcatgcc agtgtcactt 2940
gctatttttc agaacaaaaa ttagaatcca gatctgaatc ctggtgcagt gttctctcct 3000
atgccctact gggctttagt gggctaaagt tctgaagcaa gatgttaagg gctaattgaa 3060
atgcgtttat tctcctaga 3079

```

<210> 83

<211> 1298

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte Clone No: 1273641

<400> 83

```

cccggtgcct gcgggattgc tggagagaac gcggcgatgg agccgggag gaccagata 60
aagcttgacc ccaggtagac agcagatctt ctggagggtg tgaagacaa ttacggcatc 120
ccctccgctt gcttctctca gctcccaca gcagccact cctgagagcc ctgggcccctg 180
tggaacttgc cctcactagc atcctgacct tgctggcgct gggctccatt gccatcttcc 240
tggaggatgc cgtctacctg tacaagaaca ccctttgccc catcaagagg cggactctgc 300
tctggaagag ctccggcacc acggtggtgt ctgtgctgtg ctgctttggt ctctggatcc 360

```

```

ctcgttccct ggtgctggtg gaaatgacca tcacctcggt ttatgccgtg tgcctttacc 420
tgctgatgct ggatcatggtg gaaggctttg gggggaagga ggcagtgcctg aggacgctga 480
gggacacccc gatgatggtc cacacaggcc cctgctgctg ctgctgcccc tgctgtcaac 540
ggctgctgct caccaggaag aagcttcagc tgctgatgtt gggcccttcc caatacgcct 600
tcttgaagat aacgctgacc tggtagggct tgttctcgtc cccgacggaa tcttatgacc 660
cagcagacat ttctgagggg agcacagctc tatggatcaa cactttcctt ggcgtgtcca 720
cactgctggc tctctggacc ctgggcatca tttcccgta agccaggcta cacctgggtg 780
agcagaacat gggagccaaa tttgctctgt tccaggttct cctcatcctg actgccctac 840
agccctccat cttctcagtc ttggccaacg gtgggcagat tgcttggtcg cctccctatt 900
cctctaaaaac caggtctcaa gtgatgaatt gccacctcct catactggag acttttctaa 960
tgactgtgct gacacgaatg tactaccgaa ggaaagacca caaggttggg tatgaaactt 1020
tctcttctcc agacctggac ttgaacctca aagcctaagg tggatggctt ggacaatgaa 1080
aggatgctgt actcattaga atacaagatt cctttactgt ccctcaacct tgaccaaatg 1140
ggaagcattc ccccttgctc acacaagctg gcagatacat ttgactctac agatgaaggt 1200
gaacaatgtt aggataaaat tgctttggat cttgcctgga aggtgtttta agttttgtaa 1260
taaacaagat gatgtctgaa aatgtgaaaa aaaaaaaaa 1298

```

<210> 84

<211> 2106

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte Clone No: 1427389

<400> 84

```

gtggggctgc ggccgggatt tgtccctctc tggcttccg tagaggaagt ggcgcggacc 60
ttcatttggg gtttcgggtc ccccccttc ccttccccg ggtctggggg tgacattgca 120
ccgcgccccct cgtggggtcg cgttgccacc ccacgcggac tcccagctg gcgcgccccct 180
cccatattgct tgctcctggtc agggccccac cccccctccc acctgaccag ccatggggggc 240
tgcggtgttt ttcggtcgca ctttcgtcgc gttcggcccg gccttcgcgc ttttcttgat 300
cactgtggct ggggacccgc ttgcggttat catcctggtc gcaggggcat ttttctggct 360
ggtctccctg ctccggcct ctgtggtctg gttcatcttg gtccatgtga ccgaccggtc 420
agatgccccg tccagtagc gcctcctgat ttttggtgct gctgtctctg tcctcttaca 480
ggaggtgttc cgctttgct actacaagct gcttaagaag gcagatgagg ggttagcatc 540
gctgagttag gacggaagat caccatctc catccgccag atggcctatg tttctggtct 600
ctccttcggg atcatcagt gtgtcttctc tggtatcaat attttggtg atgcacttgg 660
gccaggtgtg gttgggatcc atggagactc accctattac ttctgactt cagcctttct 720
gacagcagcc attatcctgc tccatacctt ttggggagt gtgttctttg atgcctgtga 780
gaggagacgg tactgggctt tgggcctggt ggttgggagt cacctactga catcgggact 840
gacattcctg aacccctggt atgaggccag cctgctgccc atctatgcag tcaactgttc 900
catggggctc tgggccttca tcacagctgg aggttccctc cgaagtattc agcgcagcct 960
cttgtgtaag gactgactac ctggactgat cgctgacag atcccacctg cctgtccact 1020
gccatgact gagccagcc ccagccggg tccattgccc acattctctg tctccttctc 1080
gtcggtctac cccactacct ccaggggttt gctttgtcct tttgtgaccg ttagtctcta 1140
agctttacca cccagcctt ggggtcagcc agtcagtac tggtaggggt gaactctgcac 1200
ttatccccac cacctgggga cccccctgtt gtgtccagga cccccctgt gtcagtgtct 1260
tgctctcacc ctgcccaga ctcacctccc tccccctctg caggccgacg gcaggaggac 1320
agtcgggtga tgggtgattc tgccctgcgc atcccacccg aggactgagg gaacctaggg 1380
gggacccctg ggctgggggt gccctcctga tgcctcgcct ctgtatttct ccatctccag 1440
ttctggacag tgcaggttgc caagaaaagg gacctagttt agccattgcc ctggagatga 1500
aattaatgga ggctcaagga tagatgagct ctgagtttct cagtactccc tcaagactgg 1560
acatcttggg ctttttctca ggcctgaggg ggaaccattt ttggtgtgat aaatacccta 1620
aactgccttt ttttctttt tgaggtgggg ggagggagga ggtatattgg aactcttcta 1680

```



```

acctccttgg gctatatatt ctctcctcga gttgctcctc atggctgggc tcatttcggt 1740
ccctttctcc ttggtcccag accttggggg aaaggaagga agtgcatgtt tgggaactgg 1800
cattactgga actaatggtt ttaacctcct taaccaccag catccctcct ctccccaagg 1860
tgaagtggag ggtgctgtgg tgagctggcc actccagagc tgcagtgccca ctggaggagt 1920
cagactacca tgacatcgta gggaaggagg ggagattttt ttgtagtttt taattggggg 1980
gtgggagggg cggggagggt ttctataaac tgtatcattt tctgctgagg gtggagtgtc 2040
ccatcctttt aatcaagggt attgtgattt tgactaataa aaaagaattt gtaaaaaaaaa 2100
aaaaaa 2106

```

<210> 85

<211> 899

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte Clone No: 1458357

<400> 85

```

gctgtattca ggtccccgat gggcatatac atcttagccg gtgatacact acctcttacg 60
tggtgcctct ttgtgttgc tgggtgcctt tcgaaaacaa ggtgcttatg gctttcatag 120
actatttctt ttttcattct tgctattctt taaaagtgtg tgtaactggg acatcaagat 180
atgttttggg tgtagtact tattttaatt tgtttgggtc cacacttaat aacacgtgaa 240
actatttatg tgaagtcctt gttttatttt aaaattctct ttgtgtattt ggaatcaaag 300
ccagcacatt gtaacctgtg cttgtacgca aaagaattag atttctttgt ttttgtttta 360
ttttttaaat tggtgtaaaa attattatag gccagctaca tctagtagta ggtttggggg 420
acagattggg ggttggtgcca tactgttttt aaagtctcat atcatctgga atgatactta 480
gtgtatatat attttgtaaa gttttaattc agcaaatttt ttgaaattgc tgctgtttta 540
aattataaaa cctttatatt tctgctttgt agaaattata tgttttgtag tattcattga 600
ttttctttca ctgtacttaa atttagtggt agtactttaa aatttttaat ttaccagtct 660
ttaagcaac atccagaaaa aaaaaagttt tttccattt aaaatagggt cagccagttc 720
aatgtgcctt tggtatcaga gaaatattag ttcaatactg aaagaaaaat attatactc 780
ttggtatcta gaaaaacttg ttcattccat ataaatatat ctttagccac agcaaacac 840
acttaacctt tctataataa aaatgtgctt taaataaaac caaaaaaaga aaaaaaaaa 899

```

<210> 86

<211> 2000

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte Clone No: 1482837

<400> 86

```

tttgctcagt tggtcttttg ttcttttccc gctctccatt ctgctgctct tctctcctct 60
tttccccaac ctccccgac cctcctgaat ttgggaaagc acatttgcaa tattcgtgtt 120
tgctttggga cggaccctcc gtttcattct atgctttatg tgtaagagtt ttttattatt 180
attttttctt tctttctct ctctgagaaa gttgtggctg cgttttgatc ttaggtttta 240
caaagtgggt tagggaagcg gttttgggga gaaggatcac gaggaatgta ggggaagccg 300
agggatgggt gctgctgcca cgaccccccc gtccctcggc ccagccctc ctgccctccc 360
cgtcaatctc atccacaaaa tctgaaggcc ttaaaattgt gtgttgggag gatgtgaatt 420
gggaggacgg tgctactaga ctgtggatta gggatggtaa agtagggagg atgctatttt 480

```

```

gcaactatag taacgactta gtgttttga aaggaaaaga agttaaactt gaaatacgtg 540
actagaacag ttgtcatgtt tataatgtga aaaggggtgaa atcatttaga ggagggggcg 600
tctgtaagaa atcattatgc actatggctt cctcctctgg tctgggaaga agcgggggact 660
ggctggccct caggggatct gtaaatccca gaaaacagta tttttaacag caagatgtca 720
ttcaacattg gtggggaagg aagagaaaaa aatcaaaacta ttccatagaa ctagtggcc 780
ccctcactcc catgcccttc ccactcagcc tgggcccctc cccgctccat tcataaaagc 840
tgagaggggt gagctaactc tcacaaattg taatatTTTT gtagtatctg ttagtccctt 900
cgtcagttct gcagaacctt gccctttcct tttgtaatgt gaataggaag acaaaagaca 960
aaaaaaaaat ccaccaccac caaaatatcc ctttgtacat gtatgtgcgt gtgcgcgtgt 1020
gctttgtgtg tgtggttgtg tgttaaatca tgcagtattg tcgtaatctg gtgttgcagc 1080
aatggatggg actaaatcag cacctggatg cccaccccaa ccccggtggc cctgcagacc 1140
ccagtaggga ggtatgggga gagctcaggg gagtgtgggt tctgagggct actgtctggg 1200
gacacctctg aacttactgt acctcctct ccccatgaag acacctgaat agagtctaac 1260
atgcctcttc tccaacttcc tacctacaac aacagaacag ttctaagtgt gcacggccta 1320
gtggccaggg ggcaagctaa gaggtctgtc ggaggcttta tatgtgtctg gagttaaggg 1380
gagaggagga gggtagacag ggtctctccc ccaggtggga tctgaatatc tgcctcccc 1440
tcttcttcat gccacctgac tcttcggccc ccttggctgc ctttagctgt ggtactgctg 1500
acaacctctg ttgctactgc cttatccagc acagtgaaaa acttctccag cctggcaagg 1560
ccacgttggg taatagtccc tttcccatgt ccagctccta caaatatgtc ccttaatgca 1620
tttggtgaca ttacacctc actcatgtgc tctttcccta ttcactcctt cactcattca 1680
aagcattaaa atcctatgta tatataggat agacaaatat atagatatat agatatatat 1740
atatatagca agagattgat ataaaatagt aaatatcatt gctgctttgg gctgctttgg 1800
aggaggaggc catgaatatg gggaaaggcag atctgggggtg caggggtagg tagggaggct 1860
gggggaccca gtgattcagt acaatccaag ggatgcaacg cgggcttgtt taatctttgt 1920
gcctgaacag tttttccatg ttgagaaaac tgttcaggca cagagattaa acagttttct 1980
caacatggga aaaaaaaaaa 2000

```

<210> 87

<211> 1359

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte Clone No: 1517434

<400> 87

```

tgcccatcct gctgctcagc ctgggtcacca tgtgcgtcac gcagctgcgg ctcatcttct 60
acatgggggc tatgaacaac atcctcaagt tcttgggtcag cggcgaccag aagacagttg 120
gcctctacac ctccatcttc ggcgtgctcc agctgctgtg cctgctgacg gcccccgta 180
ttggctacat catggactgg aggctgaagg agtgtgaaga cgcctccgag gagcccgagg 240
agaaagacgc caaccaaggc gagaagaaaa agaagaagcg ggaccggcag atccagaaga 300
tcactaatgc catgcgggcc ttgcgccttca ccaacctgct gctcgtgggc tttgggggtga 360
cctgcctcat tcccaacctg cctctccaga tctctcctt catcctgcac acaatcgtgc 420
gaggattcat ccactccgct gtcggggggc tgtacgctgc cgtgtacccc tccaccagc 480
tcggcagcct caggggactg cagtctctga tcagcgcgct cttcgcctt ctgcagcagc 540
cgctgtttct ggccatgatg ggtcctctcc agggagaccc tctgtgggtg aacgtggggc 600
tgctccttct cagcctgctg ggcttctgccc tcccgtcta cctgatctgc taccggcgcc 660
agctggagcg gcagctgcag cagagggcagg aggatgacaa actcttctc aaaaatcaacg 720
gctcgtccaa ccaggaggcc ttcgtgtagt ggctgcgccc tcggaactgc ggtctcctgc 780
ctgtgcttca gtgactgacc cctgtcctgc cctccagag tacccacgc acccccagga 840
ccttcgcgct ctccgtgcca gcgttcacgc tccctcccg ggccctgcct cggagctctg 900
tggtggaagg acgggagagg gccccggaca cgcgcgtttt ctctgcca acgcaggggc 960
tgccctgact ttgctctgcc gccccccggg gacccggggc ctgggggtctc tgtggtgcct 1020
gcagcaggag ccaggaacgc ccggcaggca ggcgctctcc cgcagtgctc tggattctgc 1080
ctcttgccaa agcagagggg gctgccatcc cctgcctgcc acctgcccc cggctgcatg 1140

```

```

ccccacagccg tacctgcctg aggacaaagg cttgcactgt ctcgcccgcg cctggccccc 1200
acccccctccc cgaccagcct gatcaacatg gtgaagcccc gtctctacta aagatacaaa 1260
aattagggggg gcatgggtggg ggatgcctgt aatccccggc gctcggggagg ctgaggcgga 1320
tgaatcgctt gaaccaggag gtggagggtg cagtggagg 1359

```

<210> 88

<211> 1397

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte Clone No: 1536052

<400> 88

```

gctggggaag ggaccatgtg gctgccttgg gctctgttgc ttctctgggt cccagcatca 60
acgtcaatga cacctgcaag tatcactgag gccaaagacct caacaatcac aactgcattt 120
ccacctgtat catccactac cctgttttga gtgggtgcca cccacagtgc cagcatccag 180
gaggaaactg aggaggtggg gaactcacag ctcccgtgc tcctctccct gctggcattg 240
ttgctgcttc tgttggtggg ggcctccctg ctagcctgga ggatgtttca gaaatggatc 300
aaagctgggtg accattcaga gctgtcccag aaccccaagc aggcctcccc cagggaagaa 360
cttcactatg cctcgggtggg gtttgattct aacaccaaca ggatagctgc tcagaggcct 420
cgggaggagg aaccagattc agattacagt gtgataagga agacataggc ttttgtcctg 480
cctcgccatc ggagctctca tgggccccag gaagtccagg gacagctccc ttatacctgg 540
cccacgtcct tctcagcctg cctcagacaa cagtgaccaa cagacaggca gctgggtttc 600
ccaggccatc caactgttgc catcagcttg attggcttcc ccgagggcca gcagggtgg 660
gggctccgga gagcagcagg aagcactccc agccaccagt gcctgtcacc tctttccct 720
ttgccccctg ttcattcccag ctctgtgtgt ggaggacaaa gcttcttctt gcgtggctcc 780
aggaaaagat gtggctcacg taggtggcac ctgccaatag ctttgtcaat cacagcccca 840
taggaacgtc tggaattgct tgggagttgg ggagaactgt caagaagagt gaagagagt 900
ccaaagcgga gatctgttca cctggggggc atggaggggg gacccactaa agatcaagat 960
caaagattct ccccatctca cagacaagga aactgaggcc agagggagga gagaattgct 1020
catggctcca gaactggtgg caagtttctc tggactctta ggtttatttt taatatgaaa 1080
tataaaaaa gtttcaaata tcttattgag ggagaagtaa aaacttattt aaacaataaa 1140
aaaataaaaa aaagggggcg gggccccag cccgaatccg aaatcaggta aaagctgttc 1200
cctgtgtaaa attgttacc gcccataatt ccacaaaata taggaccggg agccttaaag 1260
tttaaacccc tgggggcca aattgggtgg gccatcccc atttaattgg cttggccccc 1320
aatggcgggt tttcacattg ggggaaacct ttttgccca acggctttta atgaaatcgg 1380
cccaaaccgc gggggaa 1397

```

<210> 89

<211> 1570

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte Clone No: 1666118

<400> 89

```

atgtccatca tgtcagcagg tgcaaatcac ttttccccct tgcattgatc gaggcacctc 60
ctcagttgtt tctactgcaa ctcttatttc agaacctgtt tacaaacaag ccttccagtt 120
ggtgaatggt tagccattgg agctcctacc ctgtacatca gcacatcttc tggtttacia 180

```

```

gttgggtaac aatgaaagct ggagatacta aatggaaatc cagcattgca tacccttaga 240
cctgatcaca taccagtaaa agccttaatt tagatgttag ttgtatgtgt tggacagatc 300
cttgcaaaaag tgtgtctgtc tattagttgt aaatttgaaa attataaatc tctgaatctg 360
ctactatcca agtttcatcc cttttgaaga tgaggcatga gcctattaaa atatttataa 420
tcatttttctg tcccctactg caagactttt agattcttac aaatgattac tacaggaata 480
gtggccactt aatgtcagtt actcgggtgg aagaatttat ctagtttttt tctttttctt 540
ttttggaagg atggtgtgaa aaatagcaag attagagaat gagttgtata gttttttcta 600
tcacatttca tctaaaatga tttgaaggac ttttgaagat ttttaccaac atccttaaat 660
caactccagg ttggatgaac aactgattta aaacaaacta agagaacatt aactagatgt 720
gggctttttta aaatatatag gtattgcatt tcctaccttg ttatttattc cactttgaa 780
acttttagagg gcttaacttt caactcttta aggtagtaat ggatagtttt atacttgttc 840
tcacaaaatt gttatggtca gtttatatca ttgctccatg cattgattat aaaaattcag 900
tattaatttt ttctgatctt ataagcttta taggagtttt cttttctctt ataaagtgtt 960
tcaccttatg taaaacaaat gcctgcttgc atattggaag atgttgaaat tagttttaga 1020
caaaagtggg ccatcaattc agacactctg cttggatgcc ttacctttt cattagtga 1080
ttctttgctt ctgaaacttg gcagaaactc gtttagccagt ccactgcctt tctgacaatg 1140
tgtggagtca cgtatgcttg gtatatgctt ttactacttt taaagtctta cagtttatta 1200
cttgcccaag tgttactaaa tccttttctt atgtgtactg gatggagaaa aaattatagc 1260
cagcactttg agaggaaagt tttcagaaac aatattaact ggcactacta actgaaggcc 1320
acaggagatg ctatcaatgt tatttgtaat ctgaagattg aacaaggctg tgaggctcat 1380
ttcaaaactat tttgaggtgt taaaaatat atatgctgtt tctcagctgt tccactcaaa 1440
ccgtgttagg actctcaaag gtaaaatgtc acaggggctt tcagttgtt acagagctca 1500
gcagctgtgg ttgccctgt tctacaccaa tttcagttca ataaaaatgt taactttgaa 1560
aaaaaaaaa

```

<210> 90
 <211> 718
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte Clone No: 1675560

```

<400> 90
gggtggtgct gctgtaatc ccaactactt gggaggctga ggcaggagaa tgccttgaac 60
ctgggaggca gcggttgca taagccaaga ctatgccact gcactcccg cttgggtgaca 120
aagcaatatt ctgtgtcaaa taaataaatt cattctctctg ctctcctgac ttagagaaat 180
ggtttgctta aaatgctagt aacaaacatc acagtcaaca ggagcttgct tcatgcgaag 240
gatcaatgtg atttgtggat ggagatgata gtgatgaaat tcctgtttca tggggctgtt 300
tttcttttca tctcactggg cagcagggtt agtgaggcag tgagatgctg ctgctgtgga 360
ttctgtagc tatgcctcgg ctctctggca tatcaggtag gaacctgtta caagtgaat 420
acttgaaacc tctctgacca agagcctctg atggagtggg aggtgagcta attctctgac 480
cagcttaggg cactgtttca gccactggtc acattccttg cttcaaaactg aaattcagtt 540
tggctttgag tatagggata catggtggat tcatgtactt cagtgtttgt tttgaccaa 600
gtttattttt ctagtgcatt ttctaagtca aagtgggtgaa aatatgtaat aattttagta 660
tgcagtactc agtctgaaac aataaaaatc tctgaaaaat gaaaaaaaaa aaaaaagg 718

```

<210> 91
 <211> 904
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte Clone No: 1687323

<400> 91
 gcttgtgggg ggaaaaagaa acgcaataga taaagcgggg cgcatgcgct cccggcacag 60
 gcttcgattg tgaggaaggc cggctagtct ccgagctcat cccgccttgc gcatgcggag 120
 aaggtaaacc agcgcgccga gttgaggcgc gggtttgggt gcgcgtttca gcgaagtcgc 180
 acgtgaagga tagcagtggc ctgagaaaga cccagtcagc gcagcctcca gcatcagttc 240
 accatgggga aagcatgtgt tcaaagccat tctgatggtc ctagtggccc ttatcctcct 300
 ccaactcagca ttggcccagt cccgtcgaga ctttgcacca ccaggccaac agaagagaga 360
 agccccagtt gatgtcttga cccagatagg tcgatctgtg cgaggggacac tggatgcctg 420
 gattggggcca gagaccatgc acctgggtgtc agagtcttcg tcccaagtgt tgtggggccat 480
 ctcatcagcc atttctgttg ccttctttgc tctgtctggg atcgccgcac agctgctgaa 540
 tgccttggga ctagtgtgtg attacctcgc ccagggcctg aagctcagcc ctggccaggt 600
 ccagaccttc ctgctgtggg gagcaggggc cctggctgtc tactggctgc tgtctctgct 660
 cctcggtctg gtcttggcct tgctggggcg gatcctgtgg ggctgaagc ttgtcatctt 720
 cctggccggc ttcgtggccc tgatgaggtc ggtgcccgac ccttccaccc gggccctgct 780
 actcctggcc ttgctgatcc tctacgcctt gctgagccgg ctactgggt cccgagcctc 840
 tggggcccaa ctcgaggcca aggtgcgagg gctggaacgc taggtggagg agctgcgctg 900
 gcgc 904

<210> 92
 <211> 1948
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte Clone No: 1692236

<400> 92
 gaagacctct tagcggggccc atcgctgagg tgcagggaca tgteggggcc gaactcacct 60
 cgtggcctcg gcgtgggtgct ctcaagctcat gcccgaaac caggctccga cgccgcgggtc 120
 agacggacct ctacagcgtt ccgcctcaat gccgccagct gccaggccgc ccgtgacgag 180
 ttacgcctgc gccgcctcct ggcttcgtga cgtcacgacg tccgcgcagt gcggtcgccg 240
 ccgtcgacag agtctttcct tagtaacctg ggcgatactg tggatgtttc caaggattgt 300
 cttcagtcct ggcttggga ttaaagtgtt tccgcattgt ccacctacc tttcgcaatt 360
 atcttgcagc ctctatcaga cccgtttcag aagttacact gaagacagtg catgaaagac 420
 aacatggcca taggcaatac atggcctatt cagctgtacc agtccggcat tttgctacca 480
 agaaagccaa agccaaaggg aaaggacagt cccaaaccag agtgaatatt aatgctgcct 540
 tggttgagga tataatcaac ttggaagagg tgaatgaaga aatgaagtct gtgatagaag 600
 ctctcaagga taatttcaat ctgactctca atataagggc ctaccagga tccttgaca 660
 agattgctgt ggtaactgct gacgggaagc ttgctttaa ccagattagc cagatctcca 720
 tgaagtgcgc acagctgatt ttggtgaata tggccagctt ccagagtggt acagctgcag 780
 ctatcaaggc tataagagaa agtggaaatga atctgaaccc agaagtggaa gggacgctaa 840
 ttcgggtacc cattcccca gtaaccagag agcacagaga aatgctgggt aaactggcca 900
 aacagaacac caacaaggcc aaagactctt tacggaaggc tcgcaccaac tcaatgaaca 960
 agctgaagaa atccaaggat acagtctcag aggacacat taggctaata gagaaacaga 1020
 tcagccaaat ggccgatgac acagtggcag aactggacag gcatctggca gtgaagacca 1080
 aagaactcct tggatgaaag tccactgggg ccagcaatac tccagagccc agtttctgct 1140
 ggatcccctg ggtggcacat tgggacttct ctccctcccc catctacaca gaagactgtc 1200
 accatgctga cagaagcctg tccttgtaag gccagcctt ccagggaac actcagacat 1260

```

gttcattctc ttcctgcttc tgcctctgggc cgggtgggtgg ctctcagaaa atacttgctg 1320
ctggcaaaag gcctgtactc aggcatttgc tttgacttga tgttgccaag ggactgaggg 1380
cattggcagg cttagtagca cctgctcctc atcttaggag tctccttttc aaataattag 1440
gctctgttcc cattttaaaa ctctgatatt ggccttcacc tgtgactgga cactttacta 1500
gagggccatt ttcactaaac aataaaatct aaataaattg gaaggaataa caaccacaaa 1560
ggaaagaata gagttggtct ggattgatga tctactgagga tctgtatgtg aggcacccat 1620
aacagtagtt ttgcctgtga gtcgtcttca cacatgctgt tttctctgcc tggctctctc 1680
ttccccctct tacctggcca gtectgttta tcatcaggcc ttgtcttgga tatcacgtcc 1740
tctgggaagt cttcttttcc cctctaacct aggacctca ttaccggctc tcatagcaca 1800
gtctactgct ttgtacgaat tctaagtatt cttgttgac ttaattagcc tgtatatact 1860
cagaactttg tgtaatgcct ggagcatagt aggcagtcac atgttgatc gtgaataaat 1920
tgcacatagt agctacccaa aaaaaaaaaa 1948

```

<210> 93

<211> 990

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte Clone No: 1720847

<400> 93

```

acagagactg gcacaggacc tcttcattgc aggaagatgg tagtgtaggc aggtaacatt 60
gagctctttt caaaaaagga gagctcttct tcaagataag gaagtggtag ttatgggtgg 120
aaccctcgcc tatcagtcgc gatgggtgcc accctcctg ctgtaggatg gaagcagcca 180
tggaagtggg gggaggcgca ataagacacc cctccacaga gcttggcatc atgggaagct 240
ggttctacct ctctctggct cctttgttta aaggcctggc tgggagcctt ccttttgggt 300
gtctttctct tctccaacca acagaaaaga ctgctcttca aagggtggagg gtcttcatga 360
aacacagctg ccaggagccc aggcacaggg ctggggggcct ggaaaaagga gggcacacag 420
gaggaggag gagctggtag ggagatgctg gctttacctt aggtctcgaa acaaggaggg 480
cagaataggc agaggcctct ccgttccagg ccattttttg acagatggcg ggacggaaat 540
gcaatagacc agcctgcaag aaagacatgt gttttgatga caggcagtggt ggccgggtgg 600
aacaagcaca ggccttggaa tccaatggac tgaatcagaa ccctaggcct gccatctgtc 660
agccgggtga cctgggtcaa ttttagcttc taaaagcctc agtctcctta tctgcaaaat 720
gaggcttgtg atacctgttt tgaagggttg ctgagaaaat taaagataag ggtatccaaa 780
atagtctacg gccataccac cctgaacgtg cctaattctg taagctaagc agggtcaggc 840
ctggttagta cctggatggg gagagtatgg aaaacatacc tgcccgagc tggagttaga 900
ctctgtctta acagtagcgt ggcacacaga aggcactcag taaatacttg ttgaataaat 960
gaagtagcga tttggtgtga aaaaaaaaaa 990

```

<210> 94

<211> 1638

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte Clone No: 1752821

<400> 94

```

tagatatggc gtcctctttg cttgcggggc agcgattggg gcgtgctttg ggccccggcg 60
gggagctgga gccagagcgg ctaccccgaa agctgcgggc cgagcttgag gccgcgctgg 120

```

```

ggaagaagca caagggcggt gatagctcca gtggcccccac acgcttggtt tctttccgtc 180
tcatccggga tctgcaccag catctgagag aaagggattc caaactatac ctccatgagc 240
tcttagaagg cagtgaatc tatctcccag aggttggtgaa gctccacagg aaccagaac 300
tagttgcccg gctggagaag attaagatac agctggccaa tgaggaatat aaacggatca 360
cccgaacgt cacttgtcag gatacaagac atgggtgggac tctcagcgac ctgggaaagc 420
aagtgagatc attgaaggct ctggtcatca ccatcttcaa tttcattgtc acggtggttg 480
ctgccttcgt ctgcacttac cttggaagcc aatatactt cacagaaatg gcctcgcggtg 540
tgctagctgc attgatcgtc gcctctgtgg tgggtctggc cgagctgtat gtcattggtgc 600
gggcaatgga aggcgagctg ggagaactgt aactggtgct tcatcatcaa gtctagagaa 660
gactttgggg gcttcaggct ccaattggca gtcaccgact cagtcaaccc atcagacttt 720
ttgtattcag ctccagttag tcagaagacc agcccaggcc agctgctgtt tctgtgggga 780
gccctaactc tctgtgaatt tccaaaggga gcattggagg agattgagat aacacatctt 840
taaaacagaa agaactggct ttggtctatc agtacctctt cctgaatctg gtacccatct 900
gccttctcca gttcattcta aacactgctg ggactagggt tttccatca ggagcaaatg 960
gaatccaggc cttccagaa gtagaccata ctgccttgaa cttgtccata tgtacaaact 1020
aatcaccagc tttctccata catTTTTaat gcagacctgt aattgagttc agaagcctcc 1080
aagaaaacag aaaggatccc ctttctccag tttgtgctgg aagaggagct gatcagagac 1140
atcaaataag agaaagatgg gttgctagag gatggtagaa ctggaagcaa ggcagctacc 1200
tttttgcaaa aggaaatggt gttaggcccc tttccagaa gataagacag actcatagag 1260
attaaatgat cactatggct cttcttctgt taaatggagc caaagacgcc tatgttgttc 1320
tgaagtcttg taatgtttaa cttctgagaa cttagattag tgggtgtgatg atagagtctg 1380
tataacgcac tgaaggggt atcaggctta gttatttacc caataaatat ttattgtatg 1440
cagggtattc ctattttaac tcctgtgaca acacaaagca tagcgatttc catagtctta 1500
actgttcagg gctgctcct cctggtacac tcttttgggt tcaactgtatg tactcctgtt 1560
gtcttttttt ttttttccaa agcacttttc tgttttcata aattatatac tcattcactc 1620
agtggacaaa aaaaaaaa 1638

```

<210> 95

<211> 595

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte Clone No: 1810923

<400> 95

```

gtggggcgct ccagtgatga ctggggggatc ccggcaagta acatgactaa aaagaagcgg 60
gagaatctgg gcgtcgctct agagatcgat gggctagagg agaagctgtc ccagtgtcgg 120
agagacctgg aggccgtgaa ctccagactc cacagccggg agctgagccc agaggccagg 180
aggtccctgg agaaggagaa aaacagccta atgaacaaag cctccaacta cgagaaggaa 240
ctgaagtttc ttcggcaaga gaaccggaag aacatgctgc tctctgtggc catctttatc 300
ctcctgacgc tcgtctatgc ctactggacc atgtgagcct ggcacttccc cacaaccagc 360
acaggcttcc acttggtccc ttgatcagga tcaagcaggc acttcaagcc tcaataggac 420
caagggtgctg ggggtgtccc ctcccaacct agtgttcaag catggcttcc tggcggtcca 480
ggccttgctt ccttggtcct ctggggggtt ccgggtctcc agaaggacat ggtgctggtc 540
cctcccttag cccaaggag aggcataaaa gaacacaaag ctgtaaaaaa aaaaa 595

```

<210> 96

<211> 1858

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte Clone No: 1822315

<400> 96

```

aaaagtctag atcacagtgg ggctctagga gggctagtcg ttggatttat cctaaccatt 60
gcaaatttca gcttttttac ctctttgctg atgtttttct tgtcttcttc gaaactcact 120
aaatggaagg gagaagtga gaagcgtcta gattcagaat ataaggaagg tgggcaaagg 180
aattgggttc aggtgttctg taatggagct gtaccacacag aactggccct gctgtacatg 240
atagaaaatg gccccgggga aatcccagtc gatttttcca agcagtactc cgcttcctgg 300
atgtgtttgt ctctcttggc tgcactggcc tgcctctgctg gagacacatg ggcttcagaa 360
gttggtccag ttctgagtaa aagttctcca agactgataa caacctggga gaaagtcca 420
gttggtacca atggaggagt tacagtgggtg ggcttctctt ccagtcctct tgggtgtacc 480
tttggtggca ttgcatactt cctcacacag ctgatttttg tgaatgattt agacatttct 540
gccccgcagt ggccaattat tgcatttgggt ggcttagctg gattactagg atcaattgtg 600
gactcatact taggggctac aatgcagtat actgggttgg atgaaagcac tggcatggtg 660
gtcaacagcc caacaaataa ggcaaggcac atagcaggga aacctattct tgataacaac 720
gcgtggatct gttttcttct gttcttattg cctcttctg cccaactgct gcttgggggt 780
tttggtccag ggggtgaact ttatttcatt tccacagggt gaaactggtg agtccagcta 840
aatttgcaat tccaactttc atcctaagaa taataactgt aatggcaaag cggaaatgcc 900
agttcctcct gtattccatt gagatgggat ttcacatttt cctctcatca actccccgtg 960
aatagctagc gtctttctag tgaaagagaa gaattcctag aacttatgca ttttttctct 1020
gctgaatgga agtcttgagc aatgaagcta tattgtccct acatattact atatattgaa 1080
ctgaaagtcc ttacataatc aatgtcaagt ttgtcttat tttgtttgt ttgtttaaac 1140
cagtgtagga aataaaagtg atgataattt aaatagttct cagtgaagc agagaaatgc 1200
cactgtgcta gttgccccaa tgttgatatc attttaaata gtttaagctg atgtgtatgg 1260
gagcctaaac aagtgtagta tctgaactt ctccattaa ttgctattca caattgggaa 1320
aagtgtggag attggttctt agtgagtttt gtggcctact ccacatttgt tcttccttcc 1380
tcagggttag tgatgaaaaa aagtaaatac ctttttcata tgtccattag aatgtatgaa 1440
aaaaatcatt ttaactaaaa gcaaaagaat tttatcttat atctaaaaaa tatataactt 1500
actatatgtt tcagttgctc tctgaacaaa aattatcttc aatttaatat gtggaatgtg 1560
ttttctagct ttctttgaat tatgtatggc aacctgggtt agcactggca tcctgaacag 1620
ttaagagtca ctgggaaatt attgtatttc ttataaatt tactgtcata tcaattgctg 1680
gaaaatgcta tgatttttct attattacct tctaagttgt attctctctt acactgtagc 1740
ctcaactaag gcaattctgc tatgtttgtt cttcactatg atttactgtg tgccaaagga 1800
gttttgacag ggtacagagt attttactaa aagtattttt aaatgttaaa aaaaaaaa 1858

```

<210> 97

<211> 698

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte Clone No: 1877777

<400> 97

```

tgggtgtccg catgacaacc gacgttggag tttggagggtg cttgccttag agcaagggaa 60
acagctctca ttcaaaggaa ctagaagcct ctccctcagt ggtagggaga cagccaggag 120
cggttttctg ggaactgtgg gatgtgccct tgggggcccc agaaaacaga aggaagatgc 180
tccagaccag taactacagc ctggtgctct ctctgcagtt cctgctgctg tcctatgacc 240
tctttgtcaa ttccttctca gaactgctcc aaaagactcc tgtcatccag cttgtgctct 300
tcatcatcca ggatattgca gtccctctca acatcatcat cattttctct atgttcttca 360
acaccttcgt cttccaggct ggctgggtca acctcctatt ccataagttc aaagggacca 420
tcatcctgac agctgtgtac tttgccctca gcactcctct tcatgtctgg gtcatgaact 480

```



```

tacgctggaa aaactccaac agcttcatat ggacagatgg acttcaaata ctgtttgtat 540
tccagagact agcagcagtg ttgtactgct acttctataa acggacagcc gtaagactag 600
gcgatcctca cttctaccag gactctttgt ggctgcgcaa ggagttcatg caagtccgaa 660
ggtgacctct tgtcacactg atggatactt ttccttcc 698

```

```

<210> 98
<211> 1476
<212> DNA
<213> Homo sapiens

```

```

<220>
<221> misc_feature
<223> Incyte Clone No: 1879819

```

```

<400> 98
caaggacgag gctctggcca agctgggtat caacgggtgcc cactcgtecc cgccgatgct 60
gtcccccagc ccaggaaaagg gcccccgcc agctgtggct cctcgacca aggccccgct 120
acagcttggg cctcttagct ccatcaagga aaagcagggg ccccttcttg acctgtttgg 180
ccagaagctg cctattgccc acacaccccc acctccacca gcgccaccac tgccctctgcc 240
cgaggaccca gggacccttt cagcagagcg tcgttgcttg acacagcccg tggaggacca 300
gggggtctcc acccagctac tcgcgccctc tggcagcgtg tgcttctcct acaccggcac 360
gccctggaag ttgttcttac gcaaggaggt gttctacca cgggagaact tcagccatcc 420
ctactacctg aggtcctct gtgagcagat cctacgggac accttctccg agtccctgtat 480
ccgattttcc cagaatgagc ggcggaataa gaaagacctg ctgggaggct tggagggtga 540
cctggattct ctcaccacca ccgaagacag cgtcaagaag cgcacgtgg tggccgctcg 600
ggacaactgg gcccaattact tctcccgtt ctttctctgc tcgggcgaga gtggcagcga 660
cgtgcagctg ttagccgtgt cccaccgtgg gctgcgactg ctcaagggtg cccaaggccc 720
cggcctccgc cccgaccagc tgaagattct ctgctcatac agctttgcgg aggtgctggg 780
tgtggagtgc cggggcggct ccaccctgga gctgtcactg aagagcgagc agctggtgct 840
gcacacagcc cgggcaaggg ccatcgaggc gctggttgag ctattcctga atgagcttaa 900
gaaggactcc ggctatgtca tcgccctgcg cagctacatc actgacaact gcagcctcct 960
cagcttccac cgtgggggacc tcatcaagct gctgccgggt tgccaccctg gagccaggct 1020
ggcagtttgg ctctgccggg ggccgttccg gactctttcc tgccgacata gtgcagccgg 1080
ctgccgctcc cgacttttcc ttctccaagg agcagaggag tggctggcac aagggtcagc 1140
tgtccaacgg ggaaccaggg ctggctcggt gggacagggc ctcagagggt aggaagatgg 1200
gagagggaca agcagaggca aggcctgcct gagactgagg aaggaaaggg gtttgaccac 1260
tcccagggt gccatgcggg gggaccaccc tgcgtccgt ctctgtggc tgccctctg 1320
cccgtcctg atggctcgcc ttgtctctcc agcaagactg tgcactcctt gcaggcaggg 1380
gctgggctgg atgctgctt ttgttcccac gtggtactta gttcaaggct gccccagcag 1440
atgcttaata aacagctctt cactttaaaa aaaaaa 1476

```

```

<210> 99
<211> 646
<212> DNA
<213> Homo sapiens

```

```

<220>
<221> misc_feature
<223> Incyte Clone No: 1932945

```

```

<400> 99
ccggctggag gtgacgctga ggcggcgagg gtgagtcggc gccggccgct accgcacttc 60
gggcgctcgt cctcatttc tctgtggtga atggcgacgg gatggagcgc gaggggagcg 120

```

```

gcgccagcgg cggttcggcc gggtccctgc agcagatcct gagcctgaag gttgtgcgc 180
gggtgggcaa cggaacctg tcccccaact ctacttccct ctgtcccttc ccagagatgt 240
ggtatggtgt attcctgtgg gcactggtgt cttctctctt ctttcatgtc cctgctggat 300
tactggccct cttcaccttc agacatcaca aatatggtag gttcatgtct gtaagcatcc 360
tgttgatggg catcgtggga ccaattactg ctggaatcct gacaagtgca gctattgctg 420
gagtttaccg agcagcaggg aaggaaatga taccatttga agccctcaca ctgggcactg 480
gacagacatt ttgcgtcttg gtggtctcct ttttacggat tttagctact ctatagcata 540
catccttatg ctgagatgtt gaacttaaac tttatggaat cctccaaaag aatacattat 600
ggagtgtagt gttttcttag ttcttccaaa gggagccact tggatg 646

```

<210> 100

<211> 1735

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte Clone No: 2061026

<400> 100

```

gccggctgcg ccattggcgtt ggcgttggcg gcgctggcgg cggtcgagcc ggctgcggc 60
agccgggtacc agcagttgca gaatgaagaa gagtctggag aacctgaaca ggctgcagg 120
gatgctcctc caccttacag cagcatttct gcagagagcg cagcatattt tgactacaag 180
gatgagtctg ggtttccaaa gcccccatct tacaatgtag ctacaacact gccagttat 240
gatgaagcgg agaggaccaa ggctgaagct actatccctt tggttcctgg gagagatgag 300
gattttgtgg gtcgggatga ttttgatgat gctgaccagc tgaggatagg aaatgatggg 360
attttcatgt taactttttt catggcattc ctctttaact ggattgggtt tttcctgtct 420
ttttgcctga ccacttcagc tgcaggaagg tatggggcca tttcaggatt tggctctctc 480
ctaattaaat ggatcctgat tgtcaggttt tccactatt tccctggata ttttgatgg 540
cagtactggc tctgggtggg gttccttgtt ttaggcttct tccgttttct cagaggattt 600
atcaattatg caaaagtctg gaagatgcc aaaaactttt caaatctccc caggaccaga 660
gttctcttta tttattaaag atgttttctg gcaaaggcct tctgcattt atgaattctc 720
tctcaagaag caagagaaca cctgcaggaa gtgaatcaag atgcagaaca cagaggaata 780
atcacctgct ttaaaaaaat aaagtactgt tgaaaagatc atttctctct atttgttcct 840
aggtgtaaaa ttttaatatg taatgcagaa ttctgtaatc attgaatcat tagtggttaa 900
tgtttgaaaa agctcttgca atcaagtctg tgatgtatta ataatgcctt atatattgtt 960
tgtagtcatt ttaagtagca tgagccatgt ccctgtagtc ggtagggggc agtcttgcct 1020
tattcatcct ccattctcaa atgaacttgg aattaaatat tgtaagatat gtataatgct 1080
ggccatttta aaggggtttt ctcaaaagt aaacttttgt tatgactgtg tttttgcaca 1140
taatccatat ttgctgttca agttaatcta gaaatttatt caattctgta tgaacacctg 1200
gaagcaaaat catagtgcaa aaatacattt aaggtgtggt caaaaataag tctttaattg 1260
gtaataata agcattaatt ttttatagcc tgtattcaca attctgcggg accttattgt 1320
acctaaggga ttctaaagg gtgtgctact tataaaacag aaagcactag gatacaaatg 1380
aagcttaatt actaaaatgt aattcttgac actctttcta taattagcgt tcttcacccc 1440
cacccccacc cccaccccc ttattttcct tttgtctcct ggtgattagg ccaaagtctg 1500
ggagtaagga gaggattagg tacttaggag caaagaaaga agtagcttgg aacttttgag 1560
atgatcccta acatactgta ctacttgctt ttacaatgtg ttagcagaaa ccagtgggtt 1620
ataatgtaga atgatgtgct ttctgcccc gtggtaattc atcttggttt gctatgttaa 1680
aactgtaaat acaacagaac attaataaat atctcttggt tagcaaaaa aaaaa 1735

```

<210> 101

<211> 2329

<212> DNA

<213> Homo sapiens

<220>

<221>

<222> 2084, 2101, 2110, 2128, 2137, 2156, 2177, 2226, 2265, 2296, 2303, 2310, 2325

<223> a or g or c or t, unknown, or other

<220>

<221> misc_feature

<223> Incyte Clone No: 2096687

<400> 101

```
gcagggatca ctagcatgtc tgcggagagc ggccctggga cgagattgag aaatctgcc 60
gtaatggggg atggactaga aacttcccaa atgtctacaa cacaggccca ggcccaaccc 120
cagccagcca acgcagccag caccaacccc ccgccccag agacctccaa ccctaacaag 180
cccaagagggc agaccaacca actgcaatac ctgctcagag tgggtgctcaa gacactatgg 240
aaacaccagt ttgcatggcc tttccagcag cctgtggatg ccgtcaagct gaacctccct 300
gattactata agatcattaa aacgcctatg gatatgggaa caataaagaa gcgcttggaa 360
aacaactatt actggaatgc tcaggaatgt atccaggact tcaacactat gtttaciaaat 420
tgttacatct acaacaagcc tggagatgac atagtcttaa tggcagaagc tctggaaaag 480
ctcttcttgc aaaaaataaa tgagctaccc acagaagaaa ccgagatcat gatagtccag 540
gcaaaaggaa gaggacgtgg gaggaagaa acagggacag caaaacctgg cgtttccacg 600
gtaccaaaaca caactcaagc atcgactcct ccgcagaccc agacctcctca gccgaatcct 660
cctcctgtgc aggccacgcc tcacctcttc cctgccgtca ccccggaact catcgctcag 720
acctctgtca tgacagtggg gcttccccag ccactgcaga cgcccccgcc agtgcccccc 780
cagccacaac ccccaaccgc tccagctccc cagcccgta agagccaccc acctatcatc 840
gcggccaccc cacagcctgt gaagacaaa aggggagtga agaggaaagc agacaccacc 900
acccccacca ccattgaccc cattcacgag ccacctctgc tgcccccgga gcccaagacc 960
accaagctgg gccagcggcg ggagagcagc cggcctgtga aacctccaaa gaaggacgtg 1020
cccgactctc agcagcacc agcaccagag aagagcagca aggtctcgga gcagctcaag 1080
tgctgcagcg gcatcctcaa ggagatgttt gccaaagaagc acgccgccta cgcctggccc 1140
ttctacaagc ctgtggacgt ggaggcactg ggcttacacg actactgtga catcatcaag 1200
caccatctgg acatgagcac aatcaagtct aaactggagg cccgtgagta cgtgatgtct 1260
caggagtttg gtgctgacgt ccgattgatg ttctccaact gctataagta caacctctct 1320
gacctgagg tggtggccat ggcccgaag ctccaggatg tggtcgaaat gcgctttgcc 1380
aagatgccgg acgagcctga ggagccagt gtggccgtgt cctccccggc agtgccccct 1440
cccaccaagg ttgtggcccc gccctcatcc agcgacagca gcagcgatag ctctcggac 1500
agtgcaggtt cgactgatga ctctgaggag gagcgagccc agcggctggc tgagctccag 1560
gagcagctca aagccgtgca cgagcagctt gcagccctct ctcagcccca gcagaacaaa 1620
ccaaagaaaa aggagaaaga caagaaggaa aagaaaaaag aaaagcacia aaggaaagag 1680
gaagtggag agaataaaaa aagcaaagcc aaggaaacct ctctaaaaaa gacgaagaaa 1740
aataatagca gcaacagcaa tgtgagcaag aaggagccag cgcccatgaa gagcaagccc 1800
cctcccacgt atgagtcgga ggaagaggac aagtgcagc ctatgtccta tgaggagaag 1860
cggcagctca gcttggacat caacaagctc cccggcgaga agctgggccc cgtggtgcac 1920
atcatccagt cacgggagcc ctccctgaag aattccaacc ccgacgagat tgaaatcgac 1980
tttgagaccc tgaagccgtc cactctgct gagcttgag cgctatgtca cctcctgttt 2040
gcggaagaaa aggaacctt caagctgaga aagttgatgt gatntgccgg gttcctccaa 2100
natgaaaggn ttctcggtct tcaagagncg ggagagnctc ccagttgaat tccaanttct 2160
tttgacaagc ggaaganttc cggaaaacaa agggctcttg gccttaaatt caatttggga 2220
aaaccnggga ctctcttaa tttaaaaaaa gggggctttt caagntttcc caaggaattt 2280
ccttttcccc caaggnaaag gcntaattan gcctttaaaa ggttnccca 2329
```

<210> 102

<211> 1451

<212> DNA
 <213> Homo sapiens

 <220>
 <221>
 <222> 1346, 1373, 1430
 <223> a or g or c or t, unknown, or other

 <220>
 <221> misc_feature
 <223> Incyte Clone No: 2100530

<400> 102
 ctcgagcggc ggcatttccct ggtgtctgag cctggcgcgagg aggcctatggg cagccaggag 60
 gtgctggggc acgcggcccc gctggcctcc tccggtctcc tcctgcagggt gttgtttcgg 120
 ttgatcacct ttgtcttgaa tgcattttatt ctctcgcttcc tgtcaaagga aatcgttggc 180
 gtagttaaag taagactaac gctgctttac tcaaccaccc tcttctctggc cagagaggcc 240
 ttccgcagag catgtctcag tgggggcacc cagcgagact ggagccagac cctcaacctg 300
 ctgtggcctaa cagtcacctt ggggtgtgtt ttggtccttat tcctggggctg gatctggttg 360
 cagctgcttg aagtgcctga tctaatgtt gtccctcact atgcaactgg agtgggtgctg 420
 tttggtctct cggcagtggt ggagcttcta ggagagccct tttgggtctt ggcacaagca 480
 catatgtttg tgaagctcaa ggtgattgca gagagcctgt cggtaattct taagagcgtt 540
 ctgacagctt ttctcgtgct gtggttgccct cactggggat tgtacatttt ctctttggcc 600
 cagcttttct ataccacagt tctggtgctc tgctatgtta tttatttcac aaagttactg 660
 gggtcccccag aatcaaccaa gcttcaaact ctctctgtct ccagaataac agatctgtta 720
 cccaatatta caagaaatgg agcggttata aactggaaaagg aggcctaaact gacttgaggat 780
 tttttcaaac agtctttctt gaaacagatt ttgacagaag gcgagcgata tgtgatgaca 840
 tttttgaatg tattgaactt tgggtgatcag ggtgtgtatg atatagtga taatcttggc 900
 tcccttgttg ccagattaat tttccagcca atagaggaaa gttttttatat attttttgct 960
 aaggtgcttg agaggggaaa ggatgccaca cttcagaagc aggaggacgt tgctgtggct 1020
 gctgcagtct tggagtcctt gctcaagctg gccctgctgg ccggcctgac catcactgtt 1080
 tttggctttg cctattctca gctggctctg gatattctac gagggaccat gcttagctca 1140
 ggatccggtc ctgttttgct gcgttcctac tgtctctatg ttctctctgct tgccatcaat 1200
 ggagtgcacag agtgtttcac atttgctgcc atgagcaaaagg agggagtcga caggatttcc 1260
 tctgtctgta gcagggctgg ccagccagac tggcacacat tgctgtgggg gccttctgtc 1320
 tgggagcaac tctcgggaca gcattnctca cagagaccaa gctgatccat ttntcagga 1380
 ctgagttagg tgtgcccaga cggactgaca aaatgacgtg acttcagggg aggcctgggac 1440
 aaacgaggca a 1451

<210> 103
 <211> 1685
 <212> DNA
 <213> Homo sapiens

 <220>
 <221> misc_feature
 <223> Incyte Clone No: 2357636

<400> 103
 gcgatcgagg ctgcagcgcg gccgcccggg gcacatgact gccgtcggcg tgcaggccca 60
 gaggcctttg ggccaaaggc agccccggcg gtccttcttt gaatccttca tccggaccct 120
 catcatcacg tgtgtggccc tggtgtggtt cctgtcctcg gtctccattt gtgatgggca 180
 ctggctcctg gctgaggacc gcctcttcgg gctctggcac ttctgcacca ccaccaacca 240

```

gagtgtgccg atctgcttca gagacctggg ccaggcccat gtgcccgggc tggccgtggg 300
catgggcctg gtacgcagcg tgggcgcctt ggccgtggtg gccgccattt ttggcctgga 360
gttccctcatg gtgtcccagt tgtgcgagga caaacactca cagtgcaggt gggcatggg 420
ttccatcctc ctccctgggtg ctttctgctt ctcctccggc gggctcctgg gttttgtgat 480
cctcctcagg aaccaagtca cactcatcgg cttcacccta atgttttggg gcgaattcac 540
tgccctcctt ctcctcttcc tgaacgccat cagcggcctt cacatcaaca gcatcaccca 600
tccctgggaa tgaccgtgga aatttttaggc cccctccagg gacatcagat tccacaagaa 660
aatatggtca aaatgggact tttccagcat gtggcctctg gtggggctgg gttggacaag 720
ggccttgaaa cggctgcctg tttgcccata acttgtgggt ggtcagccag aaatggccgg 780
ggggcctctg cacctgggtc gcagggccag aggcaggag ggtgcctcag tgccaccaac 840
tgcacaggct tagccagatg ttgatttttag aggaagaaaa aaacatttta aaactccttc 900
ttgaattttc ttccctggac tgggaatacag ttggaagcac aggggtaact ggtacctgag 960
ctagctgcac agccaaggat agttcatgcc tgtttcattg acacgtgctg ggataggggc 1020
tgcagaatcc ctggggctcc cagggttgtt aagaatggat cattcttcca gctaagggtc 1080
caatcagtgc ctattcttcc accagctcaa agggccttcg tatgtatgtc cctggcttca 1140
gctttggtca tgccaaagag gcagagttca ggattccctc agaatgccct gcacacagta 1200
ggtttccaaa ccatttgact cggtttgctt cctgcccgtg tgtttaaacc ttacaaaccc 1260
tggataaccc catcttctag cagctggctg tcccctctgg gagctctgcc tatcagaacc 1320
ctaccttaag gtgggtttcc ttccgagaag agttcttgag caagctctcc caggagggcc 1380
cacctgactg ctaatacaca gccctcccca aggccctgtg gtgcatgtgt ctgtcttttg 1440
tgagggttag acagcctcag ggcaccattt ttaatccag aacacatttc aaagagcacg 1500
tatctagacc tgctggactc tgcagggggg gagggggaac agcgagagct tgggtaatat 1560
ttaacaccca tgctggggat gcatggaggt gaagggggcc aggaaccagt ggagatttcc 1620
atccttgcca gcacgtctgt acttctgttc attaaagtgc tccctttcta gtcaaaaaaa 1680
aaaaa

```

<210> 104

<211> 2674

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte Clone No: 2365230

<400> 104

```

ctactcctca ccgcgcgagc gcggggaacc agtagccgcg gctgcttcgg ttgccgcggc 60
cgggtggctg tatggattct ccatgggacg agttggctct ggcccttctcc cgcacgtcca 120
tgtttccctt ttttgacatc gcgcactatc tagtgtcagt gatggcgggtg aaacgtcagc 180
cgggagcagc tgcattggca tgggaagaatc ctatttcaag ctgggttact gctatgctcc 240
actgtttttg tggaggaatt ttatcctgtc tactgcttgc agagcctcca ttgaagtttc 300
ttgcaaacca cactaacata ttactggcat cttcaatctg ggtatattac atttttttgc 360
ccgcatgacc tagtttccca gggctattca tatctacctg ttcaactact ggcttcggga 420
atgaaggaag tgaccagaac ttggaaaata gtaggtggag tcacacatgc taatagctat 480
tacaaaaatg gctggatagt catgatagct attggatggg cccgaggtgc aggtggtacc 540
attataacga attttgagag gttggtaaaa ggagattgga aaccagaagg tgatgaatgg 600
ctgaagatgt cataccctgc caaggtaacc ctgctggggg cagttatctt cacattccag 660
cacacccagc atctggcaat atcaaagcat aatcttatgt tccctttatac catctttatt 720
gtggccacaa agataacccat gatgactaca cagacttcta ctatgacatt tgctcctttt 780
gaggatacat tgagttggat gctatttggc tggcagcagc cgttttctac atgtgagaag 840
aaaagtgaag caaagtcacc ttccaatggc gttgggtcat tggcctcaaa gccggtagat 900
gtgcctcag ataatgttaa aaagaaacat actaagaaga atgaataaat ttacgtgatg 960
agctctagca agccaaaaat tttttttctt atctacctgt tatattgtgc taattttcta 1020
tgtatgtgat gtgaaatgaa gactatatat atggaatgga ggtgacagaa agaaagaaat 1080
tctttgtttg agggagactt cccctttctg gattgtattt gtagagtgtt acgagtgtat 1140

```

```

catgtgatta tgctttaccg gtataagaga ttctgttggtg attatttgaa tagttttata 1200
ttaataaaaag aagacaaaat tttttaaag tttagaaaaag cagatctgtc attgcaaagt 1260
aacaaaaaatt ttaagctttt aaaaaatgtag atttttcata tttttaaaaat ttgaatctat 1320
ttgagcttta gttcagcaga attaaaatttt tacttgacat tatcattaaa attgctaggt 1380
atggagaaca attcctattt tattttgaac actgagaaga gtaaactttt cctaaaacac 1440
tttatattat aaatgaaaat aaattgctag ttttatattt agatataaac atcatatttt 1500
ttattaatac ctacatcaaa tggaaaatat ctgaaatttt tttccatag cagggtatttt 1560
ctactagaag tagttttact acttttcatt tagaacagag tatgagtctt aatctgaagt 1620
ctttttcatg cccttgtttt aaaaaaacta ctttttttgg cctcaaaaaa atcaaggggtg 1680
taatttttaa taaattgtta atcctatgtt ttgtaatttt catttttagga gcttgactta 1740
ttttttttct ctctcataaa aacacatttg ttttaattgt aggagaaatt ttctcagcat 1800
tttgcatgtt ctttctaate tttgttggtc tgaatatatt ggtagtaatt actgtaatta 1860
ttcaacaaaa agcatatccg ttcaaaaatt tttccactat gtcttttttc tagtggtctac 1920
tgttttagtt ttctagttga atatctctga caagctttcg tatggttttg ttatattttc 1980
atctacatgt aatgtgttat taattttatt aaatgaaaac taatcacctt catgtggaaa 2040
tgctctgaga attgtcctta ggcatttggt agtaaccagc taaccaagaa gaaacagaga 2100
aaccagaact tcatatggca gtccatttag atgaagaatg atgatataaa atctgggttc 2160
ttcttagcaa aataaaaaaac aaacaagaaa agataactaaa tgatgttaat tttcttactt 2220
tatgatttag aagtccagtt ataataattaa aactctgtga catagtttct tttacaaaaa 2280
ccatgaacct actcccgtta tcagggtattt tcgatgggtt agaagtactc aagtcacatc 2340
acattcaagt tagaagtttt ttttttggtg ttgttatttt aaatttttaa caaatataaa 2400
caccagcaga tactattact tgcttaaaaa attgggaggg ggcacttttc atagtcttgg 2460
aatgctaaga agttttattt ttaatatgtt gacagaaagc tttaagtatt taagagctct 2520
gtattatatt tgatactctt acagttaaaa acttttcaaa attaatacat tgtttaattat 2580
tgaccagttt tgaagtttgg gtttaactgt agttgaaatg gaaggactct tgttttacac 2640
ttgtattaaa gataaattta ttaaaataag ttat 2674

```

<210> 105

<211> 488

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte Clone No: 2455121

<400> 105

```

gactacgggg ctgttgacgg cgctgcgatg gctgcctgcg agggcaggag aagcggactc 60
tcggttcctc tcagtcggac ttcttgacgc cgccagttgg cggggccctc tgggcccgtc 120
ccaccactgt agtcatgtac ccaccgcgcg cgccgcgcgc tcacggggac ttcactctcg 180
tgacgctgag ctttggcgag agctatgaca acagcaagag ttggcggcgg cgctcgtgct 240
ggaggaaatg gaagcaactg tcgagattgc agcggaatat gattctcttc ctccctgcct 300
ttctgctttt ctgtggactc ctcttctaca tcaacttggc tgaccattgg aaagctctgg 360
ctttcaggct aggggaagag cagaagatga ggccagaaat tgctgggtaa aaccagcaaa 420
tccaccgctc ttaccagctc ctccagaaggc ggacaccggc cctgagaact tacctgagat 480
ttcgtcac

```

<210> 106

<211> 1028

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte Clone No: 2472514

<400> 106

```
ccagcagctc ggtcctaggg cgatgttgac agacagacag aggggcggat gcagcctacc 60
tcctgggcag tgagctgcgg tctgaggccc ctgcccagct ggaaaccaca gggaggggaa 120
gggaggggag gagaggagag gagaggaacc gtcattggggc cttggagtcg agtcagggtt 180
gccaaatgcc agatgctggt cacctgcttc tttatcttgc tgctgggcct ctctgtggcc 240
accatggtga ctcttaccta cttcggggcc cactttgctg tcatccgccg agcgtccctg 300
gagaagaacc cgtaccaggc tgtgcaccaa tgggccttct ctgcggggtt gagcctgggtg 360
ggcctcctga ctctgggagc cgtgctgagc gctgcagcca ccgtgaggga ggcccagggc 420
ctcatggcag ggggcttctt gtgcttctcc ctggcgcttct gcgcacaggt gcagggtggtg 480
ttctggagac tccacagccc caccaggtg gaggacgcca tgctggacac ctacgacctg 540
gtatatgagc aggcgatgaa aggtacgtcc cactccggc ggccaggagct ggccggccatc 600
caggacgtgg tgagcgtggg gacggctggg tggcagggcg gtcagcttct gcttggactg 660
cagttcagag aacaggcgca ggttggccag tgagaggctc ggccaggcac cgaggggggtt 720
ccaggacaca ggccagagtt gccctcagg cgtgggggca aaaagctccc accctctgtc 780
tgcccaggac aaggccgctt accagattct ctagggccag tgcaaaacga gagggcaggg 840
ccctgtattc agaaacactg aaggatttca agagcattaa agcaaatagc gggccgaaca 900
tagtggtctc cacctgtaat cccagcactt tgggaggagg ttgaggcagg tgaattgctt 960
gagcccagga gttcgagacc agcctgagca acatagggag accttgtctc tactttaaaa 1020
aaaaaaaaa 1028
```

<210> 107

<211> 1551

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte Clone No: 2543486

<400> 107

```
ctgcgcctgg gctgccggtg acctggggccg agccctcccg gtcggctaag attgctgagg 60
aggcggcggg tagctggcag gcgccgactt ccgaaggccg ccgtccgggc gaggtgtcct 120
catgacttct cttgtggacc atgtccgtga tcttttttgc ctgcgtggta cgggtaaggg 180
atggactgcc cctctcagcc tctactgatt tttaccacac ccaagatttt ttggaatgga 240
ggagacggct caagagttta gccttgcgac tggcccagta tccaggctga ggttctgcag 300
aagggtgtga ctttagtata ctttttctt ctttcgggga cgtggcctgc atggctatct 360
gctcctgccg gtgtccagca gccatggcct tctgcttctt ggagaccctg tgggtgggaat 420
tcacagcttc ctatgacact acctgcattg gcttagcctc caggccatac gcttttcttg 480
agtttgacag catcattcag aaagtgaagt ggcattttta ctatgtaagt tctctcaga 540
tggagtgcag cttggaaaaa attcaggagg agctcaagtt gcagcctcca gcggttctca 600
ctctggagga cacagatgtg gcaaattggg tgatgaatgg tcacacaccg atgcacttgg 660
agcctgctcc taatttccga atggaaccag tgacagccct gggatctctc tccctcattc 720
tcaacatcat gtgtgctgcc ctgaatctca ttcgaggagt tcaccttgca gaacattctt 780
tacaggttgc ccatgaggaa attggaaca tcttggttct tctgttctt tctgtagcct 840
gcattttcca ggaatccaag agctggttct gctgggttga ccaaacctcg tgagccagcc 900
accttgacc caaatgagga gagctctgat tctcccatcc gggagcagtg atgtcaaact 960
tctgctgctg gggaaatctc atcagcaggg agcctgtgga aaagggcatg tcagtgaat 1020
ctgggaatgg ctggattcgg aaacatctgc ccatgtgtat tgatggcaga gctgttggcc 1080
acaagcgcct tttatttagg gtaaaattaa caaatccatt ctattcctct gacctatgct 1140
tagtacatat gacctttaac ccttacattt atatgattct ggggttgctt cagaagtgtt 1200
atttcatgaa tcattcatat gatttgatcc cccaggattc tattttgttt aatgggcttt 1260
tctactaaaa gcataaaata ctgaggctga tttagtgcag gcaaaaccat ttactttaca 1320
```

```

tattcgtttt caataacttgc tgttcattgtt acacaagctt cttacggttt tcttgtaaca 1380
ataaatattt tgagtaaaata atgggtacat ttttaacaaac tcagtagtac aacctaaact 1440
tgtataaaaag tgtgtaaaaaa tgtatagcca tttatatcct atgtataaat taaatgaggt 1500
ggcttcagaa atggcagaat aaatctaaag tgtttattaa caaaaaaaaaa a 1551

```

<210> 108

<211> 922

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte Clone No: 2778171

<400> 108

```

gcttcgggct cgggtggctg agcgcgcggg gaaatggcca cggggacaga ccagggtgggtg 60
ggactcgggc tgcgcgcgt tagcctgac atcttcacct actacaccgc ctgggtgatt 120
ctcttgccat tcategacag tcagcatgtc atccacaagt atttcctgcc ccgagcctat 180
gctgtcgcca tcccactggc tgcaggcctc ctgctgctcc tgtttgtggg actgttcac 240
tcctacgtga tgcgtgaagag caagagagtg accaagaagg ctcaagtgaag gtcccgcagg 300
atgaggctgc cagccccctc tctgcttccc ctccagcaca gggaccaagt gggggagcct 360
gcagaacctg tccaggcaca gtggctcctc aagcctgcct gtccctgcaga gtcccatgg 420
catggagctt acacctgact gactggagcc cctccccga ctcccacttc cagaagctag 480
gagggaggga tacctggaag actccggta cctccttctt gctcagggcc taaaagatgc 540
tggtcctccc aacctcactc tcagactccc tgccaccttt tcccctgggt tctgcgctc 600
tgctcactt cccctcctgt cacatgctga cgttggactt agcaggttct aaggccacat 660
gtgtgacctc tctgacttct ctctctccac caaggcagct tctctaccc tgacacagcc 720
ccagacccca caaagccttc tggacctgga aagcctgggg aaggactgac agaccccagg 780
accagccctg gggctcaggg cagccacccc gggccgctga ccgactgacc tctcctcacg 840
gagggccagc cccaaagccc cagggtggc ccgtttggga cagctgacca ataaactg 900
atggtgtgtt aaaaaaaaaa aa 922

```

<210> 109

<211> 985

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte Clone No: 2799575

<400> 109

```

gcccaggagg cgcgcgggtg aggcacgggt gcgcaagcga ggagttccgg ctggagaccc 60
gtgctctggg ccggcgcctt caccatggcc tcggcagagc tggactacac catcgagatc 120
ccgcatcagc cctgctggag ccagaagaac agccccagcc cagggtggga ggaggcagaa 180
actcggcagc ctgtggtgat tctcttgggc tgggggtggct gcaaggacaa gaaccttgcc 240
aagtacagt ccatctacca caaaaggggc tgcacgttaa tccgatacac agccccgtgg 300
cacatggtct tcttctccga gtcactgggt atcccttcac ttcgtgtttt ggcccagaag 360
ctgctcgagc tgctctttga ttatgagatt gagaaggagc cctgctctt ccattgtctc 420
agcaacgggt gcgtcatgct gtaccgctac gtgctggagc tctgacagac ccgtcgcttc 480
tgccgcctgc gtgtggtggg caccatcttt gacagcgctc ctggtgacag caacctggta 540
ggggctctgc gggccctggc agccatcctg gagcgccggg ccgcatgct gcgcctgttg 600
ctgctgggtg cctttgccc ggtggctgct ctgttccacg tctgcttgc tcccatcaca 660

```



```
gccctcttcc acaccactt ctatgacagg ctacaggacg cgggctctcg ctggcccgag 720
ctctacctct actcgagggc tgacgaagta gtcttgcca gagacataga acgcatggtg 780
gaggcacgcc tggcacgccg ggctctggcg cgttctgtgg atttcgtgtc atctgcacac 840
gtcagccacc tccgtgacta cctacttac tacacaagcc tctgtgtcga cttcatgcgc 900
aactgcgtcc gctgtgagg ccattgctcc atctcacctc tgctccagaa ataaatgcct 960
gacacctccc cacaaaaaaa aaaaaa 985
```

<210> 110

<211> 1562

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte Clone No: 2804955

<400> 110

```
tgctgccaga ggctggcatg ggcggggccg agtactgagc gcacggtcgg ggcacagcag 60
ggccgggtggg tgcagctggc tgcgcctcc tctccggccg ccgtctcctc cgggtcccg 120
cgaaagcatt gagacaccag ctggacgtca cgcgccggag catgtctggg agtcagagcg 180
aggtggctcc atccccgcag agtccgcgga gccccgagat gggacgggac ttgcgggccg 240
ggccccgcgt gctcctgtct ctgcttctgc tctgtctggg gtacctgact cagccaggca 300
atggcaacga gggcagcgct actggaagtt gttattgtgg taaaagaatt tcttccgact 360
ccccgccatc gggttcagttc atgaatcgct tccggaaaca cctgagagct taccatcggt 420
gtctatacta cacgaggttc cagctccttt cctggagcgt gtgtggaggc aacaaggacc 480
catgggttca ggaattgatg agctgtcttg atctcaaaga atgtggacat gcttactcgg 540
ggattgtggc ccaccagaag catttacttc ctaccagccc cccaatttct caggcctcag 600
agggggcatc ttcagatata cacacccttg cccagatgct cctgtccacc ttgcagtcca 660
ctcagcgccc caccctccca gtaggatcac tgtcctcgga caaagagctc actcgtccca 720
atgaaaccac cattcacact ggcggccaca gtctggcagc tgggcctgag gctggggaga 780
accagaagca gccggaaaaa aatgctggtc ccacagccag gacatcagcc acagtgccag 840
tctgtgcct cctggccatc atcttcatcc tcaccgcagc cctttcctat gtgctgtgca 900
agaggaggag ggggcagtca ccgcagtcct ctccagatct gccggttcat tatatacctg 960
tggcacctga ctctaatacc tgagccaaga atggaagttt gtgaggagac ggactctatg 1020
ttgcccaggc tgttatggaa ctctgagtc aagtgatect cccaccttgg cctctgaagg 1080
tgcgaggatt ataggcgtca cctaccacat ccagcctaca cgtatttgtt aatatctaac 1140
ataggactaa ccagccactg cctctcttta ggcccccat ttaaaaacgg ttatactata 1200
aaatctgctt ttcacactgg gtgataataa cttggacaaa ttctatgtgt attttgtttt 1260
gttttgcctt gctttgtttt gagacggagt ctgctctgt catccaggct ggagtgcagt 1320
ggcatgatct cggctcactg caacccccat ctcccagggt caagcgattc tcctgcctcc 1380
tctaagtag ctgggactac aggtgctcac caccacaccc ggctaatttt ttgtattttt 1440
agtagagacg ggttttcacc atgttgacca ggctggtctc gaactcctga cctggtgatc 1500
tgcccaccag gcctcccaaa gtgctgggat taaagggtgt agccacatgg ctggcctatg 1560
tt 1562
```

<210> 111

<211> 1851

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte Clone No: 2806395

<400> 111

```

gctctgcaga gtggtggccg gggccagggc cggggtgccc tccctcccac cttctccgc 60
catgagccag ggaagtccgg gggactgggc cccctagat cccaccccg gaccccccagc 120
atcccccaac cccttcgtgc atgagttaca tctctctcgc ctccagaggg ttaagttctg 180
cctctggggg gcattgctgg ccccatccg agtgcttctg gcctttatcg tctctttct 240
cctctggccc tttgcctggc ttcaagtggc cggcttagt gaggagcagc ttcaggagcc 300
aattacagga tggaggaaga ctgtgtgcca caacggggtg ctaggcctga gccgcctgct 360
gtttttctctg ctgggcttcc tccggattcg cgttcgtggc cagcgagcct ctgccttca 420
agccctgtc cttgttgtc cccacactc cactttctt gacccattg tctgtctgct 480
ctgtgacctg cccaaagtgt tgtcccgagc tgagaacctt tccgttctctg tcattggagc 540
ccttcttcga ttcaaccaag ccatcctggt atcccgcat gaccggctt ctgcagcgag 600
agtgggtggag gaggtccgaa ggcggggccac ctcaggaggc aagtggccgc aggtgctatt 660
ctttcctgag ggcacctgtt ccaacaagaa ggctttgctt aagttcaaac caggagcctt 720
catcgagggg gtgcctgtgc agcctgtcct catccgctac cccaacagtc tggacaccac 780
cagctgggca tggaggggtc ctggagtact caaagtcctc tggctcacag cctctcagcc 840
ctgcagcatt gtggatgtgg agttccttcc tgtgtatcac cccagcctg agggagcgag 900
ggacccacc ctctatgcca acaatgttca gaggtcatg gcacaggctc tgggcattcc 960
agccaccgaa tgtgagtttg tagggagctt acctgtgatt gtggtgggccc ggctgaaggt 1020
ggcggttgaa ccacagctct gggaaactggg aaaagtgtt cggaaggctg ggctgtccgc 1080
tggctatgtg gacgctgggg cagagccagg cggagtcga atgacagcc aggaagagtt 1140
tgccaggcag ctacagctct ctgacctca gacgggtggc ggtgcctttg gctacttcca 1200
gcaggatacc aagggttttg tggacttccg agatgtggcc cttgacttag cagctctgga 1260
tgggggcagg agcctggaag agctaactcg tctggccttt gagctctttg ctgaagagca 1320
agcagagggg cccaaccgcc tgcgtgacaa agacggcttc agcaccatcc tgcacctgct 1380
gctgggttca cccaccctg ctgccacagc tttgcatgct gagctgtgcc aggcaggatc 1440
cagccaaggc ctctccctct gtcagttcca gaacttctcc ctccatgacc cactctatgg 1500
gaaactcttc agcacctacc tgcgcccccc acacacctc cgaggcacct cccagacacc 1560
aaatgcctca tccccaggca accccactgc tctggccaat gggactgtgc aagcacccaa 1620
gcagaaggga gactgagtgc ctcagcctct caccctctcc tctcagggc agcgctaggg 1680
gcctcccta tgctcagcc ccatctctgc tctgtttga atttgttat tgtgttttg 1740
ttgttgtttt tttaagtga ttttaatttt ttgtttggtt gatTTTTTTTg taaaaaacta 1800
ttttatatat aaatataaat ctatatctat atctattaaa aaaaatgaat t 1851

```

<210> 112

<211> 992

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte Clone No: 2836858

<400> 112

```

ggcgcgaggc agtatggttt gaagtgggtga acatggattt ttctcggtt cacatgtaca 60
gtcctcccca gtgtgtgccc gagaacacgg gctacacgta tgcgctcagt tccagctatt 120
cttcagatgc tctggatttt gagacggagc acaaattgga cctgtattt gattctccac 180
ggatgtcccg ccgtagtttg cgcctggcca cgacagcatg caccctgggg gatggtgagg 240
ctgtgggtgc cgacagcggc accagcagcg ctgtctccct gaagaaccga gcggccagaa 300
caacaaaaca gcgcagaagc acaaacaaat cagcttttag tatcaaccac gtgtcaaggc 360
aggtcacgtc ctctggcgtc agccacggcg gcaactgtcag cctgcaggat gctgtgactc 420
gacggcctcc tgtattggac gactcttgga ttcgtgaaca gaccacagtg gaccattct 480
ggggtcttga tgatgatggt gatcttaaag gtggaaataa agctgccatt caggggaaacg 540
gggatgtggg agccgccgcc gccaccgcgc acaacggctt ctctgcagc aactgcagca 600
tgctgtccga gcgcaaggac gtgctcacgg cgcacccgcg ggccccggg cccgtgtcga 660
gagtttattc tagggacagg aatcaaaaat gtaagtctca gtcctttaaa actcagaaaa 720

```

```

agggtgtgttt tccaaattta atatttcctt tctgtaagtc tcagtgtctg cactatttgt 780
cttgggagact taaaattatc ccttgaaagc ataagaagta caccocaaac cagctttgtc 840
cttcctgtcc tcttctagtt tacattttat gtggttagta attttgtacc taaaagtatt 900

tgaaattcta taaatttgga cttgacgtga gcaaaaagaaa atttctacgt aagcgaaact 960
aataaaacta cagtcacttt caaaaaaaaa aa 992

```

```

<210> 113
<211> 1251
<212> DNA
<213> Homo sapiens

```

```

<220>
<221> misc_feature
<223> Incyte Clone No: 2844513

```

```

<400> 113
ctctgtctggc cgggtctaaag cggcagccgc cggggcgcaa tgcgagcggc tggcgtaggc 60
ttggtggact gtcactgcc a cctctccgcc cgggactttg accgcgattt ggatgatgtg 120
ttggagaaag ccaagaaggc caatgttgtg gcccttgttg cagttgccga acattcagga 180
gaatttgaaa agattatgca actttcagaa aggtataatg ggtttgtcct gccatgcttg 240
ggtgttcac cagttcaagg acttccacca gaagaccaa gaagtgtcac actaaaggat 300
ttggatgtag ctttgcccat tattgagaat tataaggatc gggtgttggc aattggagag 360
gttggactag atttctcccc cagatttgct ggcactgggtg aacagaagga agagcaaaga 420
caagtcctaa tcagacagat ccagttagcc aaaagactaa atttgcctgt aaatgtgcac 480
tcacgctctg ctggaagacc taccatcaac cttttacaag agcaagggtc tgagaaggta 540
ctgtctcatg catttgatgg tcggccatct gtagccatgg aaggagtaag agctgggtac 600
ttcttctcaa tcccccttc tatcataaga agtggacaga agcagaaact tgtgaaacaa 660
ttgcctttaa cttctatatg cttagaaaca gattcacctg cactaggacc agaaaaacag 720
gtacggaatg agccctggaa catttctatt tcagcagaat atattgcca ggtgaaaggg 780
atctcagtg aagaagttat agaagtgacg acacagaatg cattaaaact gtttcctaag 840
ctccgacact tgctccagaa atagcttcaa aaccatccat tacaaaatcg aatcaactgc 900
agggggcagc atttgaaaaa tagaaatgtt ctgatgaaga atctgaactg aagaagctgt 960
tttatagggt tatagaagat tgtaattgta gagaaatatt tctcttagaa ataaaactgg 1020
gcttggatcc tgaaaccctg gggtctgatt ctagccttgt gctgcttttc aattagccga 1080
gttctggcag gatattggga aaatactgct acttcttaca ttgccctttt atatagaacc 1140
accacctgaa ctgaaacat tgctactggg aagggtggct cccacaggaa gagtataagc 1200
actactgtga tgaggatgga gtaagctaaa gtatactttt tttttttttt g 1251

```

```

<210> 114
<211> 1397
<212> DNA
<213> Homo sapiens

```

```

<220>
<221> misc_feature
<223> Incyte Clone No: 3000380

```

```

<400> 114
ctaggacgcc cctggagccg gaaccccagc agaagccgga accagaacca aatcaccggc 60
accggctgca gccccctaaa ccaggaggc gccctggccc gcgctcgccc cccagggcct 120
catgtcggaa ccacagcctg acctggaacc gcccacacat gggctatata tgctcttcc 180
gcttgtgctg gtcttcttcc tcatgggcct ggtaggcttc atgatctgcc acgtgctcaa 240

```

```

gaagaagggc taccgctgcc gcaagctgag gggctctgag cctgaagatg cccagcttca 300
gccccctgag gacgatgaca tgaatgagga cacagtagag aggattgttc gctgcatcat 360
ccagaatgaa gtgtggatgc cacctccagc ctgcaggacg gagccccctc ccatcatcac 420
acagtgcacc tgggctctgc agccccctgc cgtccattgc agccgcagca agaggcctcc 480
acttgctcgt cagggacgct ccaaggaagg aaaaagccgc ccccgacag gggagaccac 540
tgtgttctct gtgggcaggt tccgggtgac acacattgag aagcgctatg gactgcacga 600
acaccgtgat ggctccccca cagacaggag ctggggctct cgtgggggac aggacccagg 660
gggtggtcag gggctctgggg gagggcaccc caaggcaggg atgctgccat ggagaggctg 720
ccccctgag aggccacagc cccaggtcct agccagcccc ccagtacaga atggaggact 780
cagggacagc agcctaacc ctcgtgcact tgaaggggaa cccagagctt ctgcagagcc 840
aacactgagg gccggaggga ggggcccagg cccagggtg cccactcaag aggcaaatgg 900
gcagccaagc aaaccagaca cttctgatca ccagggtgtc ctaccacagg gagcaggagg 960
tatgtgagtc tccctcattg tgctgatgga ctaccagctg gcaggggccag ggggtgggtg 1020
ggcgtgaaag cccctcccc cactggacag cactgcccc cagctgaggg accagctcta 1080
cttccacctg gagttgcaca gtctcaggct gggggcctca ggagagggtc cagccccctc 1140
gtctcttctc cttccccctg ctgcaacagg ctgcctgccc cgccttcccc aacacctcgc 1200
tccatatgat agagcgtggc agctgggagc agggccccct ccgtgggtggg ccctaaagc 1260
aatagcaccg taggccccct gccctcttag cacaagaggc ccaggccctg gcctggcctt 1320
cgtgcccttt attcattgtc aataaatccg ctcagaccat taaaaaatac aactcaaggg 1380
gtagccaaaa aaaaaaa
1397

```

<210> 115

<211> 1581

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte Clone No: 182532

<400> 115

```

acagcacagc tgacagccgt actcaggaag cttctggtat cctaggetta tctccacaga 60
ggagaacaca caagcagcag agaccatggg gccctctca gccctccct gcacacacct 120
catcaettgg aagggggtcc tgctcacagc atcactttta aacttctgga atccgcccac 180
aactgccccaa gtcacgattg aagcccagcc acccaaagt tctgagggga aggatgttct 240
tctacttgtc cacaatttgc cccagaatct tgctggctac atttggtaca aagggcaaat 300
gacatacgtc taccattaca ttatatcgta tatagttgat ggtaaaaataa ttatatatgg 360
gcctgcatac agtggaagag aaagagtata ttccaatgca tccctgctga tccagaatgt 420
cacgcaggag gatgcaggat cctacacctt acacatcata aagcgagggtg atgggactag 480
aggagaaact ggacatttca ccttcacctt atacctggag actcccaagc cctccatctc 540
cagcagcaac ttatacccca gggaggacat ggaggctgtg agcttaacct gtgatcctga 600
gactccggac gcaagctacc tgtggtggat gaatggctcag agcctcccta tgactcacag 660
cttgcaattg tccaaaaaca aaaggacctt ctttctatct ggtgtcaca agtacactgc 720
aggaccctat gaatgtgaaa tacggaacct agtgagtggc atccgcagtg acccagtcac 780
cctgaatgtc ctctatggtc cagacctccc cagcatttac ccttcattca cctattaccg 840
ttcaggagaa aacctctact tgctctgctt cgcagagtct aaccacggg cacaatattc 900
ttggacaatt aatgggaagt ttcagctatc aggacaaaag ctctttatcc cccaaattac 960
taciaaagcat agtgggctct atgcttgctc tgttcgtaac tcagccactg gcatggaaag 1020
ctccaaatcc atgacagtca aagtctctgc tcttcagga acaggacatc ttcctggcct 1080
taatccatta tagcagccgt gatgtcattt ctgtatttca ggaagactgg cagacagttg 1140
ctttcattct tccctcaaag atttaccatc agctacagtc caaaattgct ttttgttcaa 1200
ggagatttat gaaaagactc tgacaaggac tcttgaatac aagttcctga taacttcaag 1260
atcataccac tggactaaga actttcaaaa ttttaatgaa caggctgata ctcatgaaa 1320
ttcaagacaa agaaaaaac ccaattttat tggactaaat agtcaaaaca atgttttcat 1380
aattttctat ttgaaaatgt gctgattctt tgaatgtttt attctccaga tttatgcact 1440

```

```
ttttttcttc agcaattggt aaagtatact tttgtaaaca aaaattgaaa catttgcttt 1500
tgctccctaa gtgccccaga attgggaaac tattcatgag tattcatatg tttatggtaa 1560
taaagttatc tgcacaagtt c                                     1581
```

<210> 116

<211> 1566

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte Clone No: 239589

<400> 116

```
cggctcgagt atggatctcc aaggaagagg ggtccccagc atcgacagac ttcgagttct 60
cctgatgttg ttccatacaa tggctcaaat catggcagaa caagaagtgg aaaatctctc 120
aggcctttcc actaaccctg aaaaagatat atttgtggtg cgggaaaatg ggacgacgtg 180
tctcatggca gagtttgcag ccaaatttat tgtaccttat gatgtgtggg ccagcaacta 240
cgtagatctg atcacagaac aggccgatat cgcattgacc cggggagctg aggtgaaggg 300
ccgctgtggc cacagccagt cggagctgca agtgttctgg gtggatcgcg catatgcact 360
caaaatgctc tttgtaaagg aaagccacaa catgtccaag ggacctgagg cgacttggag 420
gctgagcaaa gtgcagtttg tctacgactc ctccgagaaa acccacttca aagacgcagt 480
cagtgcctgg aagcacacag ccaactcgca ccacctctct gccttgggtc ccccgctgg 540
gaagtcctat gagtgccaag ctcaacaaac catttccact gcctctagt atccgcagaa 600
gacggtcacc atgatcctgt ctgcgggtcca catccaacct tttgacatta tctcagattt 660
tgtcttcagt gaagagcata aatgcccagt ggatgagcgg gagcaactgg aagaaacctt 720
gcccctgatt ttggggctca tcttgggcct cgtcatcatg gtaacactcg cgattttacca 780
cgtccaccac aaaatgactg ccaaccaggt gcagatccct cgggacagat cccagtataa 840
gcacatgggc tagaggccgt taggcaggca cccctattc ctgctcccc aactggatca 900
ggtagaacia caaaagcact tttccatctt gtacacgaga tacaccaaca tagctacaat 960
caaacaggcc tgggtatctg aggcttgctt ggcttgtgtc catgcttaaa cccacggaag 1020
ggggagactc tttcggattt gtagggtgaa atggcaatta ttctctccat gctggggagg 1080
aggggaggag ggtctcagac agctttcgtg ctcatgggtg cttggctttg actctccaaa 1140
gagcaataaa tgccacttgg agctgtatct ggccccaaag tttagggtat gaaaacatgc 1200
ttctttgagg aggaaacccc tttagggtca gaagaatatg ggggtgcttg ctcccttgga 1260
cacagctggc ttatcctata cagttgtcaa tgcacacaga atacaacctc atgctccctg 1320
cagcaagacc cctgaaagtg attcatgctt ctggctggca ttctgcatgt ttagtgattg 1380
tcttgggaat gtttccactg taccgcacat cagcgactgc agcaccagaa aacgactaat 1440
gtaactatgc agagttgttt ggacttcttc ctgtgccagg tccaagtcgg gggacctgaa 1500
gaatcaatct gtgtgagttt gtttttcaaa atgaaataaa acacactatt ctctggcaaa 1560
aaaaaa                                     1566
```

<210> 117

<211> 1815

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte Clone No: 1671302

<400> 117

```

tttgtttctc ttattcccag gacatcaagg agactttcaa taggtgtgaa gaggtacagc 60
tgcagccccc agaggtctgg tcccctgacc cgtgccaaacc ccatagccat gacttcctga 120
cagatgccat cgtgaggaata atgagccgga tgttctgtca ggctgcgaga gtggacctga 180
cgctggaccc tgacacggct caccggcccc tgatgctgtc ccctgaccgc cgggggggtcc 240
gcctggcaga gcggcggcag gaggttgcctg accatcccaa gcgcttctcg gccgactgct 300
gcgtactggg ggcccagggtc ttccgctccg gccggcacta ctgggaggtg gaggtgggag 360
ggcggcgggg ctggggcggtg ggtgctgccc gtgaatcaac ccatcataag gaaaagggtg 420
gccctggggg ttccctcggtg ggcagcgggg atgccagctc ctgcgcgccat caccatcgcc 480
gccgcgggct ccacctgccc cagcagcccc tgcctcagcg ggaagtgtgg tgcgtgggca 540
ccaacggcaa acgctatcag gccagagct ccacagaaca gacgctgctg agccccagtg 600
agaaaccaag gcgcttttgt gtgtacctgg actatgaagc tgggcgcctg ggcttctaca 660
acgcagagac tctagcccac gtgcacacct tctcggctgc cttcctgggc gagcgtgtct 720
ttcctttctt ccgggtgctc tccaagggca ccgcacataa gctctgccct tgattatcct 780
gccaccgcga gggccctctc gtcagcactt ggggggtggg tgggtggaggg tggcccgtaa 840
gtttgagggc tcaaaggctc ttcccactgc ttgttactgt gttgcttccc actccccctt 900
gaccccaggc ccctgcttct cctctagga gccctaaagaa ccctcctggc ctccagctca 960
gccttctctc acctactatg tctgtccaac aggtctgcat gggctccctga taatgagaac 1020
agctgcctgg tcttctctcc cagtctgcct agcccagccc tgggactgga atttgagtag 1080
gggatgaggg gaaattgtaa ttctattcct taacttcctt ttcccacccc ctgctcttca 1140
acctctttat cagttctgag gctggagggt ttgggcaagg caacatcccc attccaattc 1200
cattttctga tgcagatttt agctgagggg tttggaagcc atttggggag gcaggctggg 1260
ccaaagggta gagctgggta ataatgtct attctcctgg ggaggaggga ttctaaactt 1320
tccttcctgc ctcaatttct acctccatag accggccaga atttagcttc acttgagaga 1380
gatctggaat ggtcgccatg attgaaacca cgcaccatta catcatcatt acattaatta 1440
catcaacata aattatttct tcccccttcc cttttccagc actcaaccaa ggagcaaaagc 1500
tcateccacc ccacaccctc cccaggctctg ctactgcca ggctcctctc ccctttgttc 1560
agtggagctg gcttttctcc cagccccctt ccactgcctt cactccattt ggcaagctct 1620
gagggggagc ctggggacgg gtttgggtcc ccaggaggag agccttgggt ataactctatt 1680
ttctagagag cctcttgctt gtgcacttgc agctttcgcc ctctgctttg atggctgagg 1740
tgaactcatg ttctttggga aaagggaagg cgtgctgtgg aaataaaatg tttatttgc 1800
tctctaaaaa aaaaa 1815

```

<210> 118

<211> 1566

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte Clone No: 2041858

<400> 118

```

caaagagcca ggctccagga gaggaagggc tctgcgagag gagagaggag agcgctggag 60
aggagaggct ggaggtgaga gtcccaggaa aggcagagga gaatcgtagg gacataagtg 120
tcccagcaca ggcaaggagg aatccgagga taaggttctg gagggacaga agggcccaga 180
gagagtcctt agccaggatg gaggtctgtg tgaacttgta ccaagagggtg atgaagcacg 240
cagatccccg gatccagggc taccctctga tgggggtccc cttgctaattg acctccattc 300
tctgaccta cgtgtacttc gttctctcac ttgggcctcg catcatggct aatcggaagc 360
ccttccagct ccgtggcttc atgattgtct acaacttctc actggtggca ctctccctct 420
acattgtcta tgagttcttg atgtcgggct ggctgagcac ctatacctgg cgctgtgacc 480
ctgtggacta ttccaacagc cctgaggcac ttaggatggg tcgggtggcc tggctcttcc 540
tcttctccaa gttcattgag ctgatggaca cagtgatctt tattctccga aagaaagacg 600
ggcaggtgac ctctctacat gtcttccatc actctgtgct tccctggagc tgggtgggtgg 660
gggtaaagat tgccccggga ggaatgggct ctttccatgc catgataaac tcttccgtgc 720
atgtcataat gtacctgtac tacggattat ctgcctttgg ccctgtggca caaccctacc 780

```

```

tttgggtggaa aaagcacatg acagccattc agctgatcca gtttgtcctg gtctcactgc 840
acatctccca gtactacttt atgtccagct gtaactacca gtaccagtc attattcacc 900
tcatctggat gtatggcacc atcttcttca tgctgttctc caacttctgg tatcactctt 960
ataccaaggg caagcggtg ccccggtgcac ttcagcaaaa tggagctcca ggtattgcca 1020
aggtcaaggg caactgagaa gcatggccta gataggcgcc cacctaagtg cctcaggact 1080
gcaccttagg gcagtgtccg tcagtgcctt ctccacctac acctgtgacc aaggcttatg 1140
tggtcaggac tgagcagggg actggccctc cctcccccac agctgctcta cagggaccac 1200
ggctttgggt cctcaccac tcccccggtg cagctccagg gatgtggcct cattgctgtc 1260
tgccactcca gagctggggg ctaaaagggc tgtacagtta tttccccctc cctgccttaa 1320
aacttgggag aggagcactc agggctggcc ccacaaaggg tctcgtggcc tttttcctca 1380
cacagaagag gtcagcaata atgtcactgt ggaccagtc tactcctcc accccacaca 1440
ctgaagcagt agcttcttggg ccaaaggcca ggggtggcg gggcctggga atacagcctg 1500
tggaggctgc ttactcaact tgtgtcttaa ttaaaagtga cagaggaaac cacggaaaaa 1560
aaaaaa

```

<210> 119

<211> 1055

<212> DNA

<213> Homo sapiens

<220>

<221>

<222> 1032, 1037, 1042

<223> a or g or c or t, unknown, or other

<220>

<221> misc_feature

<223> Incyte Clone No: 2198863

<400> 119

```

tcagcagcca gcaaggtctt tgagaaacac atggagctca ctgccttctt ccttttcagt 60
ggcttcccat tgccttggat aaagacccaa atgcctaaca gggcccataa ggccccacat 120
gatccacggg ctttagatgt gcagagatgt ggagcgcat gccaggtagg gtgagcagt 180
gcgtggagca gggccacttg gctgggggtg caggtgttgg aggggagcag cagcctgtcc 240
acatggccta aggtttgagc tgggtgttgc tgctgggccc ggcgagcgca gtgcagcgca 300
ccgcggggag cgaggagcgc gcggaccggc catgggcaag tcagcttcca aacagtttca 360
taatgaggtc ctgaaggccc acaatgagta ccggcagaag cagggcgtcc cccactgaa 420
gtcttgcaag aacctcaacc gggagggtca acagtattct gaggccttg ccagcacgag 480
gatcctcaag cacagcccgg agtccagccg tggccagtgt ggggagaacc ttgcatgggc 540
atcctatgat cagacaggaa aggaggtggc tgatagatgg tacagtgaat tcaagaacta 600
taacttccag cagcctggct tcacctggg gactggacac ttcacggcca tggatatgaa 660
gaacaccaag aagatgggcy tggggaaggc gtccgcaagt gacgggtcct cctttgtggt 720
ggccagatac tcccagcgg ggaatgttgt caatgaggc ttcttcgaag aaaacgtcct 780
gccgccgaag aagtaacttg ttaaagttaa tgggaagggt gcagacttaa gaacgtggat 840
atgaagtgcc tagaaccacc acaacctggc tgtgcgtctg tccctgtggg tgaatgtgct 900
tgtgtgtgtg atgcatgtga gcgtctctgg cacacacatt ggcatacagt tccgtgttct 960
ccatcttat tacaggagtg agcaaaggaa gcatttacc cgtatggttac ctgaccacg 1020
attaattgga tncctcngaa anggggatcg gtttt

```

<210> 120

<211> 1956

<212> DNA

<213> Homo sapiens

<220>

<221>

<222> 1893, 1896, 1899, 1906, 1911, 1921, 1926, 1927, 1928, 1929, 1932, 1935, 1940, 1948, 1950, 1951, 1953

<223> a or g or c or t, unknown, or other

<220>

<221> misc_feature

<223> Incyte Clone No: 3250703

<400> 120

```
cactcaagga agatataaat gacaaggctcg gctcagctct cagacaagggt ttccaagca 60
agatgaagcc caacatcatc tttgtacttt cctgctcct catcttgag aagcaagcag 120
ctgtgatggg acaaaaagggt ggatcaaaag gccgattacc aagtgaattt tcccaatttc 180
cacacggaca aaagggccag cactattctg gacaaaaagg caagcaacaa actgaatcca 240
aaggcagttt ttctattcaa tacacatata atgtagatgc caatgatcat gaccagtccc 300
gaaaaagtca gcaatatgat ttgaatgccc tacataagac gacaaaatca caacgacatc 360
taggtggaag tcaacaactg ctccataata aacaagaagg cagagaccat gataaatcaa 420
aagggtcattt tcacagggta gttatacacc ataaaggagg caaagctcat cgtgggacac 480
aaaatccttc tcaagatcag gggaatagcc catctggaaa gggaatatcc agtcaatatt 540
caaacacaga agaaaggctg tgggttcctg gactaagtaa agaacaaact tccgtctctg 600
gtgcacaaaa aggtagaaaa caaggcggat cccaaagcag ttatgttctc caaactgaag 660
agctagtagc taacaaacaa caacgtgaga ctaaaaattc tcatcaaaat aaagggcatt 720
accaaaatgt ggttgaagtg agagaggaac attcaagtaa agtacaacc tcactctgtc 780
ctgcgcacca agacaaactc caacatggat ccaaagacat ttttctacc caagatgagc 840
tcctagtata taacaagaat caacaccaga caaaaaatct caatcaagat caacagcatg 900
gccgaaaggc aaataaaaata tcataccaat cttcaagtac agaagaaaga cgactccact 960
atggagaaaa tgggtgtgcag aaagatgtat cccaaagcag tatttatagc caaactgaag 1020
agaaaataca tggcaagtct caaaaccagg taacaattca tagtcaagat caagagcatg 1080
gccataagga aaataaaaata tcataccaat cttcaagtac agaagaaaga catctcaact 1140
gtggagaaaa gggcatccag aaagggtgtat ccaaaggcag tatttcgatc caaactgaag 1200
agcaaatata tggcaagtct caaaaccagg taagaattcc tagtcaagct caagagtatg 1260
gccataagga aaataaaaata tcataccaat cttcgagtac agaagaaaga cgtctcaaca 1320
gtggagaaaa ggtgtgtacag aaagggtgtat ccaaaggcag tatttctatc caaactgaag 1380
agaaaataca tggcaagtct caaaaccagg taacaattcc tagtcaagat caagagcatg 1440
gccataagga aaataaaaatg tcataccaat cttcaagtac agaagaaaga cgactcaact 1500
atggaggaaa gagcacgcag aaagatgtat cccaaagcag tatttctttc caaattgaaa 1560
agctagtaga aggcaagtct caaatccaga caccaaatcc taatcaagat caatgggtctg 1620
gccaaaatgc aaaaggaaaag tctgggtcaat ctgcagatag caaacaagac ctactcagtc 1680
atgaacaaaa aggcagatac aaacaggaat ccagtgaagc acataatatt gtaattactg 1740
agcatgaggt tgcccaagat gatcatttga cacaacaata taatgaagac agaaatccaa 1800
tatctacata gccctgttgc ttagcaaccc attgaaaagc tggaccaata gcaagggtgtc 1860
accccgacct cagtgaagtta gggttcgttt gancngant aggaanggggt nccggaaggc 1920
naaaannnnt anttnagcnn ctggtgtntn nanacc 1956
```

<210> 121

<211> 1737

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte Clone No: 350287

<400> 121
gaaatacagt ggctcttttat taaaaataat agttggataa tataaaactga actattttatg 60
cattttttata tacttataaa tccttccaaa tagttttaat tctatccttt tacatataaaa 120
taactttaata agtgtgctgg aaaaacacag atgttcacag caccactggt tttttttttt 180
tttttttgaga taataaattc catgagaaat ctgggtttga atatttggtt actttgtctc 240
ctaattgaac accactccag gccttctgtc tgtctccctt ttaccccca aatattcaca 300
aaaaaaattt taagacaaca agtaaccata tatagggtgtt tgaatgattt tctcattttt 360
atctaatttc atttcataag tcccgagtaa tttacctacc atagggtact atactgataa 420
tataaatgaa accgaacatt ttttgctact aactctcccc aatttaaatgt gttttcgaaa 480
taaaaattta aatttttttc cttttaatta aaaagtcac tttgaagtcc ttattggctg 540
tacattttac atgtttgctg gtactattat tttgtcagt agttaagct ggcatgtaca 600
gctcttggt ttaatgaaaa gcacattgac ataatgttag taaattccaa accccggcac 660
agaatgtgag ttaaaattaa gtcttgctgg gttagtgtac aataaactat acctacagac 720
ttttttttaa tagaagaag acaaagctgc tggatatagga tttgttcctt tgaagaaaaa 780
atgagggaaa caaacacaaa aacctcaatg cagtgtataa ataacatttt gttcaactac 840
ctcttaatgt ggaattatct actttaatag tttcctgaca gtaatgttaa atagtaactg 900
ccaaatttgt tattttccca tctctcttaa aaaagtcttt atgattattt tatatagttt 960
tgagaacttt aaagccactt ttttttaacc ttacatttgc ataaaaatgt ttagctttta 1020
agtagagagc aaattatgat catatatatt gatattcatg acctgtttga ctataggatt 1080
ttttttaaaa aaatgcactt tggctataaa accatggatg atttgatcca taagatttaa 1140
atgtgccacc atttatagat tccatagacat gagcttgatg aatgggtattc tgtaattata 1200
acgtgccaca cattattgtg tcttaattgc ccttagcctg aattttaatg atcaatttgt 1260
tattgttgca gatgtgaata ttgtgcataa acttactaaa tttatgtaa attgtataaa 1320
atagaattag aagtcactaa gttctttctg tgtagaagta ataaatttat tgtaacacaa 1380
tgcagttgtg tatatgacat tctgtaattc cttgaactgg atcatatatt cataagttct 1440
gtagatactt atgcatgaac attttctcat ttagtcttg ggttcattat ttgtattgtg 1500
tttactactt gtgatcatgt agttgtgcct tactttgtga gaaagggttag cttagtaaat 1560
actgcaattt ctaaactcag tgattggaag gttattaatt ataaatgtaa ctgataaagt 1620
acgtgacagc atttaaatct gtataaagaa caatggaagg atccttattg aattgttgct 1680
tttttttaat atgtttaaat attatattaa aaacatttct ttctaaaaaa aaaaaa 1737

<210> 122

<211> 789

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte Clone No: 1618171

<400> 122

caagatataa agtagcagtt ggctaccta aatgaaaaga gcaatgttcc atggcacctg 60
aaatgttaaa aatattagaa actctcccca ccccatattc ctcccacccc aattgagctt 120
ctcgcaataa tcttctcgct tctctaacta gttgactttc attatggatg gggataggct 180
aaaaaacggg cccctgggat ggctgtgctg ccatcagtcg tgttggttta ctactcttt 240
ttctgtcttc gtttttgcac gctactgtc ctgccctctt acagccacag tagaagcgg 300
agaggcccg gaaggatagg ccatattact ctgatagatg tgatccatgt gtctgtgtac 360
tggtttttcg aagctttatc aacatttcaa atattttatt attgcatcac cagaactata 420
acagtggaaa aaggatagat tgtttctagg catgttaacg aagcaggtgt ttcctttgtg 480
tcctatcttt gcattaattt taaataacct tcaccacagc tacagttttt tttctgggct 540
ctatcagctt taatgcaacg gcagaagctt aagcaactgg tcatgagagg tcaagtgggt 600
tacttctgta tcccttccat gtacaagaga catccatttg attctcaaga gagccaaata 660
ggtcagcctc ttcagcgatt ctaaaagatt tcaagagcag aggcaggaag taggactggg 720
aatttagttc aattcattat ctgagggtgc cctaaggtag ggcaagttta aatttaactt 780
tgttctat

<210> 123
 <211> 1116
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte Clone No: 1625863

```
<400> 123
tttatatttg acaataaaagt gttagactcc atttctaaat accagacttc aaaagataag 60
gttcaaaaagt gttataagaa gatattcctt tttttgtcct agagaactta ttttctgtg 120
aaaatgccta ccacaaagaa gacattgatg ttcttatcaa gctttttcac cagccttggg 180
tccttcattg taatttgctc tattcttggg acacaagcat ggatcaccag tacaattgct 240
gttagagact ctgcttcaaa tgggagcatt ttcactactt acggactttt tcgtggggag 300
agtagtgaag aattgagtca cggacttgca gaaccaaaga aaaagtgtgc agtttttagag 360
atactgaata attcttccca aaaaactctg cattcggtga ctatcctgtt cctgggtcctg 420
agtttgatca cgtcgctgct gagctctggg ttacacctt acaacagcat cagcaaccct 480
taccagacat tcctggggcc gacgggggtg tacacctgga acgggctcgg tgcacacctc 540
gtttttgtga ccatagatact gtttgtggcg aacacgcagt ccaaccaact ctccgaagag 600
ttgttccaaa tgctttaccc ggcaaccacc agtaaaggaa cgaccacag ttacggatac 660
tcgttctggc tcatactgct cgtcattctt cttaatatag tcaactgtac catcatcatt 720
ttctaccaga aggccagata ccagcggaag caggagcaga gaaagccaat ggaatatgct 780
ccaagggacg gaattttatt ctgaattctc ttctatctca ttttggcgtt gcatctattg 840
tacatcagcc ctgagtagta actgggttagc ttctctggac aattcagcat ggtaacgtga 900
ctgtcatctg tgacagcatt tgtgtttcat gacactgtgt tcttcattga tgctgtactc 960
ctgaaaattt tccccacaag gttggggaaa tgaatgggaa atgtcgctgg tctgtgtggt 1020
attcaaagca gtagtatcat gatgagcgta acgaccttc tgacctggtc tcacgatctg 1080
aaataataaa aggctgtgct atgtttcttt tcaaaa 1116
```

<210> 124
 <211> 914
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte Clone No: 1638353

```
<400> 124
ggccaaccca cgggtggggg agcgcggcca tggcgctcct gctttcggtg ctgcgtgtac 60
tgctggggcg cttcttcgct ctcggtgggt tggccaagct ctcgaggag atctcggtc 120
cagtttcgga gcggtgaat gccctgttcg tgcagtttgc tgaggtgttc ccgctgaagg 180
tatttggtta ccagccagat cccctgaact accaaatagc tgtgggcttt ctggaactgc 240
tggctggggt gctgctgggc atgggcccac cgatgctgca agagatcagt aactgttct 300
tgattctgct catgatggg gctatcttca ccttggcagc tctgaaagag tctaagca 360
cctgtatccc agccattgtc tgcctggggg tcctgctgct gctgaatgtc ggccagctct 420
tagcccagac taagaagggt gtcagaccca ctaggaagaa gactctaagt acattcaagg 480
aatcctggaa gtagagcatc tctgtctctt tatgccatgc agctgtcaca gcaggaacat 540
ggtagaacac agagtctatc atcttggtac cagtataata tccagggtca gccagtgtg 600
aaagagacat tttgtctacc tggcactgct ttctcttttt agctttacta ctcttttgtg 660
```

```

aggagtacat gttatgcata ttaacattcc tcatgtcata tgaaaatata aaataagcag 720
aaaagaaatt taaatcaacc aaaattctga tgccccaat aaccactttt aatgccttgg 780
tgtaagtata cctctgaact tttttctgtg cctttaaaca gatatatatt ttttttaaat 840
gaaaataaaa ccatatatcc tattttattt cctcctttta aaaccttata aactataaca 900
ctgtaaaaaa aaaa                                     914

```

<210> 125

<211> 2016

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte Clone No: 1726843

<400> 125

```

gctgcctgct gcctccgcag cgcccccca gctctccctg tgctaactgc ctgcaccttg 60
gacagagcgg gtgcgcaaat cagaaggatt agttgggacc tgcccttggcg accccatggc 120
atcccccaga accgtaacta ttgtggccct ctcatgtggc ctgggactct tctttgtttt 180
catggggact atcaagctga cccccagget cagcaaggat gcctacagtg agatgaaacg 240
tgcttacaag agctatgttc gagccctccc tctgtgaag aaaatgggga tcaattccat 300
tctcctccga aaaagcattg gtgcccctga agtggcctgt ggcacgtca tgacccttgt 360
gcctggggcg cccaaagatg tggccaactt cttcctactg ttgctggtgt tggctgtgct 420
cttcttccac cagctggctg gtgatcctct caaacgctac gcccatgctc tgggtgtttg 480
aatcctgctc acttgccgcc tgctgattgc tcgcaagccc gaagaccggt cttctgagaa 540
gaagcctttg ccagggaatg ctgaggagca accctcctta tatgagaagg cccctcaggg 600
caaagtgaag gtgtcataga aaagtggag tgcaaagagt ggaccttcca ggcagtgtgcg 660
tccatgacac caggaagatg tcagtgtgtg tttttcattt gatttattta tcttggggaa 720
agtgaanaat gtaatctgca agttaatgac cctattggct tgtgtacatc tatatgctaa 780
aatgacttcc ccacattgac atttgtgctc cactctttaa cactctgggg caactctcac 840
atcttgcctc atgtacatgt atacggctac tattgaagtg taattgtgag atggactcca 900
acaagcatgt gactgtgaga ttgtgtgtgg gaaaatgtat ttaactactc tgtgtgtgtg 960
tgtgtgtgtg tgtgtgcgcg cgcgcgcacg cgcacacact cagcacaca caagcagaga 1020
aggcgtgat cttgaactaa tcctgcacag gcacccctcc ctttatagat tgattccagc 1080
aaaggcggaa taaaacaaat ttctatgaa gagaatcctg atatgaaaca agtcatgtag 1140
tctcatggcc gggaatctct ccacagatac taacaactta aacttactac tttaggagaa 1200
aaaaaaaaac attcaatttc ggacactgag ttatatatga aattaattag gctctagtcc 1260
aacagttgtt tacattttta atagtcata ttgaatttaa ttaaaacaag gcatgcatgc 1320
agtcaaatgt atagttaaat tcttcaagtg ataatatgga agtttcacct tgcctttgtc 1380
caagccccac ctattaaaaa cctttactca cagtttgaaa ctgaagcagt aaacttgttt 1440
ccagacatct ttttcagatt gtcttaagcc caaagttgcc tcacttccac tattctcagc 1500
agccaaccag gatitggcag ctgctccact gttacggttg agggaaacagg gatcagtcct 1560
gttagaagtc tgtgagcctc aaactctacc tgttctctgc aatcatccaa aatttgaaaa 1620
agaagctata tccagtgttt cactgccaaa cagattcact actcttactg attcttact 1680
gagctttgct agtataagca gagttccaag tctcccctag ggttgtctct acattttctt 1740
atcattccag tgggtagggg ttagctgggg gaaggacatt tcataagggg tagttggact 1800
gagcagtatg gacatttgct tttttcatta cgtactgttg tttttccttg ttaggtgtgc 1860
tttgggtggt ttaatatatt tgtgccagg atggggaaat gggggggggt gtgtgggaa 1920
agtacttatt attgtgtttt cttcagtgtg attgttcttg gtaattgata cctctctgtt 1980
ttatttctct cattctttca aaataaaact ttttgt                                     2016

```

<210> 126

<211> 2067

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte Clone No: 1754506

<400> 126

```
tgcctccttta agcgctccaca ggcgggcggac ggccacaatc acagctccgg gcattggggg 60
aacccgagcc ggctgcgccg ggggaatccg tgcggggccc ttccgtcccg gtcccaccc 120
cgccgcgcctc cagcacctct gaagttttgc agcgcccaga aaggaggcga ggaaggagg 180
agtgtgtgag aggaggggagc aaaaagctca ccctaaaaca tttatttcaa ggagaaaaga 240
aaaagggggg gcgcaaaaat ggctggggcga attatagaaa acatgagcac caagaagctg 300
tgcattgttg gtgggattct gctcgtgttc caaatcatcg cttttctggt gggaggcttg 360
attgctccag ggcccacaac ggcagtgtcc tacatgtcgg tgaaatgtgt ggatgcccg 420
aagaaccatc acaagacaaa atggttcgtg ccttggggac ccaatcattg tgacaagatc 480
cgagacattg aagaggcaat tccaagggaa attgaagcca atgacatcgt gttttctgtt 540
cacattcccc tccccacat ggagatgagt ccttgggttc aattcatgct gtttatcctg 600
cagctggaca ttgccttcaa gctaaacaac caaatcagag aaaatgcaga agtctccatg 660
gacgtttccc tggcttaccg tgatgacgcg tttgctgagt ggactgaaat ggcccataaa 720
agagtaccac ggaaactcaa atgcaccttc acatctccca agactccaga gcatgagggc 780
cgttactatg aatgtgatgt ccttccttct atggaaattg ggtctgtggc ccataagttt 840
taccttttaa acatccggct gcctgtgaat gagaagaaga aaatcaatgt ggggaattggg 900
gagataaagg atatccggtt ggtggggatc caccaaaatg gaggcttcac caaggtgtgg 960
tttgccatga agaccttct tacgcccagc atcttcatca ttatggtgtg gtattggagg 1020
aggatcacca tgatgtcccg acccccagtg cttctggaaa aagtcattct tgcccttggg 1080
atttccatga cttttatcaa tatcccagtg gaatggtttt ccatcgggtt tgactggacc 1140
tggatgctgc tgtttgtgga catccgacag ggcattctct atgcgatgct tctgtccttc 1200
tggatcatct tctgtggcga gcacatgatg gatcagcacg agcggaacca catcgaggg 1260
tattggaagc aagtcggacc cattgcggtt ggctccttct gcctcttcat atttgacatg 1320
tgtgagagag ggttacaact caggaatccc ttctacagta tctggactac agacattgga 1380
acagagctgg ccattggcct catcatcgtg gctggaatct gcctctgcct ctacttctctg 1440
tttctatgct tcatggtatt tcaggtgttt cggaacatca gtgggaagca gtccagcctg 1500
ccagctatga gcaaagtccg gcggctacac tatgaggggc taatttttag gttcaagttc 1560
ctcatgctta tcaccttggc ctgcgctgcc atgactgtca tcttcttcat cgttagtcag 1620
gtaacggaag gccattggaa atggggcggc gtcacagtc aagtgaacag tgcccttttc 1680
acaggcatct atgggatgtg gaatctgtat gtctttgtc tgatgttctt gtatgcacca 1740
tcccataaaa actatggaga agaccagtc aatggaatgc aactcccatg taaatcgagg 1800
gaagattgtg ctttgtttgt ttcggaactt tatcaagaat tgttcagcgc ttcgaaatat 1860
tccttcatca atgacaacgc agcttctggt atttgagtca acaaggcaac acatgtttat 1920
cagctttgca tttgcagttg tcacagtcac attgattgta cttgtatacg cacacaaata 1980
cactcattta gcctttatct caaaatgtta aatataagga aaaaagcgtc aacaataaat 2040
attctttgag tattgaaaaa aaaaaaa 2067
```

<210> 127

<211> 2180

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte Clone No: 1831378

<400> 127

```
gcgaacgtct gcacctggcg ggcgatgacg cccgatgcgg gcgccccggg atagcgtggg 60
```

```

cgaggctgcg gggccccggc ggcacgccc gcacctctcc ccagccctgg cgtggggccca 120
gcccggccca ggcagcaatg gggttcctgc agctgctggt cgtagcgggt ctggcatccg 180
aacaccgggt ggctgggtgca gccgaggtct tcgggaattc cagcgagggt cttattgaat 240
tttctgtggg gaaatttaga tacttcgagc tcaataggcc cttccagag gaagctattt 300
tgcatgatat ttcaagcaat gtgacttttc ttattttcca aatacactca cagtatcaga 360
atacaactgt ttctttttct ccgactctcc ttccaattc ctcggaaca ggcactgcca 420
gtggactggt ttctatcctt agaccagagc agagtacatg cacttgggtac ttggggactt 480
caggcataca gcctgtccag aatatggcta tcctactctc ctactcagaa agagatcctg 540
tccctggagg ctgtaatttg gagttcgatt tagatattga tcccaacatt tacttggagt 600
ataattttct tgaaacgact atcaagtttg cccagcaaaa cctaggctat gcgagaggcg 660
tagatcccc accatgtgac gctgggacag accaggactc cagggtggagg ttgcagtatg 720
atgtctatca gtattttctg cctgagaatg acctcactga ggagatgttg ctgaagcatc 780
tgacagaggat ggctcagtgtg ccccagggtga aggccagtgc tctcaagggt gttaccctaa 840
cagctaata gaagacaagt gtttccttct cctccctccc gggacaagggt gtcatatata 900
atgtcattgt ttgggacccg tttctaaata catctgtgct ctacattcct gctcacacat 960
acgcttgtag ctttgaggca ggagagggtg gttgtgcttc cctaggaaga gtgtcttcca 1020
aagtgttctt cactcttttt gccctgcttg gtttcttcat ttgtttcttt ggacacagat 1080
tctggaaaac agaattatct ttcataggct ttatcatcat gggattcttc ttttatatac 1140
tgattacaag actgacacct atcaagtatg atgtgaatct gattctgaca gctgtcactg 1200
gaagcgtcgg tggaaatgttc ttggtagctg tgtgggtggc atttggaatc ctctcgatct 1260
gcatgctctg tgttgacta gtgctggggc tcctcatctc gtcagtgact ttctttactc 1320
cactgggaaa cctaaagatt tttcatgatg atggtgtatt ctgggtcact ttctcttgca 1380
tagctatcct cattccagta gttttcatgg gctgcctaag aatactgaac atactgactt 1440
gtggagtcat tggtcctcat tcggtggttt tagccattga cagttactgg tccacaagcc 1500
tttctacat cactttgaac gtactcaaga gagcgctcaa caaggatttc cacagagctt 1560
tcacaaatgt gccttttcaa actaatgact tcattatcct ggcagtatgg ggcagtctgg 1620
ctgtaagtgg aattacgtta cagattcgaa gagagagagg acgaccgttc ttccctcccc 1680
accatacaa gttatggaag caagagagag agcgccgagt gacaaacatt ctggacccta 1740
gctaccacat tcctccattg agagagaggc tctatggccg attaaccag attaaagggc 1800
tcttcagaa ggagcagcca gctggagaga gaacgccttt gcttctgtag atgcccaggg 1860
gcttggtcag tgtgcctcag ctttgagggt catgcctgga gtgggttcaac agtctctggt 1920
gcaagtctaa taagagatca ggcataatata tctgttcttt gcataatatt atgggtgccct 1980
tattgatata tggtaagggt gtactagggg attaggatga ttgtaagaga atgagaaaga 2040
tgacaaaaag gttggtggta gggagggttt ttcttatttc caaatacttg agaaattacc 2100
ttttggttta caaatctatg atcaacttat tccattaaat agatacatta aaaaaattaa 2160
aaactgaaaa aaaaaaaaaa

```

<210> 128

<211> 991

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte Clone No: 1864943

<400> 128

```

cacggtgtca gcaggcaaca tggccgagag gcggggcctc cgggcccgcg cgtgtccgcg 60
accggtacc ctgacacccc cgcggaattc cctccgcacc tcaggcggg tgcgatgcg 120
cgccgtttt gggcggtatt caactgtctg tgcgcggcg cgttcggggc cctggccgcc 180
gcctccgcca agctggcctt cggcagcgag gtgagcatgg gtttatgcgt cttaggcatt 240
attgtgatgg cgagcaccaa ttctctgatg tggacctct ttagccgggg cctcagtttc 300
tccatgtctt cagccattgc atctgtcaca gtgactttt caaatatcct cagctcggcc 360
ttcctgggct atgtgctgta tggagagtgc caggaggtct tgtgggtggg aggagtgttc 420
cttattctct gcggactcac cctaataccac aggaagctcc caccacctg gaagccctt 480

```

```

ccacacaagc agcagtagca ccacttggt agacggacca gctggaaaga tcatgatggt 540
ggcccagcct tgggatgtca tgtgggactg tgtcctaggg cgatccagtt gtgcagcctt 600
ctgaccatca gccaaaggaa gcaggcctct gatggagcag gctctggctc tgtaaggaga 660
ggtgcagctg cagcagtgtt ctaccggaag tgttttgatc atctgtacag tgctttggat 720
tcttctctcc aggcctaccc cagtgaacct tgcagatgc tggagatcct ggggttggtc 780
tgcttttgtt atggtacttg aaaccacgct gtaattattg tcctgttgcc aaacaaaagc 840
cagtcatgta actctagaag cagtgaactgg tggggctttc tgacagtcc atgctgatgt 900
atcaggccat ctgtgtcatg cttatgtatt atggcaagaa gaggaaaact ggattaataa 960
atacgttttt ttgtaagtta aaaaaaaaaa a 991

```

<210> 129

<211> 637

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte Clone No: 1911316

<400> 129

```

ggagggcggt gctccgcgc ggtggcggtt gctatcgctt cgcagaacct actcaggcag 60
ccagctgaga agagttgagg gaaagtgctg ctgctgggtc tgcagacgcg atggataacg 120
tgcagccgaa aataaaacat cgcccttct gcttcagtgt gaaaggccac gtgaagatgc 180
tgcggtggc actaactgtg acatctatga ccttttttat catcgcaaa gccctgaac 240
catatattgt tatcactgga tttgaagtca ccgttatctt atttttcata cttttatatg 300
tactcagact tgatcgatta atgaagtggg tttttggcc tttgcttgat attatcaact 360
cactggtaac aacagtattc atgctcatcg tatctgtgtt ggcactgata ccagaaacca 420
caacattgac agttggtgga ggggtgtttg cactgttgac agcagtatgc tgtcttgccg 480
acggggccct tatttaccgg aagcttctgt tcaatcccag cggtccttac cagaaaaagc 540
ctgtgcatga aaaaaaagaa gttttgtaat tttatattac tttttagttt gataactaagt 600
attaaacata tttctgtatt cttccaaaaa aaaaaaa 637

```

<210> 130

<211> 2631

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte Clone No: 1943120

<400> 130

```

ctctcttctt gcagtgtggt aaaactacag caatcgctctt aacctgtgag atctgtcacc 60
tttgcatttt cactcatgc agctggttct ataaaccaac tcttctgctt ggggggatct 120
aatcatgacc ttttaccctt ttgtggctc ttctagtaca aggcgagtgg ataattccaa 180
cacaagactg gcagtccaaa ttgaaagaga tccagggaaat gatgacaaca atctcaattc 240
cattttttat gaacacttga caaggacct cctggagtcc ctctgtggag acttagttct 300
tggacgttgg ggcaactaca gctctggcga ttgctttatt ttggcttcag atgacctcaa 360
tgcctttgtt cacctgattg aaattggaaa tggcttctgt acctttcaac ttcgaggact 420
ggaattccga ggaacctact gccagcagag ggaggtagaa gccatcatgg agggcgacga 480
ggaggacaga ggctgctgct gctgcaaacc aggccacttg cctcacctgc tgtcccgcaa 540

```

```

cgctgccttt cacctccgct ggctcacctg ggaaatcacg cagaccagct acatcctgga 600
gggctacagc atcctggaca acaacgcggc caccatgctg caggtggttg acctccgaag 660
gacccctcatc cgctactaca tcaagagtat aatatactat atggtaacgt ctcccaaact 720
cctctcctgg atcaaaaatg aatcacttct gaagtccctg cagccctttg ccaagtggca 780
ttacattgag cgtgaccttg caatgttcaa cattaacatt gatgatgact acgtcccgtg 840
tctccagggg atcacacgag ctagcttctg caatgtttat ctagaatgga ttcaacactg 900
tgcacggaaa agacaagagc cttcaacgac cctggacagt gacgaggact ctcccttggg 960
gactctgtcc ttgcctctgt gcacctggg gaggagagct ctgggaacag ccgctcacia 1020
tatggccatc agcctggatt ctttctgtga tggcctccat gtctcttca aaggtgactt 1080
cagaataaca gcacgtgacg agtgggtatt tgctgacatg gacctactgc ataaagtgtg 1140
agctccagct atcaggatgt ccctgaaact tcaccaggac cagttcactt gccttgacga 1200
gtatgaagac ccagcagtc tctacgaggc catccagtc ttcgagaaga aggtggctat 1260
ctgccacgag ggcgacccgg cctggcgggg cgcagtgtg tccaacaagg aagagctgct 1320
caccctgcgg cacgtggtgg acgaggggtg cgacgagta aaggtcatca tgctccacag 1380
aagcttctct agcttcaagg tgatcaaggt taacaaagaa tgcgtccgag gactttgggc 1440
cgggcagcag caggagctta tatttctctg caaccgcaat ccggagcgcg gcagtatcca 1500
gaacaataag caggtoctgc ggaacttgat taactcctcc tgcgatcagc ccttggggta 1560
ccccatgtat gtctccccac taaccacatc ctacctaggg acacacaggc agctgaagaa 1620
catctggggg ggacccatca ctttggacag aattaggacc tggttctgga ccaagtgggt 1680
aaggatgcgg aaggattgca atgcccgcga gcacagtggc ggcaacattg aagacgtgga 1740
cggaggaggg gccccgacga caggtggcaa caatgccccg aatggtggca gccaggagag 1800
cagcgcagaa cagcccagaa aaggcgggtg tcagcacggg gtgtcatcct gtgaagggac 1860
acagagaaca ggcaggagga aaggcaggag ccagtccgtg caggcacact cagcgctaag 1920
ccaaaggccg cccatgctga gctcatctgg ccccatctta gagagccgcc aaacattcct 1980
ccagacgtcc acctcagtgc acgagctggc ccagaggtc tcgggcagcc ggctctcctt 2040
gcacgcctcg gccacgtccc tgcactctca gccccgcgc gtcaccacca ccggccacct 2100
gagtgctcgt gagcgggccc aggcgctcat cagggtccagc ctgggctcct ccaccagctc 2160
caccctgagc ttctctctcg gcaagaggag cttttccagc gcgctcgtca tttccggact 2220
ctctgctcgc gaggggggca ataccagtga ccccagtc tccagcagcg tcaacatcgt 2280
gatgggcccc tcagccaggg ctgccagcca ggccactcgg gtaaggggct gggcagggct 2340
caccaggaca ggctgggatg gtggcacggg ctctggcct gagcgtggca cctgccttgc 2400
gttcccaccc ttctgcctgc agaaccocat ccccttctct atggggctcc cagagtga 2460
aaggacagtg attagacacg aagtggctta gctgctcttg aaagcagaca agatacagag 2520
cagatatcct gtaaaccgata atgcccaggc aggcactgaa aggagtcacc ggatacagag 2580
gttctgcaga actgtggcca tctgccctac accggggcat gacggagaat g 2631

```

<210> 131

<211> 646

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte Clone No: 2314236

<400> 131

```

tacatttact aaaatgatgt aataaataac atgttaatag actcaagctt taccttatga 60
aattgatgta tttttaccag ttatttctaa tgtaacattg aatatataag atctgacaaa 120
tgtatgttta aacatgaatt agaagagttg agaactacca ttatgtatag ggattctcat 180
agtgtcttgg cccttaattg gaaagtgtg gcaactttaa agtacttttt actgtatgtt 240
ataattcttt ataacttaga gagagacaat ggtcactcaa actatgagaa ctatgaatta 300
ggagataaaa gtttaaatgt gttgttgttt tataacagta tgtacaagtt agttttccct 360
tatatattta cgttttcaag ttttttaatc tcatcatata catccatact ctataaaatg 420
ttttatattc aaagaactgt aaaatcctaa acattagttt tcactattga aattgttttt 480
taaagatagg cataaatagt tgtccttaga cttattcata caaatatagt catttacttc 540

```

tatgtagttt gagattctga gagttattcc aactttatga agattgattt caatgtgcct 600
gctaagtcct aaaagattca gaaagaaaat ttatatatta ttgatt 646

<210> 132

<211> 541

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte Clone No: 2479409

<400> 132

ttcacatttt ttggtttgat cttggtgtca tttaggtaat gaatctatcc aagaaatcta 60
tccttttgac ccaggttatc aaattttagt acataagggt atttataatg gtcccttctt 120
acccttttaa tgtcttttagg agctgtgttg ataatttctt tttcattatg atactggtaa 180
tttctgttct cacttttcta atcagggttg gtaggggttt atcagtttta ctgatctgac 240
tttttatttt attttatttt ttttgagaca gtcttacact gtctcccagg ctggagtga 300
gtggcgcgat ctcggttac tgcaagctct gccttcggg ttcattgcat tctcctgcct 360
cagcctcccc agtagctggg actacaggct cccacaacac gcccggttaa ttttttaaat 420
tcttagtgga gactggggtt caccggggtt accaagaatg gctcggatct ctttaacccc 480
ggggtccacc cgcttcagcc tcccaaaagt gctggggatt acaggggtga gcaccgggcc 540
c 541

<210> 133

<211> 1922

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte Clone No: 2683149

<400> 133

tggcctccga tccacctgga cacctggagg ctaagcctgg attccccctt ccctgactca 60
ggaactgctt aacgtctaca gcaaggccta ataggggacc tgagggcaca gtccctcagga 120
tgtttcgggg agaataggag ccagaacctg agcccctaag ccattccccct caccaatgat 180
ggggtcccca gtgagtcac tgctggccgg cttctgtgtg tgggtcgtct tgggctgggt 240
agggggctca gtccccaacc tgggccctgc tgagcaggag cagaaccatt acctggccca 300
gctgtttggc ctgtacggcg agaatgggac gctgactgca gggggcttgg cgcggtctct 360
ccacagcctg gggctaggcc gagttcaggg gcttcgcctg ggacagcatg ggctctgac 420
tggacgggct gcatccccag ctgcagacaa ttccacacac aggccacaga acctgagct 480
gagtgtggat gtctgggcag ggatgcctct ggggtccctca ggggtggggtg acctggaaga 540
gtcaaaggcc cctcacctac cccgtgggcc agccccctcg ggctggacc tgcctcacag 600
gcttctgttg ctggaccact cattggctga ccacctgaat gaggattgtc tgaacggctc 660
ccagctgctg gtcaattttg gcttgagccc cgctgtctct ctgaccctc gtcagtttgc 720
tctgtgtgct ccagccctgc tttatcagat cgacagccgc gtctgcatcg gcgctccggc 780
ccctgcaccc ccaggggatc tactatctgc cctgcttcag agtgccttgg cagtcctgtt 840
gctcagctc ccttctcccc tatccctgct gctgtgcgg ctcctgggac ctgctctact 900
acggcccttg ctgggcttcc tgggggccct ggcggtgggc actctttgtg gggatgcact 960
gctacatctg ctaccgcatg cacaagaagg gcggcacgca ggacctggcg gactaccaga 1020
gaaggacctg gggccggggc tgtcagtgtc cggaggcctc ttctgtctct ttgtgtgga 1080
gaacatgctg gggcttttgc ggcaccgagg gctcaggcca agatgctgca ggcgaaaacg 1140


```

aaggaatctc gaaacacgca acttggatcc ggagaatggc agtgggatgg cccttcagcc 1200
cctacaggca gctccagagc caggggctca gggccagagg gagaagaaca gccagcacc 1260
accagctctg gcccctcctg ggcaccaagg ccacagtcat gggcaccagg gtggcactga 1320
tatcacgtgg atggctcctc tgggagatgg tctacacaac ctactgatg ggctggccat 1380
aggtgctgcc ttctctgatg gcttctccag cggcctcagt accaccttag cggctcttctg 1440
ccatgagctg cccacgaac tgggtgactt tgccatgctg ctccagtcag ggctgtcctt 1500
tcggcggctg ctgctgctga gctcgtgtc tggagccctg ggattggggg gtgcagtcct 1560
gggggtgggg ctcagcctgg gccctgtccc cctcactccc tgggtgtttg gggtcactgc 1620
tggggctctc ctctatgtgg cccttgtgga catgctacca gccctgcttc gtccctccga 1680
gcccctgect acgccccatg tgctcctgca ggggctgggg ctgctgctgg gggcggcct 1740
catgcttgcc ataaccctgc tggaggagcg gctactgccc gtgaccactg agggctgatg 1800
gggccagtgg aaaggggtcg ggttgccctt ccttcccccc aaccacagga atggaggcgg 1860
gacacagggc cagtagggagc aataggattt taataaacag aaccatccc aaaaaaaaaa 1920
aa 1922

```

<210> 134

<211> 840

<212> DNA

<213> Homo sapiens

<220>

<221>

<222> 814

<223> a or g or c or t, unknown, or other

<220>

<221> misc_feature

<223> Incyte Clone No: 2774051

<400> 134

```

ggtaattcgt actgggtcatc ttctctgggt gtgagtcaaa tataagttaa acaattagct 60
ctgaaaacat tccattgagc tggggaatgc aacagtctta ttacctcatc atggaattct 120
ctagcttagt taatttaaatt attgtttctt agtttctggg tcaattaaat ttaaattgatg 180
tagtttatgc ttcgtgaacca attaaattac taggttatta caaaaaaaat tatcatcttt 240
tttgattaaa gagctgtggg tacagtatat ttataagca attttcatta gttcaaaaat 300
gttcctttag gctagattaa gcagccattc attgttagag cctggagacc ttattcgaag 360
gtgttcacg tattcacagt gcaactattc ttagaactaa agccaattga acctacttag 420
caatagcgtt atgcctttca cccttgatga ttatggagct tatagctctc agaaaacaata 480
cacctgtcag tttccatcaa ctatagcaat ccatgcagaa gacaagaggc cccctcaaag 540
caggaggggt attgttttag gtccaatttt tcttattggt ctcaaaatca ttataagggtg 600
gacagtgttt tgtgaagatt ttcttttccc cagctctaag aaaccatgtg gaaagaattc 660
attgataact gttttgatth ttcttttttt ttaagtacag gttttgctaa gtaatcacc 720
ttagttagcc tgtgtagttc agctgcctgt gagatgtttg gtgaccagct cagtgggtatc 780
ttgtattcct gatagagaat atttcagggg acanagtgtc ctttcagaca gactcaaata 840

```

<210> 135

<211> 1344

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte Clone No: 2869038

<400> 135

```

gcaaattgat ctaaaagcca ctaataaatt ctagggtttg agtctagaag ccaagcaaac 60
tgtcaccaat gtcagttgta aattagaatg caacatgagg ctccagactc atgacaatga 120
tatacatgaa aacaaaaata taattgtgtc taccttccta ctttcccttt tgacatatgt 180
agttggaatt ttacatagtc ttaaaatcca tatttagaat cttacctgtt tctataataa 240
ttagtaaaat gccaaagtag tgatagaata ttgtggcatt gaagtagccg aaaaattgtt 300
agtttttagc tcaaaaaagt aaatagatgt tgaaatgaat ttttgtatgt gccaggttga 360
agagagtgtg ccagtgcacg gaagtagtct aaaaaattaa cagttatggt ttaatatgga 420
tctgaaaagc aatctttaaa gaaatgggag aaattggggg tatcagtga cctataccaa 480
cctctctttg tacataaata tgggtgatgt gctagatata aaaatcagtg tcttactggc 540
accatttaca gtttagaaaa caatcttttt cttaaaaatg cccatctgat ttctattttt 600
aggagctact tggatttgta tgtatttttt ctacgtgaaa atatatgtac tcttcacttt 660
tgttccagta ctataattgc tcatgcactc tttctccctt ttgagaacat tcagtgaat 720
acaacttcat caaagatttg ctcaaaggag aagaatcgca tgagtgtgaa aagtagatgc 780
tcgtagccag aacagaaaag gttacacatg atcatggcac agaagatagg aggtttgact 840
tgggtggcca taatgtttat tatccttttt gaaataacag ggaccagcag cagttttctc 900
aggataaatg ctctacccca cttctctatg aacagggtgtg gggaggctta ctttccattt 960
tcatatttat acacctctct acaaaagcaa tttttaatga aggttagtgg aattgttaaa 1020
aatctgagag gaatgatgac tggaggtgtt tggggttttt ttctgtattc atttttaaa 1080
gagaaaagtt ttaaattgtg tacaggttag acccaactac taccttacta ttataggacg 1140
attctatggt tctgttaaag tattcaagta gctttctctg ggggaaaaag taccacttgg 1200
acacttaaaag gaattgggat ttttgtctac tttggataag gcagttgact tcttaagtaa 1260
aagcaatagt gtaaaatgtc attttgtttg gaatgttaag tgagcaaata aaaaacatgt 1320
tgaaattgtt gtaaaaaaaa aaaa 1344

```

<210> 136

<211> 443

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte Clone No: 2918334

<400> 136

```

ctcgagattt tttatattta tgcatgccat ttagtttgct cctaaaaata gtgatactgg 60
ttttagtttt ttacttacta aatcagtata gccaaatgtc catcttccta tgggtaatat 120
gcatcagaa tttctgagat tatttatgtg actatttttg gaaaagtttc ttttgataaa 180
acatggattt attatatgaa attcttcttg cactgtatta caatatatgc tatgatatcc 240
cttttatttt tttcaactta aatatgatgt tttatattgt tttagactta cgaatcgtgt 300
ttttcagaac cataaggga tctctatctc ctccctcact ttccttttac atatatgaa 360
aagtctatga aattcaagtc tagcatttga attctctatg ctatcattgc atttacctaa 420
ttatttactt ttaaatttta ggg 443

```

<210> 137

<211> 467

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte Clone No: 2949916

```

<400> 137
gccatttaag gagatctgtt ttgcttgaat attctgactg tcagtcgcga gacatagggg 60
gtgtgtgagt gtgagtgtgt accaagatga ggaggataat caggctccgg ctccgttttt 120
ctgacacttt tatggctgcc tttcttctgt gcctgggctt cgttctcatg ctctttccct 180
cgttgttcgc ggatgggtggc agcatcagca gctgcagaaa ctcttgttca tctcctagct 240
ccgaggagcg tcatttctcc aacttggaat aaaagcccat cctctacctg attgggccac 300
tcagatcaag ggcttaacac tagcaacagt tgctaaggca ctgctagata ccgattagct 360
gaagcctggg tgtctgaacc aatcattgcc aagggggcgg gacttgcccc atccctggaa 420
ctatgaatgt ctcagccctt tgagatcacc tgggcgtgga agaaagt 467

```

```

<210> 138
<211> 902
<212> DNA
<213> Homo sapiens

```

```

<220>
<221> misc_feature
<223> Incyte Clone No: 2989375

```

```

<400> 138
cactgcactc cagtctaggt gacagagaag gactcgtctc aaaaaataaa aataaataaa 60
aaggaagcaa ggctaatacat cagtatgtgc ttgttacaag agctatgatg aaggcactcc 120
ttcagattta accaaatgag atcatctctg tcatgtgcct cacgcctcac agggactcca 180
tgtgtgaaga ttcccccttc actcaccaga tcatctccat ggcaacagct tgcagcctgc 240
tcttggagtg ctttgttttg gcagcttctc tgctagtttg tgtatggagt gaatggagga 300
ggtaaatacca cagattaaga atatgctgtc aggagtcagg cagccaaggt cagaagccag 360
ctctgcttct cagtgccttc tctttacaac acaggacttt gcaaggaaca tataattctg 420
tgactagcgc catcttgaaa atgttgaaac tgaagtagag atgagagatc ttacgtctgc 480
ctacccagtg agatacgagg aaggtcaagg gaaaaaaaaat tccaagctct tctttatctg 540
ctataggaaa tgaacattca attttttgca tgcaacgaca agaggtcaag gaccccagaa 600
gccagcccg c tacttccaag ttgagagccc ctggtcatac cctccagttg agctcagatt 660
tgtcacaat ttaccctct cctttccttc cattcccat gacctgcaga gagagatgtc 720
agataccttc ctcttggcct cccatgggca tccataagaa acttacttga agcaagaagc 780
ccagtatagg tgtctgggca gttggacatt tctctagcc agatctgtcc gaatagagcc 840
atctgggtac atgacgcaga gggcatttga taaataactg gaaaagtcaa taaatctttg 900
tc

```

```

<210> 139
<211> 1332
<212> DNA
<213> Homo sapiens

```

```

<220>
<221> misc_feature
<223> Incyte Clone No: 3316764

```

```

<400> 139
cgcagatgtg ccttctctgg ttggttgagat gctgactcta cagcactccc gctgtgcctc 60
agcagtgagc tgggtgtaaa ggcaggaggg ttgctggggg ctgacacttc cctgccctcc 120
tccaggaggg acacatctgg ggctctatga ggaggacagc ttcatcctg ggctctggac 180
ttctctcatt tgtggccttc tggaaactcag tgacatggca tcttcagaga ttttgggggtg 240
cttctggcta cttttggcaa gccagtgagg agaggctgct gactacattt gaagggaagg 300
agtggatcct cttctttata ggtgccatcc aagtgccttg tctcttcttc tggagcttca 360

```

```

atgggcttct attggtgggt gacacaacag gaaaacctaa cttcatctct cgctaccgaa 420
ttcaggtcgg caagaatgaa cctgtggatc ctgtgaaact gcgccagtct atccgcacag 480
ttcttttcaa ccagtgcatg atatctttcc ccattggtgg cttcctctat cccttctca 540
aatggtggag agacccctgc cgccgtgagc taccacctt ccactggttc ctctgggagc 600
tggccatctt cacgctgacg gaggaagtct tgttctacta ttcacaccgg ctcttcacc 660
acccaacatt ctacaagaaa atccacaaga aacaccatga gtggacagct cccattggcg 720
tgatctctct ctatgccac cctatagagc atgcagtctc caacatgcta ccggtgatag 780
tgggcccatt agtaatgggc tcccacttgt cctccatcac catgtggttt tccttggccc 840
tcatcatcac caccatctcc cactgtggct accaccttcc cttcctgcct tcgctgaat 900
tccacgacta ccaccatctc aagttcaacc agtgctatgg ggtgctgggt gtgctggacc 960
acctccatgg gactgacacc atgttcaagc agaccaaggc ctacgagaga catgtcctcc 1020
tgctgggctt caccgcgctc tctgagagca tcccagactc cccaaagagg atggagttag 1080
agacagccta agtgtcatcc tggctgtccc tcagccatgg gatgcagaca cggcttcctg 1140
attgcaccta acaatttgcc tcttcggcc acacgcccta atgatggcac caccagggtg 1200
gagggaaagg cggttcccg gaaaagcagg gccaaaggatg aggctttctt caaactactg 1260
cccttgatgt cctcaatgg gatcaggagt tagcttaaaa aaaaaaaaaa acaactgcgg 1320
ccgcaagctt at                                     1332

```

<210> 140

<211> 1252

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte Clone No: 3359559

<400> 140

```

gtgaggaagg tagctttagt gaaaacaggg tttggagttg aacctatacg gttcaaat 60
cgacttccgt ccaccaccga gacctgcgct ccctgagga ctcgctttcc catccgcgaa 120
accaggacgg cgccgcctac accccgcggc gttcggggcg ggctgaatgg gtcgctgagt 180
aggggctaca cccacgccct tcgctccccg ccccgccac ggagcgacgg ccacggcagt 240
gtccccaaagg caccgaaacc gaggcggggg tctcggtccc tccgcgcaag gagggaggcg 300
gaccgtacgt ggcaggactc accgccccg acgtggcagg actcaccgcc ccgcgcgctg 360
ttctccgagc catggcgcca gcgctgtggc gggcctgcaa cggactcatg gccgccttct 420
tcgcgctggc ggccttggtg caggtaaatg acccagatgc agaggtgtgg gtggtgggtg 480
acacaatccc tgcagtactg accctgcttg ttggacttaa cctgaagtc acaggtaatg 540
ttatttggaa aagtatctct gcaatacaca tactcttttg tacggtgtgg gctgttggct 600
tggcgctcta cctcttgcct cgtacacaac agaactctt acatgaggaa gaaggcaggg 660
agctgtctgg tctgggtgatt attacagcat ggattatcct gtgccacagt tcctcaaaaga 720
atccagttgg tggagaat caattggcta ttgccattgt aatcacactt tcccattta 780
tctcatgggt ctacatatat attaacaagg aaatgcggct ctttggcca actcactgca 840
agacagtaat ttaaataaat tcaagaactt cgtttttaa atgaatatt tcaatcaatt 900
ttttataaac attaggggaa caagccagga gtttatttca ggtaatttgg gctaattagt 960
ttaaactcc aaataacttt ttaagggtgc atataattcg atgtaagatt ggatgggaca 1020
agtaagagat ggtctgatat tttccagacg actttctgca gggctcttgtg tcataatgta 1080
gtggaaaagg ctagagaata gaagttaaaa aatacgagtt ctaacttaac tttgtacta 1140
tgtaatttgg gcaaatatat aaacctctg gtggatatat atctataaaa taggattaat 1200
gccagagtgt acttacttac acagtaacaa ggatcaatct agataatgta tg 1252

```

<210> 141

<211> 721

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte Clone No: 4289208

<400> 141

```
ggagactgca ttcctgccc tgaaggaatg tatttctaag gcaaataaggc aacttggtac 60
tatcttattc tgagtagaga gtggagaaag tattttcaga ctgaagaaaa ctttgaaaag 120
tcaggagcta agctgctcgg agctcagtgc cgcagcatgg ctgtggtgga cgcgggaaac 180
aacgggaaaag ttcttgacag agtctgtgtc cgctcagtc ctgcactttt cctttccaaa 240
tgcatctcgt tggatatgga atagatcgta gatgtttag actgagattt gggactatgt 300
tgggaccgta caggtgaatg tgccacctcc acaaattggct tctccgagt agtcacgtca 360
cctggtgcgt ggaggtggag ctgctgctgg agtaaggctt gctgtgggac gccctcgtac 420
tttgctcccc ttgcgggtgg ttgccgacct gagagcattg ggatcctccc ccgactgggtg 480
gctaagtttg tctgtcccc gggtggctgg ggaaaggggg gttgtgggtt cgggaaaaaa 540
aagttccggg gaaattcctc ctggcaaaat tccggttggg tcacattggg aacctgggta 600
acctaaattt gggtaaaagg ggtcccta attcgcctt gggaaattcg tgggggggtt 660
ccccaaggaa cccctcggga gtcccagggg ggagaaattt gaagagcccc tttcgaaatg 720
g 721
```

<210> 142

<211> 1704

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte Clone No: 2454013

<400> 142

```
cgcttcgcgc taacgcttgc gatggttgaa tccccctcct cagccagcc taggagaaga 60
agttcgtagt cccagaggtg aggcaggagg cggcagtttc tggcgggtga gggcggagct 120
gaagtgcacg cggaggcgga agcaacgggtc ggtggggcgg agaagggggc tggccccagg 180
aggaggagga aacccttccg agaaaacagc aacaagctga gctgctgtga cagaggggaa 240
caagatggcg gcgcgaagg ggagcctctg ggtgaggacc caactggggc tccgcgcgct 300
gctgctgctg accatggcct tggccggagg ttccgggacc gcttcggctg aagcatttga 360
ctcggctctg ggtgatacgg cgtcttgcca cgggctctgt cagttgacct accccttgca 420
cacctacctt aaggaagagg agttgtacgc atgtcagaga ggttcaggc tgttttcaat 480
ttgtcagttt gtggatgatg gaattgactt aaatcgaact aaattggaat gtgaatctgc 540
atgtacagaa gcatattccc aatctgatga gcaatatgct tgccatcttg gttgccagaa 600
tcagctgcca ttcgctgaac tgagacaaga acaacttatg tccttgatgc caaaaatgca 660
cctactcttt cctctaactc tggtagggtc attctggagt gacatgatgg actccgcaca 720
gagcttcata acctcttcat ggacttttta tcttcaagcc gatgacggaa aaatagttat 780
attccagttc aagccagaaa tccagtagc accacatttg gagcaggagc ctacaaattt 840
gagagaatca tctctaagca aaatgtccta tctgcaaatt agaaattcac aagcgcacag 900
gaattttctt gaagatggag aaagtgatgg ctttttaaga tgctctctc ttaactctgg 960
gtggatttta actacaactc ttgtctctc ggtgatggta ttgcttggga tttgttgtgc 1020
aactgttgct acagctgtgg agcagtatgt tccctctgag aagctgagta tctatgggtga 1080
cttgaggttt atgaatgaac aaaagctaaa cagatatcca gcttctctc ttgtggttgt 1140
tagatctaaa actgaagatc atgaagaagc agggcctcta cctacaaaag tgaatcttgc 1200
tcattctgaa atttaagcat tttcttttta aaagacaagt gtaatagaca tctaaaattc 1260
cactcctcat agagctttta aaatgggttc attggatata ggccttaaga aatcactata 1320
aaatgcaaat aaagtactc aaatctgtga agactgtatt tgctataact ttattggtat 1380
```

```

tggtttttgta gtaattttaag aggtgggatgt ttggggattgt attattattt tactaatatc 1440
tgtagctatt ttgtttttttg ctttgggttat tggtttttttc cctttttctta gctatgagct 1500
gatcattgct ccttctcacc tcttgccatg atactgtcag ttaccttagt taacaagctg 1560
aatattttagt agaaatgatg cttctgctca ggaatggccc acaaactctgt aatttgaaat 1620
ttagcaggaa atgaccttta atgacactac attttcagga actgaaatca ttaaaatttt 1680
atttgaataa ttaaaaaaaaa aaaa 1704

```

<210> 143

<211> 964

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte Clone No: 2454048

<400> 143

```

cagacagcgg cgggcgcagg acgtgcacta tggctcgggg ctcgctgcgc cggttgctgc 60
ggctcctcgt gctggggctc tggctggcgt tgctgcgctc cgtggccggg gagcaagcgc 120
caggcacgcg cccctgctcc cgcggcagct cctggagcgc ggacctggac aagtgcattg 180
actgcgcgtc ttgcagggcg cgaccgcaca ggaacttctg cctgggctgc gctgcagcac 240
ctcctgcccc ctcccgctg ctttggccca tcttggggg cgtctgagc ctgaccttcg 300
tgctgggggt gctttctggc tttttggtct ggagacgatg ccgcaggaga gagaagtcca 360
ccacccccat agaggagacc ggcggagagg gctgccagc tgtggcgctg atccagtgc 420
aatgtgcccc ctgccagcgg gggctcgcgc actcatcatt cattcatcca ttctagagcc 480
agtctctgcc tcccagacgc ggcgggagcc aagctcctcc aaccacaagg ggggtggggg 540
gcggtgaatc acctctgagg cctgggcccc ggggttcagg gaaccttcca aggtgtctgg 600
ttgccctgcc tctggctcca gaacagaaag ggagcctcac gctggctcac acaaaacagc 660
tgacactgac taaggaactg cagcatttgc acaggggagg ggggtgccct ccttcctaga 720
ggccctgggg gccaggctga cttggggggg agacttgaca ctaggcccca ctactcaga 780
tgctctgaaa ttccaccag ggggtcaccc tgggggggta gggacctatt tttaacacta 840
gggggctggc ccactaggag ggctggccct aagatacaga ccccccaac tccccaaagc 900
ggggaggaga tattttattt ggggagagtt tggaggggag ggagaattta ttaataaaag 960
aatc 964

```

<210> 144

<211> 1564

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte Clone No: 2479282

<400> 144

```

ggaattgtgg gagttgtgtc tgccactcgg ctgccggagg ccgaaggctc ctgactatgg 60
ctccccagag cctgccttca tctaggatgg ctccctctgg catgctgctt gggctgctga 120
tggcgcgctg cttcaccttc tgccctcagtc atcagaacct gaaggagttt gccctgacca 180
acccagagaa gagcagcacc aaagaaacag agagaaaaga aaccaaagcc gaggaggagc 240
tggatgccga agtcctggag gtgttccacc cgacgcagta gtggcaggcc cttcagccag 300
ggcaggctgt ccctgcagga tcccacgtac ggctgaatct tcagactggg gaaagagagg 360
caaaactcca atatgaggac aagttccgaa ataatttgaa aggcataagg ctggatatca 420
acaccaaacac ctacacatct caggatctca agagtgcact ggcaaaattc aaggaggggg 480

```

```

cagagatgga gagttcaaag gaagacaagg caaggcaggc tgaggtaaag cggctcttcc 540
gccccattga ggaactgaag aaagactttg atgagctgaa tggtgtcatt gagactgaca 600
tgcagatcat ggtacggctg atcaacaagt tcaatagttc cagctccagt ttggaagaga 660
agattgctgc gctctttgat cttgaatatt atgtccatca gatggacaat gcgcaggacc 720
tgctttcctt tgggtggtctt caagtgggtga tcaatgggct gaacagcaca gagccctcgc 780
tgaaggagta tgctgcgttt gtgctgggcg ctgccttttc cagcaacccc aaggctccagg 840
tggaggccat cgaaggggga gccctgcaga agctgctggg catcctggcc acggagcagc 900
cgctcactgc aaagaagaag gtccctgtttg cactgtgctc cctgctgcgc cacttcccct 960
atgcccagcg gcagttcctg aagctcgggg ggctgcaggc cctgaggacc ctggtgcagg 1020
agaagggcac ggaggtgctc gccgtgcgcg tggtcacact gctctacgac ctggtcacgg 1080
agaagatggt cgcgaggag gaggtgagc tgaccagga gatgtcccca gagaagctgc 1140
agcagtatcg ccaggtacac ctctgcccag gcctgtggga acagggctgg tgcgagatca 1200
cggccacact cctggcgctg cccgagcatg atgcccgta gaaggctgct cagacactgg 1260
gcgtcctcct gaccacctgc cgggaccgct accgtcagga ccccagctc ggcaggacac 1320
tggccagcct gcaggctgag taccaggtgc tggccagcct ggagctgcag gatggtgagg 1380
acgagggcta ctccaggag ctgctgggct ctgtcaacag cttgctgaag gagctgagat 1440
gaggccccac accaggactg gactgggatg ccgctagtga ggctgagggg tgccagcgtg 1500
ggtgggcttc tcaggcagga ggacatcttg gcagtgtctg cttggccatt aaatggaaac 1560
ctgg

```

<210> 145

<211> 1385

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte Clone No: 2483432

<400> 145

```

gtccgccccg cgctgcgtcc cggagtgcaa gtgagcttct cggctgcccc gcggggccggg 60
gtgcccagcc gacatgcgcc cgcttctcgg cctccttctg gtcttcgccg gctgcacctt 120
cgcttctgtac ttgctgtcga cgcgactgcc ccgcggggcg agactgggct ccaccgagga 180
ggctggaggc aggtcgctgt ggttccccct cgacctggca gagctgcggg agctctctga 240
ggctccttca gagtaccgga aggagcacca ggctacgtg ttctgctctt tctgcggcgc 300
ctacctctac aaacagggtt ttgccatccc cggctccagc ttctgaatg ttttagctgg 360
tgcttgtttt gggccatggc tggggcttct gctgtgctgt gtgttgacct cggtggtgtg 420
cacatgctgc tacctgctct ccagtatttt tggcaaacag ttggtggtgt cctactttcc 480
tgataaagtg gccctgctgc agagaaaggt ggaggagaac agaaacagct tgtttttttt 540
cttattgttt ttgagacttt tccccatgac accaaactgg ttcttgaacc tctcgcccc 600
aattctgaac attcccatcg tgcagttctt cttctcagtt cttatcggtt tgatcccata 660
taatttcatc tgtgtgcaga cagggtccat cctgtcaacc ctaacctctc tggatgctct 720
tttctcctgg gacactgtct ttaagctgtt ggccattgcc atggtggcat taattcctgg 780
aaccctcatt aaaaaattta gtcagaaaca tctgcaattg aatgaaacaa gtactgctaa 840
tcatatacac agtagaaaag acacatgac tggattttct gtttgccaca tccctggact 900
cagttgctta tttgtgtaat ggatgtggtc ctctaaagcc cctcattgtt tttgattgcc 960
ttctataggt gatgtggaca ctgtgcatca atgtgcagtg tcttttcaga aaggacactc 1020
tgctcttgaa ggtgtattac atcaggtttt caaacagcc ctggtgtagc agacactgca 1080
acagactgct cctagaaaat gctgtttgtg gccgggcgcg gtggctcacg cctgtaatcc 1140
cagcactttg ggaggccgag gccgggtgatt cacaaggcca ggagttcaag accagcctgg 1200
ccaagatggt gaaatcctgt ctctaataaa aatacaaaaa ttagccaggc gtggtggcag 1260
gcacctgtaa tcccagctac tcgggaggct gaggcaggag aattgcttga accaagggtg 1320
cagaggttgc agtaagccaa gatcacacca ctgcactcca gcctgggtga tagagtgaga 1380
ccaca

```

<210> 146
 <211> 2031
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte Clone No: 2493824

<400> 146
 tgggcgggggg cccacggcgg ccactcactg agccccacgg gccgcagcgg cagtgcgta 60
 ggggttggcg acggatccgt tgcggctgca gctctgcagt cgggcccgttc cttcgccgcc 120
 gccaggggta gcggtgtagc tgcgcagcgt cgcgcgcgct accgcaccca gggttcggccc 180
 ataggcgtct ggcagcccgg cgccatcttc atcgagcggc atggccgcag cctgcggggcc 240
 gggagcggcc gggtaactgct tgctcctcgg cttgcatttg tttctgctga ccgcggggccc 300
 tgccctgggc tggaacgacc ctgacagaat gttgctgcgg gatgtaaaag ctcttaccct 360
 ccactatgac cgctatacca cctcccgcag gctggatccc atcccacagt tgaaatgtgt 420
 tggagggcaca gctgggtgtg attcttatac cccaaaagtc atacagtgtc agaacaaagg 480
 ctgggatggg tatgatgtac agtgggaatg taagacggac ttagatattg catacaaatt 540
 tggaaaaaact gtggtgagct gtgaaggcta tgagtcctct gaagaccagt atgtactaag 600
 aggtttcttgt ggcttggagt ataatttaga ttatacagaa cttggcctgc agaaactgaa 660
 ggagtctgga aagcagcacg gctttgcctc tttctctgat tattattata agtggtcctc 720
 ggcggattcc tgtaacatga gtggattgat taccatcgtg gtactccttg ggatcgccct 780
 tgtagtctat aagctgttcc tgagtgcagg gcagtattct cctccaccgt actctgagta 840
 tcctccattt tcccaccgtt accagagatt caccaactca gcaggacctc ctcccccagg 900
 ctttaagtct gagttcacag gaccacagaa tactggccat ggtgcaactt ctgggttttgg 960
 cagtgccttt acaggacaac aaggatatga aaattcagga ccagggttct ggacaggctt 1020
 gggaaactggg ggaatactag gatatttgtt tggcagcaat agagcggcaa cacccttctc 1080
 agactcgtgg tactaccgtt cctatcctcc ctccaccct ggacagtgga atagggctta 1140
 ctacaccctt catggaggct cgggcagcta ttcggtatgt tcaaaactcag acacgaaaac 1200
 cagaactgca tcaggatatg gtggtaccag gagacgataa agtagaaaagt tggagtcaaa 1260
 cactggatgc agaaattttg gatttttcat cactttctct ttagaaaaaa agtactacct 1320
 gttaacaatt gggaaaagg gatattcaaa agttctgtgg tgttatgtcc agtgtagctt 1380
 tttgtattct attatttgag gctaaaagtt gatgtgtgac aaaatactta tgtgttgat 1440
 gtcagtgtaa catgcagatg tatattgcag tttttgaaag tgatcattac tgtggaatgc 1500
 taaaaataca ttaatttcta aaacctgtga tgccctaaga agcatttaaga atgaagggtg 1560
 tgtactaata gaaactaagt acagaaaatt tcagtttttag gtggtttag ctgatgagtt 1620
 attacctcat agagactata atattctatt tggattata ttatttgatg tttgctgttc 1680
 ttcaaacatt taaatcaagc tttggactaa ttatgctaatt ttgtgagttc tgatcacttt 1740
 tgagctctga agctttgaat cattcagtggt tggagatggc cttctggtaa ctgaatatta 1800
 ccttctgtag gaaaagggtg aaaataagca ctgagaagg tgtgtggaat gactctgtgc 1860
 tggcaaaaat gcttgaaacc tctatatctt tttcgttcat aagaggtaaa ggtcaaattt 1920
 ttcaacaaaa gtcttttaat aacaaaagca tgcagttctc tgtgaaatct caaatattgt 1980
 tgtaatagtc tgtttcaatc ttaaaaagaa tcaataaaaa caaaaaaaaa a 2031

<210> 147
 <211> 1790
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte Clone No: 2555823

<400> 147

```

gcgggaggac cggctgaccc tggatggtga ggccgggtgc ccgcctgtgc ctggggagtg 60
tggggagggg gctgtgcctg gtgctcccc tgccttgcct cggtgcaggt ttccctctcc 120
tgaacacgct cttcatccag cgcggccggc acgagaccac ctggaccatc ctgcggcgct 180
tcggctacag cgatgccctg gagctgactg cggactatct ctcccctctg atccacgtgc 240
ccccggctg cagcacggag ctcaaccacc ttggctacca gtttgtgcag agagtgtttg 300
agaagcacga ccaggaccgc gacggcgccc tctcgcccggt ggagctgcaa agccttttca 360
gtgtgttccc agcagcgccc tggggccccg agctcccacg cacagtccgc acagaggccg 420
gccggttgcc cctgcacgga tacctctgcc agtggaacct ggtgacctac ctggacgtcc 480
ggagctgcct tggacaccta ggctacctgg gctaccccc cctctgtgag caggaccagg 540
cccatgccat cacagtcaact cgtgagaaga ggctggacca ggagaaggga cagacgcagc 600
ggagcgtcct cctgtgcaag gtggtagggg cccgtggagt gggcaagtct gccttctctg 660
aggcctttct cggccgcggc ctggggcacc aggcacagag ggagcagcct cccggctacg 720
ccatcgacac ggtgcaggtc aatggacagg agaagtactt gatcctctgt gaggtgggca 780
cagatggtct gctggccaca tcgctggacg ccacctgtga cgttgccctg ttgatgtttg 840
atggcagtga cccaaagtcc tttgcacatt gtgccagcgt ctacaagcac cattacatgg 900
acgggcagac cccctgcctc tttgtctcct ccaaggccga cctgcccga gggtgcgcgg 960
tgtctggccc atcaccggcc gagttttgcc gcaagcaccg gctaccgct cccgtgccgt 1020
tctcctgtgc tggcccagcc gagcccagca ccacctctt caccagctc gccaccatgg 1080
ccgccttccc acatttggtc cagcgagagc tgcattccctc ttccttctgg ctccgggggc 1140
tgctgggggt tgcggggcc gccgtggccg cagtccctcag cttctcactc tacagggtcc 1200
tggtgaagag ccagtgaggc cctggtacc caagccccct cccctgacct ggggtgtgct 1260
cgctgctggg gctctgcagg ggcagcacag ctggggtgca ggccaggctg ccactccggg 1320
aacgcctttg cgcgggact ttttgtttct gaaggcagtc gatctgcagc ggggccttat 1380
gctgccatgc actgccctgg ctccctgccg acccccaggg tgggcccgtg cagggtggctg 1440
agcaggagct cccaagtgcc ggccaccgct gtcagggatt gcccaccctt gggcatcatg 1500
tgtgtggggc cggggagcac aggtgtggga gctggtgacc ccagaccag aattctcagg 1560
gctctacccc ccttctctgg tcctaggtgg ccagtgggta tgaggagggc tggaaggcag 1620
agctttgggc caaaagcagg cgttgggggg tccccctca agtttgagc cgtttccgtg 1680
gttgtagcag aggaccggag gttgggttcc tgattaaact tcaactgtgt ttttctatct 1740
cggatcccag tctctgaaga caacttgctt tgattcaacc taacaaaaaa 1790

```

<210> 148

<211> 1979

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte Clone No: 2598242

<400> 148

```

ctactcctca ctggccggga caactggtct tatcacggag gctggggcca ggcagccctt 60
cggttcgggt gggcccattg accccagtc aacgccgagg gaataggacc atccaaaagc 120
ggaaccttcg cctcagaaaa agggtgcggg acccctctc accgtgcggt cagcgtgga 180
cctgccagc agccaggcca tggagctctc tgatgtcacc ctcatgagg gtgtgggtaa 240
tgagggtgat gtggtggcag gtgtggtggt gctgattcta gccttggtc tagcttggct 300
ctctacctac gtagcagaca gcggtagcaa ccagctcctg ggcgctattg tgcagcagg 360
cgacacatcc gtccctccacc tggggcatgt ggaccacctg gtggcaggcc aaggcaacct 420
cgagccaact gaactcccc atccatcaga gggtaatgat gagaaggctg aagaggcggg 480
tgaaaggtcg ggagactcca ctggggaggc tggagctggg ggtggtgttg agcccagcct 540
tgagcatctc cttgacatcc aaggcctgcc caaaagacaa gcagggtgcag gcagcagcag 600
tccagaggcc cccctgagat ctgaggatag cacctgcctc cctcccagcc ctggcctcat 660
cactgtgcgg ctcaaattcc tcaatgatac cgaggagctg gctgtggcta ggccagagga 720
taccgtgggt gccctgaaga gcaaatactt ccctggacaa gaaagccaga tgaaactgat 780

```

```

ctaccagggc cgccctgctac aagaccacgc ccgcacactg cgttctctga acattaccga 840
caactgtgtg attcaactgcc accgctcacc cccaggggtca gctgttccag gcccctcagc 900
ctccttgggc cccctgggcca ctgagccacc cagccttggt gtcaatgtgg gcagcctcat 960
gggtgctgtc tttgtgggtg tgttgggtgt ggtctgggtac ttccgaatca attaccgcca 1020
attcttcaca gcacctgcca ctgtctccct ggtgggagtc accgtcttct tcagcttctt 1080
agtatttggg atgtatggac gataaggaca taggaagaaa atgaaaggca tggctcttct 1140
cctttatggc ctccccactt ttccctggcca gagctgggccc caagggccgg ggagggaggg 1200
gtggaaagga tgtgatggaa atctcctcca taggacacag gaggcaagta tgcggcctcc 1260
ccttctcacc cacaggagta cagatgtccc tcccgtgcga gcacaactca ggtagaaatg 1320
aggatgtcat cttccttcac ttttaggggtc ctctgaagga gttcaaagct gctggccaag 1380
ctcagtgagg agcctgggct ctgagattcc ctcccacctg tggttctgac tcttcccagt 1440
gtcctgcatg tctgccccca gcaccagggt ctgctgcaa gggcagctca gcattggccc 1500
agcacaactc cgtagggagc ctggagtatc cttccatttc tcagccaaat actcatcttt 1560
tgagactgaa atcacactgg cgggaatgaa gattgtgcca gccttctctt atgggcacct 1620
agccgccttc accttcttcc tctacccttt agcaggaata ggggtgtcctc ccttctttca 1680
aagcactttg cttgcatttt attttatttt ttttaagagtc cttcatagag ctcagtcagg 1740
aaggggatgg ggcaccaagc caagccccc gcatggggag cggccaggcc acagctgctg 1800
ctcccgtagt cctcaggctg taagcaagag acagcactgg cccttggcca gcgtcctacc 1860
ctgccccact ccaaggactg ggtatggatt gctgggccc aggtctctgc ttttggggct 1920
attggagggg cagtgtctgt gactgaataa agttccattt tgtggtcaaa aaaaaaaaaa 1979

```

<210> 149

<211> 1810

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte Clone No: 2634120

<400> 149

```

ccccctgccc gcctctccgc acaataacttg aacattcacc tgtactgaag tgttacttga 60
accgggggaa tctcggacct gggggagccg ggggtgtgagg ggactggacc agcttgggact 120
gagacctgag accgggcccgg tgggcgcccc tttgggactg cggccacccc aggcttgttc 180
ttgttttact gtattgagcg gcggcaccgg ccggaccggc attatggctg ggggcgccag 240
ccaagaatgg ggacctggg actcctccag cctggctctt cccactcttt catcgtcag 300
gaaacttgta tcccatttgc ccagggaact gccactcctg gttgccatgg aaatagcagc 360
caacgggacac tcccgatgc cagtgcctaa gctggaaatg gccccctctt agttgccatg 420
ggaacctagt aacagactct gctggccctc ctctccctgc ccttccctga gcgcgggggtg 480
gggcttcggg accccgggga tgagccgggc cagggtccgc cctccgcgc aggcctccgg 540
ggggccgggg cttaccatgt aggggagggg agatctatcc acatacctca ggtggccatg 600
gtggaggtgc agctggagag tgaccacgag taccaccag gcctgctggt ggccttcagt 660
gcctgcacca ccgtgctggt ggctgtgcac ctctttgcac tcatggtctc cacgtgtctg 720
ctgccccaca ttgaagctgt gagcaacatc cacaacctca actctgtcca ccagtcgcca 780
caccagagac tgcaccgcta cgtggagctg gcctggggct tctccactgc cctgggcacc 840
tttctcttcc ttgctgaagt tgcctgggtt ggttgggtca agtttgtgcc cattggggct 900
cccttggaca caccgacccc catggtgccc acatcccggg tgcccgggac tctggcacca 960
gtggctacct cccttagtcc agcttccaat ctcccacggg cctctgcgtc tgcagaccgg 1020
tcccaggctg accagcctg cccacccgg caagcctgtg gtgggtgggg gggccatggg 1080
ccagggtggc aagcagccat ggctccaca gccatcatgg taccgtggg gctcgtgttt 1140
gtggcctttg cctgcattt ctaccgctcc ttggtggcac acaagacaga ccgctacaag 1200
caggaactag aggaactgaa tcgcctgcag ggggagctgc aggtgtgtg agactggtgt 1260
tagccaccgc tcaactgaag cactgcctcc ctccgggggtc tgtaagaggg cgcagggggc 1320
tacagacctc atccccccat cccctggctg gagccacttc cagtggccac tctcaggcag 1380
agttcagatt cctgcccgca ggtcctctgg gctgggccc ggggcagctc ccacattccc 1440

```

```

agggattttc cccatcagtc tgtcccttgg gttttgcaag ctactctgca cctgggctgg 1500
cctcagttga aggatcatgc agtagataga ggggaggcag ggagagcttg tgggaccttc 1560
agtgtctgact ttagccacca tttccattcc tatacaggat gtgaaggcca gaaggcagcc 1620
aattgttggg ttaatttttt ttttttttga gacagtctgt tccccaggct ggagtgtagt 1680
gatacagtc cagctcactg tagcctcgac cttccaggct caaaagatgc tcccaccaca 1740
gcctcccagg tagtgagtag ctggtactac aggtgtgtgc tgccacaccc gactaatttt 1800
tttgtagaga                                     1810

```

<210> 150

<211> 535

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte Clone No: 2765411

<400> 150

```

gaggaaccag aaatttgtcc ttgaataatg tttcccggtg tgggctggat cttgatagca 60
gttggttatca tcattcttct gattttttaca tctgtcaccc gatgcctatc tccagttagt 120
tttctgcagc tgaaattctg gaaaatctat ttggaacagg agcagcagat ctttaaaagt 180
aaagccacag agcatgcaac tgaattggca aaagagaata ttaaattgtt ctttgagggc 240
tcgcatccaa aagaatataa cactccaagc atgaaagagt ggcagcaa at tcatcactg 300
tatactttca atccgaaggg ccagtactac agcatgttgc acaaatatgt caacagaaaa 360
gagaagactc acagtatcag gtctactgaa ggagatacgg tgattcctgt tcttggcttt 420
gtagattcat ctggtataaa cagcactcct gagttatgac cttttgaatg agtagaaaaa 480
aaaattgttt tgaattattg cttttattaaa aaataaacat tggtaaaaaa aaaaa 535

```

<210> 151

<211> 891

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte Clone No: 2769412

<400> 151

```

gaaaagaatc cgaggcacag ataaagataa gttttactgt catgctgctt ttaacataac 60
agagcaacat cacctaggaa aaaagtgtgt aggaggattt ttaatccata tatttgtctt 120
atggctagat aaagatttct ctgaaaaaaa gaagcatgtc aggaatctct ggggtgccct 180
ttttcctctg gggacttcta gcattgttgg gcttggtctt gggtatatca ctgatcttca 240
atatttccca ctatgtggaa aagcaacgac aagataaaat gtacagctac tccagtgacc 300
acaccagggg tgatgagtat tatattgaag acacaccaat ttatggtaac ttagatgata 360
tgatttcaga accaatggat gaaaattgct atgaacaaat gaaagcccga ccagagaaat 420
ctgtaataaa gatgcaggaa gccaccccat ctgcacaggc aaccaatgaa acacagatgt 480
gctacgcctc acttgatcac agcgttaagg ggaagcgtag aaagcccagg aaacagaata 540
ctcatttctc agacaaggat ggagatgagc aactacatgc aatagatgcc agcgtttcta 600
agaccacctt agtagacagt ttctcccag aaagccaggc agtagaggaa aacattcatg 660
atgatcccat cagactgttt ggattgatcc gtgctaagag agaacctata aactagctgg 720
accatgatct agttcaatga tttggctcct attgaagatg gcttctaaga aaacaagatg 780
cacagaggac acagaaggac ttggcagcag ggtgatgacc tgatcatttg ttgatgggat 840
ggtggcttac ctcttattca cagcttacac ttatgcatgc caaatgtaag g 891

```

<210> 152
<211> 2311
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte Clone No: 2842779

<400> 152
gggcgcggca ccgcagctgg atggctgggg ccgcccggat cgcgcgcgcc gcccccgcg 60
cacgtacgtg gcatgcctgg atgtccctgc cctggctgtg gcatggcggg cccaaggctc 120
ctcttctctca ctgcccttgc cctggagctc ttgggaaggg ctgggggttc ccagccggcc 180
ctccggagcc gggggactgc gacggcctgt cgcctggaca acaaggaaag cgagtcctgg 240
ggggctctgc tgagcggaga gcggctggac acctggatct gctccctcct gggttccctc 300
atggtggggc tcagtggggc ctccccgttg cttgtcattc ccctagagat ggggaccatg 360
ctgcgctcag aagctggggc ctggcgctg aagcagctgc tcagcttcgc cctgggggga 420
ctcttgggca atgtgtttct gcatctgctg cccgaagcct gggcctacac gtgcagcgcc 480
agccctgggtg gtgaggggca gacgctgcag cagcagcaac agctggggct gtgggtcatt 540
gctggcatcc tgaccttcct ggcgttggag aagatgttcc tggacagcaa ggaggagggg 600
accagccagg cccccaacaa agacccccact gctgctgccg ccgcactcaa tggaggccac 660
tgtctggccc agccggctgc agagccccgc ctcggtgccg tggtcgggag catcaaagtc 720
agcggtacc tcaacctgct ggccaacacc atcgataact tcacccacgg gctggctgtg 780
gctgccagct tcttgtgag caagaagatc gggctcctga caaccatggc catcctcctg 840
catgagatcc cccatgaggt gggcgacttt gccatcctgc tccgggcccgg ctttgaccga 900
tggagcgcag ccaagctgca actctcaaca gcgctggggg gcctactggg cgtggccttc 960
gccatctgta cccagtcctc caagggagta gaggagacgg cagcctgggt cctgcccttc 1020
acctctggcg gctttctcta catcgcttg gtgaacgtgc tccctgacct cttggaagaa 1080
gaggaccgtt ggcgctccct gcagcagctg cttctgctct gtgcgggcat cgtggtaatg 1140
gtgctgttct cgtctctcgt ggattaaact tcctgatgc cgacgcccct gccccctgca 1200
gcaataagat gctcggatct actctgtgac cgcataatgt agaggcagag agggcgagtg 1260
gctgcgagag agaattagcc tcccgccaga caggagggag gtgcgtgtgg atgtatgtgg 1320
tgtgcacatg tggccagagg tgtgtgcgcg agaccgacac tgtgatccct gtgctgggtc 1380
cggggcccag tgtagcgctt gtccccagcc atgctgtggt tacctctcct tgccgcccctg 1440
tcaccttcac ctcttgaggt aagcagcgag gaagagcagc actggtccca agcagaggcc 1500
ttgcccctgc gggaccccgg gagtgcagc agcccaagga tcccagggtg cagggaaactc 1560
cagagctgcc cacctcccac tgccccctca gcacacacac agtccccagg cggcctaggg 1620
gccaaaggct gggcggtctt ggtccctttt cctggccctt ccttccccac ttctaagcca 1680
aagaaaggag aggcaggtgc tctgtaccc cagccccact cagcactgac agtccccagc 1740
tcctagtagt gagctgggag gcgcttcta agacccttc ctcagggtg ccctgggagc 1800
tcattcctgg ccaacacgcc ctggcagcac cagcagctct tgccacctcc agctgccaaa 1860
cagcagcctg ccgggcaggg agcagcccca ggccagagag gcctcccgtt ccagctcagg 1920
gatgctcctg ccagcacagg ggccagggac tctgggagca ggcacatagt gagccccggc 1980
agccctgccc agctcaggcc cctttccttc cccattgagg ttggggtagg tgggggcggg 2040
gagggctcca cgttgtcagc gctcaggaat gtgctccggc agagtgtga agccataatc 2100
cccaaccatt tcccttgtct gacgcccagg tactcagctg gccactcca cagccaggcc 2160
tggccctgcc cttcacctg gatgttttca gaagtggcca tcgagaggtc tggatgggtt 2220
tatagcaact ttgctgtgat tccgtttgta tctgtaaata tttgttctat agataagata 2280
caaataaata ttatccacat aaaaaaaaaa a 2311

<210> 153
<211> 2169
<212> DNA
<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte Clone No: 2966260

<400> 153

```
gctgcaggcg gcgacggcta caccatgggc cggtgctgc gggccgccc gctgccgcc 60
ctgctttcgc cgctgctgct tctgctgggt gggggagcgt tcctgggtgc ctgtgtggct 120
gggtctgatg agcctggccc agagggcctc acctccacct ccctgctaga cctcctgctg 180
cccactgggt tggagccact ggactcagag gaggctagt agaccatggg cctgggagct 240
gggctgggag cccctggctc aggcttcccc agcgaagaga atgaagagtc tcggattctg 300
cagccaccac agtactttctg ggaagaggag gaagagctga atgactcaag tctggacctg 360
ggacccactg cagattatgt ttttcctgac ttaactgaga aggcaggttc cattgaagac 420
accagccagg ctcaagagct gccaaacctc cctctccct tgcccaagat gaatctgggt 480
gagcctccct ggcataatgcc tcccagagag gaggaagaag aggaagagga agaggaggag 540
atggagaagg aagaggtaga gaaacaagat gtggaggaag aggaggagct gctccctgtg 600
aatggatccc aagaagaagc caagcctcag gtccgtgact tttctctcac cagcagcagc 660
cagaccccag gggccaccaa aagcaggcat gaagactccg gggaccaggc ctcatcaggt 720
gtggaggtgg agagcagcat ggggcccagc ttgctgctgc cttcagtcac cccaactata 780
gtgactccgg gggaccagga ctccaccagc caagaggcag aggccacagt gctgccagct 840
gcagggtctg gggtagagtt cgaggctcct caggaagcaa gcgaggaagc cactgcagga 900
gcagctgggt tgtctggcca gcacgaggag gtgccggcct tgccttcatt ccctcaaacc 960
acagctccca gtggggccga gcacccagat gaagatcccc ttggctctag aacctcagcc 1020
tcttccccac tggccctgg agacatggaa ctgacacctt cctctgctac cttgggacaa 1080
gaagatctca accagcagct cctagaaggg caggcagctg aagctcaatc caggataccc 1140
tgggattcta cgcaggtgat ctgcaaggac tggagcaatc tggctgggaa aaactacatc 1200
attctgaaca tgacagagaa catagactgt gaggtgttcc ggcagcaccg ggggccacag 1260
ctcctggccc tgggtggaaga ggtgctgcc cgccatggca gtggccacca tggggcctgg 1320
cacatctctc tgagcaagcc cagcgagaag gagcagcacc ttctcatgac actggtgggc 1380
gagcaggggg tgggtgccac tcaagatgtc ctttccatgc tgggtgacat ccgcaggagc 1440
ctggaggaga ttggcatcca gaactattcc acaaccagca gctgccaggc gcgggccagc 1500
cagggtgcga gcgactacgg cacgctcttc gtggtgctgg tggtcattgg ggccatctgc 1560
atcatcatca ttgcgcttgg cctgctctac aactgctggc agcgccggct gcccaagctc 1620
aagcacgtgt cgcacggcga ggagctgcgc ttcgtggaga acggctgcca cgacaacccc 1680
acgttggaag tggccagcga cagccagtcg gagatgcagg agaagcacc cagcctgaac 1740
ggcggcgggg cctcaacgg cccggggagc tggggggcgc tcatgggggg caagcgggac 1800
cccaggact cggacgtgtt cgaggaggac acgcacctgt gagcgagcc gaggcgcagg 1860
ccgagtgggc cgccaggacc aagcgaggtg gaccccgaaa cggacggccc ggagccagca 1920
caagccccga gcctaccgg gccgcccccg cggcctggcc ctgggcgcgg gctccttccc 1980
gcttcccccg acttcacacg gcggacttcg gaccaactcc ctactcccg cccgaggggc 2040
aggcctcaaa gcccgccttg gccccgcttt cccgcccctg aaccccgcc ccgcgggcgg 2100
cgggcggcgc ttcttgccgc ccgggactca attaaacccg cccggagacc acgcccgggc 2160
cagcgaaaaa
```

<210> 154

<211> 1480

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte Clone No: 2993326

<400> 154

```

ggatggggat ctttgtctgg tccttaacca acaggtatctt caccaactta ttagcccttt 60
cttgtaaaat ggccacatct cgcgggtggtg caggcctccg gcccacatggg atccgcctgt 120
aattactgcc acttctctca tccccattca gatgcttgga ctttcggttt cttttgcccc 180
gggtcctggg tgtgggctcc aggetcaact gagccagata gtcactctgcc agggcctgga 240
cagcagcagc aacctgagtc tcaagggcac ttacgttggg ctgagcagag gctatcttgg 300
cctgggcccc ttggtcagca tttggagtct ggctttcagt tgcccgagcc ttagtggcag 360
ccttcgagc cctagaccct ctcttgacce gcagggtggc tgccagggct tggtttgta 420
ctatctgagt ggcaagtggg gcctcagaga tctcagagac agaatttggg cccctgctgg 480
cagccttctt gcccttggat tttttgggccc tgatagccac tactgaggcc tcaatctgcc 540
tggtagctgc gtcagtgaca ttttagagcct ctatatgctc agtgtcagta tttatgacct 600
tagcaattgt cttcctggct ttggaggctt tcttggttcg gatggaggct gctgtggtgt 660
ggatactggc tgtctcattg gtaatttggc cttgggtggg agctgtatgg gtggcagttg 720
cagccagcga gacctcgggt gcactagcta tggccttatt tgccagcctt ttagccttgg 780
aagctttctt aggccttgata gaggttatca aggccttgga actggctgac tcatggcaa 840
ttggagcgtg aatattctgt gagatgactg gtagctttag gacctgcaag ggtgacttca 900
gctgtatagt gccacctca tggccagttg gggattggga gccttgggct gccttggcag 960
taactctctt catcttgttg gctttcttag gctgagcagt gactgaagaa gcctgagtat 1020
tggttacctc agtggtagggt aaagcctggc tgatctgggt aatgactggc aggtttaaag 1080
cctgccaaat tattttgggc ttgttggtgg caatctcatt ggcagctggg actggagggg 1140
cagcaggtgc agccttagta atagtcttta taggggcctt cttggtcttg cttttcttag 1200
gccggttgac aactggtggg tccatggcca gggagtcctt ggttgccgcc aacagggtat 1260
gcatcagcag gacactgtcc tcttctgttg tctcagctctg tatacttggg ggggaagggaa 1320
gccccaggct ccccggggga ggcagagggc cctgaaatag aggcacccta tatccgtagt 1380
catttctcct atccatcttt ctgggaggcc gagtaacagg tgagcctcgt cttcttgaat 1440
ccagaaggcg tctgctctct ccaagtctgc tctctccaag 1480

```

<210> 155

<211> 1222

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte Clone No: 3001124

<400> 155

```

agaaatatca tatggttact ttggtatctg acacagccat gacaccaatt gctagtgtag 60
acacaatagc tgtgtgtctt tttgcaggag cctggggagg ggccatggtg ccaatgcact 120
tactggggag actggagaag ccgcttctcc tcctgtgctg cgctccttc ctactggggc 180
tggttttgcg gggcataaag acggacatca cccccgttgc ttatttcttt ctcacattgg 240
gtggttctct cttgtttgcc tatctcctgg tccggtttct ggaatggggg cttcggtccc 300
agctccaatc aatgcagact gagagcccag ggccctcagg caatgcacgg gacaatgaag 360
cctttgaagt gccagtctat gaagaggccg ttggtgggact agaatcccag tgccgcccc 420
aagagttgga ccaaccaccc ccctacagca ctggtgtgat acccccagca cctgaggagg 480
aacaacctag ccatccagag ggggtccagga gagccaaact ggaacagagg cgaatggcct 540
cagaggggtc catggcccag gaaggaagcc ctggaagagc tccaatcaac cttcggtctc 600
ggggaccacg ggctgtgtcc actgctcctg atctgcagag cttggcggca gtccccacat 660
tagagctctc gactccaccc cctgcctatg atgtctgctt tggtcaccct gatgatgata 720
gtgtttttta tgaggacaac tgggcacccc cttaaatgac tctcccaaga tttctctct 780
ctccacacca gacctcgctt atttgactaa cattttccag cgctactat gtgtcagaaa 840
caagtgtttc tgcttggaac tcataaatgg ggacttggac cctgaggaga gtcaggccac 900
ggtaagccct tcccagctga gatatgggtg gcataatttg agtcttctgg caacatttgg 960
tgacctacc catatccaat atttcacgct ttagattgag gatgaggtag ggaggtgatc 1020
cagagaaggc ggagaaggaa gaagtaacct ctgagtggcg gctattgctt ctgttccagg 1080
tgctgttcga gctgttagaa cccttaggct tgacagcttt gtgagttatt attgaaaaat 1140

```

gaggattcca agagtcagag gagtttgata atgtgcacga gggcacactg ctagtaaata 1200
acattaaaat aactcgaatg ac 1222

<210> 156

<211> 1983

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte Clone No: 3120070

<400> 156

ggaaccgcct cccgcgggcc tettegettt tgtggcgggc cccgcgctcg caggccactc 60
tctgtgtgct cccgtcccg gcgtcctcc gacccgctcc gctccgctcc gctcggcccc 120
gcgccgccc tcaacatgat ccgctgcggc ctggcctgcg agcgtgccc ctggatcctg 180
ccctgctcc tactcagcg catcgcttc gacatcatcg cgtggccgg ccgaggctgg 240
ttgcagtcta gcgaccacgg ccagacgtcc tctgtgtggt ggaaatgctc ccaagagggc 300
ggcggcagcg ggtcctacga ggagggtgt cagagcctca tggagtacgc gtggggtaga 360
gcagcggctg ccagtctct ctgtggcttc atcctcctgg tgatctgttt catcctctcc 420
ttcttcgccc tctgtggacc ccagatgctt gtcttctctga gaggatgtgg aggtctcctt 480
gccttggtcg ctgtgttcca gatcatctcc ctggtaattt acccgtgaa gtacaccag 540
accttcaccc ttcatgccaa cctgctgtc acttacatct ataactgggc ctacggcttt 600
gggtgggcag ccacgattat cctgattggc tgtgccttct tctctgctg cctcccaac 660
tacgaagatg accttctggg caatgccaa cccaggtact tctacacatc tgcctaaact 720
gggaatgaat gtgggagaaa atcgctgctg ctgagatgga ctccagaaga agaaactgtt 780
tctccaggcg actttgaacc catTTTTTtg cagtgttcat attattaaac tagtcaaaaa 840
tgctaaaaata atttgggaga aaatatTTTt taagtagtgt tatagtttca tgtttatctt 900
ttattatgtt ttgtgaagtt gtgtctTTTt actaattacc tatactatgc caatatttcc 960
ttatatctat ccataacatt tatactacat ttgtaagaga atatgcacgt gaaacttaac 1020
actttataag gtaaaaatga gttttccaag atttaataat ctgatcaagt tcttggtatt 1080
tccaaataga atggactcgg tctgttaagg gctaaggaga agaggaagat aagggttaaaa 1140
gttggttaatg accaaacatt ctaaaagaaa tgcaaaaaaa aagtttattt tcaagccttc 1200
gaactattta aggaaagcaa aatcatttcc taaatgcata tcatttgtga gaatttctca 1260
ttaatatcct gaatcattca tttcagctaa ggcttcatgt tgactcgata tgcatctag 1320
gaaagtacta tttcatggtc caaacctgtt gccatagttg gtaaggcttt cctttaagt 1380
tgaaatattt agatgaaatt ttctctTTTt aagttctTTt tagggttagg gtgtgggaaa 1440
atgctatatt aataaatctg tagtgTTTTt gtgttatatg ttcagaacca gagtagactg 1500
gattgaaaga tggactgggt ctaatttatt atgactgata gatctggtta agttgtgtag 1560
taaagcatta gggtcattcc tgtcacaaaa gtgccactaa aacagcctca ggagaataaa 1620
tgacttgctt ttctaaatct caggtttatt tgggctctat catatagaca ggcttctgat 1680
agtttgcaac tgtctgatat aaaacatgcc tagttaaaat cctggctctt cttggtaaac 1740
agattttaaa tgtctgatat aaaacatgcc acaggagaat tcggggattt gaggtttctt 1800
gaatagcata tatatgatgc atcggatagg tcattatgat tttttaccat ttcgacttac 1860
ataatgaaaa ccaattcatt ttaaatatca gattattatt ttgtaagttg tggaaaaagc 1920
taattgtagt tttcattatg aagttttccc aataaaccag gtattctaaa cttgaaaaaa 1980
aaa 1983

<210> 157

<211> 1835

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte Clone No: 3133035

<400> 157

```

accaggctgt gtaagagctg ctggagtagg caccatttta aagaaaaaat gaagaagcag 60
caataaagaa gttgtaatcg ttacctagac aaacagagaa ctggttttga cagtgtttct 120
agagtgcctt ttattatttt cctgacagtt gtgttccacc atgattactt tctccttcag 180
cgaataggct aaatgaatat gaaacagaaa agcgtgtatc agcaaaccac agcacttctg 240
tgcaagaatt ttcttaagaa atggaggatg aaaagagaga gcttattgga atggggcctc 300
tcaatacttc taggactgtg tattgctctg ttttccagtt ccatgagaaa tgtccagttt 360
cctggaatgg ctectcagaa tctgggaagg gtagataaat ttaatagctc ttctttaatg 420
gttggtgata caccaatata taatttaacc cagcagataa tgaataaaac agcacttgct 480
cctcttttga aaggaacaag tgtcattggg gcacaaataa tacacacatg gacgaaatac 540
ttctggaaaa ttacatatg ctatgggaat catctttaat gaaactttct ctataagtt 600
aatatttttc caggatata acagtccact ttggaaagaa gatttctcag gtgactttcc 660
atatcaataa tcattatgga atttttcatg ttttcaacat aaagaacaga ggagggtggg 720
caacagagat gctttcaatg acacatgaga aaacagggaa agcccatttc attgctgaac 780
ttatttcaag gtcaatcgta tgttccact acaggatgac tgcaaaaatt gtagagtcac 840
ccaacatata tgtgttgagc atgcagatgc atgtgtcaaa ggacacatga gtaacccaag 900
actgacaggc ccagcctca ggtgagatc caggttagca gcaaagacag acattgaaca 960
attaatgaca agtacaagaa aaagtgtttc atgggcactt agaccagggg ttcctaatag 1020
tgggacctag agaagtccta cctggggaaa tgatgtttaa agggagacca gaatgaatag 1080
cagggtgtgag gtgctagaag cattgtgttt cagatagaag aaaggtaatt gtgaagacct 1140
tgagggtgaga aaggacatct gttcctagat ctggaagaag agcagtatag ctgaacaagg 1200
aacatgaaaa ggaatgtaat gggagagtga agctgaagtc actcaagtgc tacctcctgt 1260
ggcatcttgt aaacctaggc aaggaatagc cactgagtca ctttaatcac ggcaaaagtg 1320
taattcgggt tccaaaatta ggggaacact ccagatatag cccggggaat agattgcca 1380
gaggctatgg agaattgtca gaaacaagga gtccattatg gctggagcag agtgtttgct 1440
ttcatctcct ttttattttc taagactttc taagcatgct gtggtctgca agaataaaat 1500
tgctttatta aaaactttca tttatttgct tcctttttct atgtagttaa aagtctactg 1560
gtgggccagc catggtggct cacacctgta atcccagcac tttgagaggc cgagggtgcac 1620
ggatcacctg aggtcaggag ttcgagacca gcctggccaa catggtgaaa gcctgtctct 1680
actaaaaata caaaaattag ctgacaacg tggcctgtgc ctataatccc agctttggga 1740
ggctgaggta ggagaatcac ttgaaccag gaggtggagg ttgcagtgag ctgagatcgc 1800
accactgcac tccagcatgg gcaacagagt gagat 1835

```

<210> 158

<211> 819

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte Clone No: 3436879

<400> 158

```

cacgactcac tatagggaat ttggccctcg aggcaagaat tcggcacgag gtcgacaccc 60
tcaccttgaa aggtattgag cacgatgcac ggccatcaag taccactttt ctgagcccat 120
ccgcttgaga aacattcctt ttaatttaac caagaccata cagcaagatg agtggcacct 180
gcttcattta agaagaatca ctgctggctt cctcggcatg gccgtagccg tcttctctg 240
cggctgcatt gtggccacag tcagtttctt ctgggaggag agcttgacct agcagtggtc 300
tggaactcctg ttcctcatga caggatatt ttgcaccatt tccctctgta cttatgccgc 360
cagtatctcg tatgatttga accggtctcc aaagctaatt tatagcctgc ctgctgatgt 420
ggaacatggt tacagctggg ccatcttttg cgcctggtgc agtttaggct ttattgtggc 480

```



```
agctggaggt ctctgcatcg cttatccggt tattagccgg accaagattg cacagctaaa 540
gtctggcaga gactccacgg tatgactgtc ctactgggc ctgtccacag tgcgagcgac 600
tcttgagggg aacagcgagg agttcaggag tccaagcaca aagcgggtctt ttacattcca 660
acctgttgcc tgccagccct ttctggatta ctgatagaaa atcatgcaaa acctcccaac 720
ctttctaagg acaagactac tgtggattca agtgctttaa tgactattta tgcgttgact 780
gtgagaatag ggagccatgc catgggacat ttctaggtg 819
```

